

# **BOARD OF DIRECTORS MEETING**

# Tuesday 3<sup>rd</sup> October 2017 commencing at 1100

**Venue: Large Meeting Room, Institute in the park** 

| VB<br>no. | Agenda<br>Item | Time | Items for Discussion   | Owner                        | Board Action  | Preparation  |
|-----------|----------------|------|--|------------------------------|---|--------------|
|           |                |      |  | PATIENT STO                  | DRY   |              |
| Board     | l Business     |      |  |                              |   |              |
| 1.        |                | 1115 | Apologies  | Chair                        | Catherine McLaughlin, Anita Marsland  |              |
| 2.        | 17/18/133      | 1116 | Declarations of Interest   | All                          | Board Members to declare an interest in particular agenda items, if appropriate   |              |
| 3.        | 17/18/134      | 1117 | Minutes of the Previous Meeting  | Chair                        | To consider the minutes of the previous meeting to check for amendments and approve held on: 5 <sup>th</sup> September 2017 | Read Minutes |
| 4.        | 17/18/135      | 1120 | Matters Arising  | Chair                        | To discuss any matters arising from previous meetings and provide updates and review where appropriate                      | Verbal       |
| 5.        | 17/18/136      | 1140 | Key Issues/Reflections   | All                          | The Board to reflect on key issues.   | Verbal       |
| Strate    | gic Update     |      |  |                              |   |              |
| 6.        | 17/18/137      | 1150 | External Environment  Progress against strategic themes: - Liverpool Community           |                              |   |              |
|           |                |      | Services - Liverpool Women's Reconfiguration Options/Neonatal - Congenital Heart Disease | L Shepherd L Shepherd S Ryan | To update the Board on progress.  | Verbal       |

| VB<br>no. | Agenda<br>Item | Time     | Items for Discussion   | Owner                     | Board Action  | Preparation  |
|-----------|----------------|----------|--|---------------------------|---|--------------|
| Delive    | ry of outsta   | nding ca | are  |                           |   |              |
| 7.        | 17/18/138      | 1210     | Serious Incidents Report                                       | H Gwilliams               | To inform the Board of the recent serious incidents at the Trust in the last calendar month   | Read Report  |
| 8.        | 17/18/139      | 1220     | Clinical Quality Assurance<br>Committee: Chair's update        | A Marsland                | To receive and review the approved minutes from the meeting held: July 2017                   | Read report  |
| 9.        | 17/18/140      | 1230     | Learning From Deaths - Guidance - Revised Trust Policy         | S Ryan                    | To present the latest national guidance on learning from deaths and the revised Trust Policy. | Read report  |
| 10.       | 17/18/141      | 1240     | Alder Hey in the Park update                                   | D Powell                  | To receive an update on key outstanding issues / risks and plans for mitigation.              | Read report  |
| tems      | for Approva    | ı        |  |                           |   |              |
| 11.       | 17/18/142      | 1250     | - NHS England EPRR Core<br>Standards Audit/Self-<br>Assessment | H Gwilliams/<br>E Menarry | Items for approval following ratification at the Integrated Governance Committee.             | Read reports |
|           |                |          |  | 1300 – 1330 LU            | INCH  |              |
| The be    | est people d   | oing the | eir best work  |                           |   |              |
| 12.       | 17/18/143      | 1330     | People Strategy Update   | M Swindell                | To provide an update on the strategy and staff survey   | Read reports |
| 13.       | 17/18/144      | 1340     | Freedom to speak up survey 2017                                | E Saunders/<br>S Igoe     | To receive the survey recommendations.  | Read report  |
| 14.       | 17/18/145      | 1350     | Listening into Action  | K Turner                  | Two Clinical teams from the current cohort to provide an update on progress to the Board      | Presentation |
| Strong    | g Foundation   | ns       |  |                           |   |              |

| VD        | Anonde         |          |   |   | NHO  | Foundation Trust           |      |
|-----------|----------------|----------|---|---|--|----------------------------|------|
| VB<br>no. | Agenda<br>Item | Time     | Items for Discussion  | Owner                                     | Board Action   | Preparation                |      |
| 15.       | 17/18/146      | 1410     | Winter Plan   | M Barnaby                                 | To provide assurance on plans for the winter period.   | Presentation               |      |
| 16.       | 17/18/147      | 1420     | Programme Assurance update  - Deliver Outstanding Care  - Growing External Partnerships  - Global Digital Exemplar  - Park Community Estates and Facilities | J Grinnell                                | To receive an update on programme assurance including the 2017/18 change programme   | Read Report                |      |
| 17.       | 17/18/148      | 1430     | Corporate Report  | J Grinnell/<br>H Gwilliams/<br>M Swindell | To note delivery against financial, operational, HR metrics and quality metrics and mandatory targets within the Corporate Report for the month of August 2017 | Read report                |      |
| 18.       | 17/18/149      | 1450     | Board Assurance Framework   | E Saunders To receive the BAF report.     |  | Read report                |      |
| 19.       | 17/18/150      | 1500     | Resources & Business<br>Development Committee: Chair's<br>update  | I Quinlan                                 | To receive and review the approved minutes from the meeting held on: 2017.   | Read minutes               |      |
| Susta     | inability thro | ough ext | ernal partnerships  |   |  |                            | 17/  |
| 20.       |                | 1510     | International Child Health  | S Falder/<br>B Pizer                      | To receive proposals on the vision.  | Presentation/<br>Enclosure |      |
| Game      |                | esearch  | and Innovation  |   |  |                            | 17/1 |
| 21.       |                | 1520     | Global Digital Exemplar (GDE)   | P Young                                   | To update the Board on the programme   | Read report                |      |
| Any C     | Other Busin    | ess      |   |   |  |                            |      |
| 22.       |                |          |   | All                                       | Verbal   |                            |      |



NHS Foundation Trust

| VB<br>no. | Agenda<br>Item   | Time | Items for Discussion | Owner | Board Action | Preparation |  |  |  |  |  |
|-----------|--|------|----------------------|-------|--------------|-------------|--|--|--|--|--|
|           | Date And Time Of Next Meeting: Tuesday 7 <sup>th</sup> November 2017 At 10:00am, Institute In The Park, Large Meeting Room |      |                      |       |              |             |  |  |  |  |  |

# **REGISTER OF TRUST SEAL**

The Trust Seal was not used during the month of September, 2017

## **BOARD OF DIRECTORS**

Minutes of the last meeting held on **Tuesday 5<sup>th</sup> September 2017 at 10:00am**, Large Meeting Room, Institute in the park

| Present:          | Mr I Quinlan Mrs C Dove Mrs J France-Hayhurs Mr J Grinnell Mrs H Gwilliams Mr S Igoe Mrs A Marsland Mrs L Shepherd Dr S Ryan Mrs M Swindell Dame J Williams | Non-Executive Director (Chair) Non-Executive Director st Non-Executive Director Director of Finance Chief Nurse Non-Executive Director Non-Executive Director Chief Executive Medical Director Director of HR & OD Non-Executive Director  | (IQ)<br>(CD)<br>(JFH)<br>(JG)<br>(HG)<br>(SI)<br>(AM)<br>(LS)<br>(SR)<br>(MS)<br>(JW) |
|-------------------|---|--|---|
| In Attendance:    | Mr A Bateman Prof M Beresford Ms S Falder  Dr A Hughes Mrs C McLaughlin Mr D Powell Ms E Saunders Mrs J Tsao Mr M Flannagan                                 | Acting Chief Operating Officer Assoc. Director of the Board Director of Clinical Effectiveness and S Transformation Director of Medicine Director of Integrated Community Serv Development Director Director of Corporate Affairs Committee Administrator Director of Communications | (SF)<br>(AH)  |
| 108<br>109<br>117 | 4 Mr Andrew Williams<br>Mrs Anne Hyson<br>Mrs Jo Keward<br>Heidi Miller<br>Cath Wardell<br>Joan Mulvoy<br>Mr Peter Young                                    | Director of CAMHS Complaints Manager Infection Control Nurse Breastfeeding Lead Associate Chief Nurse Pharmacy Purchasing Manager Chief Information officer  | (AW)<br>(AH)<br>(JK)<br>(HM)<br>(CW)<br>(JM)<br>(PY)                                  |
| Apologies:        | Mrs M Barnaby<br>Sir D Henshaw<br>Mr C Duncan<br>Mrs C McLaughlin   | Interim Chief Operating Officer Chairman Director of Surgery Divisional Director of Community Services   | (MB)<br>(SDH)<br>(ChrD)   |

## **Staff Story**

The Board welcomed Julie Fitzpatrick Theatres Practitioner to the meeting. Julie had started at Alder Hey in 1994. In 2011 Julie was the first Health Care Assistant in the Country to complete a NVQ Level 3 qualification for a Scrub HCA. During this time Julie's sister was diagnosed with cancer; whilst this was a difficult period Julie said the support from her family and staff helped her to continue with the qualification. Later that year, Julie's husband passed away followed by her sister's death. Whilst this was an extremely difficult time Julie said the support from the Alder Centre and her management team helped her to come back to work.

Going forward Julie is going to visit Great Ormond Street Hospital and Birmingham Children's Hospital to provide advice on her role.

The Board thanked Julie for taking time to share her story as it is extremely valuable.

#### 17/18/101 Declarations of Interest

None declared.

# 17/18/102 Minutes of the previous meetings held on 4<sup>th</sup> July 2017 Resolved:

The Board received and approved the minutes from the meeting held on 4<sup>th</sup> July 2017.

# 17/18/103 Matters Arising and Action Log

The Chair welcomed: Mark Flannagan, Adam Bateman and Adrian Hughes to their first Board meeting.

All actions from the previous meeting had been included on the agenda.

# 17/18/104 Key Issues/Reflections

On behalf of the Board the Chair congratulated Louise Shepherd on receiving her CBE in the Queen's announcements.

Erica Saunders reported the Trust had been shortlisted in the category of Provider Trust of the Year for the Health Service Journal Awards.

The Board received an update on recent changes to the Board at Liverpool Clinical Commissioning Group. Dr Simon Bowers has been appointed as the new Chair. A meeting with Simon and Board members from Alder Hey was to be scheduled.

Following concerns raised at Liverpool CCG both the Accountable Officer and Director of Finance had announced their decision to resign from the roles and replacements were being sought.

# 17/18/105 External Environment/STP/Progress against Strategic Themes

Following Louise Shepherd's resignation as STP Lead for Cheshire and Merseyside the role had now been appointed to; Mel Pickup, Chief Executive at Warrington and Halton NHS Trust would be the lead going forward. Both the Chief Executive and Chair Andrew Gibson are committed to developing an Accountable Care System for Cheshire and Merseyside.

Mark Flannagan agreed to communicate Louise Shepherd's resignation as the STP Lead for Cheshire and Merseyside to staff.

**Action: MF** 

## **Liverpool Community Health Services**

NHS Improvement has requested that bids for the Liverpool Community Services are submitted no later than Friday 8<sup>th</sup> September 2017. The decision as to which organisation is preferred bidder would be announced on 3<sup>rd</sup> October.

#### **Neonatal Network**

Regular meetings are being held locally to develop a single site Neonatal service. Adam Bateman noted that the Trust currently has nine beds and is planning to extend to a further 10 cots.

# **Liverpool Women's NHS Foundation Trust**

Public consultation is due to commence in the Autumn.

# Tier 4 CAMHS Cheshire and Merseyside Bid

Tier 4 (Specialised CAMHS) services include day and inpatient services for children and young people with the most complex mental health conditions. Within the inpatient element of CAMHS Tier 4 there are several different types of service including adolescent, eating disorder, learning disability, children's and low secure units. Alder Hey is commissioned to provide an inpatient service for children aged between 5-13 years at the Dewi Jones Unit (DJU).

The DJU is based in a facility away from the main hospital site and the Community Division is developing a case for change which would support the development of a purpose built facility within the Alder Hey Campus.

Jeannie France-Hayhurst asked for the Board to be regularly updated.

#### Resolved:

Board supports the intention to develop a full business case for the redevelopment of the Dewi Jones Unit on the Alder Hey campus, which will enable the service to be delivered in line with national service specification requirements and with the capacity to deliver against both current and future demand.

## **Congenital Heart Disease**

Proposals are due to be submitted at the next NHS England Board meeting.

# 17/18/106 Serious Incidents Report

Hilda Gwilliams presented the report for July 2017. There had been six new SIRIs reported, four ongoing and one closed. Following feedback from the CQC the report format has been revised to include further detail.

The first SIRI had been a never event for wrong site surgery due to break down of communication with a trainee doctor. As trainee doctors' start at different times through the year it was agreed the introduction training pack would be reviewed to ensure information on site surgery is included.

The four ongoing incidents are all in progress within the timescales set. The Safeguarding Incident had been included for information.

Going forward Hilda Gwilliams agreed to include a lessons learnt section on each of the incidents as well as an annual review of themes.

# Resolved:

The Board received the Serious Incident Report for July noting:

Page **3** of **10** 

 Six new SIRIs, four ongoing and one closed. There had been one new safeguarding incident reported, one ongoing and none closed.

# 17/18/107 Clinical Quality Assurance Committee: Chair's Update CQAC Minutes 21st June 2017

The first of the Quality Walkabouts has been scheduled for tomorrow.

Sepsis continues to be a focus for the committee.

#### Resolved:

The Board received and noted the approved minutes from the CQAC meeting held on 21st June 2017.

# 17/18/108 Complaints Quarter 1 report

The Trust received 18 formal complaints during this period. Two complaints from this quarter were subsequently withdrawn from the process at the complainant's request and two complaints also started as an informal concern (PALS), however due to dissatisfaction with informal outcome the complainant requested this progress to the formal complaint route.

Anne Hyson is working with the learning and development team to provide training to staff on giving realistic timescales to parents.

Six complaints where upheld within the quarter and five where not upheld. Four complaints are still ongoing as six had been received in June and two surgical complaints are extremely complex in nature and level of detail in the response.

All complainants are fully updated regarding any delays in response timeframes.

Q4 reported enquires to PALS saw a significant increase of 391. Further investigation looking at enquiries linked to activity, show a correlation between the two data sets.

In Q1 2017 - 2018 PALS contacts received have dropped to 308 contacts.

A compliments section had been included in the report. Anne Hyson advised compliments are captured through wards and departments.

Non-Executive Directors on the CQAC Committee had received a number of complaints to review. Anne Hyson agreed to arrange a follow up meeting.

# Action: AH/JT

#### Resolved:

The Board received the Quarter 1 Complaints Report.

## 17/18/109 Infection and Control Quarter 1 report

The quarterly report provides the Board with the challenges for delivery of the Infection Prevention and Control Work Plan and progress to date.

At the end of Q1 53% (40/76) of the total of deliverables had been completed. 39% (30/76) of the total deliverables were in progress (amber); 8% (6/76) classified as red.

Plans are in place to recruit to the Director of Infection Prevention and Control role. Dr Cooke who retired from this role has agreed to return to cover a session per week.

Processes to review cases of MRSA/ MSSA/VRE and E Coli Bacteraemia are now in place.

An update on hand hygiene was received. A promotional campaign for hand hygiene would be held in national hand hygiene week, flu vaccinations would also be given during this time.

#### Resolved:

The Board received the Quarter 1 Infection, Prevention Control Report.

# 17/18/110 Mortality Quarter 1 report

The Board received the report noting the significant improvement in the completion of HMRG reviews. Julie Grice and the team are hoping to have worked through the rest of the backlog by the end of October 2017.

Anita Marsland reported on training recently provided by AQuA on Mortality noting it would be useful for Non-Executives to attend to have further understanding. As paediatric mortality is reported differently to adults it was agreed an in-house training session would be provided for NEDs.

Action: SR/JG

# **Resolved:**

The Board noted their thanks to Julie Grice and the team for the significant improvement.

# 17/18/111 Alder Hey in the Park

David Powell updated the Board on the current position of projects within Alder Hey in the Park:

#### Demolition

Demolition of the old site is in progress.

## Residential

Community engagement continues to progress.

# **Research and Education Phase II**

The build remains on track and is hoped to be completed in September 2018.

#### **Alder Centre**

Building of the Alder Centre is due to commence next year. Cath Kilcoyne has been appointed as Commercial Advisor for this project.

## **Park**

A review is currently place to agree on the extension.

# Community/CAMHS Estate Strategy

Currently exploring a financial analysis of proposed developments and locations.

# Resolved:

Board received an update on the current position.

# 17/18/112 Emergency Preparedness annual report and work plan Resolved:

The Board received and approved the Emergency Preparedness annual report and work plan. The Non-Executive Lead is Steve Igoe.

# 17/18/113 People Strategy update

Melissa Swindell presented the July report.

Following on from the last Board, Melissa Swindell reported on progress made with internal engagement including the launch of employee of the month, the reward and recognition plans agreed in March are on track and Annual Awards are due to be launched later the year.

The Annual Staff Survey is to be launched later this month.

PDR rates have improved to 79% departments have agreed to be at 90% by the end of October.

The Alder Hey Nursery will be able to support the Government initiative of supporting 30 hours of nursery places per week.

#### **Resolved Board Received:**

- a) The July report noting actions in place to improve internal communication and response rates to the annual staff survey.
- b) Workforce and Organisational Development Committee approved minutes from the meeting held in June 2017.
- c) Workforce and Organisational Development Committee Annual report 2016/17.

# 17/18/114 Internal Communications update

# Resolved:

Mark Flannagan presented his findings and recommendations from the internal communications review he had taken since starting in post on 17<sup>th</sup> July 2017.

# 17/18/115 Listening into Action

## **Breast feeding Services**

The Board welcomed Heidi Miller and Cath Wardell to the meeting.

Heidi provided an update on breastfeeding processes within Alder Hey highlighting gaps within the service including storage and inconsistencies in practices.

Following these findings next steps included:

- Secure a Breastfeeding co-ordinator role for 12 hours per week
- Implement e-learning training module for all clinical staff on safe management of EBM
- Implement training package for link nurses and HCAs initially
- Invest in waterless warmers to ensure EBM heated to safest standard. Policy and SOPs can then be ratified.

Heidi had included a cost breakdown for the waterless warmers, the reason why they are required and how many would be needed. Heidi noted the equipment is costly and how the Neonatal Network are working together to try to reduce the cost.

The training package referred to could be offered to external organisations at a cost.

Cath Wardell praised Heidi for work to date on ensuring breastfeeding services are safe.

## Resolved:

The Board thanked Heidi and Cath for the presentation and supported the next steps. Hilda Gwilliams agreed to contact Heidi to move the service forward.

**Action: HG** 

# Revision of Homecare Staff Office space Sept 2017

The Board welcomed Joan Mulvoy to the meeting.

Joan reported on the space issues within pharmacy noting there are three Homecare admin staff who had not been allocated an office before the hospital move due to lack of space. The area allocated for these staff was in the dispensary near busy rooms and a high volume of staff traffic.

A 1:1 room had been identified as an appropriate office space with the 1:1 room being moved to a sundries storeroom and the stores being allocated to a separate room.

Benefits from the move included:

- Homecare staff now have an office.
- Chief Technician and Deputy will have an office
- A new One to One room is available to use
- Space is used effectively.
- Purchasing / Homecare teams can communicate better.

Going forward Phase 2 will be implemented.

# Resolved:

The Board thanked Joan for her presentation.

# 17/18/116 Alder Hey Ventures

David Powell and John Grinnell updated the Board on the proposed development of Alder Hey Ventures Ltd, the purpose of which is commercialising and

Page **7** of **10** 

operationalising innovation including governance, taxation, commercial and risk issues. KPMG in a light touch capacity have provided the required Taxation, Commercial and Legal support to Alder Hey NHS Foundation Trust to ensure a robust process is followed that provides the required assurances around an SPV set up and governance.

A draft report is due to be presented at the next Research Education and Innovation Committee this month. A final version will be presented at the November Board meeting.

Action: DP/JG

#### Resolved:

The Board received an update on Alder Hey Ventures Ltd.

# 17/18/117 Programme Assurance Update

#### Resolved:

The Board went through the dashboard noting medicine had made further progress than recorded.

# 17//18/118Corporate Report

The Board received the report for July 2017.

# Financial, Growth & Mandatory Framework

For the month of July the Trust is reporting a trading deficit of £0.3m which is £0.1m behind plan.

Income is behind plan by £0.4m mainly due to income relating elective and outpatient activity. Elective activity is behind plan by 12% and outpatient activity is behind plan by 7%. These are offset by an overachievement on non-elective activity of 12%. Pay budgets are £0.2m overspent for the month relating to use of temporary staffing which has increased. The Trust is ahead with the CIP target to date by £0.1m. Cash in the Bank is £11.2m. NHSI Use of Resources rating of 3 in line with plan.

## **Performance**

The Trust is compliant with all NHSI standards with the exception of the ED 4 hour standard, which was 93% for the month; August had seen improvement.

Diagnostics, incomplete pathway and cancer all achieved despite the high number of NEL and ED attendances. 28 day breaches have reduced to one. Activity has increased within the hospital against the same period last year. Backlog remained static, no patients waiting >52 weeks and clearance rates reduced. Corporate induction hit 100% for July.

A winter plan is being developed.

#### **Patient Safety**

Clinical incident reporting remains high (352 year to date compared to 188 last year). This reflects the continued open culture of reporting incidents.

# **Patient Experience**

There were four formal complaints in July; this is the lowest in one month since January. PALS attendances are slightly lower than the previous month but are maintaining an increasing trend since April. Family and Friends responses have improved except in outpatients where there is a slight reduction in the percentage of families that would recommend Alder Hey. However there is a need to improve the number of responses in A&E and in Community. Inpatient survey metrics have all moved closer to their goal except 'patients knowing their planned date of discharge' which has deteriorated slightly.

## **Clinical Effectiveness**

The marked reduction in hospital acquired infections has been maintained this month, with a cumulative 15 HAIs compared with 33 HAIs at this point last year. MRSA and C. difficile remain at zero for the year. Year to date there have been 3.8% (235) of surgical patients discharged later then their plan, compared to 5.4% at this point last year. The number of deaths in hospital has improved slightly at 23 cumulatively, compared to 27 last year

#### Resolved:

The Board received the Corporate Report for Month 4.

# 17/18/119 Board Assurance Framework

## Resolved:

The Board received the content of the BAF, noting in particular the assurances with regard to the management contract at LCH.

# 17/18/120 Resource and Business Development Committee Resolved:

The Board received the approved minutes from the meeting held on 28<sup>th</sup> June 2017

# 17/18/121 Integrated Governance Committee: Chair's update Resolved:

The Board received the approved minutes from the meeting held on 24<sup>th</sup> May 2017.

# 17/18/122 Global Digital Exemplar

The Trust received confirmation of the first tranche of PDC funding on Friday 16<sup>th</sup> June (approximately £2.5million), this was received and we were available to drawn down from on the 10<sup>th</sup> July.

The invoice request has been completed for the remaining revenue funding (approx. £800k) will also be made available via the CCG imminently.

The Alder Hey Fast Follower Trust, Clatterbridge, are currently undergoing 'due diligence' and a site visit has been arranged there for the 20<sup>th</sup> September 2017. At the next Board update an overview of the Site Visit, copy of the Funding Agreement and Letter of intent will be circulated for formal agreement and sign off.

Peter Young highlighted difficulties with the new voice recognition system particularly in Orthopaedics. The teams were working through the issues being raised.

# 17/18/123 Research Education and Innovation Committee: Chair's update Resolved:

The Board received the approved minutes from the meeting held on 28<sup>th</sup> April 2017.

It was agreed a presentation at the next Board would be given on projects within the Alder Hey Ventures LTD.

**Action: DP** 

# 17/18/124 Any Other Business

No other business was reported.

Date and Time of next meeting: Tuesday 3<sup>rd</sup> October 2017, at 1:30pm, Large Meeting Room, Institute in the park.





# BOARD OF DIRECTORS Tuesday 3rd October 2017

| Report of:  | Chief Nurse  |  |  |  |  |
|---|--|--|--|--|--|
| Paper Prepared by:  | Chief Nurse and Clinical Risk Manager  |  |  |  |  |
| Subject/Title:  | Serious Incidents Requiring Investigation  |  |  |  |  |
| Background Papers:  | n/a  |  |  |  |  |
| Purpose of Paper:   | This report summarises all the open serious incidents in<br>the Trust and identifies new serious incidents arising in<br>the last calendar month.  |  |  |  |  |
| Action/Decision Required:                                     | For information regarding the notification and management of SIRI's.   |  |  |  |  |
| Link to: ➤ Trust's Strategic Direction ➤ Strategic Objectives | <ul> <li>Patient Safety Aim – Patients will suffer no harm in our care.</li> <li>Patient Experience Aim – Patients will have the best possible experience</li> <li>Clinical Effectiveness – Patients will receive the most effective evidence based care.</li> </ul> |  |  |  |  |
| Resource Impact   |  |  |  |  |  |

# THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY

Page 2 of 10

#### 1. Background:

All Serious incidents requiring investigation (SIRI) are investigated using a national Root Cause Analysis (RCA) investigation methodology.

Incidents are categorised as a Serious Incident Requiring Investigation (SIRI) using the definitions in the Trust "Management of Incidents including the Management of Serious Critical Incidents Policy". All new, on-going and closed SIRI incidents are detailed in Appendix A of this report.

Safeguarding children cases reported through StEIS are included in this report. Since June 2014 NHS England have additionally requested that the Trust report all Sudden Unexpected Deaths in Infancy (SUDI) and Sudden Unexpected Deaths in Childhood (SUDC) Cases onto the StEIS Database.

SIRI incidents are closed and removed from the table of on-going SIRI incidents following internal approval of the final RCA investigation report, in addition, an external quality assurance process is completed via Liverpool CCG as lead commissioners. The SIRI incident is then transferred to the Trust SIRI Action log until all actions are completed. Progress with implementation/completion of the SIRI action plans are monitored by the Clinical Quality Assurance Committee (CQAC).

# 2. SIRI performance data:

|              |     |     |     |     | SII   | RI (Genera | al) |     |     |     |     |         |     |      |     |
|--------------|-----|-----|-----|-----|-------|------------|-----|-----|-----|-----|-----|---------|-----|------|-----|
|              |     |     |     | 20  | 16/17 |            |     |     |     |     |     | 2017/18 |     |      |     |
| Month        | Jun | Jul | Aug | Sep | Oct   | Nov        | Dec | Jan | Feb | Mar | Apr | May     | Jun | July | Aug |
| New          | 2   | 0   | 1   | 1   | 2     | 2          | 1   | 0   | 1   | 2   | 3   | 1       | 2   | 4    | 0   |
| Open         | 2   | 4   | 2   | 3   | 3     | 2          | 2   | 1   | 1   | 2   | 2   | 4       | 4   | 6    | 8   |
| Closed       | 2   | 0   | 2   | 0   | 1     | 3          | 2   | 2   | 0   | 0   | 2   | 1       | 0   | 1    | 2   |
|              |     |     |     |     |       |            |     |     |     |     |     |         |     |      |     |
| Month        | Jun | Jul | Aug | Sep | Oct   | Nov        | Dec | Jan | Feb | Mar | Apr | May     | Jun | July | Aug |
| New          | 1   | 0   | 1   | 1   | 2     | 0          | 0   | 1   | 2   | 2   | 0   | 0       | 0   | 1    | 0   |
| Open         | 0   | 0   | 0   | 0   | 0     | 0          | 0   | 0   | 0   | 0   | 0   | 0       | 0   | 0    | 0   |
| Closed       | 0   | 0   | 0   | 0   | 0     | 0          | 0   | 0   | 0   | 0   | 0   | 0       | 0   | 0    | 0   |
| Total closed | 0   | 0   | 0   | 0   | 0     | 0          | 0   | 0   | 0   | 0   | 0   | 0       | 0   | 0    | 0   |

#### 3. Recommendations:

The Trust Board is asked to note new and closed incidents and progress in the management of open incidents.

|                     | New SIRI Incidents reported between the period 01/08/2017 to 31/08/2017: |     |                         |                          |  |          |                                 |  |  |  |  |  |  |
|---------------------|--|-----|-------------------------|--------------------------|--|----------|---------------------------------|--|--|--|--|--|--|
| Reference<br>Number | Date<br>investigation<br>started   | CBU | Incident<br>Description | RCA Lead<br>Investigator | 72 hour review<br>completed/ immediate<br>actions taken and<br>shared learning | Progress | 60 working<br>day<br>compliance | Duty of<br>Candour/<br>Being Open<br>policy<br>implemented |  |  |  |  |  |
|                     | Nil  |     |                         |                          |  |          |                                 |  |  |  |  |  |  |

|                     | New Safeguarding investigations reported 01/08/2017 to 31/08/2017:  For information |  |  |  |  |  |  |  |  |  |  |  |
|---------------------|---|--|--|--|--|--|--|--|--|--|--|--|
| Reference<br>Number |   |  |  |  |  |  |  |  |  |  |  |  |
|                     | Nil   |  |  |  |  |  |  |  |  |  |  |  |

|                      |                            | On                  | -going SIRI incident inve  | estigations (includ                           | ling those above)  |   |   |
|----------------------|----------------------------|---------------------|--|---|--|---|---|
| Reference<br>Number  | Date investigation started | CBU                 | Incident Description   | RCA Lead<br>Investigator                      | Progress   | 60 working day<br>compliance (or<br>within agreed<br>extension) | Duty of<br>Candour/<br>Being Open<br>policy<br>implemented  |
| StEIS 2017/<br>19060 | 31/07/2017                 | Surgery             | Grade 3 Pressure Ulcer - A 7 year old patient with a head injury sustained in a road traffic accident has a right sided below knee plaster of paris (POP) insitu. The patient has numerous abrasions from the accident including behind the right knee. The patient has now been confirmed as having a Grade 3 pressure ulcer behind the right knee thought to have been caused by friction from the plaster cast. | Kelly Black,<br>Surgical Matron               | Information gathered. RCA panel meeting being held 25/09/2017, following which RCA report is to be written.        | Yes   | Ongoing — numerous attempts made to contact family, which have been unsuccessful. Formal letter to be sent to family. |
| StEIS 2017/<br>18792 | 26/07/2017                 | Medicine            | Grade 3 Pressure Ulcer - Patient has nasopharyngeal airway (NPA) inserted into left nostril. Tissue Viability Nurse has reviewed and patient has a significant mucosal pressure ulcer to his left nostril.   | Anne Hyson,<br>Head of Quality                | RCA panel meeting held, draft report written. Report Quality checked 25 <sup>th</sup> September, submitted to CCG. | Yes   | Yes   |
| StEIS 2017/<br>18783 | 26/07/2017                 | Business<br>Support | Delay in letters to<br>GP's - Following a<br>Medisec update to   | Martin Levine,<br>Head of Clinical<br>Systems | Following completion of 72 hour review and investigation report,   | Yes   | N/A – No harm known.  |

Page 5 of 10

|                      |            |         | facilitate the switch to electronic letters, it was identified that a software bug was introduced that resulted in letters not being sent to two GP practices for a period of 3 months. Any letters associated to patients of these practices were also not sent.  No patient harm identified. |   | assurance provided that actions have been taken to mitigate the risk of reoccurrence. Liaised with CCG to agree to step this incident down from StEIS.   |     |   |
|----------------------|------------|---------|--|---|--|-----|---|
| 2017/<br>17986       | 17/07/2017 | Surgery | Unexpected death of cardiac patient.   | Rachael<br>Hanger, Theatre<br>Matron and<br>Adam Donne,<br>ENT Consultant | The baby's death was initially thought to be unexpected, and therefore reported to StEIS. Following review by clinical experts, it became apparent this was not an unexpected death. In view of that conclusion the team completed mortality reviews and a level 1 investigation. Liaised with CCG to agree to step this incident down from StEIS. | Yes | Verbal discussions have been held with the family. Duty of Candour letter not sent initially based on compassionate grounds. Following review, as patient's death was not unexpected, duty of candour not applicable. |
| StEIS 2017/<br>14196 | 02/06/2017 | Surgery | Delay in patient being reviewed. An unwell, query septic child was referred to the General Paediatric team for review by the Orthopaedic team. He had undergone  | Clinical Nurse<br>Manager ICU<br>and Sarah<br>Wood,<br>Consultant         | RCA panel meeting held 29/08/17. Draft RCA report written and submitted for quality check on 25 <sup>th</sup> September. Quality   | Yes | Yes   |

Page 6 of 10

| StEIS<br>2017/9937             | 12/04/2017 | Surgery   | bilateral hip surgery 5 days prior. He was referred as he was febrile and tachycardic. He was referred to the paediatric team around 6.30pm on 24/5/2017.  Sudden unexpected death – patient had adenotonsillectomy with subsequent deterioration, admitted to HDU, subsequent cardiac arrest and sadly died.  |                              | check completed on 25 <sup>th</sup> September, draft report returned to authors for further work to be completed.  Further work required to finalise report. Report going through quality approval stage. | Yes      | Yes  |
|--------------------------------|------------|-----------|--|------------------------------|---|----------|--|
| RCA 333<br>2016/17<br>Internal | 28/03/2017 | Community | Potential missed opportunity to diagnose - The patient was brought to ED in November 2016 as an emergency with seizures and hypertension. Despite resuscitation and intensive care she died 2 days later. Subsequent postmortem has revealed previously undiagnosed structural kidney disease which is the likely cause of the malignant hypertension. The child had presented to ED in June 2013 and October 2015 with a diagnosis of Bell's Palsy. Blood pressure should have been recorded on each of these occasions but | Amanda Turton,<br>ED Manager | Final draft report written, report going through quality approval stage.  | Internal | Being open completed, level of harm unknown. |

Page 7 of 10

|                                |            |           | was not recorded.  |              |  |                              |                         |
|--------------------------------|------------|-----------|--|--------------|--|------------------------------|-------------------------|
| RCA 332<br>2016/17<br>Internal | 28/03/2017 | Community | During a complaint investigation it became apparent that some elements of the child's inpatient stay had not been managed as robustly as they should have been. During the 4 days of the child's stay there were a number of times where his clinical condition and monitoring of vital signs triggered his PEWS score and required a review by a doctor - all required reviews do not appear to have taken place. | Senior Nurse | Final draft report written, report going through quality approval stage. | Being completed, of unknown. | open<br>, level<br>harm |

| On-going Safeguarding investigations |                                  |     |                      |                          |          |                           |                                     |
|--------------------------------------|----------------------------------|-----|----------------------|--------------------------|----------|---------------------------|-------------------------------------|
| Reference<br>Number                  | Date<br>investigation<br>started | CBU | Incident Description | RCA Lead<br>Investigator | Progress | 60 working day compliance | Being Open<br>policy<br>implemented |
| Nil                                  |                                  |     |                      |                          |          |                           |                                     |

| SIRI incidents closed since last report |                            |         |  |   |  |   |  |
|---|----------------------------|---------|--|---|--|---|--|
| Reference<br>Number                     | Date investigation started | CBU     | Incident Description   | RCA Lead<br>Investigator                    | Outcome  | Duty of Candour/Being open policy Implemented |  |
| StEIS 2017/<br>12813                    | 17/05/2017                 | Surgery | Grade 3 Pressure Ulcer - Acutely unwell patient stepped down from PICU to surgical ward. Patient was found to have a grade 2 pressure ulcer on left ear due to patient acuity and chest drain on right side. Limited options for repositioning, impacting on deterioration of pressure ulcer to grade 3. Parents fully informed of pressure ulcer and acknowledge seriousness of patient acuity. | Kelly Black,<br>Surgical Matron             | Final RCA report sent to CCG 11/09/17 and family 15/09/17.       | Yes   |  |
| StEIS 2017/<br>14923                    | 12/06/17                   | Surgery | Never Event — wrong site surgery. Patient admitted for elective procedures to both arms- right sided osteotomy and fixation, and left removal of plate. 2 scars present on left arm, plan was to remove plate via the scar on the underside of the arm however the scar on the topside of the arm was incised first.   | Neil Herbert –<br>Deputy Theatre<br>Manager | Final RCA report sent<br>to CCG 05/09/17 and<br>family 15/09/17. | Yes   |  |

# Safeguarding investigations closed since last report

Nil

# **Clinical Quality Assurance Committee**

Minutes of the last meeting held on Wednesday 19 July 2017 10.00 am, Large Meeting Room, Institute in the Park

Present: Anita Marsland (Chair) Non-Executive Director

Jeannie France-Hayhurst Non-Executive Director

Mags Barnaby Interim Chief Operating Officer

John Grinnell Director of Finance

Erica Saunders Director of Corporate Affairs
Glenna Smith General Manager – Medicine

Lachlan Stark Head of Planning and Performance

Mark Peers Public Governor Simon Hooker Public Governor

Catherine McLaughlin Director of Community Services
Cathy Umbers Associate Director of Nursing &

Governance

Jo Williams Non-Executive Director

Paul Newland Clinical Director for the Cancer &

Laboratory Medicine Care Group

Steve Ryan Medical Director Rob Griffiths Theatre Manager

Richard Cooke Director of Infection Prevention and

Control

Christian Duncan Director - Surgery

In Attendance

Karen Critchley Executive Assistant (Minutes)

# Agenda Item

17/18/24 Apologies:

Hilda Gwilliams Chief Nurse Melissa Swindell Director of HR

Joe Gibson Programme Director

17/18/25 Declaration of Interest

None declared

17/18/26 Minutes of the previous meeting held on 21 June 2017

Resolved:

CQAC approved the Minutes of the last meeting held on 21 June 2017.

17/18/27 Maters Arising and Action Log

**17/18/16** - **Visibility/Walkabout Process** – AM was disappointed that this programme was not yet in place. The previously agreed format for the visits, which would give teams the opportunity to showcase their services,

was reiterated. AM said that the programme must be in place by the end of August. CU said that diary pressures were challenging and asked for support in identifying dedicated time for this important activity. Feedback from the visits would be received by CQAC.

**17/18/16 – CQC Report** – ES said that the report had not yet been received but it was anticipated it would be available at the end of August.

**17/18/16 – Equality Issues** – It was noted that MS had met with Hannah Ainsworth. This item to remain on the action log awaiting an update from MS at the next meeting.

**17/18/16 – Quality Impact Assessment Position Statement –** To be shared with CQAC at next meeting on 16 August 2017.

**17/18/19 – Sepsis** – No update available on joint working with LCH. This to remain as an outstanding issue on the action log.

AM to review the action log outside of the meeting and to close those that had been completed.

# 17/18/28 CQC Action Plan

ES confirmed that whilst the CQC Inspection Team considered the Action Plan to be "live", most of the issues had been completed or were ongoing work. Audits had been undertaken and compliance rates of 90-100% had been demonstrated against most of the standards and areas.

Compliance with Mandatory Training – It was noted that MS would link with a colleague at LCH who had expertise in this area. It was anticipated that improvements to the ESR system would support improved reporting/monitoring. RG said that a task and finish group had been established to look at delivery of mandatory training. He agreed to provide an update to a future meeting.

<u>Transition of Care for Young People</u> – SR briefed CQAC on ongoing discussions taking place regarding the transition to adult services of a 22 year old in the care of Alder Hey.

# Resolved: The updated Action Plan was noted.

CQAC received and noted the CQC's consultation document on the next phase of regulation. Discussion ensued on how Alder Hey would fit within this framework. It was agreed that ES would ask MIAA to expand the soon to be undertaken Well-Led Review to look at the wider quality determinants. Any comments on the CQC's consultation document to be directed to ES for transmission to the CQC.

# 17/18/29 Sepsis Update

GS updated CQAC on the work being undertaken within the Sepsis and Best in Acute Care Work Streams. She reported that the target of 60 minutes or less for the identification of Sepsis in ED and start of treatment had been achieved and reported to CQC. She described the results of the audit of inpatient care, which identified the timeframe as being 90 minutes. The challenges of reviewing patients across the hospital and the IT elements were described. In order to improve this, the IM&T team were looking at how manual processes could be translated to electronic solutions. Should this not be possible, escalation would be instigated to Meditech and the issue would be included on the risk register. AM said that the Board must be assured that the timescales and targets set around Sepsis were being achieved.

**Resolved**: That by 1 September all issues preventing the achievement of the 60 minute timeframe for identification/commencement of treatment for Sepsis be resolved. At that point, any outstanding barriers to be escalated as appropriate and included on the Risk Register.

CQAC thanked RC for his contribution to the Trust and this Committee over the past three years and wished him well in his retirement. As it had not been possible to recruit a DIPC it was noted that SR would be assuming the role of Infection Control Doctor and Valya Weston. Had been appointed Associate DIPC. A revised JD for DIPC was being developed and it was anticipated that the post would be advertised in September.

# 17/18/30 Programme Assurance/Progress Update

MB said that the programme was on track with work in progress against some of the gaps.

The Committee noted that Deteriorating Patient Project was now rated green.

Work was progressing on the improving patient and staff experience in outpatient project but lots of elements were yet to be completed.

Best in Operative Care – SR confirmed that the PID would be available by the end of July and in advance of the next CQAC meeting. It was noted that elective surgery activity in June was just below 90% and below target. Non-elective activity was above target. Whilst there was currently a financial gap, there was confidence that this would be closed by focussing on activity levels and improved controls around pay spend. Pay spend would continue to be monitored by RABD but AM would ask HG to provide regular recruitment reports for CQAC.

LS updated on progress with the Winter Plan which was being developed drawing on experience from last year. It was anticipated that this would be completed by the end of July.

JG was confident that now a Programme Board had been established and was meeting monthly, there would be improvements across all areas.

LS said that in response to guidance from the CCG, a PID Review Group had been established and would ensure that QIAs are completed as part of the programme documentation for any proposals.

# 17/18/31 Corporate Report - Quality Metrics

CU briefed the Committee on the clinical incidents reported for May. She said that of the 150, the majority were low level harm, with 4 being moderate/serious. The report reflected the culture of openness around incident reporting. Other measures reported:

- Medication errors 7
- Pressure ulcers 7 Trust wide action plan in place
- Never Events 0
- Readmission to PICU 0
- Hospital Acquired Infections 3
- Readmissions of patients with long-term conditions within 28 days of discharge - 3
- Surgical patients discharged later than planned 107 an improvement against the position at the same time last year.
- Noted a decrease in the number of patients who would recommend the Trust
- Other areas requiring improvement availability of play resource and knowing planned date of discharge. These being addressed by Ward Managers. Recruitment of Play Lead is underway. MB said that planned date of discharge would be included as a quality metric in the Winter Plan. Kerry Morgan had also undertaken a detailed analysis around estimated date of discharge and her findings were being taken forward.

Whilst all of the above were below the target level, discussion ensued on the appropriateness of the quality metrics. JG suggested that a CQAC dashboard might be more meaningful. AM said she would welcome this approach.

**Resolved:** that LS would develop a bespoke CQAC dashboard for presentation, perhaps focussing a prototype/test on one area.

# 17/18/32 CQAC Terms of Reference

The Committee received the updated TOR. Discussion ensued on Membership and it was agreed that the following be included in the Membership:

- Head of Planning and Performance
- Clinical Director for the Cancer & Laboratory Medicine Care Group
- Heads of Quality (invitees)

Discussion ensued on how CQAC/the Board could be assured around service delivery within the Divisions. It was felt that this would evolve as divisions develop.

**Resolved:** To include members/invitees as noted above. Subject to that amendment the TOR were approved.

# 17/18/33 Board Assurance Framework

The Committee received the report. It was noted that the Matrons had now been recruited, with the exception of Critical Care.

# 17/18/34 Clinical Quality Steering Group – Key Issues Report

It was noted that 2 new serious incident action plans had been put in place (Surgical Division – inappropriate management of a deteriorating child; unexpected mortality and extravasation injury in elective orthopaedic patient). 41 actions on the SIRI action log remain overdue. Work was being undertaken with the divisions to resolve these issues quickly. CU said that she would be contacting the 3@Top within the divisions asking that this be given priority.

# 17/18/35 Any Other Business

Recruitment – the Committee discussed the impact on nurse recruitment of changes to nurse education. A workforce planning group would be looking at this. JF said that a potential source of nurse recruits might be Greece.

# 17/18/36 Date and Time of Next meeting

10.00 am - Wednesday 16 August 2017. (This might be subject to review).

# National Guidance on Learning from Deaths

A Framework for NHS Trusts and NHS Foundation Trusts on Identifying, Reporting, Investigating and Learning from Deaths in Care

**National Quality Board** 

First edition March 2017

# National Guidance on Learning from Deaths

# **Contents**

| 1. | 2. Executive Summary                      |  |    |  |  |  |  |  |
|----|---|--|----|--|--|--|--|--|
| 2. |   |  |    |  |  |  |  |  |
| 3. | 3. Chapter 1: Mortality Governance        |  |    |  |  |  |  |  |
| 4. | . Chapter 2: Bereaved Families and Carers |  |    |  |  |  |  |  |
| 5. | A   | nnexes   |    |  |  |  |  |  |
|    | 0   | Annex A: Board Leadership                                    | 21 |  |  |  |  |  |
|    | 0   | Annex B: Non-Executive Directors                             | 23 |  |  |  |  |  |
|    | 0   | Annex C: Responding to Deaths                                | 26 |  |  |  |  |  |
|    | 0   | Annex D: Learning Disabilities                               | 28 |  |  |  |  |  |
|    | 0   | Annex E: Mental Health                                       | 33 |  |  |  |  |  |
|    | 0   | Annex F: Children and Young People                           | 35 |  |  |  |  |  |
|    | 0   | Annex G: Maternity   | 46 |  |  |  |  |  |
|    | 0   | Annex H: Cross-system Reviews and Investigations             | 49 |  |  |  |  |  |
|    | 0   | Annex I: Roles and Responsibilities of National Bodies and   |    |  |  |  |  |  |
|    |   | Commissioners  | 52 |  |  |  |  |  |
|    | 0   | Annex J: Structured Judgement Review in Mental Health Trusts | 54 |  |  |  |  |  |
|    | 0   | Annex K: National Leads                                      | 56 |  |  |  |  |  |
|    | 0   | Annex L: Background and Links                                | 57 |  |  |  |  |  |

# **Foreword**

Following events in Mid Staffordshire, a review of 14 hospitals with the highest mortality noted that the focus on aggregate mortality rates was distracting Trust boards "from the very practical steps that can be taken to reduce genuinely avoidable deaths in our hospitals".

This was reinforced by the recent findings of the Care Quality Commission (CQC) report Learning, candour and accountability: A review of the way NHS trusts review and investigate the deaths of patients in England. It found that learning from deaths was not being given sufficient priority in some organisations and consequently valuable opportunities for improvements were being missed. The report also pointed out that there is more we can do to engage families and carers and to recognise their insights as a vital source of learning.

Understanding and tackling this issue will not be easy, but it is the right thing to do. There will be legitimate debates about deciding which deaths to review, how the reviews are conducted, the time and team resource required to do it properly, the degree of avoidability and how executive teams and boards should use the findings.

This first edition of *National Guidance on Learning from Deaths* aims to kickstart a national endeavour on this front. Its purpose is to help initiate a standardised approach, which will evolve as we learn. Following the Learning from Deaths conference on 21<sup>st</sup> March 2017 we will update this guidance to reflect the collective views of individuals and organisations to whom this guidance will apply to ensure that it is helpful.

Professor Sir Bruce Keogh

National Medical Director NHS England **Professor Sir Mike Richards** 

Chief Inspector of Hospitals
Care Quality Commission

Dr Kathy McLean

Executive Medical Director NHS Improvement

On behalf of the National Quality Board.

# **Executive Summary**

#### Introduction

- 1. For many people death under the care of the NHS is an inevitable outcome and they experience excellent care from the NHS in the months or years leading up to their death. However some patients experience poor quality provision resulting from multiple contributory factors, which often include poor leadership and system-wide failures. NHS staff work tirelessly under increasing pressures to deliver safe, high-quality healthcare. When mistakes happen, providers working with their partners need to do more to understand the causes. The purpose of reviews and investigations of deaths which problems in care might have contributed to is to learn in order to prevent recurrence. Reviews and investigations are only useful for learning purposes if their findings are shared and acted upon.
- 2. The following definitions apply for the purposes of this guidance:
- (i) Case record review: The application of a case record/note review to determine whether there were any problems in the care provided to the patient who died in order to learn from what happened, for example Structured Judgement Review delivered by the Royal College of Physicians.
- (ii) Investigation: The act or process of investigating; a systematic analysis of what happened, how it happened and why. This draws on evidence, including physical evidence, witness accounts, policies, procedures, guidance, good practice and observation in order to identify the problems in care or service delivery that preceded an incident to understand how and why it occurred. The process aims to identify what may need to change in service provision in order to reduce the risk of future occurrence of similar events.
- (iii) Death due to a problem in care: A death that has been clinically assessed using a recognised methodology of case record/note review and determined more likely than not to have resulted from problems in healthcare and therefore to have been potentially avoidable.

# Governance and Capability

Learning from a review of the care provided to patients who die should be integral to a
provider's clinical governance and quality improvement work. To fulfil the standards and
new reporting set out in this guidance for acute, mental health and community NHS
Trusts and Foundation Trusts, Trusts should ensure their governance arrangements

and processes include, facilitate and give due focus to the review, investigation and reporting of deaths, including those deaths that are determined more likely than not to have resulted from problems in care. Trusts should also ensure that they share and act upon any learning derived from these processes. The standards expected of Trust boards are set out at Annex A including having an existing executive director take responsibility for the learning from deaths agenda and an existing non-executive director take responsibility for oversight of progress. Guidance for non-executive directors is at Annex B.

- 4. Providers should review and, if necessary, enhance skills and training to support this agenda. Providers need to ensure that staff reporting deaths have appropriate skills through specialist training and protected time under their contracted hours to review and investigate deaths to a high standard.
- 5. Providers should have a clear policy for engagement with bereaved families and carers, including giving them the opportunity to raise questions or share concerns in relation to the quality of care received by their loved one. Providers should make it a priority to work more closely with bereaved families and carers and ensure that a consistent level of timely, meaningful and compassionate support and engagement is delivered and assured at every stage, from notification of the death to an investigation report and its lessons learned and actions taken.

#### Improved Data Collection and Reporting

6. The following minimum requirements are being introduced to complement providers' current approaches in relation to reporting and reviewing deaths:

# A. POLICY ON RESPONDING TO DEATHS

- Each Trust should publish an updated policy by September 2017 on how it responds to, and learns from, deaths of patients who die under its management and care, including:
  - i. How its processes respond to the death of an individual with a **learning disability** (Annex D) or **mental health needs** (Annex E), **an infant or child death** (Annex F) and a **stillbirth or maternal death** (Annex G).
  - ii. The Trust's approach to undertaking case record reviews. Acute Trusts should use an evidence-based methodology for reviewing the quality of care provided to those patients who die. The Structured Judgement Review (SJR)

case note methodology is one such approach and a programme to provide training in this methodology for acute Trusts will be delivered by the Royal College of Physicians over the coming year (the current version of the SJR approach is available at <a href="https://www.rcplondon.ac.uk/projects/outputs/national-mortality-case-record-review-nmcrr-programme-resources">https://www.rcplondon.ac.uk/projects/outputs/national-mortality-case-record-review-nmcrr-programme-resources</a> Other approaches also exist, such as those based on the PRISM methodology. Methods like SJR were not developed for mental health and community Trusts but can be used as a starting point and adapted by these providers to reflect their individual service user and clinical circumstances. <a href="Annex J">Annex J</a> provides a case study of how SJR is being adapted for mental health Trusts. Case record reviews of deaths of people with learning disabilities by acute, mental health and community Trusts should adopt the methodology developed by the Learning Disabilities Mortality Review (LeDeR) programme in those regions where the programme is available (details of the programme are available from <a href="Annex D">Annex D</a>).

iii. Cate gories and selection of deaths in scope for case record review: As a minimum and from the outset, Trusts should focus reviews on in-patient deaths in line with the criteria specified at paragraph 14(ii). In particular contexts, and as these processes become more established, Trusts should include cases of people who had been an in-patient but had died within 30 days of leaving hospital. Mental Health Trusts and Community Trusts will want to carefully consider which categories of outpatient and/or community patient are within scope for review taking a proportionate approach. The rationale for the scope selected by Trusts will need to be published and open to scrutiny.

# B. <u>DATA COLLECTION AND REPORTING</u>

• From April 2017, Trusts will be required to collect and publish on a quarterly basis specified information on deaths. This should be through a paper and an agenda item to a public Board meeting in each quarter to set out the Trust's policy and approach (by the end of Q2) and publication of the data and learning points (from Q3 onwards). This data should include the total number of the Trust's in-patient deaths (including Emergency Department deaths for acute Trusts) and those deaths that the Trust has subjected to case record review. Of these deaths subjected to review, Trusts will need to provide estimates of how many deaths were judged more likely than not to have been due to problems in care. The dashboard provided with this guidance shows what data needs to be collected and a suggested format for publishing the information,

- accompanied by relevant qualitative information and interpretation.
- Changes to the Quality Accounts regulations will require that the data
  providers publish be summarised in Quality Accounts from June 2018
  (Annex L), including evidence of learning and action as a result of this information
  and an assessment of the impact of actions that a provider has taken.

# **Further Developments**

- 7. In 2017-18, further developments will include:
  - The Care Quality Commission will strengthen its assessment of providers learning from deaths including the management and processes to review and investigate deaths and engage families and carers in relation to these processes.
  - NHS England, led by the Chief Nursing Officer, will develop guidance for bereaved families and carers. This will support standards already set for local services within the Duty of Candour<sup>1</sup> and the Serious Incident Framework<sup>2</sup> and cover how families should be engaged in investigations. Health Education England will review training of doctors and nurses on engaging with bereaved families and carers.
  - Acute Trusts will receive training to use the Royal College of Physicians'
     Structured Judgement Review case note methodology. Health Education England and the Healthcare Safety Investigation Branch (Annex L) will engage with system partners, families and carers and staff to understand broader training needs and to develop approaches so that NHS staff can undertake good quality investigations of deaths.
  - NHS Digital is assessing how to facilitate the development of provider systems and processes so that providers know when a patient dies and information from reviews and investigations can be collected in standardised way.
  - The Department of Health is exploring proposals to improve the way complaints involving serious incidents are handled particularly how providers and the wider care system may better capture necessary learning from these incidents<sup>3</sup>.

<sup>&</sup>lt;sup>1</sup> Further information is available from:

http://www.cqc.org.uk/sites/default/files/20141120 doc fppf final nhs provider guidance v1-0.pdf https://improvement.phs.uk/resources/serious-incident-framework/

https://improvement.nhs.uk/resources/serious-incident-framework/

This follows the Parliamentary and Health Service Ombudsman's report *Learning from Mistakes* (July 2016) and the Public Administration and Constitutional Affairs Committee hearings on this report.

# **Chapter 1 - Mortality Governance**

#### Context

- 8. In December 2016, the Care Quality Commission (CQC) published its review Learning, candour and accountability: A review of the way NHS trusts review and investigate the deaths of patients in England. The CQC found that none of the Trusts they contacted were able to demonstrate best practice across every aspect of identifying, reviewing and investigating deaths and ensuring that learning is implemented.
- 9. The Secretary of State for Health accepted the report's recommendations and in a Parliamentary statement<sup>4</sup> made a range of commitments to improve how Trusts learn from reviewing the care provided to patients who die. This includes regular publication of specified information on deaths, including those that are assessed as more likely than not to have been due to problems in care, and evidence of learning and action that is happening as a consequence of that information in Quality Accounts from June 2018.

# Accountability

- 10. Mortality governance should be a key priority for Trust boards. Executives and non-executive directors should have the capability and capacity to understand the issues affecting mortality in their Trust and provide necessary challenge.
- 11. This *National Guidance on Learning from Deaths* should be read alongside the *Serious Incident Framework*. Trust boards are accountable for ensuring compliance with both these frameworks. They should work towards achieving the highest standards in mortality governance. However, different organisations will have different starting points in relation to this agenda and it will take time for all Trusts to meet such standards. Over time this guidance is likely to be updated to include wider providers of NHS care and whole healthcare systems.

# Responding to Deaths

- 12. Each Trust should have a policy in place that sets out how it responds to the deaths of patients who die under its management and care. The standards expected of Trusts are set out at Annex C.
- 13. Boards should take a systematic approach to the issue of potentially avoidable mortality and have robust mortality governance processes. This will allow them to identify any areas of

<sup>&</sup>lt;sup>4</sup> https://www.gov.uk/government/speeches/cgc-review-of-deaths-of-nhs-patients]

failure of clinical care and ensure the delivery of safe care. This should include a mortality surveillance group with multi-disciplinary and multi-professional membership, regular mortality reporting to the Board at the public section of the meeting with data suitably anonymised, and outputs of the mortality governance process including investigations of deaths being communicated to frontline clinical staff.

# Death Certification, Case Record Review and Investigation

- 14. There are three levels of scrutiny that a provider can apply to the care provided to someone who dies; (i) death certification; (ii) case record review; and (iii) investigation. They do not need to be initiated sequentially and an investigation may be initiated at any point, whether or not a case record review has been undertaken (though a case record review will inform the information gathering phase of an investigation together with interviews, observations and evidence from other sources). For example, the apparent suicide of an in-patient would lead to a Serious Incident investigation being immediately instigated in advance of death certification or any case record review. The three processes are summarised below:
- (i) Death Certification: In the existing system of death certification in England, deaths by natural causes are certified by the attending doctor. Doctors are encouraged to report any death to the coroner that they cannot readily certify as being due to natural causes. Reforms to death certification, when implemented in England (and Wales), will result in all deaths being either scrutinised by a Medical Examiner or investigated by the Coroner in prescribed circumstances. Additionally, Medical examiners will be mandated to give bereaved relatives a chance to express any concerns and to refer to the coroner any deaths appearing to involve serious lapses in clinical governance or patient safety.
- (ii) Case Record Review: Some deaths should be subject to further review by the provider, looking at the care provided to the deceased as recorded in their case records in order to identify any learning. At a minimum, providers should require reviews of:
- all deaths where be reaved families and carers, or staff, have raised a significant concern about the quality of care provision;
- ii. all in-patient, out-patient and community patient deaths of those with **learning disabilities** (the LeDeR review process outlined at <u>Annex D</u> should be adopted in
  those regions where the programme is available otherwise Structured Judgement
  Review or another robust and evidence-based methodology should be used) and

#### with severe mental illness;

- iii. all deaths in a service specialty, particular diagnosis or treatment group where an 'alarm' has been raised with the provider through whatever means (for example via a Summary Hospital-level Mortality Indicator or other elevated mortality alert, concerns raised by audit work, concerns raised by the CQC or another regulator);
- iv. all deaths in areas where people are **not expected to die**, for example in relevant elective procedures;
- v. deaths where **learning will inform the provider's existing or planned improvement work**, for example if work is planned on improving sepsis care,
  relevant deaths should be reviewed, as determined by the provider. To maximise
  learning, such deaths could be reviewed thematically;
- vi. a further sample of other deaths that do not fit the identified categories so that providers can take an overview of where learning and improvement is needed most overall. This does not have to be a random sample, and could use practical sampling strategies such as taking a selection of deaths from each weekday.

The above minimum requirements are additional to existing requirements for providers to undertake specific routes of reporting, review or investigations for specific groups of patient deaths, such as deaths of patients detained under the Mental Health Act 1983 (Annex E).

Providers should review a case record review following any linked inquest and issue of a "Regulation 28 Report on Action to Prevent Future Deaths" in order to examine the effectiveness of their own review process.

Providers should apply rigorous judgement to the need for deaths to be subject to a Serious Incident reporting and investigation. For example, there may be instances where deaths clearly meet Serious Incident criteria and should be reported as such (whether or not a case record review has already been undertaken). Equally, problems identified in case record review may lead to the need for investigation whether this is an investigation under the Serious Incident Framework or other framework/procedure (see section iii)

(iii) Investigation: Providers may decide that some deaths warrant an investigation and should be guided by the circumstances for investigation in the Serious Incident Framework.

Some deaths will be investigated by other agents, notably the coroner. Indeed, the coroner has a duty to investigate any death where there are grounds to suspect that the death may have been avoidable. While care should be taken not to compromise such investigations, equally waiting until other investigations are completed may cause unacceptable delay. A good working relationship and close communication are needed to avoid problems.

Providers should review an investigation they undertake following any linked inquest and issue of a "Regulation 28 Report to Prevent Future Deaths" in order to examine the effectiveness of their own investigation process. If an inquest identifies problems in healthcare, providers may need to undertake additional investigation and improvement action, regardless of the coroner's verdict.

# Consistency and Judgement in Case Record Review

- 15. All Trusts currently undertake some form of mortality review. However there is considerable variation in terms of methodology, scope, data capture and analysis, and contribution to learning and improvement. To generate learning for improvement in healthcare, clinicians and staff should engage in robust processes of retrospective case record review to help identify if a death was more likely than not to have been contributed to by problems of care.
- 16. The Structured Judgement Review (SJR) case note methodology is an approach being rolled out by the Royal College of Physicians. Other methodologies exist and Trusts may already be using them. Trusts need to be assured that the methodology they are using is robust and evidence-based, that it will generate the information they are now being required to publish and that their staff are trained and given sufficient time and resources to undertake case record reviews and act on what they learn.
- 17. Case record review assessment is finely balanced and subject to significant inter-reviewer variation. It does not support comparison between organisations and should not be used to make external judgements about the quality of care provided.
- 18. The judgement of whether a problem may have contributed to a death requires careful review of the care that was provided against the care that would have been expected at the time of death. Research has shown that when case record review identifies a death that may have been caused by problems in care, that death tends to be due to a series of problems none of which would be likely to have caused the death in isolation but which in

combination can contribute to the death of a patient<sup>56</sup>. Some of these elements of care are likely to have occurred prior to the admission and providers should support other organisations, for example in primary care, to understand and act on areas where care could be improved.

19. Trusts should acknowledge and cooperate with separate arrangements for the review (and where appropriate investigation) of certain categories of deaths, for example suicides, homicides, and child and maternal deaths.

### Objectivity in Case Record Review

20. To ensure objectivity, case record reviews should wherever possible be conducted by clinicians other than those directly involved in the care of the deceased. If the specific clinical expertise required only resides with those who were involved in the care of the deceased, the review process should still involve clinicians who were not involved in order to provide peer challenge. Objectivity of reviews should be a component of clinical governance processes. Providers may wish to consider if their review processes should additionally be the responsibility of a designated non-executive director who could do this by chairing the relevant clinical governance committee.

# Investigations

21. This National Guidance on Learning from Deaths and the Serious Incident Framework are complementary. This guidance sets out what deaths should be subject to case record review (paragraph 14(ii)), which is inevitably a wider definition than deaths that constitute Serious Incidents. Equally, when a death meets Serious Incident criteria there is no need to delay the onset of investigation until case record review has been undertaken. A review of records will inevitably be undertaken as part of an investigation process. However, immediate action to secure additional information and evidence to support full investigation should not be lost due an inappropriate requirement for all deaths (regardless of nature) to first undergo a case record review.

<sup>&</sup>lt;sup>5</sup> Hogan et al. Preventable deaths due to problems in care in English acute hospitals: a retrospective case record review study. *BMJ Qual Saf2012*: 21: 737-45.

<sup>&</sup>lt;sup>6</sup> Hogan et al. Avoidability of hospital deaths and association with hospital-wide mortality ratios: a retrospective case record *BMJ* 2015; 351:h3239.

22. Inquiries by the coroner<sup>7</sup> and investigations by providers are conducted to understand the cause of death and contributing factors. However provider investigations are not conducted to hold any individual or organisation to account. Other processes exist for that purpose including criminal or civil proceedings, disciplinary procedures, employment law and systems of service and professional regulation, including the General Medical Council and the Care Quality Commission. In circumstances where the actions of other agencies are required then those agencies must be appropriately informed and relevant protocols must be followed.

#### Medical Examiners

23. The introduction of the Medical Examiner role will provide further clarity about which deaths should be reviewed. Medical Examiners will be able to refer the death of any patient for review by the most appropriate provider organisation(s) and this new mechanism should ensure a systematic approach to selecting deaths for review, regardless of the setting or type of care provided in the period before a patient's death. NHS Improvement and the Department of Health are commissioning research to explore whether Medical Examiners are best placed to select which deaths need further review and ensure they do not inadvertently miss or over-refer certain types of cases. Prior to the implementation of the Medical Examiner system, Trusts are advised to allow for any doctors undertaking the certification of death to refer cases for case record review to the most relevant organisation.

# Learning

- 24. Providers should have systems for deriving learning from reviews and investigations and acting on this learning. The learning should be shared with other services across the wider health economy where they believe this would benefit future patients, including independent healthcare services and social care services. Recommendations within any "Regulation 28 Report on Action to Prevent Future Deaths" from the coroner should also be integral to a provider's systems to support learning within and across their organisation and local system partners.
- 25. Regardless of whether the care provided to a patient who dies is examined using case record review or an investigation, the findings should be part of, and feed into, robust clinical governance processes and structures. The findings should be considered alongside

<sup>&</sup>lt;sup>7</sup> Coroner investigations, A short guide (February 2014) is available from: https://www.gov.uk/government/publications/guide-to-coroner-services-and-coroner-investigations-a-short-guide

- other information and data including complaints, clinical audit information, mortality data, patient safety incident reports and data and outcomes measures etc. to inform the Trust's wider strategic plans and safety priorities.
- 26. Where case record review identifies a problem in care that meets the definition of a patient safety incident (any unintended or unexpected incident which could have or did lead to harm to one or more patients receiving NHS care) then this should be reported via local risk management systems to the National Reporting and Learning System (NRLS).
- 27. All patient safety incidents reported as resulting in death or severe harm to a patient are clinically reviewed by the National Patient Safety Team at NHS Improvement to determine if there are implications for national learning and if a response is appropriate. Any deaths that are identified via case record review as due to problems in healthcare would meet the criteria for NRLS reporting. More information on the national process is available at <a href="https://improvement.nhs.uk/resources/patient-safety-alerts">https://improvement.nhs.uk/resources/patient-safety-alerts</a>. All serious incidents that relate to patients should be reported to the NRLS for the same reason.

# Cross-system Reviews and Investigations

28. In many circumstances more than one organisation is involved in the care of any patient who dies. Guidance in relation to cross-system reviews and investigations is at Annex H.

#### Roles and Responsibilities of National Bodies and Commissioners

29. Guidance is provided at Annex I. The lead roles with overall responsibility for the learning from deaths programme at each of the relevant national organisation are provided at Annex K.

# **Chapter 2 - Bereaved Families and Carers**

# **Key Principles**

30. Providers should engage meaningfully and compassionately with bereaved families and carers in relation to all stages of responding to a death and operate according to the following key principles below.

#### BEREAVED FAMILIES AND CARERS - KEY PRINCIPLES:

- bereaved families and carers should be treated as equal partners following a bereavement;
- bereaved families and carers must always receive a clear, honest,
   compassionate and sensitive response in a sympathetic environment;
- bereaved families and carers should receive a high standard of bereavement
  care which respects confidentiality, values, culture and beliefs, including being
  offered appropriate support. This includes providing, offering or directing people to
  specialist suicide bereavement support;
- bereaved families and carers should be informed of their right to raise concerns about the quality of care provided to their loved one;
- bereaved families' and carers' views should help to inform decisions about whether a review or investigation is needed;
- bereaved families and carers should receive timely, responsive contact and support in all aspects of an investigation process, with a single point of contact and liaison;
- bereaved families and carers should be partners in an investigation to the extent, and at whichever stages, that they wish to be involved, as they offer a unique and equally valid source of information and evidence that can better inform investigations;
- bereaved families and carers who have experienced the investigation process should be supported to work in partnership with Trusts in delivering training for staff in supporting family and carer involvement where they want to.

# Context

31. Dealing respectfully, sensitively and compassionately with families and carers of dying or deceased patients within the NHS is crucially important. The principles of openness, honesty, and transparency as set out in the Duty of Candour should also be applied by

- providers in all their dealings with bereaved families and carers. Yet the Care Quality Commission's report *Learning*, *candour* and *accountability* identified that NHS providers are continuing to fail too many bereaved families and carers of those who die whilst in their care.
- 32. When a patient dies under the management and care of a Trust, bereaved families and carers should be informed immediately after the death. People who are bereaved need others to recognise and acknowledge their loss. Recognition by professionals, appropriately expressed, may be particularly valued. Communication at the time of a death, and afterwards, should be clear, sensitive and honest. Bereaved families and carers should be given as much information as possible in line with the Duty of Candour for providers. Every effort should be made to hold these discussions in a private, sympathetic environment, without interruptions. Providers should ensure that their staff, including family liaison officers where available, have the necessary skills, expertise and knowledge to engage with bereaved families and carers. This includes recognising and dealing with common issues such as family members feeling guilty about their loss.
- 33. All too often the terms of the conversation people have with the NHS about a concern or complaint are set by the organisation. Organisations can often be too quick to dismiss or explain away concerns, compounding the grief of bereaved families and carers with obfuscation and a lack of openness. Paying close attention to what bereaved families and carers say can offer an invaluable source of insight to improve clinical practice. Listening to them goes hand in hand with the Duty of Candour. In particular, bereaved families and carers should be asked if they had concerns about the quality of care received by the deceased to inform decisions about the need to undertake a case record review or investigation.
- 34. When reviewing or investigating possible problems with care, involvement of bereaved families and carers begins with a genuine apology. Saying sorry is not an admission of liability and is the right thing to do. The appropriate staff member should be identified for each case, including to explain what went wrong promptly, fully and compassionately. This may include clinicians involved in the case but this may not always be appropriate and should be considered on a case by case basis.
- 35. Depending on the nature of the death, it may be necessary for several organisations to make contact with those affected. This should be discussed with the bereaved families and carers and a co-ordinated approach should be agreed with them and the

- organisations involved. If other patients and service users are involved or affected by the death they should be offered the appropriate level of support and involvement.
- 36. The provider should ensure that the deceased person's General Practitioner is informed of the death and provided with details of the death as stated in the medical certificate at the same time as the family or carers. The GP should be informed of the outcome of any investigation.

#### **Bereavement Support**

- 37. Bereavement can influence every aspect of well-being. Providers should offer a bereavement service for families and carers of people who die under their management and care (including offering or directing people to suicide bereavement support) that offers a caring and empathetic service at a time of great distress and sadness. This includes offering support, information and guidance. This should include bereavement advisors to help families and carers through the practical aspects following the death of a loved one such as:
  - arranging completion of all documentation, including medical certificates;
  - · the collection of personal belongings;
  - post mortem advice and counselling;
  - · deaths referred to the coroner;
  - emotional support, including counselling;
  - collection of the doctor's Medical Certificate of Cause of Death and information about registering a death at the Registrar's Office;
  - details of the doctor's Medical Certificate of Case of Death (this is needed to register a death at the Registrar's Office).

#### 38. The following should also be considered:

- timely access to an advocate (independent of the Trust) with necessary skills for working with bereaved and traumatised individuals;
- support with transport, disability, and language needs;
- support during and following an investigation. This may include counselling or signposting to suitable organisations that can provide bereavement or post-traumatic stress counselling, with attention paid to the needs of young family members, especially siblings;

 further meetings with the organisations involved or support in liaising with other agencies such as the police.

#### Review

- 39. If the care of a patient who has died is selected for case record review providers should:
  - have formed that decision based on the views of the family and carers. Providers should require reviews in cases where family and carers have raised a significant concern about the quality of care provision (paragraph 14 (ii)(i));
  - communicate to the family and carers the findings of the review if any problems with care are identified and any lessons the review has contributed for the future.

#### Investigations

- 40. If a provider feels that an investigation into a death is needed, early contact should have been made with bereaved families and carers so that their views helped to inform the decision.
- 41. Bereaved families and carers will expect to know: what happened; how; to the extent possible at the time, why it happened; and what can be done to stop it happening again to someone else. If a provider proceeds with an investigation, skilled and trained investigators need to be able to explain to bereaved families and carers the purpose of the investigation which is to understand what happened. If problems are identified, the investigation should be clear why and how these happened so that action can be taken to prevent the same mistakes from occurring again.
- 42. Provided the family or carer is willing to be engaged with regarding the investigation, an early meeting should be held to explain the process, how they can be informed of progress, what support processes have been put in place and what they can expect from the investigation. This should set out realistic timescales and outcomes. There should be a named person as a consistent link for the families and carers throughout the investigation, for example a family liaison officer.
- 43. Bereaved families and carers should:
  - be made aware, in person and in writing, as soon as possible of the purpose, rationale and process of the investigation to be held;

- be asked for their preferences as to how and when they contribute to the process of the investigation and be kept fully and regularly informed, in a way that they have agreed, of the process of the investigation;
- have the opportunity to express any further concerns and questions and be offered a response where possible, with information about when further responses will be provided;
- have a single point of contact to provide timely updates, including any delays, the
  findings of the investigation and factual interim findings. This may disclose
  confidential personal information for which consent has been obtained, or where
  patient confidentiality is overridden in the public interest. This should be considered
  by the organisation's Caldicott Guardian and confirmed by legal advice in relation to
  each case:
- have an opportunity to be involved in setting any terms of reference for the investigation
  which describe what will be included in the process and be given expectations about the
  timescales for the investigation including the likely completion date;
- be provided with any terms of reference to ensure their questions can be reflected and be given a clear explanation if they feel this is not the case;
- have an opportunity to respond on the findings and recommendations outlined in any final report; and,
- be informed not only of the outcome of the investigation but what processes have changed and what other lessons the investigation has contributed for the future.

### **Guidance**

- 44. NHS England will develop guidance for bereaved families and carers, identifying good practice for local services on the information that families say they would find helpful. It will cover what families can expect by way of local support in relation to investigations and what to expect when services have identified the death as complex or needing an independent investigation so potentially involving longer timeframes and multiple agency involvement.
- 45. Public Health England has published guidance which provides advice to local authorities and the NHS on developing and providing suicide bereavement support<sup>8</sup>.

https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/590838/support\_after\_a\_suicide.pdf

<sup>8</sup> 

# **Annexes**

# **Annex A - Board Leadership**

#### **BOARD LEADERSHIP - KEY POINTS**

The board should ensure that their organisation:

- has an existing board-level leader acting as patient safety director to take responsibility for the learning from deaths agenda and an existing non-executive director to take oversight of progress;
- pays particular attention to the care of patients with a learning disability or mental health needs;
- has a systematic approach to identifying those deaths requiring review and selecting other patients whose care they will review;
- adopts a robust and effective methodology for case record reviews of all selected
  deaths (including engagement with the LeDeR programme) to identify any concerns or
  lapses in care likely to have contributed to, or caused, a death and possible areas for
  improvement, with the outcome documented;
- ensures case record reviews and investigations are carried out to a high quality, acknowledging the primary role of system factors within or beyond the organisation rather than individual errors in the problems that generally occur;
- ensures that mortality reporting in relation to deaths, reviews, investigations and learning is regularly provided to the board in order that the executives remain aware and non-executives can provide appropriate challenge. The reporting should be discussed at the public section of the board level with data suitably anonymised;
- ensures that learning from reviews and investigations is acted on to sustainably change clinical and organisational practice and improve care, and reported in annual Quality Accounts;
- **shares relevant learning** across the organisation and with other services where the insight gained could be useful;
- ensures sufficient numbers of nominated staff have appropriate skills through specialist training and protected time as part of their contracted hours to review and investigate deaths;
- offers timely, compassionate and meaningful engagement with bereaved families and carers in relation to all stages of responding to a death;
- acknowledges that an **independent investigation** (commissioned and delivered entirely separately from the organisation(s) involved in caring for the patient) may in

- some circumstances be warranted, for example, in cases where it will be difficult for an organisation to conduct an objective investigation due to its size or the capacity and capability of the individuals involved; and,
- works with commissioners to review and improve their respective local
  approaches following the death of people receiving care from their services.
   Commissioners should use information from providers from across all deaths, including
  serious incidents, mortality reviews and other monitoring, to inform their commissioning
  of services. This should include looking at approaches by providers to involving
  bereaved families and carers and using information from the actions identified following
  reviews and investigations to inform quality improvement and contracts etc.

# **Annex B - Non-Executive Directors**

# Context

- 1. The board of directors of an NHS Trust or Foundation Trust is collectively responsible for ensuring the quality and safety of healthcare services delivered by the Trust, and in the case of a Foundation Trust taking into consideration the views of the board of governors.
- 2. Boards must ensure robust systems are in place for recognising, reporting, reviewing or investigating deaths and learning from avoidable deaths that are contributed to by lapses in care. Providers should ensure such activities are adequately resourced. Commissioners are accountable for quality assuring the robustness of providers' systems so that providers develop and implement effective actions to reduce the risk of avoidable deaths, including improvements when problems in the delivery of care within and between providers are identified.
- 3. All Trust directors, executive and non-executive, have a responsibility to constructively challenge the decisions of the board and help develop proposals on strategy. Non-executive directors, in particular, have a duty to ensure that such challenge is made. They play a crucial role in bringing an independent perspective to the boardroom and should scrutinise the performance of the provider's management in meeting agreed goals and objectives and monitor the reporting of performance. Non-executive directors should satisfy themselves as to the integrity of financial, clinical and other information, and that clinical quality controls and systems of risk management, for example, are robust and defensible.

#### Learning from Deaths

- 4. Executive and non-executive directors have a key role in ensuring their provider is learning from problems in healthcare identified through reviewing or investigating deaths by ensuring that:
  - the processes their organisation have in place are robust, focus on learning and can withstand external scrutiny, by providing challenge and support;
  - quality improvement becomes and remains the purpose of the exercise, by championing and supporting learning, leading to meaningful and effective actions that improve patient safety and experience, and supporting cultural change; and

- the information the provider publishes is a fair and accurate reflection of its achievements and challenges.
- 5. From April 2017, providers will start to collect and publish new data to monitor trends in deaths. Alongside this, they will need to establish an ongoing learning process. Board oversight of this process is as important as board oversight of the data itself. As a critical friend, non-executive directors should hold their organisation to account for its approach and attitude to patient safety and experience, and learning from all deaths, particularly those assessed as having been avoidable. The roles and responsibilities of non-executive directors include:
  - i. Understand the process: ensure the processes in place are robust and can withstand external scrutiny, by providing challenge and support. For example:
    - be curious about the accuracy of data and understand how it is generated; who is generating it, how are they doing this, is the approach consistent across the Trust, are they sufficiently senior/experienced/trained?
    - seek similar data and trend information from peer providers, to help challenge
      potential for improvements in your own organisation's processes, but understand
      limitations of any direct comparisons;
    - ensure timely reviews/investigations (what is the interval between death and review or investigation?), calibre of reviewer/investigator and quality of the review or investigation;
    - is the Care Record Review process objective, conducted by clinicians not directly involved in the care of the deceased?
    - how was the case-record review selection done? For example, does selection reflect the evidence base which suggests older patients who die or those where death may be expected are no less likely to have experienced problems in healthcare that are associated with potentially preventable death? Does it ensure all vulnerable patient groups (not just those with learning disabilities or mental health needs) are not disadvantaged?
    - are deaths of people with learning disabilities reviewed according to the LeDeR methodology?
    - for coordination of responses to reviews/investigations through the provider's clinical governance processes, who is responsible for preparing the report, do problems in care identified as being likely to have contributed to a death feed into the organisation's Serious Incident processes?

# ii. Champion and support learning and quality improvement such as:

- ensuring the organisation has a long-term vision and strategy for learning and improvement and is actively working towards this;
- understanding the learning being generated, including from where deaths may be expected but the quality of care could have been better;
- understanding how the learning from things going wrong is translated into sustainable effective action that measurably reduces the risks to patients ensuring that learning and improvements are reported to the board and relevant providers;
- supporting any changes in clinical practice that are needed to improve care resulting from this learning;
- ensuring families and carers are involved reviews and investigations, and that nominated staff have adequate training and protected time to undertake these processes;
- paying attention to the provision of best practice and how the learning from this can be more broadly implemented.

# iii. Assure published information; ensure that information published is a fair and accurate reflection of the provider's achievements and challenges, such as:

- ensuring that information presented in board papers is fit for publication i.e. it is meaningful, accurate, timely, proportionate and supports improvement;
- checking that relevant team are working towards a timely quarterly publication, in line with the Quality Accounts regulations and guidance;
- checking that arrangements are in place to invite, gather and act on stakeholder feedback on a quarter by quarter basis;
- ensuring the organisation can demonstrate to stakeholders that "this is what we said we would do, and this is what we did" (learning and action), and explain the impact of the quality improvement actions.

# **Annex C - Responding to Deaths**

Trusts should have a policy in place that sets out how they respond to the deaths of patients who die under their management and care.

#### POLICY FOR RESPONDING TO DEATHS - KEY POINTS

The policy should include how providers:

- determine which patients are considered to be under their care and included for case record review if they die (it should also state which patients are specifically excluded);
- report the death within the organisation and to other organisations who may
  have an interest (including the deceased person's GP), including how they
  determine which other organisations should be informed;
- respond to the death of an individual with a learning disability (<u>Annex D</u>) or mental health needs (<u>Annex E</u>), an infant or child death (<u>Annex F</u>) and a stillbirth or maternal death (<u>Annex G</u>) and the provider's processes to support such deaths;
- review the care provided to patients who they do not consider to have been under their care at the time of death but where another organisation suggests that the Trust should review the care provided to the patient in the past;
- review the care provided to patients whose death may have been expected, for example those receiving end of life care;
- record the outcome of their decision whether or not to review or investigate the
  death, which should have been informed by the views of bereaved families and
  carers;
- engage meaningfully and compassionately with bereaved families and carers this should include informing the family/carers if the provider intends to review or
  investigate the care provided to the patient. In the case of an investigation, this
  should include details of how families/carers will be involved to the extent that they
  wish to be involved. Initial contact with families/carers are often managed by the
  clinicians responsible for the care of the patient. Given that providers must offer
  families/carers the opportunity to express concerns about the care given to patients
  who have died, then the involvement of clinicians who cared for the patient may be
  considered a barrier to raising concerns. Providers should therefore offer other routes
  for doing this;
- offer guidance, where appropriate, on obtaining legal advice for families,

carers or staff. This should include clear expectations that the reasons, purpose and involvement of any lawyers by providers will be communicated clearly from the outset, preferably by the clinical team, so families and carers understand the reasons and are also offered an opportunity to have their own advocates.

# **Annex D - Learning Disabilities**

# Context

- 1. Since the 1990s, there have been a number of reports and case studies which have consistently highlighted, that in England, people with learning disabilities die younger than people without learning disabilities. The Confidential Inquiry of 2010-2013 into premature deaths of people with learning disabilities (CIPOLD) reported that for every one person in the general population who died from a cause of death amenable to good quality care, three people with learning disabilities would do so<sup>9</sup>. Overall, people with learning disabilities currently have a life expectancy at least 15 to 20 years shorter than other people <sup>10</sup>.
- 2. A concerning finding from CIPOLD was that assumptions were sometimes made that the death of a person with learning disabilities was 'expected' or even inevitable, because that person had learning disabilities. As with the CQC report of 2016<sup>11</sup>, CIPOLD also identified deaths that should have been, but were not, reported to mandatory review processes, including safeguarding reviews and to the coroner.
- 3. The lives of people with learning disabilities often involve a complex array of service provision with multiple care and support staff. If we are to improve service provision for people with learning disabilities and their families, and reduce premature deaths, we need to look wider than NHS-related circumstances leading to a person's death, in order to identify the wider range of potentially avoidable contributory factors to their death. A cross-sector approach to reviewing deaths of people with learning disabilities is imperative; one that includes families, primary and secondary healthcare, and social and third sector care providers. Such a balanced approach across acute and other settings is needed from the outset of a review process, in order to accurately determine if there are any concerns about the death, or to identify examples of best practice that could lead to service improvement.

<sup>&</sup>lt;sup>9</sup> Heslop P, Blair P, Fleming P, Hoghton M, Marriott A, Needleman D, Russ L. (2013) Confidential Inquiry into premature deaths of people with learning disabilities. Bristol: University of Bristol.

<sup>&</sup>lt;sup>10</sup> Glover G,et al, 2017. Williams R. Heslop P, Oyinlola J, Grey J. (2016) Mortality in people with intellectual disabilities in England. *Journal of Intellectual Disabilities Research, 61, 1, 62-74; Health and Care of People with Learning Disabilities, 2014-15, NHS Digital, 9 December 2016.* 

<sup>&</sup>lt;sup>11</sup> Learning, candour and accountability: A review of the way NHS Trusts review and investigate the deaths of patients in England, Care Quality Commission December 2016.

- 4. There is unequivocal evidence that demands additional scrutiny be placed on the deaths of people with learning disabilities across all settings. This work has already been started by the Learning Disabilities Mortality Review (LeDeR) programme, commissioned by Healthcare Quality Improvement Partnership (HQUIP) for NHS England. Once fully rolled out, the programme will receive notification of all deaths of people with learning disabilities, and support local areas to conduct standardised, independent reviews following the deaths of people with learning disabilities aged 4 to 74 years of age. These will be conducted by trained reviewers.
- 5. The purpose of the local reviews of death is to identify any potentially avoidable factors that may have contributed to the person's death and to develop plans of action that individually or in combination, will guide necessary changes in health and social care services in order to reduce premature deaths of people with learning disabilities.

# Scope

- 6. A conceptual definition of learning disabilities is used in the Learning Disabilities White Paper 'Valuing People' 12 (2001).
- 7. At present, NHS England is working with NHS Digital to explore the options and potential of 'flagging' the records of people with learning disabilities on the NHS Spine <sup>13</sup>. Over time, this could provide an access point for identifying that a person who has died had learning disabilities.
- 8. The LeDeR programme currently supports local reviews of deaths of people with learning disabilities aged 4 years and over. The lower age limit is set at 4 years of age because before that age, it can be difficult to be sure that a child has learning disabilities as defined above.

### Operationalising Mortality Reviews of People with Learning Disabilities

9. The LeDeR programme has an established and well-tested methodology for reviewing the deaths of people with learning disabilities.

<sup>&</sup>lt;sup>12</sup> Valuing People: A New Strategy for Learning Disability for the 21st Century, Department of Health, 2001. LeDeR briefing paper.

<sup>&</sup>lt;sup>13</sup> Spine supports the IT infrastructure for health and social care in England, joining together over 23,000 healthcare IT systems in 20,500 organisations.

# Current process



- 10. All deaths of people with learning disabilities are notified to the programme. Those meeting the inclusion criteria for mortality review receive an initial review of their death by an independent, trained reviewer.
- 11. The standardised review process involves discussing the circumstances leading up to the person's death with someone who knew them well (including family members wherever possible), and scrutinising at least one set of relevant case notes. Taking a cross-agency approach, the reviewer develops a pen portrait of the individual and a comprehensive timeline of the circumstances leading to their death, identifies any best practice or potential areas of concern, and makes a decision, in conjunction with others if necessary, about whether a multi-agency review is indicated.
- 12. A full multi-agency review is required if the criteria for the current themed priority review are met (death of a person from a Black and Minority Ethnic background or aged 18-24), or where an assessment of the care received by the person indicates deficiencies in one or more significant areas. A full multi-agency review is recommended if there have been any concerns raised about the death, if any 'red flag alerts' have been identified in the initial review, or if the reviewer thinks that a full multi-agency review would be appropriate. The purpose of the multi-agency review is to gain further learning which will contribute to improving practice and service provision for people with learning disabilities, so the review process concludes with an agreed action plan and recommendations that are fed back to the regional governance structures for the programme.

<sup>&</sup>lt;sup>14</sup> 'Red flag' alerts are those identified in the initial review that may suggest potential problems with the provision of care e.g. no evidence that an assessment of mental capacity has been considered when this would have been appropriate; delays in the person's care or treatment that adversely affected their health.

- 13. The LeDeR programme currently operates independently of, but communicates and cooperates with, other review and investigatory processes. This enables an integrated approach to initial reviews of deaths of people with learning disabilities to be taken whenever possible, so as to avoid unnecessary duplication but ensure that the specific focus of the different review or investigation processes is maintained.
- 14. Alignment of LeDeR with SJR for example will enable a balanced approach to be taken to reviewing deaths of people with learning disabilities that draws on contributions from across acute and other settings. Deaths of people with learning disabilities that occur in hospital settings should be subject to the LeDeR review process in order that insights from families, primary and secondary healthcare, and social and third sector care providers are all included in the mortality review.
- 15. The LeDeR programme provide annual reports on its findings, collating learning and recommendations at the regional and national level on how best to take forward the learnings across the NHS.
- 16. Because of the different methodology adopted by the LeDeR programme, it would not be appropriate to use the same definition of 'avoidable death' as used by the SJR, nor to compare rates of avoidable deaths across and between the two review processes. The LeDeR programme will continue to use the Child Death Review Process terminology of 'potentially avoidable contributory causes of death' and the Office for National Statistics definition of avoidable deaths using ICD-10 coding of the underlying cause of death <sup>15</sup>.

#### Integration of the LeDeR Process into National Level Mortality Review Structures

17. When a death of a person with learning disabilities occurs, mandatory review processes need to take precedence, working with the LeDeR programme reviewers to ensure that a coordinated approach is taken to the review of the death in order to minimise duplication and bring in the learning disabilities expertise of the LeDeR reviewers, whilst recognising that some investigatory processes will be more focused than that of LeDeR which is cross-agency in nature and may require the provision of additional information.

<sup>&</sup>lt;sup>15</sup> Office for National Statistics (2016) Revised Definition of Avoidable Mortality and New Definition for Children and Young People.

https://www.ons.gov.uk/aboutus/whatwedo/statistics/consultationsandsurveys/allconsultationsandsurveys/reviewofavoidablemortalitydefinition

18. Learning and recommendations from LeDeR reviews will identify opportunities for improvement at the local, regional and national level. Governance structures that can support the cross-agency implementation of recommendations from mortality reviews are required at all levels, but in particular for the reviews of deaths of people with learning disabilities. Such structures exist in the form of regional steering groups for the LeDeR programme, and these are usually best placed within the safeguarding framework. Not all deaths of people with learning disabilities are safeguarding issues; however the existing multi-agency framework and statutory responsibility mean that this is a natural 'home' for governance of mortality reviews.

#### **Guidance for Providers**

#### 19. Key points to note are:

- All deaths of people with learning disabilities aged four years and older are subject to review using LeDeR methodology;
- The LeDeR programme is currently being rolled out across England. Full coverage is anticipated in all Regions by the end of 2017. If there is a death of a person with learning disabilities in an acute setting in an area that is not yet covered by the LeDeR programme, Trusts are recommended to use the SJR process or a methodology of equivalent quality that meets the requirements for the data that must be collected as an interim measure:
- If a Trust wishes to complete its own internal mortality review, it is recommended that
  it uses the LeDeR initial review process and documentation available at:
   <a href="http://www.bristol.ac.uk/media-library/sites/sps/leder/Initial%20Review%20Template%20version%201.2.pdf">http://www.bristol.ac.uk/media-library/sites/sps/leder/Initial%20Review%20Template%20version%201.2.pdf</a> The
  provider can then submit that as an attachment to the LeDeR notification web-based
  platform once their internal review is completed;
- Once the LeDeR review has been completed, a copy will be sent to the relevant governance body at the Trust where the death occurred;
- Trusts are encouraged to identify appropriate personnel to undertake LeDeR training and review processes. Reviewers would be expected to conduct reviews independent of the Trust in which they work.

# **Annex E - Mental Health**

- Physical and mental health are closely linked. People with severe and prolonged mental illness are at risk of dying on average 15 to 20 years earlier than other people<sup>16</sup>. In addition, people with long term physical illnesses suffer more complications if they also develop mental health problems.
- 2. Reporting and reviewing of any death of a patient with mental health problems should consider these factors i.e. premature death of those with a mental disorder and the increased risk of complications for those with physical and mental health difficulties.

# Inpatients detained under Mental Health Act

- 3. Regulations<sup>17</sup> require mental health providers to ensure that any death of a patient detained under the Mental Health Act (1983) is reported to the Care Quality Commission without delay. In 2015, the Care Quality Commission reported concern that providers were failing to make this notification in 45% of cases. The Commission has since updated its notifications protocols to ensure that providers ensure they report in a timely way.
- 4. Under the Coroners and Justice Act 2009, coroners must conduct an inquest into a death that has taken place in state detention, and this includes deaths of people subject to the Mental Health Act. Providers are also required to ensure that there is an appropriate investigation into the death of a patient in state detention under the Mental Health Act (1983).
- 5. In circumstances where there is reason to believe the death may have been due, or in part due to, to problems in care including suspected self-inflicted death then the death must be reported to the provider's commissioner(s) as a serious incident and investigated appropriately. Consideration should also be given to commissioning an independent investigation as detailed in the Serious Incident Framework.

# People with Mental Health Disorders in Prisons

6. Evidence shows that there is a high incidence of mental health problems in prisons: 72% of adult male and 71% of female prisoners may have 2 or more mental disorders (e.g.

<sup>&</sup>lt;sup>16</sup> The Five Year Forward View For Mental Health (NHS England, 2016) is available at: <a href="https://www.england.nhs.uk/wp-content/.../Mental-Health-Taskforce-FYFV-final.pdf">https://www.england.nhs.uk/wp-content/.../Mental-Health-Taskforce-FYFV-final.pdf</a>

<sup>&</sup>lt;sup>17</sup> Regulation 17, Care Quality Commission (Registration) Regulations 2009

personality disorder, psychosis, anxiety and depression, substance misuse); 20% have 4 or more mental disorders.

- 7. There have been large increases in the number of natural and non-natural deaths in prisons over the most recent five-year reporting period. The increase in recent years in non-natural deaths in prisons are due to a number of factors. Prisons contain a high proportion of vulnerable individuals, many of whom have experienced negative life events that increase the likelihood of suicide or self-harm. Issues that increase risk include drug/alcohol abuse, family background, social disadvantage or isolation, previous sexual or physical abuse, and mental health problems. The increase in part reflects an ageing prison population. Prisons are also very challenging environments particularly so for those prisoners who have a learning disability. Average estimates of prevalence of learning disabilities amongst adult offenders in the UK is thought to be between 2-10%. This figure is much higher for children who offend 18. Prisoners with learning disabilities are also more likely than other prisoners to suffer mental ill health. As such, the mental wellbeing of prisoners with learning disabilities should be a key consideration for healthcare staff of NHS providers along with all other prison staff.
- 8. The Serious Incident Framework states that in prison and police custody, any death will be referred (by the relevant organisation) to the Prison and Probation Ombudsman (PPO) or the Independent Police Complaints Commission (IPCC) who are responsible for carrying out the relevant investigations. Healthcare providers must fully support these investigations where required to do so. The PPO has clear expectations in relation to health involvement in PPO investigations into death in custody. Guidance published by the PPO 19 must be followed by those involved in the delivery and commissioning of NHS funded care within settings covered by the PPO.

<sup>&</sup>lt;sup>18</sup> Equal Access Equal Care, Guidance for Prison Healthcare Staff treating Patients with Learning Disabilities (2015) available at <a href="https://www.england.nhs.uk/.../equal-access-equal-care-guidance-patients-ld.pdf">https://www.england.nhs.uk/.../equal-access-equal-care-guidance-patients-ld.pdf</a>

<sup>&</sup>lt;sup>19</sup> Guidance is available online: http://www.ppo.gov.uk/updated-guidance-for-clinical-reviews/

# **Annex F - Children and Young People**

# Infant and Child Mortality

- 1. Over the last 20 years, the UK has gone from having one of the lowest mortality rates for 0 to 14 year olds in Europe to one of the highest<sup>1.</sup> In 2014, 4, 419 children and young people aged 0 to 18 years old died in England and Wales. 24% of deaths in children and young people are thought to be preventable<sup>2.</sup> In the year ending March 2016, 68% of all deaths occurred in hospital, 22% in the home, 4% in a public place, and 4% in a hospice. In the year ending March 2016, 32% of all deaths occurred following a perinatal or neonatal event, 26% in children with chromosomal, genetic and congenital anomalies, 8% in children with 'sudden unexpected and unexplained' death, 7% in children with malignancy, 6% in children with acute medical or surgical illnesses, 6% in children with infection, 5% in children suffering trauma, 3% in young people taking their life, and 2% following deliberately inflicted injury, abuse or neglect<sup>2</sup>.
- 2. In child mortality review, professionals have moved away from defining 'avoidability' to instead using the language of 'a preventable death' where the latter is defined as a death in which 'modifiable factors may have contributed to the death and which, by means of nationally or locally achievable interventions, could be modified to reduce the risk of future child deaths'<sup>3</sup>. In the year ending March 2016, 54% of deaths in hospital and 31% of death in the home were identified as having modifiable factors. Most modifiable factors are found in children dying from perinatal/neonatal events, followed by trauma, followed by those with chromosomal, genetic and congenital anomalies<sup>2</sup>.

# National Data on Causes of Death and International Comparisons<sup>4</sup>

3. The UK ranks 15 out of 19 Western European countries on infant (under one year of age) mortality and has one of the highest rates for children and young people in Western Europe<sup>5</sup>. There is a strong association between deprivation and mortality; for example infant mortality is more than twice as high in the lowest compared with the highest socioeconomic groups<sup>6</sup>.

# Infants (under 1 year)

4. Around 60% of deaths during childhood occur in infancy. Infant mortality can be split into neonatal mortality (deaths 0–27 days) and post-neonatal mortality (28–365 days). Births without signs of life (stillbirths if after 24 weeks of pregnancy) do not contribute to infant mortality but are also an important indicator of maternal and child health. The Infant

Mortality Rate (IMR) is an indicator of both population health and the quality of healthcare service. It is also a key international indicator in the United Nation's Sustainable Development Goals and in UNICEF international comparisons.

- 5. Neonatal mortality accounts for between 70% and 80% of infant deaths. The great majority of neonatal deaths are due to perinatal causes, particularly preterm birth, and are strongly related to maternal health, as well as congenital malformations. The remainder of infant deaths are post-neonatal and are due to a broad range of causes including sudden infant death syndrome (SIDS). Stillbirths (defined in the UK as a baby born without signs of life after 24 completed weeks of pregnancy) account for half of all deaths during the perinatal period. In 2014, the IMR across the UK was 3.9 deaths per 1,000 live births. Although there has been an overall decline in the IMR across the UK over the past 45 years, in recent years the reduction in infant mortality in the UK has not equalled the gains observed in comparable countries. An international study of mortality in the UK compared with similar wealthy countries in Europe and elsewhere showed the UK to have IMR in 1970 similar to the average of the group, but that the UK had become among the worst performing 10% by 2008<sup>7</sup>.
- 6. Social inequalities play a role in almost all the leading causes of infant death. The mechanisms underlying this social gradient are related to increased risk of preterm delivery in more deprived groups, as well as to maternal health during pregnancy (for example, smoking, poor nutrition, substance abuse) and uptake of recommended practices such as breastfeeding and safe infant sleeping positions<sup>8</sup>. Maternal age is also associated with infant mortality<sup>6</sup>. Many of the causes of infant mortality are preventable and necessitate actions at both a population and individual level<sup>9</sup>:
  - maximising the health and wellbeing of women before conception and during pregnancy (smoking cessation programmes, promotion of breastfeeding and promoting healthy weight in women of childbearing age)
  - protecting and supporting health promotion and early intervention services (universal midwifery and health visiting services for new mothers)
  - promoting evidence-based research into maternal and infant health, and translating findings into improved practice, standards of care, and ultimately policy
  - identifying best practice and reducing variations in outcomes across health care services

# Children (1-9 years)

- 7. The main factors that contribute to death during childhood are different to those that contribute to death during infancy or adolescence. The common causes of death amongst 1 to 9 year-olds are cancer, injuries and poisonings, congenital conditions and neurological and developmental disorders. Injuries and poisonings from external causes are the leading cause of death in boys aged one to four years, whilst cancer is the leading cause of death in girls of the same age<sup>5</sup>. For both girls and boys five to nine years of age, cancer is the leading cause of death. Very early life also still has an impact on mortality in later childhood; children who were born preterm remain more likely to die before age 10 years compared to children born at term.
- 8. In the period 2012-2014, the mortality rate in children aged 1-9 years in the U.K. was 12.1 per 100,000 population. Although the mortality rate has declined across the UK since the 1970s, the UK's recent progress has been significantly lower than in other wealthy European countries, and concerningly the incidence of death due to diseases such as asthma and diabetes is higher than equivalent high-income countries. The scale of difference between the UK child mortality rate and the average suggests there are around 130 excess deaths of 1- to 9-year-olds each year in the UK<sup>10</sup>.
- 9. Many childhood deaths are preventable. As with infants there is a strong association between deprivation, social inequality, and mortality. Causes amenable to interventions include environmental and social factors as well as health service factors and key actions include the following<sup>9</sup>:
  - creating safe environments, including access to information and safety equipment schemes to promote safety in the home;
  - reduce road speed limits in built-up areas to 20mph;
  - ensuring that clinical teams looking after children with long-term conditions such as
    asthma, epilepsy and diabetes deliver care to the highest standards, incorporating
    good communication, open access for patients and families, use of established tools
    such as the epilepsy passport and asthma plan, adherence to the components
    prevalent in the best practice tariff for diabetes, and address early the optimal
    conditions for safe transition to adult services. Implicit in this is teaching selfmanagement and ownership of the condition;
  - increasing the provision of high-quality end-of-life care and access to appropriate palliative care:

delivering integrated health systems across primary and secondary care; whilst
providing the optimal configuration of specialist services for children with complex
conditions needing tertiary care, such as cardiac, renal conditions and children's
cancer.

# Young People (10-19 years)

- 10. After the first year of life, adolescence is the life stage when children are most likely to die. The factors leading to death in adolescence are different to those in earlier childhood, and differ between males and females. The most common causes of death in this age group are injuries, violence and suicide, followed by cancer, substance misuse disorders and nervous system and developmental disorders.
- 11. Although the mortality rate in young people has decreased across the UK since the 1970s, progress recently has been slower than that seen in other wealthy countries<sup>10</sup>. The UK's 'average' adolescent overall mortality today is a mixed picture. Whilst our injury mortality rate is amongst the lowest, we have a higher rate of deaths due to 'non communicable diseases' such as asthma than other equivalent wealthy countries. Social inequalities are important since injury and illness are associated with poor environmental conditions and hazards such as smoking, alcohol, and drug use<sup>8</sup>.
- 12. Many deaths are preventable and key actions include9:
  - reducing deaths from traffic injuries through the introduction of graduated licensing schemes;
  - improving adolescent mental health services;
  - improving services for children with long term conditions, and especially those transitioning to adult care;
  - increasing the involvement of young people and their families with rare and common long-term conditions in developing guidelines, measuring outcomes, service design and research trials.
- 13. Underpinning all efforts to reduce child mortality in England lies an urgent need to collect high-quality data to better understand the reasons why children die, to allow accurate international comparisons, and to inform health policy. This requires a national system for the analysis of child mortality data, as well as improved child death review processes.

### Historical Background to the Process of Child Mortality Review

- 14. Since 1<sup>st</sup> April 2008, Local Safeguarding Children's Boards in England have had a statutory responsibility for Child Death Review (CDR) processes. The relevant legislation underpinning such responsibility is enshrined in the Children's Act 2004 and applies to all children under 18 years of age. The processes to be followed when a child dies are described in Chapter 5 of the statutory guidance document, *Working Together to Safeguard Children*<sup>11</sup>. The overarching purpose of child death review is to understand how and why children die, to put in place interventions to protect other children, and to prevent future deaths. *Working Together* describes two interrelated processes:
  - a "Rapid Response" multi-professional investigation of an individual unexpected death; and,
  - ii. a Child Death Overview Panel (CDOP) review of all deaths in a defined geographical area. The purpose of the CDOP is to establish the exact cause of death, identify patterns of death in community and remedial factors, and to contribute to improved forensic intelligence in suspicious deaths. The family should be kept central to the process.

# Drivers for Change including new Legislation

- 15. The review of child deaths has been, to date, far more comprehensive than that for adults. However the following drivers for change exist:
  - i. Variation in process. There is significant variation across the system in how child deaths are reviewed, which deaths are reviewed, and the quality of the review. Specifically:
    - 'unexpected' deaths in the community are generally reviewed as per the Sudden Unexpected Deaths in Infancy (SUDI) process. However there is variation in when a death is considered "unexpected" and in the timing of triggering investigations.
    - hospital deaths are usually reviewed at a Mortality and Morbidity (M&M) meeting.
      However there is wide variation, across the NHS, in how these meetings are
      convened, no standardisation on terminology, and a confused array of
      investigations (root cause analysis, serious incident inquiry, mortality review) that
      follow certain types of deaths.

- there is wide variation in CDOP processes (size, structure and functioning) and many CDOP panels are dislocated from governance processes within their local children's hospital.
- ii. The Wood Review<sup>12</sup>. In 2016, Alan Wood recommended that national responsibility for child death reviews should move from the Department for Education to the Department of Health, that DH should re-consider how CDOPs should best be supported within the new arrangements of the NHS, and that DH should determine how CDOPs might be better configured on a regional basis with sub-regional structures to promote learning. He also recommended that child deaths be reviewed over a population size that allowed a sufficient number of deaths to be analysed for patterns and themes. He went further to recommend that the NHS consider the role CDOPs should play in the process for achieving a common national standard for high quality serious incident investigations. Finally, he supported the intention to introduce a national child mortality database, and urged DH to expedite its introduction.
- iii. The National Adult Case Review programme<sup>13</sup>. This programme uses a very different structured judgment review (SJR) methodology to that used in child mortality review. It focuses on problems in heath care processes within an organization rather than trying to understand the cause of death. Cases in which care is judged to be poor are scored according to an 'Avoidability of Death' scale. It is important to recognise that many 16 and 17 year olds die in adult ITU's and therefore it is important to understand what processes should take precedence in the review of such patients.
- iv. Medical Examiner process. The Medical Examiner will be introduced across England. This appointee will link with bereaved families as well as the Coroner and their involvement will affect all mortality review processes.
- v. CQC report: Learning, Candour, and Accountability<sup>14</sup>. This report identified inconsistencies in: the involvement of families and carers; the process of identifying and reporting the death; how decisions to review or investigate a death was made; variation in the quality of reviews and investigations; and variation in the governance around processes and questionable demonstration of learning and actions.
- vi. Legislative change (Children and Social Work Bill 2017). The Wood Review recommendation that national responsibility for child death reviews should move from the Department for Education to the Department of Health is being enacted through

the Children and Social Work Bill 2017. Under the new legislation, local authorities and clinical commissioning groups are named as 'child death review partners' and must make arrangements for the review of each death of a child normally resident in the local authority area. They may also, if they consider it appropriate, make arrangements for the review of a death in their area of a child not normally resident there. The proposed legislation also states that the 'child death review partners' must make arrangements for the analysis of information about deaths reviewed and identify any matters relating to the death or deaths in that area a) relevant to the welfare of children in the area or to public health and safety and b) to consider whether it would be appropriate for anyone to take action in relation to any matters identified.

### National Child Mortality Programme

- 16. NHS England is undertaking a national review of child mortality review processes both in the hospital and community. A key aim is to make the process easier for families to navigate at a very difficult time in their life. Central to the programme is the creation of a National Child Mortality Database, which is currently being commissioned. The effective functioning of the national database requires high-quality, standardised data arising from simplified and standardised local mortality and CDOP review processes. NHS England have therefore established 3 work streams:
  - the simplification and standardisation of mortality review processes in the community and hospital;
  - a review of the governance arrangements and standardisation of CDOP processes;
  - the creation of the national child mortality database.
- 17. The goals of the NHS England's child mortality review programme are to:
  - establish, as far as possible, the cause or causes of each child's death;
  - identify any potential contributory or modifiable factors;
  - provide on-going support to the family;
  - ensure that all statutory obligations are met;
  - learn lessons in order to reduce the risk of future child deaths;
  - establish a robust evidence base to inform national policy across government to reduce avoidable child mortality across the UK nations.

18. NHS England, the Department of Health and the Department for Education are working together to produce new statutory guidance for child death review. This guidance will cover the processes which should take place following the death of a child, and in particular how the death should be reviewed at local mortality meeting and child death overview panel. This new guidance will be published in late 2017.

# Reporting

19. The definitions used within the adult Case Review programme for record review and to identify problems in care are not recognised within Working Together. NHS England's work programme intends to identify best practice and standardise processes across deaths in hospital and the community, to improve the experience of families and professionals. The deaths of children who are treated in acute, mental health and community NHS Trusts should be included by Trusts in quarterly reporting from April 2017. The information should come from child death review processes, and should include reporting problems related to service delivery.

#### **Board Leadership**

- 20. Hospital Trust, Local Authority, Community Trust, Mental Health Trusts, and CCG boards should ensure that learning is derived from the care provided to children who die, by the appropriate application of the child mortality review process, and that learning is shared and acted on.
- 21. Many of the points around board leadership relating to adult deaths (set out in the main body of this guidance) also apply for child deaths. For example, providers must ensure that they have a board-level leader designated as patient safety director to take responsibility for the learning from deaths agenda (Annex A) and he or she should also have specific responsibility for the learning from child mortality processes. The director should ensure that the reviews are delivered to a high quality, with sufficient numbers of trained staff to lead the child mortality review process.
- 22. Particular attention should be paid to the deaths of children and young people with learning disabilities or mental health conditions, as these present with frequent comorbidities and are often a more vulnerable group.
- 23. Providers should acknowledge that an independent investigation (one commissioned and delivered entirely separately from the organisation(s) involved in caring for the patient) may be required where the integrity of the investigation is likely to be challenged.

# Best Practice in responding to Death of a Child who dies under a Trust's Care

24. All Trusts should have a policy in place that sets out how they respond to the deaths of children who die under their care. In doing this they should be mindful of current expectations described within Working Together to Safeguard Children (2015) and of NHS England's current review of child mortality review processes. New statutory guidance on child death review will be published in late 2017.

# 25. That policy should also set out how Trusts:

- communicate with bereaved parents and carers. This should include providing an
  honest and compassionate account of the reasons for death and knowledge of any
  potential problems in care that may need further review, ensuring initial contacts are
  managed by clinicians responsible for the care of the patient, and offering support to
  express concerns about the care given to patients who have died;
- achieve independence (where relevant) and objectivity in the child mortality review process, as well as lay membership within wider clinical governance systems.

#### **Cross-system Reviews and Investigations**

26. When the death of a child involves treatment across the health care pathway (primary: secondary: tertiary care) it is expected that child mortality review processes will not be duplicated and that a single overarching meeting will be convened. Child mortality review processes should interface with existing organisational governance systems. The NHS England child death review programme is mindful of expectations arising from the Serious Incident Framework, which sets out the circumstances in which further investigation is warranted in certain situations. It is therefore anticipated that when a review identifies a problem in care that meets the definition of a patient safety incident (any unintended or unexpected incident which could have or did lead to harm to one or more patients receiving NHS care) then this is reported via local risk management systems to the National Reporting and Learning System (NRLS). Regardless of the type of review, its findings must form an integral part of and feed into the organisation's clinical governance processes and structures. Review findings should be considered alongside other information and data including complaints, clinical audit information, patient safety incident reports and other outcomes measures to inform the Trust's wider strategic plans and safety priorities.

#### **Bereaved Families and Carers**

- 27. Working Together places the family at the heart of its processes. However it is recognised that the multitude of investigations that may unfold following a child's death can cause great confusion and distress to parents. The national bereavement group and bereavement charities are closely involved with developing NHS England's child death review programme both in the co-design of systems and public guidance that explains processes.
- 28. The national Child Death Review programme recognises the following principles:
  - bereaved families and carers should be treated as equal partners both in the delivery of care and following a bereavement;
  - bereaved families and carers should receive a high standard of bereavement care, including being offered appropriate support;
  - bereaved families and carers must always receive an honest, caring and sensitive response;
  - bereaved families and carers should receive timely, responsive contact and support in all aspects of any review process, with a single point of contact and liaison.

#### Learning Disabilities and Mental Illness

29. NHS England's National Child Mortality Review programme fully recognises the unique challenge in reviewing the deaths of children with learning disabilities and mental health disorders. The Programme is working closely with the Learning and Disabilities Mortality Review (LeDeR) programme, and also aims to align itself with the Children and Young People's (CYP) Mental Health Programme and Specialised Commissioning particularly with regard to deaths in Tier 4 inpatient CAMHS Units. It will also work closely with the National Programme on Suicide in Young People. Going forward, the programme will ensure that there are appropriate mechanisms in place to allow data flows to occur unencumbered between all these systems and the national Child Mortality Database.

#### Conclusion

30. This section highlights the very different circumstances that pertain to the death of a child in acute, mental health and community organisations. Although infant and child mortality has declined in the UK, these improvements have not been sustained in comparison to other European countries. While poverty and inequality have a major impact on child mortality, we can nonetheless do much in front line service delivery to improve outcomes for children, and experiences for both bereaved parents and the professionals who deliver care. Sadly, deaths in childhood are often an inevitable consequence of congenital malformations, birth events, and long-term conditions or chronic illness. Many, however, have preventable factors, and there is therefore an absolute imperative to scrutinise all deaths both locally and nationally to ensure that learning always occurs.

31. NHS England is seeking to address this by establishing a National Child Mortality

Database to allow analysis and interpretation of child mortality data. The programme will

also seek to improve, standardise and simplify the processes that follow the death of a

child. This is predominantly to improve the experience of bereaved parents at such an

overwhelming time, but also to enable uniformly robust data collection, to ultimately lead

to a reduction in infant and child mortality in this country.

#### References

- 1. Viner RM, Hargreaves DS, Coffey C, Patton GC, Wolfe I. <u>Deaths in young people aged 0-24 years in the UK compared with the EU15+ countries, 1970-2008: analysis of the WHO Mortality Database.</u> Lancet. 2014 Sep 6;384 (9946):880-92
- 2. Department for Education. Child Death Reviews year ending 31<sup>st</sup> March 2016. Available from: <a href="https://www.gov.uk/government/statistics/child-death-reviews-year-ending-31-march-2016">https://www.gov.uk/government/statistics/child-death-reviews-year-ending-31-march-2016</a>
- 3. Government HM. Working Together to Safeguard Children. London. Department for Education. 2013
- 4. RCPCH. State of Child Health. Report 2017
- 5. Wolfe I, Donkin A, Marmot M et al. UK child survival in a European context: recommendations for a national countdown collaboration. Archives of Disease in Childhood. 2015
- 6. Office for National Statistics. Child Mortality in England and Wales: 2014; Available from: <a href="http://www.ons.gov.uk/peoplepopulation">http://www.ons.gov.uk/peoplepopulation</a>and
- community/birthsdeathsandmarriages/deaths/bulletins/childhoodinfantandperinatalmortalityinenglanda ndwales/2014
- 7. Eurostat.Infant mortality rate (tps00027). 2014. Available from: <a href="http://ec.europa.eu/eurostat/web/population-demography-migration-projections/deaths-life-expectancy-data//main-tables">http://ec.europa.eu/eurostat/web/population-demography-migration-projections/deaths-life-expectancy-data//main-tables</a>
- 8. Roberts J Bell R. Social inequalities in the leading causes of early death a life cause approach. 2015
- 9. Royal College of Paediatrics and Child Health, National Children's Bureau. A policy response to the report Why Children Die: deaths in infants, children, and young people in the UK (Part B). London. 2014 10. Viner RM, Hargreaves DS, Coffey C et al. Deaths in young people aged 0-24 years in the UK compared with the 15+ countries. 1970-2008. Analysis of the WHO mortality database. Lancet 2014: 384(9946): 880-892.\
- 11. Government HM. Working Together to Safeguard Children. London. Department for Education. A guide to inter-agency working to safeguard and promote the welfare of children. 2013
- 12. Government HM. Wood Report. Review of the role and functions of Local Safeguarding Children Boards. March 2016
- 13. Royal College of Physicians. National Mortality Case Record Review Programme. Oct 2016. Available at: <a href="https://www.rcplondon.ac.uk/projects/national-mortality-case-record-review-programme">https://www.rcplondon.ac.uk/projects/national-mortality-case-record-review-programme</a>
  14. Care Quality Commission. Learning, candour and accountability. 2016. Available at: <a href="https://www.cqc.org.uk/sites/default/files/20161213-learning-candour-accountability-full-report.pdf">https://www.cqc.org.uk/sites/default/files/20161213-learning-candour-accountability-full-report.pdf</a>

## **Annex G - Maternity**

- 1. In England, maternity care is generally safe and for the majority of women and their babies there is a good outcome. However, when things go wrong, the impact is devastating and has a profound effect on the parents, partners, siblings and extended family members.
- 2. Dr Bill Kirkup was tasked by the Secretary of State for Health to investigate and report on maternity services at Morecambe Bay NHS trust. The Report of the Morecambe Bay Investigation in 2015<sup>20</sup> highlighted a number of failures over a number of years at the Trust which resulted in poor care and the tragic deaths of mothers and babies. The report makes recommendations for mandatory reporting and investigation of serious incidents of maternal deaths, late and intrapartum stillbirths and unexpected neonatal deaths. It recommends a requirement that investigation of these incidents be subject to a standardised process, which includes input from and feedback to families, and independent, multidisciplinary peer review. In *Learning not Blaming*<sup>21</sup> the Government accepted this recommendation.
- 3. In October 2016, Safer maternity care: next steps towards the national maternity ambition was published setting out an action plan for the Government's vision for making NHS maternity services some of the safest in the world, by achieving the national ambition to halve the rates of stillbirths, neonatal deaths, brain injuries that occur during or soon after birth and maternal deaths, by 2030 with an interim measure of 20% by 2020. The plan details the actions needed at national and local level that build on the progress already made to improve the safety of maternity services.
- 4. Currently MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquires across the UK)<sup>22</sup>, appointed by Health Quality Improvement Partnership and funded by NHS England, run the national Maternal, Newborn and Infant

The report of the Morecambe Bay Investigation (March 2015): <a href="https://www.gov.uk/government/news/morecambe-bay-investigation-report-published">https://www.gov.uk/government/news/morecambe-bay-investigation-report-published</a>

The government response to the Freedom to Speak Up consultation, the Public Administration Select Committee report 'Investigating Clinical Incidents in the NHS', and the Morecambe Bay Investigation (July 2015).

<sup>&</sup>lt;sup>22</sup> 'MBRRACE-UK' is the <u>collaboration</u> appointed by the Healthcare Quality Improvement Partnership (<u>HQIP</u>) to continue the national programme of work investigating maternal deaths, stillbirths and infant deaths, including the Confidential Enquiry into Maternal Deaths (CEMD). The aim of the MBRRACE-UK <u>programme</u> is to provide robust information to support the delivery of safe, equitable, high quality, patient-centred maternal, newborn and infant health services.

Clinical Outcomes Review to conduct surveillance of all late fetal losses, stillbirths and neonatal deaths, biennial topic-specific confidential enquiries into aspects of stillbirth and neonatal death or serious neonatal morbidity and surveillance and confidential enquiries of all maternal deaths.

- 5. Surveillance reports on stillbirths and neonatal deaths are published annually. Reports on maternal deaths are published on a triennial basis, because the number of maternal deaths from individual causes is small, and thus three years' worth of data is required to identify consistent lessons learned for future care and to maintain anonymity and confidentiality.
- 6. A maternal death is defined internationally as a death of a woman during or up to six weeks (42 days) after the end of pregnancy (whether the pregnancy ended by termination, miscarriage or a birth, or was an ectopic pregnancy) through causes associated with, or exacerbated by, pregnancy. Deaths are subdivided on the basis of cause into: direct deaths, from pregnancy-specific causes such as preeclampsia; indirect deaths, from other medical conditions made worse by pregnancy such as cardiac disease; or coincidental deaths, where the cause is considered to be unrelated to pregnancy, such as road traffic accidents. Maternal deaths are very rare. The MBRRACE-UK report 'Saving Lives, Improving Mothers Care highlights that for 2012-14, the maternal death rate was 8.5 per 100,000 women. Overall, 241<sup>23</sup> women among 2,341,745 maternities in 2012–14 died during or within 42 days of the end of pregnancy in the UK.
- 7. Better Births (2016)<sup>24</sup>, the report of the NHS England commissioned National Maternity Review, set out a five year forward view for improving outcomes of maternity services in England. The report highlighted the lack of a standard approach to investigating when things wrong during before, during or after labour: Reviews and investigation are currently undertaken using different protocols and processes by different organisations. The Report recommended there should be a national standardised investigation process for when things go wrong, to get to the bottom of what went wrong and why and how future services can be improved as a consequence. Work has now begun on the development of a Standardised Perinatal Mortality Review Tool that will enable maternity

<sup>&</sup>lt;sup>23</sup> Of these 41 deaths were classified as coincidental

<sup>&</sup>lt;sup>24</sup> https://www.england.nhs.uk/wp-content/.../02/national-maternity-review-report.pdf

- and neonatal services to systematically review and learn from every stillbirth and neonatal death in a standardised way.
- 8. Maternal deaths, neonatal deaths and stillbirths occurring in acute, mental health and community Trusts should be included by Trusts in quarterly reporting from April 2017.
- 9. It should be borne in mind that in addition to hospital obstetric units, maternal deaths can occur in a local midwifery facility (for example, a local midwifery unit or birth centre) or during home births. The definition also covers up to 42 days after the end of pregnancy.

# Annex H - Cross-system Reviews & Investigations

- 1. In many circumstances more than one organisation is involved in the care of any patient who dies, with the most common combinations being primary care and acute care, ambulances services and acute care, or mental health services combined with any of these. Case record reviews typically have to rely on the records held by a single organisation, but even these records can provide indications of possible problems in earlier stages of the patient pathway.
- 2. Where possible problems are identified relating to other organisations, it is important the relevant organisation is informed, so they can undertake any necessary investigation or improvement. Most trusts already have effective systems to notify other organisations when concerns are raised via incident reports, and are likely to be able to adapt these to address potential problems identified in case record review.
- 3. Trusts should consider whether they can routinely arrange joint case record reviews or investigations for groups of patients where more than one organisation is routinely providing care at the time of death for example, for older people with dementia and frailty receiving frequent input from their GP and from community mental health nurses. Commissioners have a role in encouraging appropriate routine collaboration on case record review.
- 4. Where the provision of care by multiple providers, and particularly the coordination of that care, is thought to have potentially contributed to the death of a patient, investing the significant resources required to coordinate major and complex investigations must be considered. For example, the Serious Incident Framework outlines the principles which underpin a serious incident investigation process and the relevant content is set out in paragraphs 5 to 10 below.
- 5. The organisation that declares the serious incident is responsible for recognising the need to alert other providers, commissioners and partner organisations as required in order to initiate discussions about subsequent action.

- 6. All organisations and agencies involved should work together to undertake one single investigation wherever this is possible and appropriate. Commissioners should help to facilitate discussions relating to who is the most appropriate organisation to take responsibility for co-ordinating the investigation process. Commissioners themselves should provide support in complex circumstances. For example, where no one provider organisation is best placed to assume responsibility for co-ordinating an investigation, the commissioner may lead this process. If commissioners do not have the capability or capacity to manage this type of activity this should be escalated to ensure appropriate resources are identified. This may be something to consider escalating through the relevant Quality Surveillance Group or through specific review panels and clinical networks. This should ensure the cumulative impact of problems with care can be resolved.
- 7. In some circumstances the local authority or another external body may be responsible for managing and co-ordinating an investigation process. Where this is the case, providers and commissioners must contribute appropriately and assure themselves that problems identified will be addressed.
- 8. Often in complex circumstances, separate investigations are completed by the different provider organisations. Where this is the case, organisations (providers and commissioners and external partners as required) must agree to consider cross boundary issues, such as gaps in the services that may lead to problems in care. The contributing factors and root causes of any problems identified must be fully explored in order to develop effective solutions to prevent recurrence. Those responsible for coordinating the investigation must ensure this takes place. This activity should culminate in the development of a single investigation report.
- 9. To determine oversight of an investigation, the RASCI (Responsible, Accountable, Supporting, Consulted, Informed) model supports the identification of a single 'lead commissioner' with responsibility for managing oversight of serious incidents within a particular provider. This means that a provider reports and engages with one single commissioning organisation who can then liaise with other commissioners as required. This approach is particularly useful where the 'accountable commissioner' is geographically remote from the provider (and therefore removed from other local systems and intelligence networks) and/or where multiple commissioners' commission services from the same provider. It facilitates continuity in the management of serious incidents, removes ambiguity and therefore the risk of serious incidents being

overlooked and reduces the likelihood of duplication where there is confusion regarding accountability and/or responsibility and general management of the serious incident process.

#### Healthcare Safety Investigation Branch

- 10. The Healthcare Safety Investigation Branch (HSIB) will provide capability at national level to offer support and guidance to NHS organisations on investigations, and to carry out up to 30 investigations itself per year where there is a deeper learning opportunity for the NHS. Through a combination of setting exemplary practice and structured support to others, the HSIB is expected to make a decisive difference to the NHS, promoting a culture of learning and a more supportive relationship with patients, families and staff.
- 11. Providers will benefit from the HSIB, and their expert advice on safety improvement. It should mean timely investigations, with a genuine commitment to openness, transparency and engagement with staff and patients and their families and carers that adopt an ethic of learning and continuous improvement. The HSIB will contribute strongly to the culture change that is needed in the NHS.

## **Annex I - Roles and Responsibilities of National Bodies and Commissioners**

- 1. Each national organisation will have a single lead at executive level who has accountability, internally and externally for that organisation's support of delivering against the national programme on learning from deaths. This will include ensuring progress is reported to the National Quality Board and ensuring that learning from deaths remains a priority area in future developments. A list of the lead roles for each national organisation is at <u>Annex K</u> and will be made available on each organisation's website.
- 2. As the independent regulator of health and social care, the Care Quality Commission will use this national guidance on learning from deaths to guide its monitoring, inspections and regulation of services. Inspectors will use new key lines of enquiry in relation to safety and governance, set out in the Care Quality Commission's assessment framework, to assess learning from deaths, collect evidence and identify good practice. Where specific concerns are identified, the Care Quality Commission can use its powers to take action with individual providers and will report its findings of good and poor progress in individual inspection reports or national publications to help encourage improvement.
- 3. NHS Improvement will continue to provide national guidance for managing serious incidents. Local processes setting out what deaths should be subject to case record review will inevitably use a wider definition than deaths that constitute Serious Incidents. Equally, when a death clearly meets Serious Incident criteria there is no need for an initial stage of case record review to be completed before work to initiate and support a full investigation is undertaken. Serious Incident guidance provides the framework upon which the Care Quality Commission and commissioners (including CCGs and NHS England) will assess the quality of investigations undertaken across the NHS. NHS Improvement will, alongside the Healthcare Safety Investigation Branch and others, support implementation of best practice in investigations by Trusts.
- 4. As the revised inspection regime of the Care Quality Commission will assess providers' ability to learn from deaths as a key component of high quality care, work to address this will be factored into NHS Improvement's work to support providers in achieving good or outstanding Care Quality Commission care ratings. Regional teams will work with

- providers, their commissioners and NHS England to identify areas where improvements can be made and the strategies which can help deliver the change required.
- 5. Nationally, NHS Improvement commissions (via the Healthcare Quality Improvement Partnership) the work of the Royal College of Physicians to develop and roll-out the Structured Judgement Review methodology, which will be providing a national training programme for acute Trusts to support them to carry out the methodology for adult inpatient deaths.
- 6. **NHS England** has a direct commissioning role as well as a role in leading and enabling the commissioning system. This national guidance on learning from deaths will guide its practice in both of these areas.
- 7. The National Institute for Health and Care Excellence (NICE) has produced best practice guidelines on the care of the dying, covering adults and children. These guidelines are supported by measurable quality standards that help Trusts demonstrate high quality care, and by information for the public describing the care that should be expected in the last days of life.

## Annex J - Structured Judgement Review in Mental Health Trusts

#### **Background**

Some mental health providers have seen a missed opportunity in not learning more
widely from deaths by reviewing the safety and quality of care of a wider group of people.
This is despite research showing that people with mental health problems have greater
health care needs than the general population and may suffer unnecessarily with
untreated or poorly managed long-term conditions.

#### Where Next - Making a Decision on the Review Method

- 2. Since 2014 hospitals in Yorkshire and the Humber have been working together with the AHSN Improvement Academy to refine a mortality review method called Structured Mortality Review (SJR), a method proposed for all acute hospitals in England. The acute sector methodology reviews phases of care appropriate to their settings, such as initial assessment and first 24 hours, care during a procedure, discharge/end of life care and assessment of care overall. Written explicit judgements of care and phase of care scores form the basis of the reviews. This now forms the basis of the national acute hospitals mortality review programme.
- 3. This methodology and review format was seen as potentially valuable by three regional Mental Health trusts and they have individually worked to create phase of care headings more appropriate to mental health care, with the support of the Improvement Academy and Professor Allen Hutchinson. These three trusts are at different stages of implementation. In the early adopter trust the tool was also adapted to include a pen picture to enable the reviewer to understand both the life and death of the person, considering this fundamental to understanding areas for learning that may include review of physical health and lifestyle choices. In the same trust this approach was used within Learning Disability services prior to the introduction of the Learning Disability Review of Deaths (LeDeR) programme. In another trust both the mental health care and community care facilities have been using the methods.

#### Introducing the Review Process

4. Just as with the acute services, future reviewers require initial training in how to make explicit judgements of the quality and safety of care and how to assess care scores for

- each phase of care. Assessments are made of both poor and good care and it is common to find that good care is far more frequent than poor care.
- 5. One of the findings from introducing the methods into mental health care is that many of the reviewers naturally have a focus on the mental health care component of the services. But review teams have found that using this review method they also identify common long-term conditions such as diabetes and heart disease that do not appear to have been well managed. For example, in one hospital it became evident that many people had a number of co-existing comorbid/long term conditions, yet it was unclear from the records whether or not the person was receiving support and or review from primary care and or secondary care services for their physical health. There is value, therefore, in also training up review staff who have an understanding of what good care looks like in long-term conditions within the context of mental health facilities.
- 6. Scoring of the phases of care is a new approach for many clinical staff in mental health care (just as has been the case in acute care) and scoring was initially felt to be very daunting by some reviewers. Nevertheless, as staff become more confident with its use, scoring can often be seen as a natural outcome of their judgements on the level of care provided. Some of the hospital teams have set up a mortality-reviewers support group to provide peer review and guidance. Feedback of the good care may be shared with both the individual staff and the wider teams this is often well received. Of course, concerns also have to be discussed with services to identify areas for improvement.

#### Where Next

- 7. The use of the structured judgement method often receives very positive feedback from staff trained in this methodology and so in one centre SJR is being rolled out for wider use to review the quality of care being received whilst people are currently receiving services. Looking forward, it has been recognised that whilst services can learn from each case, more can be learnt from the aggregation of cases, where patterns of poor care and good care emerge. In one case study that has sought for such patterns it is of note that where patterns exist of poorer care, these have been in the main linked to the management of physical ill health within mental health and learning disability services.
- 8. For further details please contact Allyson Kent <a href="mailto:allyson.kent@nhs.net">allyson.kent@nhs.net</a>, or Professor Allen Hutchinson <a href="mailto:allen.hutchinson@sheffield.ac.uk">allen.hutchinson@sheffield.ac.uk</a> Yorkshire and The Humber AHSN Improvement Academy.

## **Annex K - National Leads**

The list below provides the lead role with overall responsibility for the learning from deaths programme at relevant national organisations:

- NHS Improvement Executive Medical Director
- Care Quality Commission Chief Inspector of Hospitals
- Department of Health Director of Acute Care and Workforce
- NHS England National Medical Director

## **Annex L - Background and Links**

Learning Disabilities Mortality Review (LeDeR) programme

Background is available at http://www.bristol.ac.uk/sps/leder

#### **Quality Accounts**

Background is available at:

http://www.nhs.uk/aboutNHSChoices/professionals/healthandcareprofessionals/quality-accounts/Pages/about-quality-accounts.aspx

#### Healthcare Safety Investigation Branch

The new Healthcare Investigation Branch (HSIB) will offer support and guidance to NHS organisations on investigations, and carry out certain investigations itself. It is envisaged that the HSIB will be established to:

- i. generate investigation findings and recommendations which drive action on the reduction or prevention of incident recurrence;
- conduct investigations and produce reports that patients, families, carers and staff value, trust and respect; and,
- iii. champion good quality investigation across the NHS, and lead on approaches to enhance local capability in investigation.

The HSIB will be hosted by NHS Improvement and will undertake a small number of investigations annually. It will focus on incident types that signal systemic or apparently intractable risks in local healthcare systems. The HSIB and the role of Chief Investigator will play a crucial part in developing the culture of safety, learning and improvement in the NHS that will be one of the key elements of national policy and cross-system action in the years ahead.



## RM57 – HOSPITAL MORTALITY REVIEW POLICY

| Version:                     | 1   |
|------------------------------|---|
| Name of ratifying committee: | Clinical Quality Assurance Committee            |
| Date ratified:               | 20 <sup>th</sup> September 2017                 |
| Name of originator/author:   | Julie Grice, Chair of Hospital Mortality Review |
|                              | Group / Sarah Stephenson, Head of Quality       |
| Name of approval committee:  | Hospital Mortality Review Group                 |
| Date approved:               | 14 <sup>th</sup> September 2017                 |
| Executive Sponsor:           | Dr Steve Ryan, Medical Director                 |
| Key search words:            | Mortality, death, HMRG, review, M&M, Leder,     |
|                              | learning, disability,                           |
| Date issued:                 |   |
| Review date:                 | April 2018                                      |











### Quick Reference Guide – Hospital Mortality Review Policy

Please refer to the full policy for further guidance.

#### <u>Departmental Mortality Review (e.g. Trauma, Neonates, etc)</u>

Monthly Death Register (DR) received (usually 2<sup>nd</sup> week of the **Hospital Mortality** month) by HMRG Administrator Review Group Death Register (DR) reviewed every month for DR circulated by HMRG Administrator to any patients with Learning Disabilities Departmental Mortality Leads (DMLs) DMLs work with clinicians to identify patients Any patients with Learning Disabilities reported they had involvement with and will review on the LeDeR Database as soon as identified **HMRG Administrator assigns HMRG Reviewers** DMLs inform HMRG Administrator which within one month of receiving the DR Depts will be undertaking reviews within one month of receiving the DR HMRG Administrator informs the HMRG Reviewer of any completed Departmental Completed Departmental Mortality Review Mortality Review Forms for the patient they are forwarded to the Division's Head of Quality reviewing **Outcomes of Departmental Mortality Review** and associated action plan discussed and HMRG Administrator provides the HMRG approved by the relevant Division Risk and Reviewer with the relevant case notes, additional Governance Committee (standard monthly information (RCA's, Complaints, CDOP, etc) and agenda item) the Primary Review form Decision if further investigation and review (e.g. Completed HMRG Reviews forwarded to HMRG Root Cause Analysis) is required Administrator. DMLs invited to HMRG meeting. Completed Departmental Mortality Review HMRG meeting where completed HMRG Reviews Forms emailed to the HMRG Administrator are discussed along with any relevant within 2 months of patient's death Departmental Mortality Review Forms and associated action plans - within 4 months of patient's death Departmental Mortality Review action plans followed up **monthly** in the relevant Division Risk and Governance Meetings Decision if further investigation and review (e.g. Root Cause Analysis) is required HMRG feedback to DMLs within two weeks of the HMRG meeting with copy of the review **Quarterly report** to Clinical Quality Steering Group (CQSG) and Division Risk and Governance Meetings highlighting any identified actions, further investigations, lessons learnt, etc.

September 2017 Page 2 of 24

### **Version Control, Review and Amendment Logs**

| Version Control Table |                     |   |         |                        |  |  |
|-----------------------|---------------------|---|---------|------------------------|--|--|
| Version               | Version Date Author |   | Status  | Comment                |  |  |
| 1                     | Sept 2017           | Julie Grice, Chair of                   | Current | Guideline updated to a |  |  |
|                       |                     | Hospital Mortality                      |         | Policy                 |  |  |
|                       |                     | Review Group / Sarah                    |         | -                      |  |  |
|                       |                     | Stephenson, Head of                     |         |                        |  |  |
|                       |                     | Quality                                 |         |                        |  |  |
| -                     | October             | October Kent Thorburn Archived HMRG Gui |         | HMRG Guideline         |  |  |
|                       | 2013                | HMRG Chair                              |         |                        |  |  |

| Record of changes made to Hospital Mortality Review Policy – Version 1 |  |                             |  |  |  |  |  |  |
|--|--|-----------------------------|--|--|--|--|--|--|
| Section  | Section Page Change/s made Reason for change |                             |  |  |  |  |  |  |
| Number Number  |  |                             |  |  |  |  |  |  |
|  |  | Not applicable - New Policy |  |  |  |  |  |  |

September 2017 Page 3 of 24

#### Contents

| Sect       | <u>iion</u>                                    |  | Page |
|------------|--|--|------|
| 1          | Introduction                                   | <u>on</u>  | 5    |
| 2          | <u>Definitions</u>                             | <u> </u>   | 5    |
| 3          | <u>Duties</u>                                  |  | 6    |
| 4          | Conductin                                      | g HMRG Mortality Reviews                           | 8    |
| 5          | Learning [                                     | <u>Disabilities</u>                                | 9    |
| 6          | Concerns of families                           |  | 10   |
| 7          | <u>Learning Lessons from Mortality Reviews</u> |  | 11   |
| 8          | Monitoring                                     | 1  | 12   |
| 9          | Further Inf                                    | <u>formation</u>                                   | 12   |
| <u>App</u> | <u>endices</u>                                 |  |      |
| <u>App</u> | endix A  | Departmental Mortality Review Form                 | 14   |
| <u>App</u> | endix B  | Hospital Mortality Review Group (HMRG) Review Form | 17   |

September 2017 Page 4 of 24

#### 1 Introduction

- 1.1 The death of any patient is incredibly difficult for the patient's family and also the staff involved.
- 1.2 The Care Quality Commission's 'Learning, Candour and Accountability' (December 2016) and the National Quality Board's 'National Guidance on Learning from Deaths' in March 2017, require all NHS Trusts to implement processes to ensure learning from deaths is integral to the Trust's clinical governance and quality improvement work.
- 1.3 It is essential that learning from mortality reviews is both shared and acted upon.

#### 2 Definitions

- 2.1 <u>Departmental Mortality Leads (DMLs)</u> Nominated mortality lead for a team / department.
- 2.2 <u>Departmental Mortality Review</u> Review conducted at departmental level by the multidisciplinary team involved in the care of the patient. This can include mortality reviews for or by external bodies (e.g. Trauma mortality reviews, Neonatal mortality reviews).
- 2.3 <u>Hospital Mortality Review Group (HMRG)</u> Committee established by the Clinical Quality Assurance Committee (CQAC) to conduct independent high quality mortality reviews following the death of any hospital inpatients.
- 2.4 <u>Learning Disabilities Mortality Review (LeDeR) Programme</u> National programme delivered by the University of Bristol. It is commissioned by the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England. The LeDeR Programme was established to support local areas to review deaths of people with learning disabilities, and to use the lessons learned to make improvements to service provision.
- 2.5 Mortality Ratio Hospital Standardised Mortality Ratio (HSMR) is an indicator of healthcare quality that measures whether the number of deaths in a hospital is higher or lower than you would be expected in England. HSMR can be both a measure of safe, high-quality care and a warning sign that things are going wrong. HSMR is reported in the quarterly mortality report to Trust Board. The HSMR is the ratio of the observed number of in-hospital deaths divided by the number that is expected, and is based on 56 diagnoses. Although the scores are based on a basket of diagnoses that are more commonly found in adults, it allows a comparison of the performance of Alder Hey against other Trusts.
- 2.6 <u>Sequential Probability Ratio Test (SPRT)</u> SPRT can be used to monitor the performance of Paediatric Intensive Care Unit (PICU) services in such a way as to give early warning of potentially irregular results. SPRT charts display

September 2017 Page 5 of 24

an upper warning limit and an upper action limit to help identify whether mortality is occurring at a higher level than expected. If these limits are triggered, this suggests that mortality is occurring higher than expected, and the deaths should be investigated to determine whether they could have been prevented. SPRT is reported in the quarterly reports to the Trust Board.

- 2.7 <u>Death Register</u> Monthly report produced by the IM&T Department listing all inpatient deaths in the month.
- 2.8 <u>Child Death Overview Panels (CDOP)</u> Local Safeguarding Children Boards (LSCB) are responsible for ensuring that a review of each death of a child normally resident in the LSCB's area is undertaken by a CDOP. The purpose of the child death review is to learn lessons and help prevent further such child deaths.

#### 3 Duties

#### 3.1 Chief Executive

 Has ultimate executive accountability for the quality of services in the Trust.

#### 3.2 <u>Medical Director</u> –

- Executive Director responsibility for mortality review in the Trust.
- Provide the Trust Board with assurance regarding the Trust Mortality Review process.
- Provide support and guidance to the HMRG Chair and Departmental Mortality Leads as required.
- Take action where concern is raised through mortality ratio analysis and / or mortality reviews.

#### 3.3 HMRG Chair -

- Chair the monthly Hospital Mortality Review Group
- Produce quarterly reports to the Clinical Quality Steering Group (CQSG)
- Produce quarterly reports to Trust Board
- Lead on developing the processes to ensure learning from deaths is shared widely across the Trust, with the support of the HMRG Group members.
- Ensure that HMRG cases are reviewed within 4 months of patient's death.
- Where HMRG reviews exceed the 4 month target, take action to increase the rate of reviews completed and bring reviews back to within target timescale.
- Liaise with the PICU Departmental Mortality Lead to ensure mortality ratio analysis is presented at the HMRG meetings.
- Ensure any concerns / questions raised by the patient's family are addressed as part of the HMRG review and acted on accordingly.

September 2017 Page 6 of 24

- Ensure families are given feedback which addresses any concerns / questions they have raised. The Bereavement Team can provide support to the family if requested.
- Share monthly report to monitor compliance with review timescales with HMRG members.

#### 3.4 <u>Departmental Mortality Leads (DMLs)</u> –

- Share the Death Register with clinical teams (medical / nursing / AHPs)
- Inform the HMRG Administrator what teams / clinicians are taking responsibility for completing the departmental review.
- Inform other DMLs if a joint departmental review is indicated
- Ensure a departmental review is completed within two months by the team involved in the patient's care.
- Report to the relevant Division Risk and Governance Committee to highlight any teams not completing the departmental review in the two month timescale.
- Monitor completion of action plans following departmental reviews
- Ensure completed departmental reviews and action plans are submitted to the Division Risk and Governance Committee for review, discussion and approval.
- Circulate summary learning points following each HMRG meeting to share learning.

#### 3.5 PICU Departmental Mortality Lead -

- Monitor the monthly Cumulative Sum of Mortality (CUSUM) and Sequential Probability Ratio Test (SPRT) produced by the Paediatric Intensive Care Unit (PICU), and highlight any concerns immediately to the Medical Director / HMRG Chair.

#### 3.6 HMRG Administrator –

- Liaise with Departmental Mortality Leads (DMLs) to identify the departments / clinicians completing departmental mortality reviews.
- Where case notes are not scanned on Image Now, liaise with Medical Records Department to obtain the hard copy notes of deceased patients listed on the monthly Death Register.
- Assign the clinicians who will complete the Hospital Mortality Reviews for the cases listed on the Death Register within one month of the Death Register being published.
- Summary learning points sent to DMLs by the HMRG Administrator following each HMRG meeting.
- Produce monthly report to monitor compliance with review timescales for the HMRG Chair.

#### 3.7 Heads of Quality (HoQ) -

- Ensure completed departmental mortality reviews and action plans are reviewed at the Division Risk and Governance Committee as a standing agenda item.
- Where a departmental mortality review raises concerns that a death was avoidable, instigate Trust risk management process to trigger a further detailed review (e.g. RCA). (Refer to the Management of

September 2017 Page **7** of **24** 

- Incidents and Serious Incidents Requiring Investigation (SIRI) Policy (RM2))
- If required, and following the Trust process detailed in the Management of Incidents and Serious Incidents Requiring Investigation (SIRI) Policy (RM2), ensure the death is reported on the Strategic Executive Information System (STEIS) where applicable.
- Use Trust governance processes to ensure learning from deaths is shared widely and acted upon across the Divisions.

#### 3.8 Learning Disabilities Clinical Lead -

- Following the publication of the Death Register, review all patients aged 4 years old and above, residing in England at the time of their death, to identify any patients with a Learning Disability.
- Ensure the Learning Disability Liaison Team are reporting the deaths of all patients with Learning Disabilities onto the Learning Disabilities Mortality Review (LeDeR) database.
- Attend HMRG meetings to raise appropriate questions in relation to patient's who had a Learning Disability.

#### 3.9 CDOP Lead Nurse -

- Ensure where available that sudden unexpected death in infancy (SUDI) and sudden unexpected deaths in childhood (SUDiC) reports and Child Death Overview Panels (CDOP) reports are shared with the HMRG Administrator to aid HMRG reviewers in their review process.
- Attend monthly HMRG meetings. If CDOP Lead Nurse not available a Safeguarding Representative to attend where possible.

#### 3.10 Bereavement Team -

- Will inform family members at an appropriate time that the policy of Alder Hey Children's NHS Trust is to review the deaths of all inpatients.
- Offer families the opportunity to raise any questions or concerns they may have in relation to the patient's last admission, or from an earlier stage in the patient's medical journey if the family feel it is relevant to the review of their child's death.
- Attend HMRG meetings to represent and share the questions and concerns of deceased patients' families.

#### 3.11 Departmental Mortality Review Lead Clinician -

- When conducting the Departmental Mortality Reviews, lead clinicians should ensure all relevant staff are invited to attend the mortality review meeting to discuss the case.

#### 4 Conducting HMRG Mortality Reviews

- 4.1 The HMRG mortality reviews should make use of all available data sources to enable a detailed and thorough review of events leading up to and following a patient's death. This includes, but is not limited to:
  - Patient's case note on Image Now / Meditech / hard copy notes

September 2017 Page 8 of 24

- Clinic letters on Medisec
- Incident reports
- Any investigations (e.g. Root Cause Analysis (RCA) Reports)
- SUDI and SUDiC reports
- CDOP forms
- Post mortem reports
- Coroner's Reports
- Death Certificate
- PALS concerns
- Formal Complaints / Trust response
- External mortality reports (e.g. Trauma, Neonatal)
- Safeguarding reports
- Claim reports
- 4.2 Where available, this information will be made available to the HMRG reviewer by the HMRG Administrator.
- 4.3 The Structured Judgement Review documentation recommended in the National Quality Board's 'National Guidance on Learning from Deaths' (2017), is not currently being used at Alder Hey as it is not validated for children and young people. Until further national guidance for paediatrics is published, the Departmental and HMRG Mortality Review Forms in Appendix A and B will continue to be used.
- 4.4 For Departmental and HMRG Mortality Reviews, the Trust's Being Open and Duty of Candour Policy (RM47) may apply to the review of a patient's death, where a moderate or above incident is reported. Policy processes will be followed.
- 4.5 For Departmental and/or HMRG Mortality Reviews, where an incident is logged on Ulysses following a patient's death (e.g. due to the death being deemed avoidable), the Trust process detailed in the Management of Incidents and Serious Incidents Requiring Investigation (SIRI) Policy (RM2) will be followed. Advice will be taken from the Governance and Quality Assurance Team regarding the level of Root Cause Analysis (RCA) required. The Chair of the HMRG will be informed and the resulting RCA will form part of HMRG group's consideration. Where applicable, the death must be reported on the Strategic Executive Information System (STEIS).

#### 5 Learning Disabilities

5.1 Following the preventable death of Connor Sparrowhawk in July 2013 at Southern Health NHS Foundation Trust, the independent Mazars (2015) review was commissioned by NHS England. The report highlighted that unexpected deaths of adult Mental Health and Learning Disability patients were not sufficiently reviewed or investigated. The report also highlighted the views and concerns of families were not actively sought, and where concerns were raised they were not responded to.

September 2017 Page 9 of 24

- 5.2 Many adult Trusts only conduct mortality reviews on cases where the death is unexpected or is flagged through an incident report. At Alder Hey Children's NHS Foundation Trust, all inpatient deaths are reviewed.
- 5.3 The Learning Disabilities Mortality Review (LeDeR) Programme was set up to ensure all deaths of patients with Learning Disabilities are comprehensively reviewed. Following notification of a patient's details to the LeDeR database, all deaths will receive an initial review by LeDeR. If any concerns are identified about the death by LeDeR, or it is felt that further learning could come from a fuller review of the death, a detailed, multiagency review will be held. Where possible this will be through the HMRG process, with a LeDeR representative present.
- 5.4 Since January 2017, all patients aged 4 years old and above, residing in England at the time of their death, are required to be reported to the LeDeR database. Further details of the LeDeR process can be viewed on their website: http://www.bristol.ac.uk/sps/leder/
- 5.5 Reviewers conducting Departmental Mortality Reviews and HMRG Reviews must consider the implications of a patient's Learning Disability.

#### 6 Concerns of families

- 6.1 The publication 'National Guidance on Learning from Deaths' (2017), requires Trusts to ask bereaved families if they have any concerns about the quality of care received by the deceased patient.
- 6.2 At Alder Hey, this process will be led by the Bereavement Team who actively support families throughout the bereavement process.
- 6.3 The Bereavement Team will inform family members at an appropriate time that the policy of Alder Hey Children's NHS Trust is to review the deaths of all inpatients. The Bereavement Team will offer families the opportunity to raise any questions or concerns they may have in relation to the patient's last admission, or from an earlier stage in the patient's medical journey if the family feel it is relevant to the review of their child's death.
- 6.4 Any concerns raised should be notified by the Bereavement Team to the HMRG Administrator as soon as possible, in order that the concerns / queries can be incorporated into the HMRG review process.
- 6.5 Families raising concerns as part of the HMRG process, does not exclude families also raising these concerns through the Patient and Liaison Service (PALS) and Complaints process. In this situation, the processes in the Complaints and Concerns Policy (RM6) will be followed. If during the complaint investigation, it is found at any point that a patient safety incident has occurred, the Trust process detailed in the Management of Incidents and Serious Incidents Requiring Investigation (SIRI) Policy (RM2) will be followed.

September 2017 Page 10 of 24

- (A patient safety incident is any unintended or unexpected incident which could have or did lead to harm for one or more patients receiving NHS care.)
- 6.6 Following completion of the HMRG review, where no further investigation is required (e.g. RCA), feedback should be provided to the family by clinicians. The Bereavement Team can provide support to the family if requested. The format of this feedback (e.g. face to face meeting, letter, phone call, etc.) will be led by the family.
- 6.7 If a moderate or above incident has been logged relating to the patients case, this feedback will be as part of the Trust's Being Open and Duty of Candour Policy (RM47). In this situation Senior Managers / Clinicians will feedback to the family in a face to face meeting if acceptable to the family. The Bereavement Team can provide support to the family if requested.

#### 7 Learning Lessons from Mortality Reviews

- 7.1 The three reports: 'National Guidance on Learning from Deaths' (2017), 'Learning, Candour and Accountability' (December 2016) and 'Independent review of deaths of people with a Learning Disability or Mental Health problem in contact with Southern Health NHS Foundation Trust April 2011 to March 2015' (2015), all agree that more needs to be done to ensure learning from deaths is shared and acted upon.
- 7.2 The process for sharing information from mortality reviews needs to be managed in a number of ways to ensure the maximum number of staff have access to the information. These include, but are not limited to:
  - Reports to key Trust committees (e.g. Division Risk and Governance Committees, Clinical Quality Steering Group (CQSG), Trust Board, Infection Control Committee, etc)
  - Summary learning points sent to DMLs by the HMRG Administrator following each HMRG meeting.
  - Trust internal communication methods (e.g. Trust intranet, Trust newsletter, etc)
  - Presentations (e.g. Grand Round)
- 7.3 Monitoring actions arising from mortality reviews will be the responsibility of the action lead, with the Division's Head of Quality and the Chair of HMRG monitoring compliance.
- 7.4 Any opportunities to spread the learning from deaths further than Alder Hey should be taken (e.g. presenting at meetings and conferences, etc) .

September 2017 Page 11 of 24

#### 8 Monitoring

8.1 The following monitoring will take place to confirm compliance with this policy:

| Monitoring  | Lead<br>Responsible   | Frequency | Responsible Committee                        |
|---|-----------------------|-----------|--|
| Report produced to monitor compliance with mortality review timescales                        | HMRG<br>Administrator | Monthly   | HMRG   |
| Report produced summarising findings and learning points from all completed mortality reviews | HMRG Chair            | Quarterly | Clinical Quality<br>Steering Group<br>(CQSG) |
| Report produced summarising findings and learning points from all completed mortality reviews | HMRG Chair            | Quarterly | Trust Board                                  |

#### 9 Further Information

- 9.1 National Quality Board (2017), *National Guidance on Learning from Deaths*<a href="https://www.england.nhs.uk/wp-content/uploads/2017/03/nqb-national-guidance-learning-from-deaths.pdf">https://www.england.nhs.uk/wp-content/uploads/2017/03/nqb-national-guidance-learning-from-deaths.pdf</a>
- 9.2 Care Quality Commission (2016), Learning, Candour and Accountability A review of the way NHS trusts review and investigate the deaths of patients in England <a href="https://www.cqc.org.uk/sites/default/files/20161213-learning-candour-accountability-full-report.pdf">https://www.cqc.org.uk/sites/default/files/20161213-learning-candour-accountability-full-report.pdf</a>
- 9.3 Mazars (2015), Independent review of deaths of people with a Learning Disability or Mental Health problem in contact with Southern Health NHS Foundation Trust April 2011 to March 2015 <a href="https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2015/12/mazars-rep.pdf">https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2015/12/mazars-rep.pdf</a>
- 9.4 Management of Incidents and Serious Incidents Requiring Investigation (SIRI) Policy (RM2)
- 9.5 Being Open and Duty of Candour Policy (RM47)

September 2017 Page 12 of 24

- 9.6 Policy for Supporting Staff Involved in Traumatic/Stressful Incidents, Complaints or Claims (E31)
- 9.7 Complaints and Concerns Policy (RM6)
- 9.8 Equality Analysis

September 2017 Page 13 of 24

### Appendix A - Departmental Mortality Review Form

|  | Alder Hey Children's NBS Foundation Trust  |  |  |  |
|--|--|--|--|--|
| SERVICE GROUP / DEPARTMENTAL MORTALITY REVIEW FORM |  |  |  |  |
|  | Please complete electronically   |  |  |  |
| SEC  | TION A - PATIENT DETAILS   |  |  |  |
| 5)<br>7)<br>8)<br>9)<br>10)                        | Hospital Number: 2) Date of Birth:  Date of Death: 4) Lead Clinician:  CBU: 6) Service Group:  Clinical Diagnosis:  Context of Involvement:  Patient Risk Factors:  Probable Cause of Death:  Did the patient have a Learning Disability (e.g. Developmental Delay, ASD)?  Yes Possibly / was on pathway No Details: |  |  |  |
|  |  |  |  |  |
| SEC  | TION B - PLANNING FOR DEATH  |  |  |  |
| 1)   | Was the patient's death anticipated or not? (please tick)  Yes No  |  |  |  |
|  | If the death was anticipated, at which stage in the patient's treatment was this the case?   |  |  |  |
| 3)   | 3) Did the patient have a 'Life Plan' or 'Limitation of Treatment'? (please tick) Yes □ No □   |  |  |  |
|  |  |  |  |  |
| SEC  | TION C - CLINICAL MANAGEMENT AND TREATMENT   |  |  |  |
| Pi   | ease consider each of the factors listed in this section and record whether the factor applies to this patient and, if relevant, what the consequences were.   |  |  |  |
|  | Appropriate and timely admission to Alder Hey on this occasion? (please tick) Yes No   |  |  |  |
| 1b)<br>1c)   | If not, why not?  Did this contribute to the patient's death? (please tick) Yes □ No □ Possibly □  |  |  |  |
| 2a)  | Were medical / surgical reviews of a timely and senior enough nature, in relation to the patient's condition? (please tick) Yes ☐ No ☐   |  |  |  |
| 2b)<br>2c)   |  |  |  |  |
| 3a)  | If any procedures were performed, was the most senior practitioner present of suitable skill and experience for that procedure on that patient? (please tick)  Yes No Not applicable   |  |  |  |

September 2017 Page **14** of **24** 

|      | If not, why not? ☐ Did this contribute to the patient's death? (please tick) Yes ☐ No ☐ Possibly ☐   |
|------|--|
| 30)  | Did this contribute to the patient's death? [please tick) Fes   No   Possibly  |
|      |  |
| SEC  | TION C - CLINICAL MANAGEMENT AND TREATMENT (cont.)   |
| 4a)  | Were there any deficiencies or errors in clinical management? (e.g. failure of prescribing antibiotics / anticoagulation; admission of incorrect drug or dose; failure to refer to another specialty or PICU; etc.) (please tick) Yes No |
| 4b)  | If 'yes', what were they?  |
| 4c)  | Did this contribute to the patient's death? (please tick) Yes 🔲 No 🔲 Possibly 🔲  |
| 5a)  | Were there any failings in technical skill undertaking the procedure? (please tick)  |
| EP)  | Yes No Not applicable  |
|      | If 'yes', what were they?  Did this contribute to the patient's death? (please tick) Yes  No Possibly  |
|      |  |
| 6a)  | Were any deficiencies in patient monitoring / observations / nursing care identified?  (please tick) Yes □ No □  |
|      | If 'yes', what were they?  |
| 6c)  | Did this contribute to the patient's death? (please tick) Yes  No Possibly   |
| 7a)  | Any delays in accessing support services at Alder Hey? (e.g. radiology, laboratory services,   |
| 7b)  | theatres, PICU, etc.) (please tick) Yes No II No II If 'yes', what were they?  |
|      | Did this contribute to the patient's death? (please tick) Yes ☐ No ☐ Possibly ☐  |
|      |  |
|      | Any other concerns relating to the management of this patient? (please tick) Yes No II  If 'yes', what were they?  |
|      | Did this contribute to the patient's death? (please tick) Yes No Possibly  |
|      |  |
| 9)   | If you believe that the death was preventable in some way that is not covered above, please record what the major avoidable factors were:  |
|      |  |
| 10a) | Has follow-up been offered or already undertaken? (please tick) Yes 🔲 No 🔲   |
| 10b) | If not, why not?   |
|      |  |

September 2017 Page 15 of 24

September 2017 Page 16 of 24

## Appendix B - Hospital Mortality Review Group (HMRG) Review Form

| Alder Hey Children's NHS NHS Foundation Trust                  |  |         |                 |  |  |  |
|--|--|---------|-----------------|--|--|--|
| Audit No: HOSPITAL MORTALITY REVIEW GROUP (HMRG) – REVIEW FORM |  |         |                 |  |  |  |
|  | You have been nominated to complete a mortality audit primary review. Please complete the form below using the case notes and any supporting information provided. The first section has been completed for you. |         |                 |  |  |  |
| Q1)  | Hospital number:   |         |                 |  |  |  |
| Q2)  | Gender: Male 🔲 Fema  | ale 🗌   |                 |  |  |  |
| Q3)  | Date of admission:   |         |                 |  |  |  |
| Q4)  | Transferred from another hospi   | tal?    | Yes No No       |  |  |  |
|  | If yes, where was the chil   | d trans | ferred from?    |  |  |  |
| Q5)  | Date of birth:   |         |                 |  |  |  |
| Q6)  | Date of death:   |         |                 |  |  |  |
| Q7)  | Place of death:  |         |                 |  |  |  |
| Q8)  | Admitting ward:  |         |                 |  |  |  |
| Q9)  | Admitting consultant:  |         |                 |  |  |  |
| Q10)   | Further information provided as  | part of | Primary Review: |  |  |  |
|  | Incident report/s  |         |                 |  |  |  |
|  | Root Cause Analysis  |         |                 |  |  |  |
|  | Complaints   |         |                 |  |  |  |
|  | PALS   |         |                 |  |  |  |
|  | Legal  |         |                 |  |  |  |
|  | Bereavement Team   |         |                 |  |  |  |
|  | Child Protection   |         |                 |  |  |  |
|  | CDOP Form  |         |                 |  |  |  |
|  | Trauma Review  |         |                 |  |  |  |
| Q11)   | Name of reviewing consultant:  |         | ı               |  |  |  |

September 2017 Page 17 of 24

| CLINICAL DIAGNOSIS   |  |  |  |  |
|--|--|--|--|--|
| Q12) Brief clinical summary: see Death Summary letter  |  |  |  |  |
| Q13) Clinical diagnosis:   |  |  |  |  |
| Q14a) Did the patient have a Learning Disability (e.g. developmental delay, ASD)?                |  |  |  |  |
| Yes ☐ Possibly/was on pathway ☐ No ☐   |  |  |  |  |
| Details:   |  |  |  |  |
| Q14b) Was the patient known to CAMHS? Yes 🔲 No 🔲   |  |  |  |  |
| Details:   |  |  |  |  |
| Q15) Was the lead consultant clearly identified in the case notes? Yes (please select from list) |  |  |  |  |
| Q16a) Other consultants involved:  |  |  |  |  |
| Q16b) Other teams involved:  |  |  |  |  |
| Divisions None (please select from list)   |  |  |  |  |
| Service Group None (please select from list)   |  |  |  |  |
| If 'other' please specify:   |  |  |  |  |
| Divisions None (please select from list)   |  |  |  |  |
| Service Group None (please select from list)   |  |  |  |  |
| If 'other' please specify:   |  |  |  |  |
| Divisions None (please select from list)   |  |  |  |  |
| Service Group None (please select from list)   |  |  |  |  |
| If 'other' please specify:   |  |  |  |  |
| DDD #OUG ADMINISTRATION TO ALDED USY   |  |  |  |  |
| PREVIOUS ADMISSION(S) TO ALDER HEY   |  |  |  |  |
| Q17) Did the patient have a previous admission to Alder Hey? Yes 🔲 No 🔲                          |  |  |  |  |
| Q18) If yes, was the last admission a readmission with the same problem?                         |  |  |  |  |
| Yes No Not known   |  |  |  |  |
| Q19) Please detail any relevant previous admission/attendances:                                  |  |  |  |  |
| Q20) Did the patient have a chronic illness? Yes 🔲 No 🔲 Not known 🗖                              |  |  |  |  |
| If yes, please specify:  |  |  |  |  |
|  |  |  |  |  |

September 2017 Page 18 of 24

| OPERATIONS / PROCEDURES PERFORMED IN THIS ADMISSION   |  |  |  |  |  |
|---|--|--|--|--|--|
| Q21) Were any operations/procedures performed during the last admission?  |  |  |  |  |  |
| Yes No (If no, go to Q22)   |  |  |  |  |  |
| Q22) 1st operation / procedure:  Date of operation/procedure: Operation/procedure: Grades of surgeon/anaesthetist:          |  |  |  |  |  |
| 2 <sup>no</sup> operation / procedure:  Date of operation/procedure:  Operation/procedure:  Grades of surgeon/anaesthetist: |  |  |  |  |  |
| 3 <sup>rd</sup> operation / procedure:  Date of operation/procedure: Operation/procedure: Grades of surgeon/anaesthetist:   |  |  |  |  |  |
| 4 <sup>th</sup> operation / procedure:  Date of operation/procedure:  Operation/procedure: Grades of surgeon/anaesthetist:  |  |  |  |  |  |
| 5 <sup>th</sup> operation / procedure:  Date of operation/procedure: Operation/procedure: Grades of surgeon/anaesthetist:   |  |  |  |  |  |
| 6 <sup>th</sup> operation / procedure:  Date of operation/procedure:  Operation/procedure:  Grades of surgeon/anaesthetist: |  |  |  |  |  |
| CAUSE OF DEATH / POST MORTEM  |  |  |  |  |  |
| Q23a) Case referred to coroner? Yes No  |  |  |  |  |  |
| If yes, name of consultant referring case:  |  |  |  |  |  |
| Q23b) Case discussed with coroner? Yes 🔲 No 🔲 (If no, go to Q26)  |  |  |  |  |  |
| If yes, name of consultant discussing case:   |  |  |  |  |  |
| Q24) Discussion with coroner documented in medical record? Yes 🔲 No 🔲   |  |  |  |  |  |
| Q25) Outcome of discussion with coroner:  |  |  |  |  |  |
| Q26) Request for hospital post mortem? Yes 🔲 No 🔲 (If no, go to Q31)  |  |  |  |  |  |

September 2017 Page 19 of 24

| Q27) If yes, request for post mortem made to parents by:             | Consultant [     | Other 🔲          |  |  |  |  |
|--|------------------|------------------|--|--|--|--|
| If other, please state grade:  |                  |                  |  |  |  |  |
| Q28) Permission for hospital post mortem given? Yes                  | □ No [           | 1                |  |  |  |  |
| Q29) Type of post mortem performed: Full hospital pos                | t mortem [       | <b>-</b>         |  |  |  |  |
| Limited hospital   | oost mortem [    | <b>-</b>         |  |  |  |  |
| Q30) Findings of post mortem:  |                  |                  |  |  |  |  |
| Q31) Death certificate issued? Yes No                                |                  |                  |  |  |  |  |
| Q32) Cause of death:   |                  |                  |  |  |  |  |
| 1a)  |                  |                  |  |  |  |  |
| b)   |                  |                  |  |  |  |  |
| c)   |                  |                  |  |  |  |  |
| 2)   |                  |                  |  |  |  |  |
| Q33) Do you agree with the probable cause of death on t              | ne Service Group | Mortality Review |  |  |  |  |
| form (Section B)?  Yes No  |                  |                  |  |  |  |  |
| If no, state reasons:  |                  |                  |  |  |  |  |
| Q34) Death certificate correct? Yes No                               |                  |                  |  |  |  |  |
| If no, why?  |                  |                  |  |  |  |  |
| Q35) Any SUDC issues? Yes No   |                  |                  |  |  |  |  |
| Action: Referred to:   |                  |                  |  |  |  |  |
| 000)   | V                |                  |  |  |  |  |
| Q36) Healthcare associated infection related to death?               | Yes 🔲 N          | 10 🔲             |  |  |  |  |
| FOLLOW-UP / DOCUMENTATION  |                  |                  |  |  |  |  |
| Q37) Offer / arrangements for follow up documented? Yes No           |                  |                  |  |  |  |  |
| Q38) Followup: Declined  Awaiting                                    | Has occurred     |                  |  |  |  |  |
| Done locally Unknown   |                  |                  |  |  |  |  |
| Q39) Has there been feedback / follow-up with the referral hospital? |                  |                  |  |  |  |  |
| Yes No Notapplicable   |                  |                  |  |  |  |  |
|  |                  |                  |  |  |  |  |

September 2017 Page **20** of **24** 

| If no, should there have been? Yes 🔲 No 🔲  |
|--|
| If yes, what aspects?  |
| Q40) Overall evaluation of case note documentation of this admission:                              |
| Adequate – no issues 🔲 Inadequate 🔲  |
| Comments on documentation:   |
|  |
| SERVICE GROUP / DEPARTMENTAL MORTALITY REVIEWS   |
| Q41) Service Group / Departmental review(s) of case? Yes 🔲 No 🔲                                    |
| If no, which Service Groups / Departments?   |
| Divisions None (please select from list)   |
| Service Group None (please select from list)   |
| If 'other' please specify:   |
| Divisions None (please select from list)   |
| Service Group None (please select from list)   |
| If 'other' please specify:   |
| in out of product specially.   |
| Divisions None (please select from list)   |
| Service Group None (please select from list)   |
| If 'other' please specify:   |
| Q42) Departmental / Service Group Mortality Review – Minutes and action plans: (cut and paste)     |
|  |
|  |
|  |
|  |
|  |
| Q43) Do you agree with the assessment (section C) of the clinical management and treatment issues? |

September 2017 Page 21 of 24

| Yes No 🗆   |  |
|--|--|
| If not, what are the areas of disagreement?  |  |
|  |  |
| HMRG   |  |
|  |  |
| Q44) How would you rate the care given?  |  |
| <ol> <li>Aspects of the care provided were less than adequate; and different management<br/>would reasonably be expected to have altered the outcome.</li> </ol>     |  |
| <ol> <li>Aspects of the care provided were less than adequate; and different management<br/>may have altered the outcome.</li> </ol>                                 |  |
| <ol> <li>Aspects of the care provided were less than adequate; and different management<br/>would not reasonably be expected to have altered the outcome.</li> </ol> |  |
| Adequate or above standard care provided   |  |
| Q45) Please tick whichever one description best matches:-  |  |
| Example of good practice   |  |
| Adequate / standard practice   |  |
| Aspects of clinical care could have been better  |  |
| 4) Aspects of organisational care could have been better   |  |
| 5) Aspects of clinical and organisational care could have been better  |  |
| Q46) If your assessment from Q44 and Q45 above varies from the Service Group / Departmental Review, please explain why:  |  |
| Q47) Requires formal HMRG discussion? Yes No   |  |
| Q48) Any further information/clarification required?   |  |
| Q49) Any significant questions that remain unanswered?   |  |
|  |  |

September 2017 Page 22 of 24

### Diagnostic Categories - only one primary & no more than two secondary

#### Diagnostic/Disease Categories

- Deliberately inflicted injury, abuse or neglect
- D2. Suicide or deliberate self-inflicted harm
- D3. Trauma & other external factors excludes deliberate self-inflicted harm (D2)
- D4. Malignancy
- D5. Acute Medical or Surgical condition subcategories:

D5a. Medical D5b. Surgical D5c. Cardiac

- D6. Chronic medical condition
- D7. Chromosomal, genetic and congenital anomalies
- D8. Perinatal/Neonatalevent
- D9. Infection / Sepsis (proven or clinical) subcategory:
- D9a. Healthcare-associated infection (home or away)
- D10. Sudden unexplained, unexpected death/SUDI/SUDC excludes SUDE (D5)

Primary:

Secondary:

### Recurring Themes

#### Recurring Themes

- R0. No RT
- R1. Failure to recognise severity of illness subcategories: R1a. Failure to ask for Senior/Consultant review
- R2. Possible management issues subcategories:

R2a. External R2b. Delay in Transfer R2c. in Alder Hey R2d. Delay in supporting services or accessing supporting service

R2e. Difference of opinion re: Rx - Patients & families

R2f. Difference of opinion re: Rx - Clinical teams

R3. Communication issues - subcategories:

R3a. Patients & families R3b. Clinical teams

- R4. Death inevitable before admission
- R5. Potentially avoidable death subcategories:

R5a. Alder Hey R5b. Medical R5c. External

R6. Cause(s) of death issue – subcategories:

R6a. Incomplete or inaccurate Death Certificate

R6b. Should have had a post-mortem R6c. Not agreed

R6d. Failure to discuss with the Coroner

R7. Documentation - subcategories:

R7a. Recording R7b. Filing

- R8. Failure of follow-up
- R9. Withdrawal / Limitation of care
- R10. Example of Good Practice
- R11. Learning disability
- R12. Known to CAMHS

Recurring themes:

September 2017 Page 23 of 24

| FOLLO                       | WING DISCUSSION AT HMRG M | EETING                          |
|-----------------------------|---------------------------|---------------------------------|
| Learning points identified: |                           |                                 |
|                             |                           |                                 |
|                             |                           |                                 |
| Actions identified:         | Lead for action:          |                                 |
|                             | Lead for action:          |                                 |
|                             | Lead for action:          |                                 |
| Outcome of primary review:  | No further action         |                                 |
|                             | Need further information  |                                 |
| DiagnosticCategories:       |                           |                                 |
|                             |                           |                                 |
| Recurring themes:           |                           |                                 |
|                             | HMRG Primary              | Review Form – Amended June 2017 |
|                             |                           |                                 |
|                             |                           |                                 |
|                             |                           |                                 |
|                             |                           |                                 |
|                             |                           |                                 |
|                             |                           |                                 |

September 2017 Page **24** of **24** 

#### ALDER HEY IN THE PARK PROJECT

| HIGHLIGHT REPORT                            |     | Da    | te:  | 04/0 | 07/17 | 7     |       |   |       |      |   | Pe   | eriod: | Jun | ne 201 | 17  |    |    |     |       |    | SRO: David Powell   |
|---|-----|-------|------|------|-------|-------|-------|---|-------|------|---|------|--------|-----|--------|-----|----|----|-----|-------|----|---|
| Site & Park Development                     | Rej | ort N | Numl | ber: |       |       |       |   |       |      |   |      |        | 11  |        |     |    |    |     |       |    | Author: Sue Brown   |
| Programme 2017/18                           |     | \pr-1 |      |      |       | ay-17 |       |   | Jun-1 |      |   |      | l-17   |     |        | Aug |    |    |     | Sep-1 |    |   |
| Week Commencing                             | 3   | 10 1  | 7 2  | 4 1  | 8     | 15 2  | 22 29 | 5 | 12 1  | 9 26 | 3 | 10 1 | L7 2   | 4 3 | 1 7    | 14  | 21 | 28 | 4 : | 11 18 | 25 |   |
| Decommissioning & Demolition (Phase 1 & 2)  |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Programme progressing on track and advance to demolish to M/N block now agreed as part of phase one. No issues with dust have arisen, monitoring continues as per plan. The management plan is in place covering both: 1. demolition of retained estate; 2. R&E II construction, levels have remained safe todate.  |
| Residential                                 |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Community Engagment continues to progress in realtion to the scale of the scheme, once resolved the appointment of the prefferred bidder (Elect) will follow. Bidder working with LCC planners to ensure all consultation material is acceptable within the rules of the planning process to ensure that the final scheme has a high level of acceptance to all parties. Preffered bidder (elect) has submitted a planning pre-application. The Trust has placed the consultation process on hold until the Liverpool Community Health Bid process has concluded before dates are agreed. |
| Research & Education Phase II               |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Research and Education phase II build remains on track, contract with Morgan Sindell still awaiting final agreement.  University partners yet to sign sign off financial agreements although this was expected end of August beginning of september, it remains outstanding although all agreed in prinicipal.  |
| Alder Centre                                |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | On Track. Dicussions and regular meetings in process and progressing with the Appointed Architect and users to refine the design. Tender for the construction due to go out end of October.   |
| Park  |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Recently secured £28k of funding from a charity to develop accessible pathways in the park forest area.  The Trust design was accepted fo rentry to the Chelsea flower show 2018, funding however has not been secured, so the plan will be to re-submit next year, feedback on the design from Chelsea was very positve. The Development team are confident that they have an interested partrner in M&G who may agree to be the major sponsor in 2019.  |
| International Design & Build<br>Consultancy |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Contract prepared and exchanged with Xl'AN, contract documents and drawings being translated via china centre prior to commencement of the design review and agreement on a timeline. Jersey review, they have agreed on a £60k design review exercise with DP, discussions and weekly input over 3/4 months to the Jersey team and this work is ongoing with weekly visits to jersey by team members. Possability this work will be extended beyond November and additional income achieved. Sharepoint documentation still to be fully developed.                                       |
| Community Cluster Building                  |     |       |      |      |       |       |       |   |       |      |   |      |        |     |        |     |    |    |     |       |    | Design brief being prepared in order to lauch a RIBA design competition at the end of September, this includes , Neurological Assessment, Community Paeds, Psychology, orthotics and Police station in phase one. There is also the option for phase two which could include the Dewi Jones re locationfrom Alder Park and a new and separatley funded Sandfield Park School. Three will be potential in the future for addition of a small rehabilitation unit if the Trust wishes to pursue the option. Sharepoint documentation still to be fully developed.                           |
| Estates Strategy/Corporate Offices          |     |       |      |      |       |       |       |   |       |      |   |      | Ī      |     |        |     |    |    |     |       |    | Currently exploring and conducting a financial analysis of proposed developments and locations for Community services where current premisies have recieved notification of end of tenancy. Also financial analysis of options for relocation to off site premeises for CAMHS and Corprate services due to conclude at the end of September. Sharepoint documentation still to be fully developed   |



# BOARD OF DIRECTORS Tuesday 3<sup>rd</sup> October 2017

| Report of:   | Chief Nurse  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|
| Paper Prepared by:   | Emergency Preparedness & Business Continuity Manager   |  |  |  |  |  |  |
| Subject/Title:   | NHS England EPRR Core Standards Audit 2017/18  |  |  |  |  |  |  |
| Background Papers:   | <ul> <li>Appendix A: NHS England EPRR Core Standards Letter</li> <li>Appendix B: (for viewing electronically, no printing required):         Assurance Spreadsheet     </li> <li>Appendix C: 2017/18 Work plan</li> <li>Appendix D: Statement of Compliance</li> </ul> |  |  |  |  |  |  |
| Purpose of Paper:  | The Board is asked to ratify the EPRR Self-Assessment Results  |  |  |  |  |  |  |
| Action/Decision Required:  | The Board is asked to ratify a 'substantial compliance' declaration.   |  |  |  |  |  |  |
| Link to:  ➤ Trust's Strategic  Direction  ➤ Strategic Objectives | <ul> <li>Deliver outstanding care</li> <li>The Best People Doing Their Best Work</li> </ul>  |  |  |  |  |  |  |
| Resource Impact:   | Funding for ED EPRR Clinical Lead to focus on CBRNE/Major incident 2017/18 work plan   |  |  |  |  |  |  |



### 1. Background:

In line with the Emergency Preparedness Resilience and Response (EPRR) Core Standards, the Trust is required to:

- Undertake an annual self-assessment of the core standards (Appendix B)
- Produce a work plan for the year ahead, based on any gaps in assurance (Appendix C)
- Complete a statement of compliance for ratification by the Trust Board (Appendix D)
- Present findings from the self-assessment/key lines of enquiry to NHS England during their visit to the Trust on Friday 27<sup>th</sup> October 2017.

Further detail regarding the audit/visit is available in the NHS England letter attached as **Appendix A**.

### 2. Key Issues:

### 2.1 Assurance Spreadsheet - Governance 'Deep Dive':

This year's assurance deep dive topic is organisational governance and is referenced in the attached core standards spreadsheet (**Appendix B**) in the section entitled 'governance'.

Core standard DD2 states 'the organisation has published the results of the 2016/17 NHS EPRR assurance process in their annual report'. The 16/17 results weren't published in the EPRR annual report however; was taken to the board last year for approval. Future annual reports will ensure that the results of the EPRR assurance process will be included.

Core standard DD3 states 'the organisation has an identified, active Non-executive Director/Governing Body Representative who formally holds the EPRR portfolio for the organisation'. A report from the Emergency Preparedness Group is submitted to each Integrated Governance Committee (IGC) which is chaired by Steve Igoe, Non-Executive Director. Following receipt of the governance deep dive, the Non-Executive Director has agreed to formally hold the EPRR portfolio for the organisation.

### 2.2 2017/18 Workplan:

Attached is the 2017/18 EPRR work plan. The majority of the work plan refers to the Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE)/Hazardous Materials (HAZMAT) planning and training required, which was identified in the 2016/17 work plan. The Emergency Department EPRR Clinical Lead took up post on 21st August 2017 and the Chief Nurse (Accountable Emergency Officer) has agreed that additional funding/hours can be provided for the clinical lead to complete these actions as a priority. A work plan is currently under development for review by the Chief Nurse.

### 2.3 Statement of Compliance:

Following completion of the core standards self-assessment spreadsheet, it is recommended that the Trust declares 'substantial' compliance. **The Board is asked to ratify this declaration.** The statement of compliance and associated documentation was returned to NHS England by the deadline of 22<sup>nd</sup> September 2017 and if the Board ratifies this level of compliance, then a signed copy of the statement will be submitted to NHS England.



### 2.4 NHS Strategic Asset Assurance Visit 27/10/17:

In light of recent incidents, this year's assurance process includes an emphasis on NHS Strategic Assets. Alder Hey as a Major Trauma Centre is considered to provide vital services and will this year receive a greater level of scrutiny in the form of a visit to Alder Hey on 27<sup>th</sup> October 2017. The following leads will be visiting the Trust:

- Paul Dickins, Regional Head of EPRR, NHS England
- Jim Deacon, Head of Emergency Preparedness, NHS England
- Joanne Richardson, EPRR Operations Manager, NHS England

There are key areas that the visiting team would like to visit while they are on site, these include, but not restricted to:

- The Emergency Department
- The location the organisation would manage an emergency from (Incident Coordination Centre)
- The store of CBRN equipment (Acute trusts)
- · Location of any stockpiled equipment

The following staff will attend to represent the Trust:

- Chief Nurse (Emergency Preparedness Accountable Officer)
- Chief Operating Officer
- Director of Nursing
- Trauma Leads
- Emergency Department EPRR Clinical Lead
- Emergency Preparedness and Business Continuity Manager

An update will be provided to the Board on the outcome of this visit.



NHS England

10 July 2017

Skipton House

80 London Road

London SE1 6LH

Publications Gateway Reference 06967

Simon Weldon Director of NHS Operations and Delivery

To: Provider Accountable Emergency Officers

CCG Accountable Emergency Officers

NHS England Regional Directors

NHS England Regional Directors of Assurance and Delivery

NHS England Directors of Commissioning Operations

NHS England LHRP Co-chairs

Cc: NHS England Heads of EPRR

NHS England Business Continuity team

**CCG** Accountable Officers

**CCG Clinical Leads** 

**CSU Managing Directors** 

Clara Swinson, Director General – Public Health, Department of Health

Helen Shirley-Quirk CB, Director Health Protection and Emergency Response, Department of Health

Dr Kathy McLean, Executive Medical Director, NHS Improvement

Dr Ruth May, Executive Director of Nursing, NHS Improvement

Dear colleague

### Process for 2017-18 Emergency Preparedness, Resilience and Response (EPRR) Assurance

The last few months have been busy for us all in relation to NHS resilience and response. These events make the annual NHS EPRR Assurance process even more important and this letter starts this process for 2017-18. As in previous years, NHS England will lead the process via Local Health Resilience Partnerships (LHRP) in order to seek assurance that both the NHS in England and NHS England are prepared to respond to emergencies, and are resilient in relation to continuing to provide safe patient care. The format and process this year will follow that of 2016-17.

The purpose of this process is to assess the preparedness of the NHS, both commissioners and providers, against common NHS EPRR Core Standards which remain unchanged for this year. A task and finish group is currently reviewing the Core Standards ahead of the 2018/19 process and these will be published in the autumn.

The EPRR Core Standards are available on the NHS England internet site <a href="http://www.england.nhs.uk/ourwork/eprr/">http://www.england.nhs.uk/ourwork/eprr/</a>

Local Health Resilience Partnerships continue to play an integral part of the process and constituent members are asked to support NHS England in conducting the process.

The NHS EPRR assurance process concludes with a submission to the NHS England Board in March 2018. Once this has been accepted by the Board, NHS England will be in a position to provide national EPRR assurance for 2017/18 to the Department of Health and the Secretary of State for Health.

In light of the current UK risks and threats, this year's process will include an additional element of assurance for NHS Strategic Assets. This additional element will include a site visit to meet with the relevant leaders within these organisations. This process is described in section 4 of this letter.

#### 1. Timeframes

The timelines for this year's process will be in line with those for the 2016/17 process.

All organisations should commence their self-assessment immediately so as to give suitable time to undertake this in a measured and calculated manner.



Once organisations have taken their self-assessment results to their **Boards/Governing Bodies** there will be Local Health Resilience Partnership confirm and challenge process to provide organisations with a peer review.

Following this, Local Health Resilience Partnership Co-Chairs will submit their reports to the NHS Regional Teams where there will be a regional consolidation process, via confirm and challenge meetings. NHS England regions will determine the local arrangements and dates for submission.

By the 31 December 2017, Regional Teams will submit their consolidated data to the Central Team where national consolidation will take place. This will be complete by Wednesday 28 February 2018 so that the national report can be prepared and considered by the NHS England Board by 1 April 2018.

#### 2. Actions

### 2.1 Providers of NHS funded care

The following organisations are required to undertake the 2017-18 NHS EPRR assurance process:

- Acute hospital service providers
- Specialist hospital providers
- Ambulance service providers (including patient transport organisations)
- Community service providers (this includes NHS Trusts, Foundation Trusts and social enterprises)
- Mental health service providers
- NHS111 providers

Local Health Resilience Partnerships may wish to include other organisations not mentioned above, at their discretion.

Provider organisations are asked to undertake a self-assessment against the relevant individual core standards and rate their compliance. These individual ratings will then inform the overall organisational rating of compliance and preparedness.

Once this process has taken place, organisations are required to take a statement of compliance to a public Board meeting. Provider organisations are also required to publish their statement of compliance in their annual report. This Board report, along with the Core Standards assurance ratings and rectification plans, should then form the submission to the Clinical Commissioning Group and Local Health Resilience Partnership. The Local Health Resilience Partnership will undertake a formal review via a confirm and challenge meeting.

Organisations which operate across Local Health Resilience Partnerships borders should present their self-assessment and supporting evidence to their lead commissioner and host Local Health Resilience Partnership. This documentation should also be shared with other relevant Local Health Resilience Partnerships /stakeholders as necessary.

### 2.2 Commissioners of NHS funded care

The following organisations are required to undertake the 2017-18 EPRR assurance process:

- Clinical commissioning groups
- NHS England regional and central teams.

Commissioning organisations (including NHS England) are required to undertake a self-assessment against the relevant individual NHS EPRR Core Standards and these individual ratings will then inform the overall organisational rating of compliance and preparedness.

Once this process has taken place commissioners are expected to take a statement of compliance to their Governing Bodies/Senior Management Teams. This report along with the Core Standards assurance ratings and rectification plan should then form the submission to the Local Health Resilience Partnership. The Local Health Resilience Partnerships will undertake a confirm and challenge meeting.

Commissioners which operate across Local Health Resilience Partnership borders should present their self-assessment and supporting evidence to their regular host Local Health Resilience Partnership. This documentation should also be shared with other relevant Local Health Resilience Partnerships s/stakeholders as necessary.

Clinical Commissioning Groups are asked to support NHS England in the additional assurance of the UK NHS strategic asset (Section 4).

### 2.3 Local Health Resilience Partnerships (LHRPs)

It is expected that Local Health Resilience Partnerships s will review and consider all relevant organisations self-assessments, Board or Governing Body papers (or equivalent) and rectification plans and provide a mechanism across their geography to facilitate confirm and challenge.

Local Health Resilience Partnerships are expected to:

- Ensure that commissioners of services are actively involved
- Seek further evidence where an organisation considers itself less than **Fully Compliant**.

- Conduct a 'deep dive' into core EPRR Governance in all organisations included in the assurance process
- Provide the NHS England Regional Director of Operations and Delivery with a report on the preparedness of all organisations in their Partnership.
- Actively monitor progress of those organisations reporting an overall rating of Non-Compliant until the Partnership is content that the organisation has attained an agreed level of compliance
- Actively engage with local NHS Improvement colleagues to support this process

Records should be kept of the reviews undertaken and include any evidence requested.

### 2.4 NHS England Regional Teams

NHS England Regional Teams will coordinate a submission to evidence their level of assurance and to help inform the national assurance assessment. Regional Teams will be asked to complete template(s) which will follow this letter and:

- Request any evidence of the work completed and/or plans put in place that they feel is necessary to support and/or challenge organisation(s)
- Be able to distinguish between the preparedness of NHS England and the preparedness of other organisations.
- Demonstrate where improvement is needed and the mitigation in hand at individual organisational/team level.
- Be able to identify and set out instances of good practice against the core standards so
  that this can be shared across regions to improve the overall preparedness and
  resilience of NHS England and the NHS in England.
- Actively engage with NHS Improvement colleagues to support this process
- Undertake the strategic asses assurance process (Section 4.)

Records should be kept of the reviews undertaken and include any evidence requested. It is expected that all actions in section 2 above will be completed by 31st December 2016.

### 2.5 NHS England Business Continuity Assurance

NHS England business continuity assurance will be undertaken once and in conjunction with the NHS England Business Continuity Team, via the NHS EPRR Core Standards template.

The NHS England Business Continuity Team will liaise directly with NHS England Regional Teams alongside the NHS England central EPRR team to gain assurance of NHS England arrangements.

The NHS England Business Continuity Team will liaise directly with each Commissioning Support Unit (CSU) to gain their business continuity assurance, which will then be incorporated into the NHS England Board paper.

### 3. Assurance Deep dive

This year's EPRR assurance deep dive topic is core EPRR organisational governance. There has been a significant amount of organisational change over recent years and there is a need to ensure that EPRR is secured appropriately, within all our organisations. This deep dive will include

assurance of areas such as internal organisational EPRR accountability, regular reports to public Board meetings, a realistic work program and a solid training and exercise program.

Following on from the CBRN 'deep-dive' carried out during the 2014-15, the HAZMAT/ CBRN assessment remains incorporated into the NHS EPRR Core Standards.

Acute hospitals should expect ambulance service providers to work with them to assess and challenge their level of HAZMAT/CBRN preparedness (using the NHS EPRR Core Standards). NHS England continues to fund ambulance service providers, via the National Ambulance Resilience Unit (NARU), to undertake this. In addition to this assessment, ambulance service providers are funded to provide training to support the acute hospital response.

Specialist, community and mental health service providers should note that some HAZMAT/ CBRN core standards are relevant and pertinent to their organisations, and they also have a duty of care towards self-presenting patients who have been exposed to a HAZMAT or CBRN incident.

### 4. NHS Strategic Asset Assurance

In light of recent incidents, this year's assurance process will include an emphasis on NHS Strategic Assets. These are organisations that are considered to provide vital services and will this year receive a greater level of scrutiny. The organisations covered within the NHS Strategic Asset assurance process for 2017/18 are:

- Ambulance services
- Major Trauma Centres
- Burns Centres
- High level Isolation Units (infectious disease units)
- High Security Mental Health Facilities
- Geographically remote organisations

Ambulance services are receiving an enhanced assurance process which is being led by the National Ambulance Resilience unit and this program is well under way.

NHS England will lead the enhanced assurance process for all other strategic organisations. This will include a site visit to each organisation and the key lines of enquiry for these visits will be shared with the respective organisations, in advance. The visits will consist of representation from NHS England, NHS Improvement and the lead Clinical Commissioner. This team will expect to meet with the organisation's Accountable Emergency Officer and Emergency Preparedness Manager/Lead.

NHS England will work with these organisations to schedule these events.

### 5. Organisational Assurance Ratings

Organisations will be expected to state an overall assurance rating as to whether they are Fully, Substantially, Partially or Non-Compliant with the NHS EPRR Core Standards.

1. Acute, specialist, Community and mental health providers should calculate their overall organisation compliance level by using the 'EPRR Core Standards' and 'HAZMAT CBRN Core Standards' tabs together (therefore standards 1-66 as a single rating).

- 2. Patent Transport, 111, NHS England (regional and national), CCGs, CSUs and other NHS funded providers should calculate their overall organisation compliance level by using the 'EPRR Core Standards' tab only (therefore standards 1-52 only).
- 3. Ambulance providers should report 3 compliance levels:
  - Calculate EPRR Core Standards against Core Standards 1-66 as per No 1 above.
  - Calculate their overall compliance against 'MTFA Core Standards' and
  - Calculate their overall compliance 'HART Core Standards' separately applying the criteria in the national letter (gateway 05356) letter for each tab.
- 4. The deep dive results should be reported separately and should not be included in any overall organisational compliance rating.

The definitions of these ratings remain the same as the 2016/17 process and are detailed below:

| Compliance Level | Evaluation and Testing Conclusion   |
|------------------|---|
| Full             | Arrangements are in place the organisation is fully compliant with all core standards that the organisation is expected to achieve. The Board has agreed with this position statement.  |
| Substantial      | Arrangements are in place however the organisation is not fully compliant with one to five of the core standards that the organisation is expected to achieve. A work plan is in place that the Board has agreed.                                 |
| Partial          | Arrangements are in place however the organisation is not fully compliant with six to ten of the core standards that the organisation is expected to achieve. A work plan is in place that the Board has agreed.                                  |
| Non-compliant*   | Arrangements in place do not fully address 11 or more core standards that the organisation is expected to achieve. A work plan has been agreed by the Board and will be monitored on a quarterly basis in order to demonstrate future compliance. |

<sup>\*</sup> Should an organisation be Non-Compliant, the Local Health Resilience Partnership will regularly monitor progress throughout the year until it is has attained an agreed level of compliance.

### 6. Summary:

In summary, please can you:

- 1. Note that all organisations will undertake a self-assessment against the NHS EPRR Core Standards.
- 2. Note the approach to the 2017/18 EPRR assurance process that is expected to be followed by NHS England and Local Health Resilience Partnerships.
- 3. Note the timeframes for the delivery of the 2017/18 assurance process.
- 4. Liaise with local partners and stakeholders to achieve the outcomes required.
- 5. Note the additional implications of the NHS Strategic Asset assurance process for 2017/18 for the relevant organisations

Senior managers are asked to bring the contents of this letter to the attention of their emergency preparedness, resilience and response staff and disseminate to other organisations as applicable.

For further information, please see the NHS England EPRR web-page<sup>1</sup> or if you have any further queries, please contact Stephen Groves (National Head of EPRR) at <a href="mailto:stephengroves@nhs.net">stephengroves@nhs.net</a>.

Yours sincerely,

Simon Weldon

Director of NHS Operations and Delivery

Melde

<sup>&</sup>lt;sup>1</sup> http://www.england.nhs.uk/ourwork/eprr/



# NHS England Core Standards for Emergency preparedness, resilience and response $\ensuremath{\text{v}5.0}$

The attached EPRR Core Standards spreadsheet has 6 tabs:

EPRR Core Standards tab: with core standards nos 1 - 37 (green tab)

Governance tab:-with deep dive questions to support the EPRR Governance'deep dive' for EPRR Assurance 2017 -18(blue) tab)

HAZMAT/ CBRN core standards tab: with core standards nos 38-51. Please note this is designed as a stand alone tab (purple tab)

HAZMAT/ CBRN equipment checklist: designed to support acute and ambulance service providers in core standard 43 (lilac tab)

MTFA Core Standard: designed to gain assurance against the MTFA service specification for ambulance service providers only (orange tab)

HART Core Standards: designed to gain assurance against the HART service specification for ambulance service providers only (yellow tab).

This document is V50. The following changes have been made:

• Inclusion of EPRR Governance questions to support the 'deep dive' for EPRR Assurance 2017-18

|              |  | la u   | T                  |      |           |
|--------------|--|--|--------------------|------|-----------|
|              |  | Self assessment RAG  Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.   |                    |      |           |
|              | Core standard  |  | Action to be taken | Lead | Timescale |
|              |  | Green = fully compliant with core standard.  |                    |      |           |
| Govern       | ance   |  |                    |      |           |
| 1            | Organisations have a director level accountable emergency officer who is responsible for EPRR (including business continuity management)   | Chief Nurse is the Accountable Officer. Letter confirming this sent to NHS England dated 13th April 2017   | N/A                |      |           |
| 2            | Organisations have an annual work programme to mitigate against identified risks and incorporate the lessons identified relating to EPRR (including details of training and exercises and past incidents) and improve response.  | Annual Report including workplan submitted to IGC on 24/07/17 and going to Trust Board on 05/09/17   | N/A                |      |           |
|              | Organisations have an overarching framework or policy which sets out expectations of emergency preparedness,   |  | N/A                |      |           |
| 3            | resilience and response.   | Also SOP for Strategic Commander and Tactical Commander.<br>Trust Business Continuity Plan and Policy in place, along with<br>local ward/department business continuity plans. |                    |      |           |
|              |  |  |                    |      |           |
| 4            | The accountable emergency officer ensures that the Board and/or Governing Body receive as appropriate reports, no less frequently than annually, regarding EPRR, including reports on exercises undertaken by the organisation, significant incidents, and that adequate resources are made available to enable the organisation to meet the requirements of these core standards. | Update provided every 2 months to the Integrated Governance Committee, which is a sub Committee of the Board. EPPR annual report submitted to Trust Board for ratification.    | N/A                |      |           |
| Duty to      | assess risk  |  |                    |      |           |
| 5            | Assess the risk, no less frequently than annually, of emergencies or business continuity incidents occurring which affect or may affect the ability of the organisation to deliver its functions.  | Risks recorded via the Trust Ulysses Risk Register with reference to the LHRP Risk Register included.  | N/A                |      |           |
| 6            | There is a process to ensure that the risk assessment(s) is in line with the organisational, Local Health Resilience Partnership, other relevant parties, community (Local Resilience Forum/ Borough Resilience Forum), and national risk registers.   | As above. LHRP Risk Register also reviewed at the LHRP<br>Strategic and Practitioner EPRR meetings   | N/A                |      |           |
|              | There is a process to ensure that the risk assessment(s) is informed by, and consulted and shared with your  | Organisations notified as and when required and also discussed   | N/A                |      |           |
| 7<br>Duty to | organisation and relevant partners.  maintain plans – emergency plans and business continuity plans  | and monitored at LHRP meetings   |                    |      |           |
| 8            | Effective arrangements are in place to respond to the risks the organisation is exposed to, appropriate to the role, size and scope of the organisation, and there is a process to ensure the likely extent to which particular  | Major Incident Policy and Major Incident Command & Control Plan  |                    |      |           |
| 9            | types of emergencies will place demands on your resources and capacity.  | Trust Business Continuity Policy and Plan. Local Ward/<br>Department business continuity Plans produced.   |                    |      |           |

|    |   | Self assessment RAG   |                           |               |           |
|----|---|---|---------------------------|---------------|-----------|
|    |   | Jen assessment NAG  |                           |               |           |
|    |   | Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.   |                           |               |           |
|    | Core standard   | Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months.  | Action to be taken        | Lead          | Timescale |
|    |   | Green = fully compliant with core standard.   |                           |               |           |
|    | Have arrangements for (but not necessarily have a separate plan for) some or all of the following (organisation | ODDAIG Dies ausliebte beweren erwiese aufgebie  | Refresh CBRNE/HAZMAT Plan | ED EDDD       | 2/24/2040 |
| 10 | dependent) (NB, this list is not exhaustive):   | CBRNE Plan available, however, requires refreshing  | Refresh CBRNE/HAZMAT Plan | Clinical Lead | 3/31/2018 |
| 11 |   | Heatwave Plan, Cold Weather Plan in place, along witih developing Winter Plan   |                           |               |           |
| 12 |   | Pandemic Flu Plan updated and approved at IPC Committee on  |                           |               |           |
| 13 |   | 9/08/17 Mass vaccination would be in consultation with PHE, CCG etc.  |                           |               |           |
|    |   | Mass casualties is referenced in the Trust Major Incident   |                           |               |           |
|    |   | Command & Control Plan. Mass Casualty exercise held on  |                           |               |           |
| 14 |   | 21/08/17. Cheshire & Merseyside mass casualty matrix for  |                           |               |           |
|    |   | receiving casualties. MRF/NHS E Mass Fatalities Plan  |                           |               |           |
| 15 |   | Fuel Plan   |                           |               |           |
| 16 |   | Escalation Plan approved and Winter Plan under development  |                           |               |           |
| 17 |   | Infectious Diseases Plan undergoing update  |                           |               |           |
| 18 |   | Evacuation Plan currently being updated to reflect whole hospital evacuation with a plan to be in place by December 2017                |                           |               |           |
| 19 |   | Lockdown Plan and action cards available with further update to be considered regarding lockdown options                                |                           |               |           |
| 20 |   | Business Continuity Action cards available for utitliies, IT and communications failure   |                           |               |           |
| 21 |   | MRF/NHSE Mass Fatalities Plan.  |                           |               |           |
| 22 |   | Burns plan for large scale incidents currently under update   |                           |               |           |
| 23 |   | following release of national document  Not applicable  |                           |               |           |
|    | Ensure that plans are prepared in line with current guidance and good practice which includes:                  | Plans prepared in line with current guidance along with verson  |                           |               |           |
|    |   | control. Have asked peers to provide copies of their plans where  |                           |               |           |
|    |   | required, using good practice examples.   |                           |               |           |
|    |   |   |                           |               |           |
|    |   |   |                           |               |           |
| 24 |   |   |                           |               |           |
|    |   |   |                           |               |           |
|    |   |   |                           |               |           |
|    |   |   |                           |               |           |
|    |   |   |                           |               |           |
|    | Arrangements include a procedure for determining whether an emergency or business continuity incident has       | On Call policy and on call 24/7 rota, major incident/business   |                           |               |           |
|    | occurred. And if an emergency or business continuity incident has occurred, whether this requires changing the  | continuity SOP for Strategic and Tactical Commander. Business   |                           |               |           |
| 25 | deployment of resources or acquiring additional resources.  | Continuity Severity levels chart available to assist in determining level of business continuity incident. Definition of major incident |                           |               |           |
|    |   | and examples referenced.  |                           |               |           |
|    |   |   |                           |               |           |
| •  | •   | ·   |                           |               |           |

|       |   | Self assessment RAG  |   |                  |           |
|-------|---|--|---|------------------|-----------|
|       |   | Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.  |   |                  |           |
|       | Core standard   | Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months.   | Action to be taken  | Lead             | Timescale |
|       |   | Green = fully compliant with core standard.  |   |                  |           |
|       | Arrangements include how to continue your organisation's prioritised activities (critical activities) in the event of<br>an emergency or business continuity incident insofar as is practical.  | Local business continuity plans in place identifying critical services which must continue. Overarching list of critical areas will be finalised at EPG in September 2017.   |   |                  |           |
| 27    | Arrangements explain how VIP and/or high profile patients will be managed.  | VIPs managed in line with 'External Communications Policy (including VIP/Media Visits'   |   |                  |           |
|       | Preparedness is undertaken with the full engagement and co-operation of interested parties and key stakeholders (internal and external) who have a role in the plan and securing agreement to its content   | Planning meetings leading up to events take place with key areas affected e.g Meditech downtime, UPS electrical testing etc.   |   |                  |           |
| 29    | Arrangements include a debrief process so as to identify learning and inform future arrangements  | Debrief arrangements referenced in plans and debrief meetings organised following major incident or business continuity incidents  |   |                  |           |
| Comma | nd and Control (C2)   |  |   |                  |           |
| 30    | Arrangements demonstrate that there is a resilient single point of contact within the organisation, capable of receiving notification at all times of an emergency or business continuity incident; and with an ability to respond or escalate this notification to strategic and/or executive level, as necessary. | 24/7 2nd and 1st On Call rota is available, and staff contactable via switchboard.   |   |                  |           |
| 31    | Those on-call must meet identified competencies and key knowledge and skills for staff.   | Strategic Leadership is a crisis training is being organised. In addition, Strategic and Tactical Commanders have received local training from the Emergency preparedness & Business Continuity Manager regarding responding to major incidents and business continuity incidents - checklist to be developed to ensure this training covers everything listed in the National Occupational standards for Strategic, Tactical and Operational staff. Implement this as mandatory training. | Develop core competency<br>checklist for strategic, tactical<br>and operational staff, in line<br>with National Occupational<br>Standards | EP&BC<br>Manager | 3/31/2018 |
| 00    | Documents identify where and how the emergency or business continuity incident will be managed from, ie the Incident Co-ordination Centre (ICC), how the ICC will operate (including information management) and the key roles required within it, including the role of the loggist.                               | Arrangements referenced in the Trust Major Incident Command and Control Plan and the Strategic and Tactical Major Incident/business continuity SOP. MRF contacts directory.  |   |                  |           |
|       | Arrangements ensure that decisions are recorded and meetings are minuted during an emergency or business continuity incident.   | Loggist list of staff available to record decisions made along with loggist books.   |   |                  |           |
| 24    | Arrangements detail the process for completing, authorising and submitting situation reports (SITREPs) and/or commonly recognised information pictures (CRIP) / common operating picture (COP) during the emergency or business continuity incident response.   | Arrangements for internal sitreps included in the Major Incident<br>Command and Control Plan. External situation report requests<br>from NHS England will be included in the next update of the plan   | _   |                  |           |
|       | Arrangements to have access to 24-hour specialist adviser available for incidents involving firearms or chemical, biological, radiological, nuclear, explosive or hazardous materials, and support strategic/gold and tactical/silver command in managing these events.   | CBRNE/HAZMAT plan includes reference to contacting PHE for advice on a 24 hour basis   |   |                  |           |
|       | Arrangements to have access to 24-hour radiation protection supervisor available in line with local and national mutual aid arrangements;   | CBRNE/HAZMAT plan includes reference to contacting PHE for advice on a 24 hour basis   |   |                  |           |

| Core standard   | Self assessment RAG  Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.  Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months.  Green = fully compliant with core standard. | Action to be taken | Lead | Timescale |
|---|---|--------------------|------|-----------|
| Arrangements demonstrate warning and informing processes for emergencies and business continuity incidents. | Communications Team liaise with NHS England during major incidents. Communications action card included in Major Incident Command & Control Plan.   |                    |      |           |

|         |   | Self assessment RAG  |                    |      |           |
|---------|---|--|--------------------|------|-----------|
|         |   | Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.  |                    |      |           |
|         | Core standard   | Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months.   | Action to be taken | Lead | Timescale |
|         |   | Green = fully compliant with core standard.  |                    |      |           |
| 38      | Arrangements ensure the ability to communicate internally and externally during communication equipment failures  | Radios available to communicate during communication failure.<br>Recent cyber incident demonstrated need to develop continuity<br>plan in the event of loss of IT network/external links which is<br>being taken forward   |                    |      |           |
| Inform  | ation Sharing – mandatory requirements  | The Tay of Marine In the American Company of the Co |                    |      |           |
| 39      | Arrangements contain information sharing protocols to ensure appropriate communication with partners.   | The Trust Major Incident Policy includes reference to information sharing  |                    |      |           |
| Co-ope  |   |  |                    |      |           |
| 40      | Organisations actively participate in or are represented at the Local Resilience Forum (or Borough Resilience Forum in London if appropriate)   | the Trust is represented at the LHRP Strategic Meeting and LHRP HRG meeting  |                    |      |           |
| 41      | Demonstrate active engagement and co-operation with other category 1 and 2 responders in accordance with the CCA  | Good networking arrangements in place at LHRP meeting and during exercises.  |                    |      |           |
| 42      | Arrangements include how mutual aid agreements will be requested, co-ordinated and maintained.  | Mutual aid would be requested via NHS England Strategic Coordinating Group/Tactical Coordinating Group   |                    |      |           |
| 43      | Arrangements outline the procedure for responding to incidents which affect two or more Local Health Resilience Partnership (LHRP) areas or Local Resilience Forum (LRF) areas.             | Direction would be sought from NHS England Strategic and<br>Tactical Command, whilst following Trust Major Incident<br>Command & Control Plan  |                    |      |           |
| 44      | Arrangements outline the procedure for responding to incidents which affect two or more regions.  | As above   |                    |      |           |
| 45      | Arrangements demonstrate how organisations support NHS England locally in discharging its EPRR functions and duties   | SITREPs would beprovided to NHS England in line with agreed battle rhythm as per recent cyber incident and Manchester Terrorism incident   |                    |      |           |
| 46      | Plans define how links will be made between NHS England, the Department of Health and PHE. Including how information relating to national emergencies will be co-ordinated and shared       | Major Incident Policy references different agencies and this would be coordinated via SGC/TCG arrangements   |                    |      |           |
| 47      | Arrangements are in place to ensure an Local Health Resilience Partnership (LHRP) (and/or Patch LHRP for the London region) meets at least once every 6 months                              | Not applicable   |                    |      |           |
| 48      | Arrangements are in place to ensure attendance at all Local Health Resilience Partnership meetings at a director level  | The Accountable Director has delegated this requirement to the Director of Nursing, who chairs the Trust Emergency   |                    |      |           |
| Trainin | g And Exercising  |  |                    |      |           |
|         | Arrangements include a current training plan with a training needs analysis and ongoing training of staff required to deliver the response to emergencies and business continuity incidents | action will be taken to ensure training is in line with meets National Occupational Standards for Strategic, Tactical and Operational staff and which of this training needs to be   |                    |      |           |
| 49      |   | 'mandatory'.  Last communication cascade test took place on 17/07. Desk top exercise held on 21/08/17. last live exercise held October 2016.  Next live exercise being scheduled for November 2017, with joint Live/Hybrid exercise with Whiston Hospital to be held in July   |                    |      |           |
|         |   | 2018.  |                    |      |           |

|    | Core standard   | Self assessment RAG  Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months.  Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months.  Green = fully compliant with core standard.  | Action to be taken | Lead | Timescale |
|----|---|--|--------------------|------|-----------|
| 50 | Arrangements include an ongoing exercising programme that includes an exercising needs analysis and informs future work.  | Exercises referenced in annual work plan.  |                    |      |           |
| 51 | Demonstrate organisation wide (including oncall personnel) appropriate participation in multi-agency exercises  | Staff can attend multi agency exercises when there are sufficient spaces available to attend. Ambulance service, Trauma Leads, NHS England attended recent Trust Mass Casualty Exercise. Emergency Department Lead and Director of Nursing attended 'Exercise Elsa'. Large number of staff will be involved in joint 'Exercise Gemini' with Whiston in July 2018 |                    |      |           |
| 52 | Preparedness ensures all incident commanders (oncall directors and managers) maintain a continuous personal development portfolio demonstrating training and/or incident /exercise participation. | This is held via the Emergency Preparedness Manager and<br>Training Department   |                    |      |           |

| 2015 D | Core standard   | Cluritying information  | Acute healthcare providers<br>Specialist providers | Ambulance service<br>providers | Patient Transport Providers | Community services<br>providers | Mental healthcare<br>providers<br>NHS England local teams | NHS England Regional & national | CCGs<br>CSUs flusiness continuity | only)<br>Primary care<br>(GP, community pharmacy) |     | Sidence of assurance   | Self assessment RAG Red - Not compliant with core standard and not list the EPRR work jaw within the next 12 months. Amber - Not compliant but evidence of progress and in the EPRR work plain for the next 12 months. Green = fully compliant with core standard.   | Action to be taken Lead  | Tie | lmescale  |
|--------|---|---|--|--------------------------------|-----------------------------|---------------------------------|---|---------------------------------|-----------------------------------|---|-----|--|--|--|-----|-----------|
| DD1    | The organisation's Accountable Emergency Officer has taken the result of the 2016/17 EPRR assurance process and annual work plan to a public Board'Governing Body meeting for sign off within the last 12 months. |   | Υ Υ  | Y                              | Y                           | Y                               | Y   | Υ                               | Y                                 |   |     | Organisation's public Board/Governing Body report Organisation's public website  | The Core Standards spreadshest and results along with the<br>workplan were submitted to Integrated Governance Committee or<br>14/09/16 and then to Trust Board on 04/10/16. The EPRR annu-<br>report was submitted to Integrated Governance Committee on<br>24/07/17 and due to go to Trust Board on 05/09/17.   | 4  |     |           |
| DD2    | The organisation has published the results of the 2016/17 NHS EPRR assurance process in their annual report.  | There is evidence that the organisation has published their 2016/17 assurance process results in their Annual Report  | YY   | Υ                              | Y                           | Y                               | Υ   |                                 | Y                                 |   | Υ . | Organisation's Annual Report<br>Organisation's public website  | The results were not included in the annual report.  | Reference the results from the<br>core standards audit in future<br>Annual Reports<br>EP&B0<br>Manag   |     | 3/31/2018 |
| DD3    | The organisation has an identified, active Non-executive Director/Governing Body Representative who formally holds the EPRR portfolio for the organisation.   | • The organization has an identified Non-securities Director/Convening Body Representative and formally Notice the EPRIR portion. The organization has goodly designed for the resource of the Ordan Security S |  | Y                              | Y                           | , A                             | Y   | Y                               | Y                                 |   |     | Organisation's Annual Report (Organisation's packide Board'Orwaning Body report (Organisation's packie webste Hinrules of meetings | A report from the Emergency Preparactivess Group is submitted in<br>each Integrated Governance Committe (GC) which meets every<br>ten months. (GC is a Trust Board sub committee and is channed<br>by a Note Teacouter Detector who has appead to be the active Nor<br>securities Director who, (blowing publication of programming deep<br>dive, formally holds the EPRR portfolio for the organization<br>of the Committee Commi |  |     |           |
| DD4    | The organisation has an internal EPRR oversight/delivery group that oversees and drives the internal work of<br>the EPRR function   | <ul> <li>The organisation has an internal group that meets at least quarterly that agrees the EPRR work priorities and oversees the delivery of the<br/>organisation's EPRR function.</li> </ul>  | Y  | Υ                              | Y                           | Y                               | Υ   | Υ                               | Υ                                 |   | Υ   | Minutes of meetings  | The Trust Emergency Preparedness Group is established and<br>meets quarterly. Terms of Reference available.  |  |     |           |
| DD5    |   | - The organization's Accountable Emergency Officer is a regular attendes at the organization's meeting that provides oversight to the delivery of the EPRR work program.  The organization's Accountable Emergency Officer has attended at least 50% of these meetings within the last 12 months.   | YY   | Y                              | Y                           | r Y                             | Y   |                                 | Y                                 |   | Y   | Minutes of meetings  | The Trust Accountable Officer has delegated this responsibility the Director of Avarigin, The Director of Naturing receive of Naturing receive the Chell Nurse. This arrangement has been in place since June 2017 and will continue going forward.  | The Director of Nursing will continue to chair the Emergency Preparedness Group, on behalf of the Chief Nurse. The Director of Nursing formally updates the Chief NurselEPRR Accountable Officer on at least a quarterly basis.  | n/a | а         |
| DD6    | The organisation's Accountable Emergency Officer regularly attends the Local Health Resilience Partnership meetings   | • The organisation's Accountable Emergency Officer is a regular attended at Local Health Resilience Partnership meetings. The organisation's Accountable Emergency Officer has altended at least 75% of these meetings within the last 12 months.   |  |                                | YY                          |                                 |   |                                 | Y                                 |   | Y   | Minutes of meetings  | The Trust Accountable Officer has disequent this responsibility to<br>the Director of Nations; The Director of National proposts to the<br>Chief Nation. This arrangement has been in place since June<br>2017 and will continue going forward.  | The Director of Nursing will only continue but after the LHRP Strategic meetings and the Emergency Preparedness Manager will attend the practicener meetings. The Director of Nursing formally updates the Chief Nursing EPRR Accountable Officer on at least a quarterly basis. | n/a | a         |

| (NB th | ious materials (HAZMAT) and chemical, biological, radiolgocial and nuclear (CBRN) r<br>is is designed as a stand alone sheet)   |  | Self assessment RAG Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months. Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months. Green = fully compliant with core standard. | Action to be taken   | Lead                     | Timescale |
|--------|---|--|--|--|--------------------------|-----------|
| ų.     | Sole standard   | Old Hyllig Hill Hill Hall  |  |  |                          |           |
|        | Preparedness  |  |  | 1  | I                        | I         |
| 53     | There is an organisation specific HAZMAT/ CBRN plan (or dedicated annex)  | Arrangements include:  - command and control interfaces  - tried and tested process for activating the staff and equipment (inc. Step 1-2-3 Plus)  - pre-determined decontamination locations and access to facilities  - management and decontamination processes for contaminated patients and fatalities in line with the latest guidance  - communications planning for public and other agencies  - interoperability with other relevant agencies  - access to national reserves / Pods  - plan to maintain a cordon / access control  - emergency / contingency arrangements for staff contamination  - plans for the management of hazardous waste  - stand-down procedures, including debriefing and the process of recovery and returning to (new) normal processes  - contact details of key personnel and relevant partner agencies | There is a CBRNE/HAZmat plan, however, this requires refreshing and can be taken forward following appointment of ED EPRR Clinical Lead/HAZMAT trainer   | The ED Emergency<br>Preparedness Lead is in<br>post from 21/08/17 and will<br>refresh plan.                                  | ED EPRR<br>Clinical Lead | 3/31/2018 |
| 54     | Staff are able to access the organisation HAZMAT/ CBRN management plans.  | Decontamination trained staff can access the plan  | CBRNE/HAZMAT plan is available in Tactical Command Room  |  |                          |           |
| 55     | HAZMAT/ CBRN decontamination risk assessments are in place which are appropriate to the organisation.   | Documented systems of work     List of required competencies     Impact assessment of CBRN decontamination on other key facilities     Arrangements for the management of hazardous waste  | Dynamic Risk assessment is referenced in plan depending on the type of incident.   |  |                          |           |
| 56     | Rotas are planned to ensure that there is adequate and appropriate decontamination capability available 24/7.   |  | Rotas need to be planned to ensure that there is adequate and appropriate decontamination capability available 24/7.   | The ED emergency<br>preparedness lead is in<br>post from 21/08/17 and will<br>review arrangements<br>required going forward. | ED EPRR<br>Clinical Lead | 3/31/2018 |
| 57     | Staff on-duty know who to contact to obtain specialist advice in relation to a HAZMAT/<br>CBRN incident and this specialist advice is available 24/7.   | For example PHE, emergency services.   | This will be sourced via PHE and is referenced in the plan for staff to refer to   |  |                          |           |
|        | Decontamination Equipment   |  |  |  |                          |           |
| 58     | There is an accurate inventory of equipment required for decontaminating patients in place and the organisation holds appropriate equipment to ensure safe decontamination of patients and protection of staff.                 | Acute and Ambulance service providers - see Equipment checklist overleaf on separate tab Community, Mental Health and Specialist service providers - see Response Box in 'Preparation for Incidents Involving Hazardous Materials - Guidance for Primary and Community Care Facilities' (NHS London, 2011) (found at: <a href="http://www.london.com.nhs.uk/">http://www.london.com.nhs.uk/</a> store/documents/hazardous-material-incident-guidance-forprimary-and-community-care.pdf) Initial Operating Response (IOR) DVD and other material: <a href="http://www.jesip.org.uk/what-will-jesip-do/training/">http://www.jesip.org.uk/what-will-jesip-do/training/</a>   | Equipment checklist completed  |  |                          |           |
| 59     | The organisation has the expected number of PRPS suits (sealed and in date) available for immediate deployment should they be required (NHS England published guidance (May 2014) or subsequent later guidance when applicable) | There is a plan and finance in place to revalidate (extend) or replace suits that are reaching the end of shelf life until full capability of the current model is reached in 2017   |  |  |                          |           |
| 60     | There are routine checks carried out on the decontamination equipment including: A) Suits B) Tents C) Pump D) RAM GENE (radiation monitor) E) Other decontamination equipment   | There is a named role responsible for ensuring these checks take place   | The Emergency Department clinical lead for<br>EPRR carries out this role   |  |                          |           |

|    | ous materials (HAZMAT) and chemical, biological, radiolgocial and nuclear (CBRN) r<br>s is designed as a stand alone sheet)   | esponse core standards   | Self assessment RAG Red = Not compliant with core standard and not in the EPRR work plan within the next 12 months. Amber = Not compliant but evidence of progress and in the EPRR work plan for the next 12 months. Green = fully compliant with core standard. | Action to be taken                       | Lead                     | Timescale |
|----|---|--|--|--|--------------------------|-----------|
| Q  | Core standard   | Clarifying information   |  |  |                          |           |
| 61 | There is a preventative programme of maintenance (PPM) in place for the maintenance, repair, calibration and replacement of out of date Decontamination equipment for: A) Suits B) Tents C) Pump D, RAM GENE (radiation monitor) E) Other equipment |  |  |  |                          |           |
| 62 | There are effective disposal arrangements in place for PPE no longer required.  | (NHS England published guidance (May 2014) or subsequent later guidance when applicable)   | In line with NHS E guidance and clinical waste provider  |  |                          |           |
|    | Training  |  |  |  |                          |           |
| 63 | The current HAZMAT/ CBRN Decontamination training lead is appropirately trained to deliver HAZMAT/ CBRN training  |  | ED Clinical EPRR lead is the named officer who is appropriately trained  |  |                          |           |
| 64 | Internal training is based upon current good practice and uses material that has been supplied as appropriate.  | - Documented training programme - Primary Care HAZMAT/ CBRN guidance - Lead identified for training - Established system for refresher training so that staff that are HAZMAT/ CBRN decontamination trained receive refresher training within a reasonable time frame (annually) A range of staff roles are trained in decontamination techniques - Include HAZMAT/ CBRN command and control training - Include ongoing fit testing programme in place for FFP3 masks to provide a 24/7 capacity and capability when caring for patients with a suspected or confirmed infectious respiratory virus - Including, where appropriate, Initial Operating Response (IOR) and other material:  http://www.jesip.org.uk/what-will-jesip-do/training/ | Now that the ED Clinical EPRR Lead is in post, this training programme will be re-established.   | Provide 1 day CBRNE -<br>HAZMAT Training | ED EPRR<br>Clinical Lead | 3/31/2018 |
| 65 | The organisation has sufficient number of trained decontamination trainers to fully support its staff HAZMAT/ CBRN training programme.  |  | ED Clinical EPRR lead is the named decontamination trainer and will be working towards training an additional 2 trainers   |  |                          |           |
| 66 | Staff that are most likely to come into first contact with a patient requiring decontamination<br>understand the requirement to isolate the patient to stop the spread of the contaminant.  | Including, where appropriate, Initial Operating Response (IOR) and other material: http://www.jesip.org.uk/what-will-jesip-do/training/ Community, Mental Health and Specialist service providers - see Response Box in 'Preparation for Incidents Involving Hazardous Materials - Guidance for Primary and Community Care Facilities' (NHS London, 2011) (found at: http://www.londoncon.nhs.uk/_store/documents/hazardous-material-incident-guidance-for-primary-and-community-care.pdf)   | This is referenced in the CBRNE/HAZMAT plan  |  |                          |           |

HAZMAT CBRN equipment list - for use by Acute and Ambulance service providers in relation to Core Standard 43.

| No         | Equipment  | Equipment model/ generation/ details etc. | Self assessment RAG Red = Not in place and not in the EPRR work plan to be in place within the next 12 months. Amber = Not in place and in the EPRR work plan to be in place within the next 12 months. Green = In place. |
|------------|--|---|---|
| E1         | EITHER: Inflatable mobile structure Inflatable frame   |   | N/A   |
|            | Liner  |   | N/A   |
| E1.2       | Air inflator pump  |   | N/A   |
| E1.3       | Repair kit   |   | N/A   |
| E1.2       | Tethering equipment  |   | N/A   |
|            | OR: Rigid/ cantilever structure  |   |   |
| E2         | Tent shell   |   | N/A   |
|            | OR: Built structure  |   |   |
| E3         | Decontamination unit or room   | Decontamination Shower Room               |   |
| <b>-</b>   | AND:   |   |   |
| E4<br>E5   | Lights (or way of illuminating decontamination area if dark)  Shower heads   |   |   |
| E6         | Hose connectors and shower heads   |   |   |
| E7         | Flooring appropriate to tent in use (with decontamination basin if   |   |   |
|            | needed)  |   |   |
| E8         | Waste water pump and pipe Waste water bladder  |   | Wasta water storage tank  |
| E9         | PPE for chemical, and biological incidents   |   | Waste water storage tank  |
| E10        | The organisation (acute and ambulance providers only) has the expected number of PRPS suits (sealed and in date) available for immediate deployment should they be required. (NHS England published guidance (May 2014) or subsequent later guidance when applicable).   |   |   |
| E11        | Providers to ensure that they hold enough training suits in order to facilitate their local training programme   |   | Upon delivery of new CBRNE live suits, there will be sufficient training suits available  |
| E12        | Ancillary  A facility to provide privacy and dignity to patients   |   |   |
| E13        | Buckets, sponges, cloths and blue roll   |   |   |
| E14        | Decontamination liquid (COSHH compliant)   |   |   |
| E15        | Entry control board (including clock)  |   |   |
| E16        | A means to prevent contamination of the water supply   |   |   |
| E17        | Poly boom (if required by local Fire and Rescue Service)   |   | Not applicable  |
| E18        | Minimum of 20 x Disrobe packs or suitable equivalent (combination  |   | тчот аррисавіе  |
| E19        | of sizes)  |   | Not required  |
|            | Minimum of 20 x re-robe packs or suitable alternative (combination of sizes - to match disrobe packs)  |   | Re-robe supplies available  |
| E20        | Waste bins Disposable gloves   |   |   |
| E21        | Scissors - for removing patient clothes but of sufficient calibre to execute an emergency PRPS suit disrobe  |   |   |
| E22        | FFP3 masks   |   |   |
| E23<br>E24 | Cordon tape Loud Hailer  |   |   |
| E25        | Signage  |   | This will be developed now ED clinical lead in post   |
| E26        | Tabbards identifying members of the decontamination team   |   |   |
|            | Chemical Exposure Assessment Kits (ChEAKs) (via PHE): should an acute service provider be required to support PHE in the collection of samples for assisting in the public health risk assessment and response phase of an incident, PHE will contact the acute service provider to agree appropriate arrangements. A Standard Operating Procedure will be issued at the time to explain what is expected from the acute service provider staff. Acute service providers need to be in a position to provide this support. |   | Support will be provided as requested   |
|            |  |   |   |
|            | Radiation  |   |   |
| E28        | Radiation RAM GENE monitors (x 2 per Emergency Department and/or HART team)  |   |   |
| E29        | RAM GENE monitors (x 2 per Emergency Department and/or HART team) Hooded paper suits   |   |   |
| E29<br>E30 | RAM GENE monitors (x 2 per Emergency Department and/or HART team) Hooded paper suits Goggles   |   |   |
| E29        | RAM GENE monitors (x 2 per Emergency Department and/or HART team) Hooded paper suits   |   |   |

|      | Core standard  | Claritying information  | Acute health care providers<br>Specialist providers | Ambulance service providers | Community services providers | Mental healthcare providers | NHS England local teams NHS England Regional & national | ccas | CSUs (business continuity only) | (GP, community pharmacy) (GP, community pharmacy) (Gher NHS funded organisations | Evidence of assurance | Self assessment RAG  Not - Nito compliant with core standard and not in the EPRR work plan within the next 12 months.  Amber + Not compliant but evidence of progress and in the EPRR work plan within the next 12 months.  Green = fully compliant with core standard. | Lead | Timescale |
|------|--|---|---|-----------------------------|------------------------------|-----------------------------|---|------|---------------------------------|--|-----------------------|---|------|-----------|
| Gove | rnance   | Constitution by MYCA analytic to the authority annual and a state of analysis absolute default which the contract annual factors  |   |                             |                              |                             |   |      |                                 |  |                       |   |      |           |
| 1    | Organisations have an MTFA capability at all times within their operational service area.  | <ul> <li>Organisations have MITA capability to the nationally agreed safe system of work standards defined within this service sportfaction.</li> <li>Organisations have MITA capability to the nationally agreed frame (reported lity) standards of endined within this service sportfaction.</li> <li>Organisation have latent sufficient steps to ensure their MITA capability remains complaint with the National MITA Standard Operating Procedure during local and national displayments.</li> </ul>  |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 2    | Organisations have a local policy or procedure to ensure the effective prioritisation and deployment (or<br>redeployment) of MTFA staff to an incident requiring the MTFA capability.  | Deployment to the Home Office Model Response sites must be within 45 minutes.   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 3    |  | Organisations markins a minimum of the competent MTPA staff on duty at all times. Competence is desirated by the marketary minimum harmal procurements identified the better Acquisited inservacions, any successful MTPA application must have undergone a Physical Competence Assessment (PCA) to the nationally agreed standard. Assessment (PCA) to the nationally agreed standard Corganisations markine the enrishman feed of alraing competence among all operational MTPA staff and defined by the national standards and the competence of the MTPA capitally Corganisations markine that each operational MTPA staff and staff and the process of the MTPA capitally These records mark include a record of marking competence across the MTPA staff staff. |   | Y                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 4    | Organisations ensure that agromptiste personal equipment is available and maintained in accordance with the detailed specification in MTFA SOPs (Reference C).   | To prouse intercognative selety rittles deplument plus references in the National Standard Operating Procedures, organisations should use the<br>instead buying framework conditated by NASI values for your provide seasures frough the four personagement process that be local<br>procurement is intercognation.  All ITA equipment is intercognation.  All ITA equipment is maintained to realize all standards and must be made available in line with the national MFTA hotics to move<br>transfer.  All ITA equipment is maintained or continged to applicable British or EN standards and in line with manufacturers' recommendations.  |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 5    | Organisations maintain a local policy or procedure to ensure the effective identification of incidents or patients that may benefit from deployment of the MTFA capability.  | Organisations ensure that Control rooms are compilant with JOPs (Reference B).     With Trusts using Pathways or AMPDS, ensure that any potential MTFA incident is recognised by Trust specific arrangements.   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 6    | Organisations have an appropriate revenue depreciation scheme on a 5-year cycle which is maintained locally to replace nationally specified MTFA equipment.  |   |   | Y                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 7    | Organisations use the NARU coordinated national change request process before reconfiguring (or changing) any MTFA procedures, equipment or training that has been specified as nationally interoperable.  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 8    | Organisations maintain an appropriate register of all MTFA safety critical assets.   | Assets are defined by their reference or inclusion within the National MITFA Standard Operating Procedures.  This register must include; individual asset identification, any applicable serving or maintenance activity, any identified defects or faults, the expected replacement data and any applicable statutory or negulatory requirements (including any other records which must be maintained for that time of equipment).  |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 9    | Organisations ensure their operational commanders are competent in the deployment and management of NHS<br>MTFA resources at any live incident.  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 10   | Organisations maintain accurate records of their compliance with the national MTFA response time standards and make them available to their local lead commissioner, external regulators (including both NHS and the Health & Safety Executive) and NHS England including NAML operating under an NHS England contract).   |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 11   | In any event that the organizations is unable to maintain the MTFA capability to the interoperability standards, that<br>provided has robust and timely menchanisms to make an endification to the National Ambulance Resilience Unit<br>(NARU) on-call system. The provider must then also provide notification of the specification default in writing to<br>their lead commissioners. |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 12   | Organisations support the nationally specified system of recording MTFA activity which will include a local<br>procedure to ensure MTFA staff update the national system with the required information following each live<br>deployment.  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 13   | Organisations ensure that the availability of MTFA capabilities within their operational service area is notified<br>nationally every 12 hours via a norminated national monitoring system coordinated by NARU.<br>Organisations maintain a set of local MTFA risk assessments which are compliment with the national MTFA risk  |   |   | Υ                           | $\prod$                      |                             |   |      |                                 |  |                       |   |      |           |
| 14   | assessments covering specific training venues or activity and pre-identified high risk sites. The provider must also<br>ensure there is a local process / procedure to regulate how MTFA staff conduct a joint dynamic hazards<br>assessment (JDHA) at any live deployment.  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 15   | Organisations have a robust and timely process to report any lessons identified following an MTFA deployment or  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 16   | Organisations have a robust and timely process to report, to NARU and their commissioners, any safety risks related to equipment, training or operational practice which may have an impact on the national interoperability of the MTFA sortion as soon as it practicable and no later than 7 days of the risk being identified.  |   |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 17   | Organisations have a proces to acknowledge and respond appropriately to any national safety notifications issued for MTFA by NARU within 7 days.   |   |   | Y                           |                              |                             | Т   |      |                                 |  |                       |   |      |           |
| 18   |  | Patient positioning     Casualty Collection Point procedures.   |   | Y                           |                              |                             |   |      |                                 |  |                       |   |      |           |
| 19   | Organisations ensure that staff view the appropriate NARU training and briefing DVDs   | National Strategic Guidance. PKP 100% Gold commanders. Specialist Architecture Service Reported to MTFA x PKP 100% MTFA commanders and teams. Non-Specialist Architecture Service Response to MTFA x KPI 80% of operational staff.  |   | Υ                           |                              |                             |   |      |                                 |  |                       |   |      |           |

|  |   |                 |        |        |           | le l   |     | 8              | 8   | Self assessment RAG  |                    |      |           |
|--|---|-----------------|--------|--------|-----------|--------|-----|----------------|---|--|--------------------|------|-----------|
|  |   | 2               | ders   | viders | ş .       | ogeu   |     | la ori         | isa io                                    | Red = Not compliant with core standard and not in the<br>EPRR work plan within the next 12 months. |                    |      | 4         |
|  |   | pivos s         | prov   | s bro  | team team | ale 6  |     | untinu<br>arms | 18.0                                      | Amber = Not compliant but evidence of progress and in the  |                    |      | 4         |
| Core standard  | Clarifying information  | care p          | ervice | ervice | local     | Regi   |     | alty pt        | Fig. Evidence of assurance                | EPRR work plan for the next 12 months.   | Action to be taken | Lead | Timescale |
|  |   | ealth<br>st pro | uce s  | nity s | gance     | gand   |     | care           | o 1 → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 → 0 → | Green = fully compliant with core standard.  |                    |      |           |
|  |   | cute h          | mprila | omme   | HS En     | R E    | s g | SUs (I         | Z 2                                       |  |                    |      | 4         |
| Governance   |   | 4 8             | ₹      | 0 3    | 8 Z       | Z      | ٥   | ८ ६७           | 8   |  |                    |      |           |
| Organisations maintain a HART Incident Response Unit (IRU) capability at all times within their operational service  | <ul> <li>Organisations maintain the four core HART capabilities to the nationally agreed safe system of work standards defined within this service<br/>specification.</li> <li>Organisations maintain the four core HART capabilities to the nationally agreed interoperability standard defined within this service specification.</li> </ul>                              |                 | Y      |        |           |        |     |                |   |  |                    |      |           |
| 3702.  | <ul> <li>Organizations take sufficient steps to ensure their HART unit(s) remains complaint with the National HART Standard Operating Procedures during local and national decloyments.</li> </ul>  |                 |        |        |           |        |     |                |   |  |                    |      |           |
| Organisations maintain a HART Urban Search & Rescue (USAR) capability at all times within their operational  | <ul> <li>Organizations maintain the minimum level of training competence among all operational HART staff as defined by the national training standards<br/>for HART.</li> </ul>  |                 | v      |        |           |        |     |                |   |  |                    |      |           |
| service area.  | <ul> <li>Organizations ensure that each operational HART operative is provided with no less than 37.5 hours protected training time every seven weeks. If designated training staff are used to augment the live HART team, they must receive the equivalent protected training hours within the seven week</li> </ul>  |                 |        |        |           |        |     |                |   |  |                    |      |           |
|  | period (in other words, training hours can be converted to live hours providing they are re-scheduled as protected training hours within the seven week period).  |                 |        |        |           |        |     |                |   |  |                    |      |           |
| Organisations maintain a HART Inland Water Operations (IWO) capability at all times within their operational service area.   | <ul> <li>Crganisations ensure that all HART operational personnel are Paramedics with appropriate corresponding professional registration (note s.3.4.6 of<br/>the specification).</li> <li>As part of the selection process, any successful HART applicant must have passed a Physical Competence Assessment (PCA) to the nationally</li> </ul>                            |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
|  | agreed standard and the provider must ensure that standard is maintained through an ongoing PCA process which assesses operational staff every 6 months and any staff returning to duty after a period of absence exceeding 1 month.  |                 |        |        |           |        |     |                |   |  |                    |      |           |
| Organisations maintain a HART Tactical Medicine Operations (TMO) capability at all times within their operational  | <ul> <li>Organizations ensure that comprehensive training records are maintained for each member of HART staff. These records must include; a record of mandated training completed, when it was completed, any outstanding training or training due and an indication of the individual's level of</li> </ul>  |                 |        |        |           | 1 1    |     |                |   |  |                    |      |           |
| 4 service area.  | competence across the HART skill sets.  |                 | Y      |        |           |        |     |                |   |  |                    |      |           |
|  | Four HART staff must be released and available to respond locally to any incident identified as potentially requiring HART capabilities within 15   |                 |        |        | -         | +      | -   | +              |   |  | +                  | 1    | +         |
|  | minutes of the call being accepted by the provider. Note: This standard does not apply to pre-planned operations or occasions where HART is used to support wider operations. It only applies to calls where the information received by the provider indicates the potential for one of the four-HART core capabilities to be required at the scene. See also standard 13. |                 |        |        |           |        |     |                |   |  |                    |      |           |
|  | <ul> <li>Organisations maintain a minimum of six competent HART safe on duty for live deployments at all times.</li> <li>Once HART capability is confirmed as being required at the scene (with a corresponding safe system of work) organisations can ensure that six</li> </ul>   |                 |        |        |           |        |     |                |   |  |                    |      |           |
| g Organisations maintain a local policy or procedure to ensure the effective prioritisation and deployment (or   | HART staff are released and available to respond to scene within 10 minutes of that confirmation. The six includes the four already mobilised.  Organisations maintain a HART service capable of placing six competent HART staff on-scene at strategic sites of interest within 45 minutes.  |                 |        |        |           |        |     |                |   |  |                    |      |           |
| 5 redeployment) of HART staff to an incident requiring the HART capabilities.  | These sites are currently defined within the Home Office Model Response Plan (by region). Competence is denoted by the mandatory minimum training requirements identified in the HART capability matrix.  |                 | Y      |        |           |        |     |                |   |  |                    |      |           |
|  | <ul> <li>Organisations maintain any live (on-duty) HART teams under their control maintain a 30 minute 'notice to move' to respond to a mutual aid request outside of the host providers operational service area. An exception to this standard may be claimed if the live (on duty) HART team is</li> </ul>   |                 |        |        |           |        |     |                |   |  |                    |      |           |
|  | already providing HART capabilities at an incident in region.   |                 |        |        |           |        |     |                |   |  |                    |      |           |
|  |   |                 |        |        |           |        |     |                |   |  |                    |      |           |
| 6 Organisations maintain a criteria or process to ensure the effective identification of incidents or patients at the point of receiving an emergency call that may benefit from the deployment of a HART capability.  |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations ensure an appropriate capital and revenue depreciation scheme is maintained locally to replace   | - To procure interoperable safety critical equipment (as referenced in the National Standard Operating Procedures), organisations should have processes in place to use the national buying frameworks coordinated by NARU unless they can provide assurance through the change   |                 | _      |        |           |        |     |                |   |  |                    |      | +         |
| / nationally specified HART equipment.   | management process that the local procurement is interoperable.   |                 |        |        |           |        |     |                |   |  |                    |      |           |
| 8 Organisations use the NARU coordinated national change request process before reconfiguring (or changing) any<br>HART procedures, equipment or training that has been specified as nationally interoperable.   |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| 9 Organisations ensure that the HART fleet and associated incident technology are maintained to nationally specified standards and must be made available in line with the national HART notice to move' standard.   |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations ensure that all HART equipment is maintained according to applicable British or EN standards and in line with manufacturers recommendations.   |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations maintain an appropriate register of all HART safety critical assets. Such assets are defined by their reference or inclusion within the National HART Standard Operating Procedures. This register must include;   |   |                 |        |        |           | 1 1    |     |                |   |  |                    |      |           |
| 11 Individual asset identification, any applicable servicing or maintenance activity, any identified defects or faults, the expected replacement date and any applicable statutory or regulatory requirements (including any other records   |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| which must be maintained for that item of equipment).  |   |                 |        |        |           |        |     |                |   |  |                    |      | 1         |
| estate specification.  |   |                 | Υ      |        | _         | $\bot$ |     |                |   |  | 1                  |      | 1         |
| 13 Organisations ensure their inclinent commanders are competent in the deployment and management or NHS HART resources at any live incident. In any event that the provider is unable to maintain the four core HART capabilities to the interoperability   |   |                 | Υ      |        | _         | +      |     |                |   |  | 1                  | 1    | 1         |
| that you have any power of the second of the |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| ostault in wrang to their lead commissioners.  Organisations support the nationally specified system of recording HART activity which will include a local procedure to ensure HART staff update the national system with the required information following each live   |   |                 | Υ      |        |           |        |     |                |   |  | 1                  |      |           |
| deployment.  |   |                 | H      |        |           | +      |     |                |   |  | 1                  |      | +         |
| Organisations maintain accurate records of their compliance with the national HART response time standards and<br>make them available to their local lead commissioner, external regulators (including both NHS and the Health &<br>Safety Executive) and NHS England (including NARU operating under an NHS England contract).  |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations ensure that the availability of HART capabilities within their operational service area is notified nationally every 12 hours via a nominated national monitoring system coordinated by NARU.  |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations maintain a set of local HART risk assessments which compliment the national HART risk assessments covering specific training venues or activity and pre-identified high risk sites. The provider must also   |   |                 | v      |        |           |        |     |                |   |  |                    |      |           |
| ensure there is a local process / procedure to regulate how HART staff conduct a joint dynamic hazards<br>assessment (JDHA) at any live deployment.  |   |                 | Y      |        |           |        |     |                |   |  | 1                  |      |           |
| Organisations have a robust and timely process to reportany lessons identified following a HART deployment or<br>19 training activity that may be relevant to the interoperable service to NARU within 12 weeks using a nationally   |   |                 | Υ      |        |           |        |     |                |   |  | 1                  |      |           |
| approved lessons database.  Organisations have a robust and timely process to report, to NARU and their commissioners, any safety risks  |   |                 |        |        |           | +      |     | _              |   |  | +                  | 1    | + -       |
| 20 related to equipment, training or operational practice which may have an impact on the national interoperability of<br>the HART service as soon as is practicable and no later than 7 days of the risk being identified.  |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| Organisations have a proces to acknowledge and respond appropriately to any national safety notifications issued for HART by NARU within 7 days.   |   |                 | Υ      |        |           |        |     |                |   |  |                    |      |           |
| <del></del>  |   |                 |        |        |           |        |     |                |   |  |                    |      |           |

Organisation: Alder Hey Children's NHS Foundation Trust

ACTIONS AND PROGRESS FROM 2016 / 2017

|                               | NS AND PROGRESS FROM 2010   | 07 2017   |  |  |
|-------------------------------|---|---|--|--|
| Core<br>standard<br>reference | Core standard description   | Improvement required to achieve compliance  | Action to deliver improvement  | Update on progress since last year   |
| 8                             | Evacuation Plan   | Evacuation Plan requires update to consider secondary points of evacuation in the event of bomb threat  | Continue with meetings to review arrangements update plan based on dynamic risk assessment   | Identified that this would be based on dynamic risk assessment at the time, however, further consideration currently being given regarding arrangements for whole hospital evacuation – plan is under development, to be completed by March 2018.            |
| 8                             | Excess Deaths/Mass Fatalities   | An additional area for holding bodies during excess deaths is currently being identified  | Identify contingency area  | Contingency area identified and agreed. Contingency plan detailing contingency arrangements to be developed.   |
| 23                            | Arrangements to ensure the ability to communicate internally and externally during communication equipment failures   | Telephone-bleep system resilience needs to be clear with business continuity action cards available, long with sufficient resilience in place if telephones/bleeps lost | Complete contingency action cards for telephone and bleep failure.  Meet with key Executives regarding requirement for radios in event of communications failure   | Complete   |
| 41/50                         | Rotas are planned to ensure that there is adequate and appropriate decontamination capability available 24/7. The organisation has sufficient number of trained decontamination trainers to fully support its staffs HAZMAT/CBRN training programme | New ED lead for<br>Emergency planning to be<br>identified (due to<br>retirement). ED Lead was<br>also a HAZMAT/CBRNE<br>Trainer.  | Appoint new ED lead and then take action to provide training to staff to allow decontamination capability. ED to identify additional HAZMAT/CBRNE trainers and organise attendance at the NWAS course, following in house training from Trust trainer. | The ED EPRR Clinical lead for Emergency Planning is in post from 21/08/17 (9.75 hrs per week) and one of their roles will be to review 24/7 decontamination capability. The ED EPRR Clinical Lead is also the trained decontamination trainer for the Trust. |

| Core standard reference | Core standard description | Improvement required to achieve compliance            | Action to deliver improvement           | Update on progress since last year |
|-------------------------|---------------------------|---|---|------------------------------------|
| DD5                     | Fuel Plan                 | Update fuel plan to include reference to heating fuel | Reference heating fuel in the Fuel Plan | Complete                           |

### ACTIONS ARISING FROM 2017 / 2018 ASSURANCE PROCESS

| Core<br>standard<br>reference | Core standard description  | Improvement required to achieve compliance   | Action to deliver improvement   | Deadline |
|-------------------------------|--|--|---|----------|
| 10/53                         | There is an organisation specific HAZMAT/ CBRN plan (or dedicated annex)   | There is an organisation<br>CBRNE/HAZMAT plan, however, due<br>to the ED EPRR Clinical Lead only just<br>being appointed, the plan requires<br>update/refresh  | Update/refresh CBRNE/HAZMAT plan<br>Action Lead: ED EPRR Clinical Lead  | 31/03/18 |
| 31                            | Those on-call must meet identified competencies and key knowledge and skills for staff.                                    | Whilst on call staff receive local major incident and business continuity training, this will be developed further to ensure the training meets the National Occupational Standards for Strategic, Tactical and Operational Staff. | Develop core competency checklist for strategic, tactical and operational staff, in line with National Occupational Standards.  | 31/03/18 |
| 56                            | Rotas are planned to ensure that there is adequate and appropriate decontamination capability available 24/7               | Review of rotas to ensure decontamination capability 24/7  | ED EPRR Clinical Lead is in post from 21/08/17 (9.75 hrs per week). Rotas will be reviewed this year in liaison with ED Manager | 31/03/18 |
| 64                            | Internal HAZMAT/CBRNE training is based upon current good practice and uses material that has been supplied as appropriate | The HAZMAT/CBRNE one day training programme needs to be reintroduced.  | ED EPRR Clinical Lead is in post from 21/08/17 (9.75 hrs per week) and will re-establish 1 day HAZMAT/CBRNE training for staff. | 31/03/18 |

Actions arising from Governance Deep Dive Standard (these actions aren't included as part of the main Core Standards Assessment, but will be taken forward):

| Core<br>standard<br>reference | Core standard description  | Improvement required to achieve compliance   | Action to deliver improvement  | Deadline |
|-------------------------------|--|--|--|----------|
| DD2                           | The organisation has published<br>the results of the 2016/17 NHS<br>EPRR assurance process in<br>their annual report | Publish the results of future EPRR assurance processes in the Emergency Preparedness Annual Report | Publish the results of the 17/18 NHS<br>EPRR assurance process in the 17/18<br>Annual Report | 31/03/18 |

# Cheshire & Merseyside Local Health Resilience Partnership (LHRP) Emergency Preparedness, Resilience and Response (EPRR) assurance 2017-2018

### **STATEMENT OF COMPLIANCE**

Alder Hey Children's NHS Foundation Trust has undertaken a self-assessment against required areas of the the NHS England Core Standards for EPRR v5.0.

Following assessment, the organisation has been self-assessed as demonstrating the Substantial compliance level (from the four options in the table below) against the core standards.

| Compliance Level | Evaluation and Testing Conclusion   |
|------------------|---|
| Full             | Arrangements are in place and the organisation is fully compliant with all core standards that the organisation is expected to achieve. The Board has agreed with this position statement.  |
| Substantial      | Arrangements are in place however the organisation is not fully compliant with one to five of the core standards that the organisation is expected to achieve. A work plan is in place that the Board or Governing Body has agreed.   |
| Partial          | Arrangements are in place however the organisation is not fully compliant with six to ten of the core standards that the organisation is expected to achieve. A work plan is in place that the Board or Governing Body has agreed.  |
| Non-compliant    | Arrangements in place do not appropriately address 11 or more core standards that the organisation is expected to achieve. A work plan has been agreed by the Board or Governing Body and will be monitored on a quarterly basis in order to demonstrate future compliance. |

The results of the self-assessment were as follows:

| Number of applicable standards  | Standards rated as <b>Red</b> | Standards rated as<br>Amber | Standards rated as<br>Green |
|---|-------------------------------|-----------------------------|-----------------------------|
| 60  | 0                             | 4                           | 56                          |
| Acute providers: 60** Specialist providers: 51** Community providers: 50** Mental health providers: 48** CCGs: 38 |                               |                             |                             |

<sup>\*\*</sup>Also includes HAZMAT/CBRN standards applicable to providers: Standards: Acutes 14 / Specialist, Community, Mental health 7
Ambulance Service are required to report statements for 3 compliance levels as stated on page 6 of the Gateway letter 06967

Where areas require further action, this is detailed in the attached core standards improvement plan and will be reviewed in line with the organisation's EPRR governance arrangements.

I confirm that the above level of compliance with the core standards has been agreed by the organisation's board / governing body along with the enclosed action plan and governance deep dive responses.

| Signed by the organisa                 | tion's Accountable Emergency Officer |
|--|--------------------------------------|
|  |                                      |
| Date of board / governing body meeting | Date signed                          |



### **Board of Directors**

### 3<sup>rd</sup> October 2017

| Report of:   | Director of Human Resources & Organisational Development                         |
|--|--|
| Paper Prepared by:   | Director of Human Resources & Organisational Development                         |
| Subject/Title:   | People Strategy Update for August 2017   |
| Background Papers:   | n/a  |
| Purpose of Paper:  | To present to the Board monthly update of activity for noting and/or discussion. |
| Action/Decision Required:                                  | The Committee is asked to note the contents of the report.                       |
| Link to:  Trust's Strategic Direction Strategic Objectives | The Best People Doing their Best Work  |
| Resource Impact:   | None   |

### **Section 1 - Engagement**

### **Reward & Recognition**

In response to the monthly Star Awards, 122 nominations were received during August. The winner was voted for by the panel (comprising a range of staff and staff side) and arrangements are being made for presentation by an Executive Director in early October. Nominations for September will be reviewed in October.

The annual staff awards will be launched at the beginning of October. Co-ordination is in progress, with categories identified and a separate independent judging panel to that on the monthly awards. The evening ceremony will be held in February 2018.

'Fab Change Week' in late October will be celebrated through a number of different staff engagement initiatives, and is being led by the LiA 'Reward and Recognition' group.

### **Staff Survey**

The 2017 Staff Survey campaign was launched on 22<sup>nd</sup> September. The staff survey strategy group have developed a Trust wide communication program aimed at managers to promote and engage staff to complete the survey. The program includes face to face meetings with managers to promote survey completion; a pocket guide for managers with reminders about previous actions "you said...we did.." plus weekly statistics on departmental response rates. The strategy group will meet weekly throughout the survey timeline, until 1<sup>st</sup> December to support the on-going campaign, and will review the results early 2018, to inform future Trust wide and local conversations and action plans.

### Section 2 - Availability of key skills

### **Employee Consultations**

### **Trust Nursery**

The recent Nursery consultation has concluded with one facilities post at risk. The post holder has been found a redeployment post and is currently undertaking a 4 week trial.

#### **Hotel Services**

Domestics and Portering staff (Portering and Portering Supervisors) organisational change programmes were initiated on 9 June 2017 which consisted of proposed reductions of staff (Portering Supervisors) and review of shift patterns/rotas in the other groups. The three consultations were due to conclude on 24 July 2017. A number of issues were raised by staff and staffside during the consultation in each of the staffing groups and further investigation is being undertaken by management requiring an extension to each of the consultations until 25<sup>th</sup> August 2017. A review meeting was undertaken on 8<sup>th</sup> September 2017 with key management stakeholders and union representatives to agree deliverables. The consultation period was extended to 30<sup>th</sup> September 2017 with further management/union meetings to be scheduled in early October 2017

### **Home Care Service – Community Division**

An Organisational Change is in progress within the Home Care team for the following reasons: natural expiry of packages, progression of packages into adult services and having no further expansion of packages within the service since Nov 2016 commissioned by the CCG. This has resulted in seven Band 3 HCA staff being effected as displaced, four of whom area already displaced and are working temporarily within the Trust covering for agency, bank etc. These staff have been placed on the Trust's redeployment register and it is hoped that suitable alternative positions can be sort. A briefing paper has been submitted to Staff Side and signed off by Senior Management and formal consultations are in progress.

Formal consultation has been concluded with no additional comments from either staff or staff side, the final consultation paper is pending official sign off. In the duration, all staff affected have been allocated alternatives roles and are either currently undertaking trails or have completed and been accepted. One individual has been since identified as requiring further information before Home Care Organisation can be concluded.

### **Complex Care Team**

Organisational change process for services which were formally LCH, and are the same as Alder Hey Home Care Team affecting two individuals as a result of expiry of packages. Briefing paper completed and invite to consultation have been instigated.

### **Education, Learning and Development**

### **Apprenticeships**

The first cohort of internally delivered apprenticeship qualifications for our existing staff will commence in October 2017 with Healthcare Support and Team Leading. We have over 30 staff currently enrolled. Work is still ongoing to develop this qualification portfolio further with Blackburne House as a support to ensure the apprenticeship strategy remains on track. We are also supporting Liverpool Community Health with their apprenticeship planning.

### **Management & Leadership Development**

A detailed paper has been presented to the Workforce and OD Committee with regards progress against the strategy, however for the purposes of this report, a brief overview of activity over the last 12 months is below:

- Delivery of Work based Coaching training (11 managers)
- Leading by Values programme (2 cohorts 23 managers)
- New Managers Induction (34 since April 17)
- 360 degree feedback facilitation
- Individual coaching sessions

All activities have been rates highly by participants. September and October sees the roll out of the HR Management Skills programme, Team Leader apprenticeships and planning for the next work-based coaching programme.

### **Widening Participation**

### **Schools Placement Support Programme**

To date in 2016/17, 60 BTEC Health and Social Care students from local schools have completed a two week placement programme at Alder Hey. In September 2017, we have organised another induction and have 65 students attending who will commence their placement in October. The programme is very successful, with a number of students securing a place at Edge Hill or John Moores universities to study for degrees in Children's Nursing/Learning Disabilities/Child Studies/Child Health and Wellbeing/Social Work. The universities guarantee the students an interview if they have completed a placement at Alder Hey as they see this as valuable experience.

### **Pre-employment Programme**

The Trust is working in partnership with Job Centre Plus, and we are now participating in various schemes which will allow us to develop a "grow our own "strategy. We have recently recruited 10 unemployed local people to participate in a pre-employment programme which consists of 1 week induction and 9 weeks work experienced based learning. Following the 10 weeks all learners who have successfully completed the program will be given the opportunity to apply for internal vacancies and join our bank.

### **Careers Events**

Alder Hey hosted a careers event which was attended by 15 Year 10 students from a local school in June 2017. During the event the pupils were given the opportunity to listen to speakers from different professions describing their own personal career experiences and achievements. The students were also allowed to spend some time in our innovation hub learning about our 3D printing technology and attended basic life support session.

Alder Hey has signed up to collaborate with Merseyside Health Sector Career & Engagement Hub and Health Education England to enable strong links in the community and promote Alder Hey as an employer of choice. Human Resources and leads from our clinical areas will be attending a careers event on Tuesday 28<sup>th</sup> November based at the Titanic Hotel which will be co-ordinated by the Merseyside Health Sector Career & Engagement Hub. We will be promoting Ophthalmology, Theatres, and Radiology careers to year 10 pupils from several local schools.

We have also attended a number of high profile recruitment events, such as the RCN Jobs Fair at the Liverpool Echo Arena.

### **Section 3 - Structure & Systems**

### **Employee Relations Activity**

By the end of August the Trusts ER activity remains at 18 cases. These are 2 formal disciplinary cases, 4 formal Bullying and Harassment cases (2 cases have moved to informal mediation stages), 5 formal grievances, and 3 Employment Tribunal (ET) cases. In addition there are 2 final absence dismissal cases and 2 formal capability cases.

The senior HR team recently held an 'HR Case Summit' to review all cases and to look at best practice in case management. The summit demonstrated that we are managing all cases robustly, however the team will be introducing a 'lessons learned' session, in order to support more junior members of the HR team to increase their case management knowledge.

### **Employment Tribunal Cases**

- The ET Claim relating to unfair dismissal and wrongful dismissal, due to be heard on 30<sup>th</sup> and 31<sup>st</sup> August was postponed at the Trusts request on compassionate leave grounds, has been rescheduled for 7<sup>th</sup>, 8<sup>th</sup> and 9th February 2018.
- An ET Claim relating to unlawful deduction of wages and breaches of the Agency Workers Regulations due to be heard on 7 and 8 June 2017 was postponed to allow for inclusion of an additional respondent. The Tribunal hearing is now scheduled to take place between 6<sup>th</sup> to 8<sup>th</sup> December 2017
- An ET claim relating to constructive / unfair dismissal and disability discrimination has been lodged. A pre-hearing was held in August and the case will be heard at Tribunal on 26<sup>th</sup> 27<sup>th</sup> 28<sup>th</sup> Feb and 1<sup>st</sup> March.

### **Corporate Report**

The HR KPIs in the July Corporate Report are:

- Sickness has increased slightly to 5%
- Corporate Induction has increased to 100% compliance
- PDR compliance has increased to 79%
- Mandatory training compliance has remained the same at 76%

Actions to address shortfalls are being addressed by members of the HR & L&D team with the CBU management teams. Ongoing ESR training and support has been provided to managers by the HR Team to ensure accuracy in recording.

### **Payroll Key Performance Indicators**

We are achieving the KPI of 99.5% payroll accuracy, and have done so now for the past three months. This has been achieved through good partnership working with our payroll provider, ELFS, and through increased training, support and focus for managers who were generating the majority of the errors.

### **Workforce Sustainability Group**

A task and finish group has recently been set up to focus on improving spend on temporary staffing. This working group reports through the Change Programme. To date, the group have identified some quick wins in the top 20 areas for pay overspend, but are now looking at more detailed work around reasons for overspend, and the impact upon workforce resilience and sustainability.

### **NHS Professionals (NHSP)**

NHSP are the Trust's provider of bank staff and flexible workers. Comparing Alder Hey Bank performance in August to the National & Northwest average statistics for the same period demonstrate very positive results, as Alder Hey has by far the highest Bank fill & lowest

Agency Fill compared to both the North West & National statistics, using only 0.2 WTE agency in August (nursing).

#### **Enhancements to ESR**

The HR team have been continuing to work on developments in ESR and the roll out of the ESR portal is progressing well- 1734 paper payslips went electronic by August payday.

The training on the ESR app has been well received and bespoke sessions have also been held across departments. Step by step guides have also been provided to managers and staff with many opting to follow the guides as opposed to full training, as they have found it very easy to access and use. To date the app and process has been well received amongst managers and staff. Further roll out of the portal and Manager Self Service will provide managers with a more user friendly platform for accessing their workforce data.

The Trust has also been undertaking a comprehensive data cleanse of 'position based competencies' and their alignment to job roles. As a result of this a full training matrix was revised to ensure that that the appropriate competences are aligned to positions correctly, which has now been captured in ESR. This has enabled the HR &OD team to run more accurate reports through BI.

#### Section 4 - Health & Wellbeing


#### **Team Prevent**

A Health Trainer is now working with the Trust providing stress management and relaxation/mindfulness training. These sessions have proved popular and will be scheduled and promoted accordingly. A session is being planned for management training in respect of how to recognise signs of stress with strategies on how to manage it. Further to the stress management sessions, the health trainer has confidentially supported a number of staff with stress symptoms to help them avoid absence from work where possible. The health trainer is working closely with theatres management team to consider a program of support for staff who may have experienced stress at work or signs of PTSD.

# **National Guardian**Freedom to Speak Up

### Freedom to Speak Up Guardian Survey 2017

Findings and recommendations



The National Guardian's Office

#### Introduction



The requirement for trusts and foundation trusts to have a Freedom to Speak Up Guardian has been in place since October 2016, just as I took up post as National Guardian.

The National Guardian's Office set out its expectations about the role early on but I have been struck by the wide range of approaches that organisations have taken in implementing the role. This survey has given us the first opportunity to quantify some of this variation.

Enabling organisations to implement the role in a way that is right for them is important as no two organisations are the same. The new role allows for it to be integrated into the priorities of individual trusts. The diverse occupations

and professional backgrounds of those in the guardian or champion / ambassador role has also proven to be a great source of strength. We have built up a unique network of individuals where traditional barriers between grade and profession simply do not exist and where everyone can draw upon the experience and expertise of everyone else. I am proud to lead this network and see it as a potentially powerful force for change and a source of skill, commitment, and knowledge that I hope others in and around the healthcare system can draw upon.

Consistency in approach does, however, have a part to play. I want everyone working in the health system to know that they can go to a Freedom to Speak Up Guardian for support and advice about speaking up and for their expectations to be met, no matter which organisation they are in. Some of the recommendations in this report therefore focus on ensuring that, amongst all the variation, a consistent core to the guardian role is maintained.

The guardian role is not an easy one. Our expectations are high and broad and, as patient safety and staff wellbeing are at its heart, we believe that it is a role in which it is well worth investing. Investment includes support and guardians need the support and commitment of their senior leaders to do their job and sufficient time to be reactive and proactive in culture change. The recommendations, drawn from the experience of guardians will enable trusts and foundation trusts to ensure that this role will meet the needs of all their staff.

I hope that senior leaders, guardians, champions, ambassadors and all those with an interest in speaking up will welcome this report. It is an honest reflection of how this new role is developing at the start of the Freedom to Speak Up journey, and I look forward to repeating this exercise next year to see how the recommendations have been implemented.

Dr Henrietta Hughes, National Guardian for the NHS

#### **Background and summary**

The development of the Freedom to Speak Up Guardian role was a recommendation made by Sir Robert Francis in "Freedom to Speak Up" in <u>2015</u>. The standard NHS contract requires all trusts and foundation trusts to nominate a Freedom to Speak Up Guardian by October 2016.

Guidance on the role including a job description was issued by the National Guardian's Office, initially in April 2016, with a revised form being issued in June 2016. Support was given to guardians and trusts throughout 2016 /17, including foundation training and the development of regional networks to promote local learning and sharing of good practice.

Whilst the overall requirements of the role have been published, the role is not centrally funded, with trusts being expected to implement the role according to local need and resources. As this is a new initiative, and one that requires a broad range of skills and qualities, up until this point the National Guardian's Office has not issued detailed guidance on the grading of the role, where the role should fit in within organisational structures, or how the role should be resourced.

This survey is intended to provide a more systematic understanding of how the role has been implemented, who is being appointed to the role and, for the first time, ask the new network of guardians for their thoughts on Freedom to Speak Up within their trusts.

Ensuring that the needs of staff are met and that Freedom to Speak Up develops in a way that responds to local circumstances, are fundamental principles of the role. The results of this survey have helped identify some potential issues. These are highlighted and trust and foundation trust leadership teams are encouraged to reflect on these and, where necessary, make changes to ensure that the guardian role is properly resourced, embedded and used as the source of support, learning and improvement that it is intended to be.

The questions included in the survey can be found in the **Annex** to this report. These are divided into broad groups looking at how the guardian role has been implemented, who is in the role, and perceptions of Freedom to Speak Up. Respondents were also asked to consider what support they felt they needed from the National Guardian's Office and for examples of success and challenges that they face.

The survey was distributed to 493 email addresses and was open between 12 June and 30 June 2017. A total of 234 responses were received (a 47% response rate).

### **Key findings and recommendations (1-4)**

| #  | AREA                            | RECOMMENDATION   |
|----|---------------------------------|--|
| 1. | Appointment                     | We recommend that appointment of guardians is made in a fair and open way, and that senior leaders assure themselves that workers throughout their organisation have confidence in the integrity and independence of the appointee.  |
| 2. | Potential conflicts of interest | We recommend that all guardians / ambassadors / champions reflect on the potential conflicts that holding an additional role could bring and that they devise mechanisms to ensure that there are alternative routes for Freedom to Speak Up matters to be progressed should a conflict become apparent when supporting someone who is speaking up.  |
|    |                                 | We see particular potential for conflicts to arise where a guardian also has a role as a human resources professional and recommend that guardians do not have a role in any aspect of staff performance or human resources investigations.  |
| 3  | Local networks                  | We recommend that all trusts consider developing a local network of ambassadors / champions, depending on local need, to help provide assurance that all workers have appropriate support and opportunities to speak up, and to give guardians alternative routes to pursue speaking up matters should they be faced with a real or perceived conflict. Members of a local network could also cover the guardian role when the guardian is absent, on leave etc. |
| 4  | Diversity                       | We recommend that all trusts take action to ensure that all workers, irrespective of their ethnicity, age, sexuality or other diversity characteristics, have someone they feel able to go to for support in speaking up.  |
|    |                                 | Guardians should consult with relevant representative groups in developing their approach on this matter. Guardians should also take action to assure themselves that any potential barriers to speaking up that particular groups face are understood and tackled.  |

### **Key findings and recommendations (5-10)**

| #  | AREA                        | RECOMMENDATION   |
|----|-----------------------------|--|
| 5  | Communication and training  | We recommend that all guardians use all appropriate communication channels to ensure that all staff know of their role, and work with colleagues to ensure that Freedom to Speak Up is incorporated in all relevant staff training and development programmes, and particularly in staff inductions.  In conjunction with the relevant parts of their organisation, guardians should monitor the effectiveness of their communication and training activities. Guardians should ensure that the language and message of communications and training are consistent with national guidance. |
| 6  | Partnership                 | We recommend that all guardians continue to develop working partnerships with all relevant parts of their organisation.  |
| 7  | Access to senior leadership | We recommend that all guardians have direct and regular access to their chief executive and non-executive director with responsibility for speaking up.  |
| 8  | Board reporting             | We recommend that guardians or a representative from a local network of champions / ambassadors personally presents regular reports to their board. Board reports should include measures of activity and impact and, where possible, include 'case studies' describing real examples of speaking up that guardians are handling.  |
| 9  | Feedback                    | We recommend that guardians always gather feedback on their performance, from their line managers, the partners they work with, and from those they are supporting.  |
| 10 | Time                        | We strongly recommend that all trusts provide ring-fenced time for anyone appointed as a guardian / ambassador / champion to carry out their role and attend training, regional and national network meetings, and other events.   |



#### **Fairness**

Freedom to Speak
Up Guardians
should be
appointed in a fair
and open way



#### Conflict

Freedom to Speak
Up Guardians
should guard
against potential
conflicts caused
by holding
additional roles



#### Reach

The Freedom to Speak Up message should reach everyone – developing a local network of ambassadors can help with this



#### **Diversity**

All staff groups, especially the most vulnerable, need routes to enable them to speak up – staff networks can support this



#### Communication

Freedom to Speak
Up messages
should be included
in training and
feedback on
how it generates
change should
be disseminated
regularly

### Freedom to Speak Up Guardian Survey 2017

#### 10 principles for the role.

These principles are derived from the findings of our 2017 Freedom to Speak Up Guardian Survey.



#### **Partnership**

Freedom to Speak
Up Guardians
need to forge
strong partnerships
with teams
and individuals
throughout their
organisation



#### Leadership

Leaders should demonstrate their commitment to Freedom to Speak Up and CEOs and NEDs should meet regularly with their Guardian



#### **Openness**

Freedom to Speak
Up Guardians
should present
regular reports
to their Board,
in person



#### **Feedback**

Freedom to Speak
Up Guardians
should gather
feedback on
their performance



#### Time

Freedom to Speak
Up Guardians
should have
enough time and
other resources
to meet the needs
of workers in their
organisation

### **Detailed findings and discussion**

## 1. How the Freedom to Speak Up Guardian role has been implemented

#### Appointment to the role

At the time of the survey, the requirement to have nominated a guardian had been in effect for nine months, though we know that many trusts had taken early action in response to the Francis recommendations. It is not surprising, therefore, to note that **59%** of respondents had been in post for over 6 months, with **17%** being in post for 18 months or longer.

We asked how individuals were appointed to the guardian / champion / ambassador role. **60%** of respondents had been personally approached, volunteered, or were nominated. Whilst **56%** of this group were also interviewed as part of the process, this illustrates the 'personal' nature of many of the appointments.

The guardian role is one that requires a high degree of personal integrity, and the individual in the role needs to work alongside senior leaders whilst also capturing the confidence of staff throughout the organisation. In addition, the person needs to be able to act independently and under their own initiative. Given this, we see potential difficulties if appointments are made to the role without a transparent, fair and open process and we would always recommend that appointments are made in this way. To give further confidence that appointees have the confidence of workers, we know of some trusts where the appointment process has incorporated staff elections, values based recruitment, and other elements where staff representatives can be involved in the process.

#### **#1.** Appointment

We recommend that appointment of guardians is made in a fair and open way and that senior leaders assure themselves that workers throughout their organisation have confidence in the integrity and independence of the appointee

The survey did not specifically address the appointment of Freedom to Speak Up ambassadors / champions who usually play a supporting role to the guardian and who are often employed to increase the 'reach' of Freedom to Speak Up across a trust. Whilst appointments to these roles clearly need to meet local needs we would encourage them to be made upholding the same principles we recommend in relation to the appointment of guardians.

#### Who is in the role?

The vast majority of respondents (84%) indicated that they held another role alongside that of guardian or champion / ambassador. This 'other' role includes a broad range of clinical and non-clinical roles (table 1.1).

| 1.1 Other role                 | % respondents |
|--------------------------------|---------------|
| Nurse                          | 23%           |
| Corporate Services             | 18%           |
| Allied Healthcare Professional | 11%           |
| Administrative / clerical      | 7%            |
| Human Resources                | 6%            |
| Organisational Development     | 6%            |
| Governor                       | 6%            |
| Doctor                         | 5%            |
| Safety                         | 4%            |
| Midwife                        | 2%            |
| Chaplaincy                     | 2%            |
| Healthcare Assistant           | 1%            |
| Therapist                      | 1%            |
| Maintenance / ancillary        | 0.5%          |
| Other*                         | 28%           |

<sup>\*</sup>responses include: company secretary, adult safeguarding lead, front of house manager, non-executive director, IT director, oral health promoter, listening into action lead, staff side chair

We think that this variety brings richness to the network of guardians and ensures that there is a wide range of peer-support available for guardians. This diversity brings a broad breadth of knowledge, insight and experience to bear on the guardian role, which will help ensure that it continues to develop to reflect the needs of all NHS workers.

However, carrying out two (or more) roles does not come without its challenges, both in terms of ensuring that enough time is given to the guardian role, and in managing potential conflicts of interest and perceptions of the ability of a guardian to act independently.

#### #2. Potential conflicts of interest


We recommend that all guardians / ambassadors / champions reflect on the potential conflicts that holding an additional role could bring and that they devise mechanisms to ensure that there are alternative routes for Freedom to Speak Up matters to be progressed should a conflict become apparent when supporting someone who is speaking up. We see particular potential for conflicts to arise where a guardian also has a role as an HR professional and recommend that guardians do not have a role in any aspect of staff performance or HR investigations.

The development of a local network of ambassadors / champions can help provide alternative routes to avoid conflict when a speaking up matter is being pursued, whilst also increasing 'reach' across larger or widely dispersed organisations. A network can also provide a diverse range of individuals for staff to seek support from. It is encouraging to see that **63%** of respondents said that they were part of a local network of this type.

#### #3. Local networks

We recommend that all trusts consider developing a local network of ambassadors / champions, depending on local need, to help provide assurance that all workers have appropriate support and opportunities to speak up, and to give guardians alternative routes to pursue speaking up matters should they be faced with a real or perceived conflict. Members of a local network could also cover the guardian role when the guardian is absent, on leave etc.

As with professional background, a similarly broad range of grading / band is also represented within the guardian network (see below)



| 1.2 Band / grade    | % respondents |
|---------------------|---------------|
| Very Senior Manager | 7%            |
| 9                   | 2%            |
| 8d                  | 4%            |
| 8c                  | 9%            |
| 8b                  | 10%           |
| 8a                  | 16%           |
| 7                   | 26%           |
| 6                   | 8%            |
| 5                   | 3%            |
| 4                   | 3%            |
| 3                   | 0.5%          |
| Volunteer           | 1%            |
| Other*              | 11%           |

<sup>\*</sup>responses include: non-executive director and independent / self-employed role


The guardian role is a broad one that requires reach and credibility from the frontline to the board and, most importantly, the ability to support, encourage, and capture the trust of any worker within an organisation (table 1.2). Given that, we see this wide range of banding as a strength. However, we do appreciate that it may be more difficult for individuals in lower banded roles to gain the confidence of, and challenge, senior leaders. Similarly, those in higher banded roles may be faced with barriers that being further up the 'hierarchy' can bring when trying to capture the trust and confidence of staff at lower grades. Nevertheless, we are reassured by the experiences of our guardians and those who are speaking up to them that these barriers are being overcome.

We continue to believe that appointments to a guardian role need to have the personal qualities of individuals front and centre, rather than focusing on banding. However, when this area is being considered we would encourage trusts to look at the job description in the round and ensure that whoever is in the role is appropriately rewarded for their work.

Building on this, it is clearly helpful if guardians have experience of speaking up themselves, and we note with interest that **42%** of respondents said that they had. Respondents provided us with a wide range of examples illustrating their experience, these included matters of abuse in a residential care setting, unsafe staffing levels, staff being pressurised to make decisions outside their area of competence, lack of support for vulnerable groups, challenging decisions made by senior leaders, fraud, and reports of bullying behaviour amongst senior colleagues.

It is essential that all workers in an organisation feel able to speak up and able to access the support of a guardian / ambassador / champion should they need it. To do this, they need to be able to turn to someone whom they can trust. We therefore note with interest the demographic profile of respondents to the survey.

**91%** of respondents are white (table 1.3), **79%** are women (table 1.4), **44%** are between 45 – 54 years old (table 1.5), **91%** did not consider themselves to have a disability (table 1.6), and **88%** are straight / heterosexual (table 1.7).



| 1.3 Ethnicity                               | % respondents |
|---|---------------|
| White                                       | 91%           |
| Mixed / multiple ethnic groups              | 1%            |
| Asian / Asian British                       | 3%            |
| Black / African / Caribbean / Black British | 5%            |
| Chinese                                     | 0.5%          |
| Other                                       | 0%            |

| 1.4 Gender        | % respondents |
|-------------------|---------------|
| Male              | 20%           |
| Female            | 79%           |
| Prefer not to say | 1%            |

| 1.5 Age           | % respondents |
|-------------------|---------------|
| 16 – 34           | 6%            |
| 35 – 44           | 24%           |
| 45 – 54           | 44%           |
| 55+               | 24%           |
| Prefer not to say | 2%            |

| 1.6 Response to the question "Do you consider yourself to have a disability?" | % respondents |
|---|---------------|
| Yes   | 6%            |
| No  | 91%           |
| Prefer not to say   | 3%            |

| 1.7 Sexuality           | % respondents |
|-------------------------|---------------|
| Bisexual                | 1%            |
| Gay man                 | 4%            |
| Gay woman / lesbian     | 0.5%          |
| Heterosexual / straight | 88%           |
| Prefer not to say       | 7%            |

Whilst none of these factors should present a barrier to workers speaking up to guardians, we are aware that they may do so for some and therefore recommend that all trusts take action to assure themselves that all staff have a range of individuals they can go to for support in speaking up, including individuals of differing diversity characteristics. We would also encourage guardians to forge close working partnerships with staff diversity networks and consider recruiting and training members of these groups as champions / ambassadors, or developing some other means of partnership working so that the trust has the assurance that all workers feel supported and able to speak up.

#### #4. Diversity

We recommend that all trusts take action to ensure that all workers, irrespective of their ethnicity, age, sexuality or other diversity characteristics, have someone they feel able to go to for support in speaking up. Guardians should consult with relevant representative groups in developing their approach on this matter. Guardians should also take action to assure themselves that any potential barriers to speaking up that particular groups face are understood and tackled.

#### 2. Freedom to Speak Up Guardian activities

In addition to one-to-one support for people speaking up, guardians are engaged in a wide range of communication and engagement activities

| 2.1 Activity                        | % respondents |
|-------------------------------------|---------------|
| Communication of role internally    | 88%           |
| Communication of role externally    | 11%           |
| Involvement in staff induction      | 62%           |
| Involvement in other staff training | 52%           |
| Attending team meetings             | 65%           |
| Carrying out surveys                | 16%           |
| Other*                              | 25%           |

<sup>\*</sup>responses include: developing steering and other working groups, back-to-floor visits, attending out-of-hours services, taking part in leadership programmes

A wide range of partnerships are also being forged

| 2.2 Partnership                    | % respondents |
|------------------------------------|---------------|
| Senior leaders / the Board         | 83%           |
| HR                                 | 82%           |
| Organisational Development teams / | 50%           |
| similar                            |               |
| Communications teams               | 73%           |
| Training and Development teams     | 49%           |
| Unions / staff-side                | 54%           |
| Staff diversity networks           | 36%           |
| Patient representative groups      | 18%           |
| Internal Audit                     | 15%           |
| Other*                             | 15%           |

<sup>\*</sup>responses include: patient experience teams, safety and quality teams, occupational health, information governance and guardians in other trusts

We think this broad range of activities (table 2.1), and developing partnership working (table 2.2), is encouraging. We would advocate that all guardians continue to communicate their role, work with colleagues to ensure that Freedom to Speak Up messages are incorporated into staff training and development programmes (particularly staff inductions), and continue to forge working relationships throughout their organisation.

#### #5. Communication and training

We recommend that all guardians use all appropriate communication channels to ensure that all staff know of their role, and work with colleagues to ensure that Freedom to Speak Up is incorporated in all relevant staff training and development programmes, and particularly in staff inductions. In conjunction with the relevant parts of their organisation, guardians should monitor the effectiveness of their communication and training activities. Guardians should ensure that the language and message of communications and training are consistent with national guidance.

#### #6. Partnership

We recommend that all guardians continue to develop working partnerships with all relevant parts of their organisation.

The relationships between a guardian and their chief executive and non-executive director with responsibility for speaking up are particularly important ones. A guardian needs to support their senior leaders in creating a culture where speaking up can flourish whilst also maintaining their independence to enable confidential investigations to happen and, if appropriate, to step outside of their organisation's leadership altogether. We are therefore pleased to note that 86% of respondents said that they had direct access to their chief executive (with 14% saying that they did not), and 76% of respondents said that they have direct access to their non-executive director with responsibility for speaking up (with 24% saying that they did not). We believe, however, that all guardians should have this direct access.

#### #7. Access to senior leadership

We recommend that all guardians have direct and regular access to their chief executive and non-executive director with responsibility for speaking up.

Boards need to be kept abreast of all matters related to speaking up. This encompasses being sighted on both the issues being raised, and apparent barriers to speaking up. Board members also need to model speaking up behaviours, demonstrate their responsiveness and, in particular, provide feedback so that people who are speaking up are assured that they are being listened to and that action is being taken. In addition, so that Freedom to Speak Up messages can be taken to the board in an unfettered manner, and so that the independence of a guardian can be seen in practice, we believe it is important that guardians present regular reports to their board in person. We are therefore disappointed to note that only **55%** of respondents said that they present reports to board meetings in person.

#### #8. Board reporting

We recommend that guardians or a representative from a local network of champions / ambassadors personally presents regular reports to their board.


Asking for, receiving, and acting on feedback is a central aspect of an effective speaking up process with a lack of feedback being a significant barrier to encouraging workers to speak up in the first place. We therefore see it as essential that guardians role-model this behaviour by always asking for feedback, both from the people who speak up to them (guardians have been provided with a standard from of wording to use when asking for this feedback), and from others who can comment on their performance more generally. However, only 46% of respondents said that they gathered feedback on their performance (with 54% saying that they don't).

#### #9. Feedback

We recommend that guardians always gather feedback on their performance, from their line managers, the partners they work with, and from those they are supporting

#### 3. Implementation of and support for the role

**51%** of respondents said that they didn't have any ring-fenced time for the guardian role and the total proportion of respondents who had one day or less assigned to the role was **70%**.



| 3.1 Amount of ring-fenced time | % respondents |
|--------------------------------|---------------|
| None                           | 51%           |
| Up to 0.5 days / week          | 7%            |
| Up to 1 day / week             | 12%           |
| Up to 2 days / week            | 13%           |
| Up to 3 days / week            | 10%           |
| Up to 4 days / week            | 1%            |
| Up to 5 days / week            | 6%            |

Whilst we do see that some aspects of the role can be carried out alongside other work, and that many respondents are part of a local network of champions / ambassadors which widens the opportunities for speaking up, the general lack of time ring-fenced for the role is a cause for concern (table 3.1). The guardian role includes both proactive and reactive elements and time is needed to communicate the role, engage with staff, form partnerships across the organisation, consider and triangulate data that might indicate barriers to speaking up, and report to and engage with the board and the wider network of guardians. This is in addition to supporting

people who wish to speak up and ensuring that each issue that is brought up is properly handled, that feedback is given, and that any lessons that should be learnt are learnt. We therefore strongly recommend that every trust sets aside ring-fenced time for guardians to carry out their role.

#### #10. Time

We strongly recommend that all trusts provide ring-fenced time for anyone appointed as a guardian / ambassador / champion to carry out their role and attend training, regional and national network meetings, and other events.


How much time that should be set aside will need to consider local circumstances and, of course, guardians / champions / ambassadors who are already in the role will be able to offer their own thoughts and advice.

We asked whether respondents felt that they had sufficient time for the guardian role (table 3.2). **38%** agreed or strongly agreed with the statement 'I have sufficient time to carry out the guardian role appropriately for my organisation', **38%** disagreed or strongly disagreed, and **25%** neither agreed nor disagreed.

| 3.2 Response to the question 'I have sufficient time to carry out the guardian role appropriately for my organisation' | % respondents |
|--|---------------|
| Strongly agree   | 12%           |
| Agree  | 26%           |
| Neither agree nor disagree   | 25%           |
| Disagree   | 30%           |
| Strongly disagree  | 8%            |

The proportion of respondents agreeing or strongly agreeing with this statement varied depending on how much time was ring-fenced for the guardian role (table 3.3).

| 3.3 Time ring-fenced for the guardian role | Proportion of respondents agreeing or strongly agreeing with the statement 'I have sufficient time to carry out the guardian role appropriately for my organisation' |
|--|--|
| None                                       | 26%  |
| Up to 0.5 days per week                    | 38%  |
| Up to 1 day a week                         | 32%  |
| Up to 2 days a week                        | 47%  |
| Up to 3 days a week                        | 48%  |
| Up to 4 days a week                        | 100%   |
| Up to 5 days a week                        | 100%   |



We also asked respondents for their thoughts on how confident they were about meeting the needs of their staff. Overall, **41%** of respondents agreed or strongly agreed with the statement 'I am confident that I am meeting the needs of staff in my trust', **37%** neither agreed nor disagreed, and **22%** disagreed or strongly disagreed.

| 3.4 Response to the question 'I am confident that I am meeting the needs of staff in my trust' | % respondents |
|--|---------------|
| Strongly agree   | 4%            |
| Agree  | 37%           |
| Neither agree nor disagree   | 37%           |
| Disagree   | 17%           |
| Strongly disagree  | 5%            |

Again, the response to this question varied depending on the amount of time ringfenced for the guardian role.



| 3.5 Time ring-fenced for the guardian role | Proportion of respondents agreeing or<br>strongly agreeing with the statement 'I<br>am confident that I am meeting the<br>needs of staff in my trust' |
|--|---|
| None                                       | 36%   |
| Up to 0.5 days per week                    | 31%   |
| Up to 1 day a week                         | 36%   |
| Up to 2 days a week                        | 43%   |
| Up to 3 days a week                        | 50%   |
| Up to 4 days a week                        | 100%  |
| Up to 5 days a week                        | 64%   |

Whilst the numbers of respondents having 4 or 5 days a week ring-fenced for the role are low, and therefore the reliability of this analysis is limited, these apparent trends are interesting and not unexpected. Setting time aside to allow an individual to carry out Freedom to Speak Up work not only allows them to get that work done but, potentially, increases their confidence in their ability to meet the needs of staff.

Looking at budgets, **67%** of respondents indicated that there was no specific non-pay budget set aside for Freedom to Speak Up activities (though we do note that **24%** of respondents didn't know whether a budget had been set aside or not).

| 3.6 Non-pay budget for Freedom to Speak Up activities | % respondents |
|---|---------------|
| There is no specific budget set aside                 | 67%           |
| Less than £500  | 1%            |
| Over £500 but less than £1,000                        | 1%            |
| Over £1,000 but less than £2,000                      | 1%            |
| Over £2,000 but less than £5,000                      | 3%            |
| Over £5,000 but less than £10,000                     | 2%            |
| Over £10,000  | 1%            |
| Don't know  | 24%           |

We also asked whether respondents felt that they had access to the budget that they need. **28%** agreed or strongly agreed with the statement 'I have access to the budget I need', **44%** neither agreed nor disagreed and **29%** disagreed or strongly disagreed.

| 3.7 Response to the question 'I have access to the budget I need' | % respondents |
|---|---------------|
| Strongly agree  | 8%            |
| Agree   | 20%           |
| Neither agree nor disagree  | 44%           |
| Disagree  | 21%           |
| Strongly disagree   | 8%            |

Common sense suggests that Freedom to Speak Up activities require some budgetary investment though, given its cross-cutting nature, this may not always translate into the requirement to have a specific budget set aside and, depending on local change initiatives and other campaigns, Freedom to Speak Up messages can be incorporated in other activities.


We asked respondents whether they felt supported by their chief executive and senior management team and the response was encouraging:

| 3.8                     | "My senior management team supports me" | "My chief executive supports me" |
|-------------------------|---|----------------------------------|
| Proportion of           | 81%                                     | 85%                              |
| respondents agreeing or |   |                                  |
| strongly agreeing with  |   |                                  |
| the statement           |   |                                  |
| Proportion of           | 16%                                     | 12%                              |
| respondents neither     |   |                                  |
| agreeing nor            |   |                                  |
| disagreeing             |   |                                  |
| Proportion of           | 3%                                      | 3%                               |
| respondents disagreeing |   |                                  |
| or strongly disagreeing |   |                                  |

We hope this support continues. Whilst Freedom to Speak Up, by its nature, can be challenging and can shine a light on sometimes uncomfortable truths, we would encourage all senior leaders to think of the issues it raises as opportunities for improvement and for all those involved to seek to continue to pursue the agenda in an open and transparent way, acknowledging issues and promoting the changes that we know organisations can and do make in response to them.

Freedom to Speak Up is now an integral part of the well-led domain of Care Quality Commission (CQC) inspections. Whilst this is a recent initiative, listening and responding to people who speak up, and tackling the barriers to speaking up, is a natural ingredient of good leadership, which itself has always been a significant element of the CQC-rating process. It is therefore with interest that we observed the apparent correlation between CQC-rating and perceptions of the support that respondents felt they received from senior managers and chief executives.

| 3.9 CQC rating       | Proportion of respondents agreeing or strongly agreeing with the statement "My senior management team supports me" | Proportion of respondents agreeing or strongly agreeing with the statement "My Chief Executive supports me" |
|----------------------|--|---|
| Outstanding          | 92%  | 92%   |
| Good                 | 84%  | 89%   |
| Requires improvement | 83%  | 84%   |
| Inadequate           | 54%  | 64%   |




Whilst we have not carried out any analysis beyond looking at this simple trend, this result does suggest that trusts and foundation trusts which have higher CQC-ratings do tend to be the ones that support their guardians most, and emphasises the correlation between Freedom to Speak Up and the general quality of service that an organisation delivers.

With regard to support more generally, **78%** of respondents agreed or strongly agreed with the statement 'I have access to the support I need', **15%** neither agreed or disagreed, and **8%** disagreed or strongly disagreed.

| 3.10 Response to the question 'I have | % respondents |
|---------------------------------------|---------------|
| access to the support I need'         |               |
| Strongly agree                        | 34%           |
| Agree                                 | 44%           |
| Neither agree nor disagree            | 15%           |
| Disagree                              | 8%            |
| Strongly disagree                     | 0%            |

Again, there may be a correlation between CQC rating and perceived levels of support with a higher proportion of respondents in outstanding trusts responding positively to this question:

| 3.11 CQC rating      | Proportion of respondents agreeing or strongly agreeing with the statement "I have access to the support I need" |
|----------------------|--|
| Outstanding          | 92%  |
| Good                 | 77%  |
| Requires Improvement | 77%  |
| Inadequate           | 72%  |



### 4. Perceptions of Freedom to Speak Up

We asked respondents for their opinions about a number of elements of speaking up

| 4.1 Statement   | 1 Statement Proportion of respondents agreeing or strongly agreein with the statement |             |      |                      |            |  |
|---|---|-------------|------|----------------------|------------|--|
|   | CQC rating  |             |      |                      |            |  |
|   | Overall   | Outstanding | Good | Requires improvement | Inadequate |  |
| The guardian role is making a difference                                      | 60%   | 70%         | 51%  | 66%                  | 54%        |  |
| My organisation has a positive culture of speaking up                         | 55%   | 77%         | 65%  | 43%                  | 45%        |  |
| Speaking up is taken seriously in my organisation                             | 72%   | 84%         | 81%  | 68%                  | 36%        |  |
| There are significant barriers to speaking up in my organisation (graph p.22) | 25%   | 0%          | 21%  | 27%                  | 45%        |  |
| My organisation is actively tackling barriers to speaking up                  | 70%   | 85%         | 72%  | 71%                  | 45%        |  |
| People in my organisation do not suffer detriment as a result of speaking up  | 43%   | 62%         | 54%  | 34%                  | 27%        |  |
| Managers<br>support staff to<br>speak up<br>(graph p.24)                      | 41%   | 77%         | 53%  | 29%                  | 18%        |  |
| Senior leaders<br>support staff to<br>speak up                                | 67%   | 85%         | 78%  | 55%                  | 45%        |  |
| My organisation sees speaking up as an opportunity to learn and improve       | 75%   | 69%         | 81%  | 71%                  | 64%        |  |



Overall these results indicate that there is a way to go in creating the culture change that we wish Freedom to Speak Up to generate, particularly in relation to perceptions of the support that managers give to speaking up. However, there are some encouraging responses: **72%** of respondents agree or strongly agree with the statement "speaking up is taken seriously in my organisation"; **70%** of respondents agree or strongly agree with the statement "my organisation is actively tackling barriers to speaking up"; and **75%** agree or strongly agree with the statement "my organisation sees speaking up as an opportunity to learn and improve". Our ambition is that responses to these questions will become more positive as the guardian role becomes embedded into the fabric of the NHS.

Whilst the trend towards more positive responses being given by trusts that are rated as 'outstanding' is of interest, we should note that the numbers of responses received from outstanding (and inadequate) trusts is small compared to trusts rated as good or requiring improvement.

Looking at these responses based on the services provided by an organisation, it is interesting to note that guardians / ambassadors / champions that work in organisations that provide mental health services tend to respond most positively to the questions we asked about Freedom to Speak Up culture, with those who work in ambulance services responding the most negatively.

| 4.2 Statement                     | Proportio  | on of reenand | onte agroc    | ing or etropal | V          |
|-----------------------------------|--|---------------|---------------|----------------|------------|
| 4.2 Statement                     | Proportion of respondents agreeing or strongly agreeing with the statement |               |               |                |            |
|                                   | Services provided  |               |               |                |            |
|                                   | Acute  | Community     | Mental        | Ambulance      | Specialist |
|                                   |  |               | Health        |                |            |
| The guardian role                 | 57%  | 65% +         | 65% +         | 61%            | 50% -      |
| is making a                       |  |               |               |                |            |
| difference                        |  |               |               |                |            |
| My organisation                   | 48%  | 59%           | 66% +         | 44% -          | 52%        |
| has a positive                    |  |               |               |                |            |
| culture of                        |  |               |               |                |            |
| speaking up                       | 66%  | 73%           | 82% +         | 44% -          | 62%        |
| Speaking up is taken seriously in | 00%  | 13%           | Ø∠% <b>+</b>  | 44% -          | 02%        |
| my organisation                   |  |               |               |                |            |
| There are                         | 25%  | 29%           | 23% +         | 39% -          | 32%        |
| significant barriers              | 2070   | 2370          | 2070 <b>T</b> | 3370-          | J2 /0      |
| to speaking up in                 |  |               |               |                |            |
| my organisation                   |  |               |               |                |            |
| My organisation is                | 68%  | 69%           | 74% +         | 50% -          | 64%        |
| actively tackling                 |  |               |               |                |            |
| barriers to                       |  |               |               |                |            |
| speaking up                       |  |               |               |                |            |
| People in my                      | 35%  | 41%           | 44% +         | 23% -          | 28%        |
| organisation do                   |  |               |               |                |            |
| not suffer                        |  |               |               |                |            |
| detriment as a                    |  |               |               |                |            |
| result of speaking                |  |               |               |                |            |
| up<br>Managers support            | 36%  | 38%           | 39% +         | 33% -          | 36%        |
| staff to speak up                 | 30%  | 30%           | J970 <b>+</b> | 33% -          | 30%        |
| Senior leaders                    | 62%  | 69%           | 75% <b>+</b>  | 55% -          | 64%        |
| support staff to                  | 02/0   | 0370          | 7 3 70 +      | 3370-          | J-70       |
| speak up                          |  |               |               |                |            |
| My organisation                   | 73%  | 76%           | 80% +         | 55% -          | 66%        |
| sees speaking up                  | 1070   | ' ' ' '       | 30,01         |                | 3375       |
| as an opportunity                 |  |               |               |                |            |
| to learn and                      |  |               |               |                |            |
| improve                           |  |               |               |                |            |

- + most positive response
- least positive response

#### 5. Successes and challenges

We asked respondents to provide examples of success and challenges. Whilst many respondents felt it was too early to give specific examples, there were some clear themes.

**Successes:** The most common examples of success were around communication where successful awareness campaigns had been run and messages sent out in corporate communications. There were also common themes around staff confidence and supporting staff with guardians having examples of feedback to suggest that they had given individuals more confidence to speak up and being thanked for the support they had given individuals at a difficult time.

Other successes included the emergence of strong leadership for speaking up amongst senior leaders, the development of good partnership working, a sense of achievement from making progress with individual cases, and comments about how Freedom to Speak Up has supported more general change in an organisation.

**Challenges:** By far the most cited challenge was around not having sufficient time to do all that that the role encompasses. Compounding challenges were ones of geography, where services are spread out and delivered in a large number of sites, and the need to balance the workload against pressures of another role that a guardian may hold.

Other sources of challenge were lack of support or general wariness of managers, potential conflicts with other responsibilities that a guardian may hold, general feelings of a lack of support (particularly amongst senior managers), and an existing lack of confidence amongst staff about speaking speaking up.

**Other:** We asked respondents whether they had been on the introductory / foundation training for the guardian role, how supported they felt by the National Guardian's Office, and what other training and support they felt that they needed. **70%** of respondents had attended introductory / foundation training, with **47%** of respondents also attending other training connected to the role. Respondents gave a range of opinions on their requirements for further training and guidance. The National Guardian's Office will continue to offer foundation training sessions and move to a model where initial training can be delivered at the regional level.

The National Guardian's Office will also work with Health Education England and the NHS Leadership Academy to source appropriate training and development to help to continually develop and improve the skills that individuals in the guardian network possess. Respondents gave a range of suggestions about how the National Guardian's Office can better support the guardian network. It will look into those suggestions and work with the network to ensure that all guardians receive the support they need.

#### **Annex**

#### **Survey questions**

#### A. ABOUT YOU AND WHAT YOU DO

B.

#### 1. How were you appointed?

- I was personally approached and interviewed
- · I was personally approached but was not interviewed
- I volunteered and was interviewed
- I volunteered but was not interviewed
- I was elected and interviewed
- I was elected but was not interviewed
- I was nominated and interviewed
- I was nominated but was not interviewed
- I was recruited internally through open competition
- I was recruited externally through open competition
- I work for an external provider
- Other (please specify)

#### 2. How long have you been in post?

- · Not yet started
- Less than 3 months
- 3 6 months
- 7 12 months
- 13 18 months
- 18 months or longer

#### 3. Do you have another role?

- Yes
- No

#### 4. If yes, please select from the following which best describes you

- Doctor
- Nurse
- Healthcare Assistant
- Midwife
- Dentist
- AHP
- Healthcare Scientist
- Therapist

- Admin & Clerical
- Maintenance / Ancillary
- Technician
- HR
- Corporate Services
- OD
- Safety
- Chaplain
- Governor
- Other (please specify)

#### 5. What grade or band are you?

- VSM
- 9
- 8d
- 8c
- 8b
- 8a
- 7
- 6
- 5
- 4
- 3
- 2
- Volunteer
- Other (please specify)

#### 6. How much time is ring-fenced for you to carry out the guardian role?

- None
- Up to 0.5 days per week
- Up to 1 day per week
- Up to 2 days per week
- Up to 3 days per week
- Up to 4 days per week
- Up to 5 days per week

### 7. Are you part of a network of guardian champions / ambassadors (or similar) in your organisation?

- Yes
- No
- Don't know

#### 8. Do you have a Freedom to Speak Up Guardian 'buddy'?

- Yes
- No
- Don't know

### 9. What communication and training activities do you carry out as part of your role?

- Communication / publicity of your role through internal channels (e.g. staff newsletters)
- Communication / publicity of your role externally (e.g. local press, speaking engagements)
- Attending or incorporating Freedom to Speak Up messages in staff inductions
- Attending or incorporating Freedom to Speak Up messages in other staff training
- Attending team meetings
- Carrying out surveys about Freedom to Speak Up
- Other (please specify)

#### 10. Which parts of your organisation do you regularly work with?

- · Senior leaders / the Board
- HR
- Communication teams
- Organisational Development teams (or similar)
- Training and development teams
- Union / staff side representatives
- Staff diversity networks
- Patient representative groups
- Other (please specify)

#### 11. Do you have direct access to my CEO?

- Yes
- No
- Don't know

### 12. Do you have direct access to the Non-Executive Director who has speaking up as part of their portfolio?

- Yes
- No
- Don't know

#### 13. Do you present reports to Board meetings in person?

- Yes
- No
- Don't know

#### 14. Do you gather feedback on your performance?

- Yes
- No

### 15. What non-pay budget is there for guardian activities in your trust (budget per annum)?

- There is no specific budget set aside for guardian actives
- Less than £500
- Over £500 but less than £1000
- Over £1000 but less than £2000
- Over £2000 but less than £5000
- Over £5000 but less than £10,000
- More than £10,000
- Don't know

#### 16. Do you have personal experience of speaking up?

- Yes
- No

It would be helpful to know a little more of your experience if you are willing to describe it below. This information will be used to help the NGO understand the speaking up experience that exists within the guardian network

#### C. ABOUT YOUR ORGANISATION

#### 17. What service/s does your trust provide (select all that apply)?

- Acute
- Community
- Mental Health
- Ambulance
- Specialist
- Other (please specify)

#### 18. Approximately, how many staff are employed in your Trust?

#### 19. On how many sites?

- 1
- 2-3

- 4 7
- 8 − 10
- More than 10 sites

#### 20. What is your organisation's current CQC rating?

- Outstanding
- Good
- · Requires improvement
- Inadequate

#### D. YOUR THOUGHTS ON YOUR ROLE AND YOUR ORGANISATION

#### 21. How far do you agree or disagree with the following statements:

- I have sufficient time to carry out the guardian role appropriately for my organisation
- I am confident that I am meeting the needs of staff in my trust
- My senior management team supports me
- My Chief Executive supports me
- I have access to the support I need
- I have access to the budget I need

#### 22. How far do you agree or disagree with the following statements:

- The guardian role is making a difference
- My organisation has a positive culture of speaking up
- Speaking up is taken seriously in my organisation
- There are significant barriers to speaking up in my organisation
- My organisation is actively tackling barriers to speaking up
- People in my organisation do not suffer detriment as a result of speaking up
- · Mangers support staff to speak up
- Senior leaders support staff to speak up
- My organisation sees speaking up as an opportunity to learn and improve

#### **E. TRAINING**

### 23. Have you attended the introductory guardian-training workshop? (tick one)

- Yes
- No
- Don't know

- 24. Have you attended any other training connected to your guardian role? (tick one)
  - Yes
  - No
- 25. What other training and support would you find helpful
  - None
  - · Influencing skills
  - · Equality / diversity training
  - · Presentation skills
  - · Listening skills
  - · Report writing / general writing skills
  - · Dealing with difficult conversations training
  - Personal resilience
  - Network building
  - Other (please specify)
- 26. On a scale of 0 to 10 where 0 is 'not at all' and 10 is 'fully supported' please indicate your response to the following statement: I am sufficiently supported by the National Guardian's Office?
- 27. What further support from the National Guardian's Office would you find helpful?
- F. SUCCESSES AND CHALLENGES
- 28. What success have you had in your guardian role? Please describe your achievements so far.
- 29. What are the most challenging aspects of your role?
- **G. PERSONAL DETAILS**
- 30. What is your age?
  - 16-34
  - 35-44
  - 45-54
  - 55+
  - Prefer not to say
- 31. Do you consider yourself to be disabled?
  - Yes
  - No

Prefer not to say

### 32. What is your ethnic group? Please choose an answer that best describes your ethnic group or background

- White
- Mixed / multiple ethnic groups
- Asian / Asian British
- Black / African / Caribbean / Black British
- Chinese
- Other ethnic group

#### 33. What is your religion or belief?

- No religion
- Buddhist
- Jewish
- Muslim
- Agnostic
- Christian
- Sikh
- Hindu
- · Prefer not to say
- Other

#### 34. What is your sexuality?

- Bisexual
- Gay man
- Gay woman / lesbian
- Heterosexual / straight
- · Prefer not to say
- Other

#### 35. Are you

- Single
- Separated
- Divorced
- Widowed
- Married or in a civil partnership
- · Prefer not to say

#### 36. What is your gender?

Male

- Female
- Prefer not to say
- Other
- 37. Is your gender the same as the gender identity that you were born with?
  - Yes
  - No
  - · Prefer not to say
- 38. Are you currently pregnant or have you been pregnant in the last year?
  - Yes
  - No
  - · Prefer not to say
- 39. Have you been on maternity leave within the past year?
  - Yes
  - No
  - Prefer not to say



# **Programme Assurance Summary Change Programme**

#### Programme Summary (to be completed by Executive Sponsor of the assurance framework)

Half way though the year the level of progress across the programme (quality and financial) is not at an acceptable level. The financial plan in 17/18 assumed the transformation programme would ramp up from September and driving a stepped improvement in the financial run rate in the second half of the year; the current forecasts do not deliver the required step-up, which is manifesting as part of the over all control total risk. There continues to be a significant amount of projects with red or red/amber ratings and or low financial savings. The performance is similar across the workstreams particularly in the best people doing their best work and delivering outstanding care. The strong foundations workstream is beginning to pick up momentum.

Following a detailed Executive Team discussion the CEO has asked for a formal 6 month review of progress against our business plan objectives which will be brought to the November Board. This will shift the focus onto benefits tracking of the programme. The financial performance of the programme is incorporated into our financial recovery plan.

#### J Grinnell 26 Sep 17

#### **Programme Summary** (to be completed by **External Programme Assessment**)

- 1. This Board report contains assurance reports submitted to the following sub-Cttes: CQAC on 20 Sep 17 and R&BD on 28 Sep 17.
- 2. The scope of the programme and the contribution to CIP benefits are shown in the following slides; the financial contributions are of particular concern, being significantly below target (delivery at est. 50%), and will be the subject of a rigorous review during October 2017.
- 3. The overall assurance ratings continue to raise concern and in some key areas there is little or no current assurance evidence; this is particularly the case in the red rated projects in the 'Quality' and 'Workforce' work streams. Actions agreed to remedy these issues include Executive Sponsor focus and addressing the lack of applied capability to some key projects.

#### J Gibson 21 Sep 17

#### **CIP Summary** (to be completed by **Programme Assurance Framework**)

Overall for the year CiP has reporting a gap of £2m, this gap has not improved for two months. Fcous needs to be put into resolving this urgently.



## **Change Programme**

30 August 2017 v12

Trust Board



CQAC

R&BD

WOD

R&BD

R&BD

**Internal Delivery** Group (CiP)

**Programme Assurance Framework** 

**Programme Delivery Board** 27/40 = £ indicated projects

## Deliver **Outstandina Care**

Hilda / Steve

- 1. Deteriorating Patient
- 2. Experience in Outpatients £ SG
- 4. GP Streaming
- 5. Best in Acute Care £

## **Growing Through** External **Partnerships**

John

- 1. Establish Alder Hey as Leader of Children's Health across C & M
- 3. Best in Operative Care £ SG a) Single Service, 2 Site, Neonatal Service £
  - b) Expand Mental Health Offering £
  - c) Step Down Model for Patients with Complex Needs £
  - 2. Strengthen the Stoke Partnership £
  - 3. International Health & Non-NHS Patients £
  - 4. Transformation of **New Community** Services (SALT) £
  - 5. CHD Liverpool Partnership £
  - 6. Aseptics £

## The Best People **Doing Their Best** Work

Melissa/Hilda

- 1. Staff Engagement & SG **Development**
- a) Apprenticeships £
- b) Engagement & Communication
- 2. Workforce Reviews
- a) Specialist Nurse Review £
- b) AHP Review £
- c) Portering £
- d) Domestics £
- 3. Agile Working
- 4. Temporary Staffing £
- 5. e-Rostering £

## **Global Digital** Exemplar

John/Steve

- 1. Speciality Packages £ SG
- 2. Voice Recognition £

## Park, Community **Estate & Facilities**

David

SG

- 1. Decommission & Demolition
- 2. R&E 2
- 3. Alder Centre
- 4. Park
- 5. Residential Development
- 6. International Design & **Build Consultancy £**
- 7. Reprovision of Retained **Estates**
- 8. Neuro-Developmental **Hub (TBC)**

## RE&I

## **Game Changing** Research & **Innovation**

David

- 1. The Academy £
- 2. The Innovation Co £
- 3. Implement New **Apps for Alder Hey**
- 4. Expand Commercial Research £

## Strong **Foundations**

John

- 1. Inventory Management £
- 2. Collaborative Procurement £
- 3. Energy £
- 4. Post-mobilisation Review

**Listening into Action** - A staff-led process for the changes we need



## **CIP Status at Month 05**


## **Trust Position**


| Risk Adjusted Forecast      | at 6 <sup>th</sup> Sep<br>£000's |
|-----------------------------|----------------------------------|
| Implemented (Posted)        | 4,317                            |
| Fully Developed Plan        | 178                              |
| Plans in Progress           | 1,571                            |
| Subtotal: Forecast Delivery | 6,067                            |
| Opportunity                 | 903                              |
| Gap                         | 1,031                            |
| Target                      | 8,000                            |


## 2017/18 CIP target is £8.0m:


- In year forecast £6.1m (76%)
- Current risk £1.9m (24%)

## Progress over the last 4 months









Inspired by Children



## **CIP Status at Month 05**

## Performance, by Theme

|                                       |        | In Month             |        | • | Year to Date |                      | In Year Forecast |      |        |          |                    |
|---------------------------------------|--------|----------------------|--------|---|--------------|----------------------|------------------|------|--------|----------|--------------------|
| Workstream                            | Target | Achieved<br>(Posted) | Gap    |   | Target       | Achieved<br>(Posted) | Gap              |      | Target | Forecast | Gap                |
|                                       | £000's | £000's               | £000's |   | £000's       | £000's               | £000's           |      | £000's | £000's   | £000's             |
| Deliver Outstanding Care              | 54     | 20                   | -34    |   | 210          | 64                   | -145             |      | 587    | 356      | -2 <mark>31</mark> |
| Growing Through External Partnerships | 13     | 6                    | -8     |   | 66           | 29                   | -38              |      | 159    | 129      | -30                |
| The Best People Doing Their Best Work | <br>29 | 0                    | -29    |   | 111          | 0                    | -111             |      | 402    | 122      | -280               |
| Game Changing Research and Innovation | <br>17 | 9                    | -8     |   | 85           | 43                   | -42              | - [  | 230    | 130      | -100               |
| Solid Foundations                     | <br>0  | 0                    | 0      |   | 0            | 0                    | 0                | - [- | 142    | 0        | -142               |
| Subtotal: Strategic Workstreams       | 113    | 34                   | -79    |   | 471          | 136                  | -335             |      | 1,520  | 737      | -783               |
| Business as Usual                     | 315    | 431                  | 116    |   | 1,225        | 1,703                | 478              |      | 6,480  | 5,330    | -1,150             |
| Unidentified                          | <br>0  | 0                    | 0      |   | 0            | 0                    | 0                | Ĩ    | 0      | 0        | 0                  |
| Grand Total                           | 428    | 465                  | 37     |   | 1,696        | 1,839                | 143              |      | 8,000  | 6,067    | -1,933             |

|                                       |    |                   |                    | Risk Rating          | g (In Year) |        |        |
|---------------------------------------|----|-------------------|--------------------|----------------------|-------------|--------|--------|
| Workstream                            | (P | emented<br>osted) | Fully<br>Developed | Plans in<br>Progress | Opportunity | Gap    | Total  |
|                                       | 1  | E <b>000</b> 's   | £000's             | £000's               | £000's      | £000's | £000's |
| Deliver Outstanding Care              |    | 157               | 0                  | 198                  | 0           | 231    | 587    |
| Growing Through External Partnerships |    | 69                | 0                  | 60                   | 30          | 0      | 159    |
| The Best People Doing Their Best Work |    | 0                 | 0                  | 122                  | 95          | 185    | 402    |
| Game Changing Research and Innovation |    | 130               | 0                  | 0                    | 0           | 100    | 230    |
| Solid Foundations                     |    | 0                 | 0                  | 0                    | 0           | 142    | 142    |
| Subtotal: Strategic Workstreams       |    | 356               | 0                  | 381                  | 125         | 658    | 1,520  |
| Business as Usual                     |    | 3,961             | 178                | 1,191                | 777         | 373    | 6,480  |
| Unidentified                          |    | 0                 | 0                  | 0                    | 0           | 0      | 0      |
| Grand Total                           |    | 4,317             | 178                | 1,571                | 903         | 1,031  | 8,000  |

Inspired by Children



## Programme Assurance Summary Delivering Outstanding Care

Work Stream Summary (to be completed by Executive Sponsor of the assurance framework)

The latest forecast is savings of £0.4m, which is better than the previous update but still very low, and not sufficient to meet the financial objectives of the programme. The only projects currently forecasting savings are Best in Operative Care and Experience in Outpatients. The Executive sponsor is requested to review the saving potential as a matter of urgency, converting the opportunities into savings and increasing the value of the overall forecast.

Claire Liddy, Deputy Director of Finance – 12 Sep 17

### Work Stream Summary (to be completed by External Programme Assessment)

Of the projects that have evidence lodged on the SharePoint site and are rated:

- 'Deteriorating Patient' The 'Sepsis' project documentation on SharePoint is not currently being updated and the milestone plan is over two months out of date. This is a significant issue given the importance of this project and the gap was highlighted at the August Programme Board and September Trust Board. Resolution is required immediately.
- 'Outpatients' is providing a high level of documentary evidence giving a sound assurance rating.
- 'Best in Operative Care' is also being regularly updated and has a good suite of evidence.

Projects that are red rated, as highlighted at Programme Board/Trust Board, are:

- 'Best in Operative Care' not updated since Programme Board/Trust Board and requiring benefits to be defined and a plan.
- 'GP Streaming' awaiting a high level description of the project and any documentary evidence (nothing yet on SharePoint).

Joe Gibson, External Programme Assessment 12 Sep 17

# Programme Assurance Framework Delivering Outstanding Care (Completed by Assurance Team)



| Sub-Committee   | CQAC                        | Report Date       | 12 Sep 17                  |
|-----------------|-----------------------------|-------------------|----------------------------|
| Workstream Name | Delivering Outstanding Care | Executive Sponsor | Hilda Gwilliams/Steve Ryan |

## **Current Dashboard Rating:**

| 1.0 Deliver O | utstanding Care 1 | 17/18 £TBC                        |   |                                    |   |   |   |   |   |   |   |   |   |
|---------------|-------------------|-----------------------------------|---|------------------------------------|---|---|---|---|---|---|---|---|---|
| CQAC 1.1      | CQAC              | Deteriorating Patient<br>(Sepsis) | This project will ensure prompt recognition and management of the deteriorating patient and implementation of the Sepsis Pathway  | Hilda<br>Gwilliams                 | • | • | • |   | • | • | • | • | Project implementation meeting notes available but last record early June. PID complete. Benefits defined, tracking/reporting to commence. Milestone Plan is not being updated - actions from 26 June onwards to be updated. Comms/ Engagement Plan available, evidence to be provided where possible. Risks on Ulysses. EA/QIA complete. Last updated 6 July 2017  |
| CQAC 1.2      | CQAC              | Experience in<br>Outpatients      | The project will improve patient & staff experience; understand demand and capacity; improve flow and environment   | Hilda<br>Gwilliams                 | • | • | • | • | • | • | • | • | SG meeting notes available to July. PID completed. Benefits defined - tracking/dashboard uploaded 29 Aug 17. Milestone Plans (Booking and Scheduling in particular) show some 'OM' tasks and requires populating with new actions. Comms/ engagement activities to be updated and evidence provided where possible. Risks available on Ulysses. Last updated 6 September 2017   |
| CQAC 1.3      | CQAC              | Best in Operative Care            | The "Best in Operative Care" strategy aims to deliver the best paediatric operative care in the world, as measured by low rates of mortality and harm, and high staff satisfaction rates  | Steve Ryan                         | • | • | • | • | • | • | • | • | Steering Group notes available on SharePoint. PID available. Targets/benefits defined in PID, tracking/reporting to commence. Milestone Plan to be fully defined/populated and updated for September. Comms tracker available. Risks available on Ulysses. EA/QIA complete. Last updated 11 September 2017  |
| CQAC 1.6      | CQAC              | GP Streaming                      |   | Mags<br>Barnaby                    |   |   |   |   |   |   |   |   | PID to be available at end of July. No documentation available on SharePoint.   |
| CQAC 1.7      | CQAC              | Best in Acute Care                | The 'Best in Acute Care' strategy aims to deliver the best/safest paediatric acute care in the world, as measured by low rates of mortality and harm, and high staff satisfaction. We will achieve this through a strategy centered on patient safety, excellence and staffing wellbeing. | Steve Ryan<br>(Hilda<br>Gwilliams) |   |   |   |   |   |   |   |   | Draft PID uploaded and incorporates the following projects/workstreams: Resuscitation; Deteriorating Patient/Sepsis; 7 Day Services - inclusive of Out of Hours; PEWs/Deterioration; Outreach; Medical Management of Complex Surgical Patients). The PID includes the scope with benefits yet to be defined. Minutes/notes of meetings are present, as is identification of high level stakeholders. Last updated 29 August 2017. |

### **Financial Reporting:**

| Project Title                   | RAG Rating | Budget £ | Forecast £ | Variance | Comments  |
|---------------------------------|------------|----------|------------|----------|---|
|                                 |            |          |            | £        |   |
| Deteriorating Patient           | Black      |          |            |          | No financial benefits identified to date  |
| Reduce Variations by Developing | Black      |          |            |          | No financial benefits identified to date  |
| Clinically Effective Pathways   |            |          |            |          |   |
| Experience in Outpatients       | Amber      | 180k     | 198k       | -180k    | Financial target based on 3% reduction in DNA rate in Medical specialities.   |
|                                 |            |          |            |          |   |
| Best in Operative Care          | Green      | 407k     | 157k       | -250     | Financial target based on indicative 2% growth in Elective and Daycase income in all Surgical specialties. Following detailed |
|                                 |            |          |            |          | review and activity forecast, there is high confidence of increased income in Urology, Plastics and Pre-Op Assessment.        |
| 7 Day Services                  | Black      |          |            |          | No financial benefits identified to date  |
| Reduce Infections               | Black      |          |            |          | No financial benefits identified to date  |
| Total                           |            | 587k     | 356k       | -231k    |   |



## **Programme Assurance Summary Growing Through External Partnerships**

Work Stream Summary (to be completed by Executive Sponsor of the assurance framework)

The majority of projects are now amber rated which is improving trend, however efforts must be put into delivering green ratings. The financial forecast for this work stream is particularly poor especially given the vast opportunity for business development. The Executive sponsor is requested to undertake a stock take of the finances and provide a re-forecast by October that will aid the trust financial position as a matter of urgency. Clear miles stones and profiling must be agreed with divisions.

Claire Liddy, Deputy Director of Finance – 19 September 2017

### Work Stream Summary (to be completed by External Programme Assessment)

The work stream has made definite inroads to improve the assurance base since the previous sub-Committee review in June 2017. At that time only 5 projects were able to be assessed and the ratings were 3 red rated, 1 amber and 1 green. The latest position shows all 8 projects having commenced, with evidence on SharePoint, and of those 1 green rated, 6 amber and 1 red. This positive trend should be supported and continued.

Of particular concern is the continuing lack of evidence on SharePoint concerning the Liverpool CHD Partnership and the £90k shortfall in the financial contribution to the CIP programme.

The Executive Sponsor should work with all 'corporate leads 'of projects to attain green ratings as a matter of urgency.

Joe Gibson, External Programme Assessment – 19 September 2017

# Programme Assurance Framework Growing Through External Partnerships (Completed by Assurance Team)



| Sub-Committee   | R&BD                                  | Report Date       | 19 September 2017 |
|-----------------|---------------------------------------|-------------------|-------------------|
| Workstream Name | Growing Through External Partnerships | Executive Sponsor | John Grinnell     |

### **Current Dashboard Rating:**

|             |                    | i a rading.   |  |  |                        | rotored                               |                          |                                     | Feranti                            | enad                    |  | De De | lanea             | Delivered   |
|-------------|--------------------|---|--|--|------------------------|---------------------------------------|--------------------------|-------------------------------------|------------------------------------|-------------------------|--|-------|-------------------|---|
| Project Ref | Assurance<br>Group | Project Title   | Project Description  | Executive<br>Sponsor<br>Assures<br>the project | OVERALL<br>PROJECT RAG | An effective project team is in place | Scope and<br>Approach is | Targets / benefits defined/on track | Milestone plan is defined/on track | Stakeholders<br>engaged | Risks are identified and being managed | es t  | Equality Analysis | Comments for attention of the Project Team, Steering Group and sub-Committee  |
| *           | <b>*</b>           |   | ·  | *  |                        | -                                     | ٠                        |                                     | ٧                                  |                         | 1                                      | · ·   |                   |   |
| R&BD 2.1c   | R&BD               | Single Service, 2 Site,<br>Neonatal Service   | Lead services to review options to collaborate and maximise joint working across the NM LDS and C&M Footprint including a single Neonatal Service with LWH                                   | Steve Ryan                                     |                        | •                                     | •                        | •                                   | •                                  | •                       | •                                      | •     | •                 | Now in implementation planning phase. Outline PID available. Milestone plan in development with further definition required. Definition of benefits in 'working draft' fromat with further work needed to establish SMART metrics.  Comprehensive evidence of wide stakeholder engagement. Risk Register commenced and QIA/EA to be uploaded when signed off. Last updated 25 August 2017.  |
| R&BD 2.1di  | R&BD               | STP AH @ C&M<br>Strong Community<br>Services Offer -<br>Transition of New<br>Community Services | To ensure safe and efficient transfer of selection of Specialist Paediatric Community Services from LCH  | John<br>Grinnell                               |                        | •                                     | •                        |                                     | •                                  |                         |  | •     | •                 | Team have requested closure of this project. Closure Report to be presented to July RABD meeting was not submitted, Executive Sponsor is requested to ensure closure at 28 September R&BD meeting . Last updated 18 August 2017   |
| R&BD 2.1d   | R&BD               | STP AH @ C&M<br>Transforming Mental<br>Health Services  | Improvements to primary and specialist<br>mental health services locally. Improve<br>access to 24/7 crisis resolution and secure<br>Alder Hey as a provider of Tier 4 childrens<br>services. | John<br>Grinnell                               |                        | •                                     | •                        | •                                   | •                                  | •                       |  | •     | •                 | PID to be presented to Steering Group meeting in September 2017. Last updated 25 August 2017  |
| R&BD 2.2    | R&BD               | Strengthen the Stoke<br>Partnership   | Lead services to review options to collaborate and maximise joint working with Stoke partners  | John<br>Grinnell                               |                        |                                       |                          |                                     |                                    |                         |  |       |                   | DRAFT Business Case on SharePoint - any eventual project subject to outcome of current discussions; meeting with NHSE 12 Sep 17. Last updated 30 August 2017  |
| R&BD 2.3    | R&BD               | International Health & Non-NHS Patients   | Establish International service offer including: International Health Partnerships and non-NHS patients  | John<br>Grinnell                               |                        | •                                     | •                        |                                     | •                                  |                         | •                                      | •     | •                 | Steering Group meeting notes available. PID complete. Milestone Plan is defined and on SharePoint shows slippage with Dubai workstream and PP privileges. Details/evidence of comms/engagement to be provided where possible. Risks now on Ulysses. EA/QIA complete. Last updated 17 July 2017  |
| R&BD 2.4    | R&BD               | Improving Pathways<br>for Children with<br>Complex Needs<br>between Hospital and<br>Home        | To improve the experience of patients with complex needs between hopsital and home, reducing length of stay and delivering high quality, community based, services.                          | John<br>Grinnell                               |                        |                                       |                          |                                     | •                                  |                         |  | •     | •                 | Draft PID in evideince with more work required, particularly on benefits and measures. Some evidence of team working but attendees at meetings, as well as action logs, need to be documented. A detailed action plan is in place and would benefit from a 'red line' showing the date of the latest amnedments/changes. Evidence of stakeholder engagement, confirmation of risks registred and EA/QIA are all outstanding. Last updated 18 August 2017. |
| R&BD 2.5    | R&BD               | CHD Liverpool<br>Partnership  |  | Steve Ryan                                     |                        |                                       |                          | _                                   |                                    | _                       |  |       |                   | PID to be available at end of July. No documentation available on SharePoint.   |
| RABD 2.6    | R&BD               | Aseptics  | Validate and commission aseptic unit. To provide internal service which reduces outsourcing to minimal levels. Take unit to licence to offer income generating opportunities.                | John<br>Grinnell                               |                        |                                       |                          |                                     |                                    |                         |  |       |                   | DRAFT Business Case on SharePoint: Proposal for commissioning, validation and licensing of the Pharmacy Aseptic Services Unit. Executive Sponsor of Assurance Framework to decide if other project documents are required in evidence. Current issues include no evidence of live tracking of milestones / risks / benefits and no documented evidence of meetings.   |

# Programme Assurance Framework Growing Through External Partnerships (Completed by Assurance Team)



| Sub-Committee   | R&BD                                  | Report Date       | 19 September 2017 |
|-----------------|---------------------------------------|-------------------|-------------------|
| Workstream Name | Growing Through External Partnerships | Executive Sponsor | John Grinnell     |

## **Financial Reporting:**

| Project Title                           | RAG Rating | Budget £ | Forecast £ | Variance<br>£ | Comments                                 |
|---|------------|----------|------------|---------------|--|
| High Quality Acute and Emergency Care   | Black      |          |            |               | No financial benefits identified to date |
| Develop Clinical Services Support Offer | Black      |          |            |               | No financial benefits identified to date |
| Strong Specialist Services Offer        | Black      |          |            |               | No financial benefits identified to date |
| Strong Community Services Offer         | Green      | 159k     | 69k        | -90k          |  |
| Expand Mental Health Offering           | Black      |          |            |               | No financial benefits identified to date |
| Intermediate Care Unit                  | Black      |          |            |               | No financial benefits identified to date |
| Strengthen Existing Partnerships        | Black      |          |            |               | No financial benefits identified to date |
| International Health & Non NHS Patients | Red        |          |            |               |  |
| Total                                   |            | 159k     | 69k        | 90k           |  |

## **Programme Assurance Summary**



## **Global Digital Exemplar**

Work Stream Summary (to be completed by Executive Sponsor of the assurance framework)

The work stream is making strong progress and the assurance ratings are green. Work must now commence to identify and quantify the financial and non-financial benefits. The executive sponsor needs to agree a deadline of when this work will complete and the benefits will realise in 17/18 initially. A comprehensive update to RABD should be provided in Q3..

Claire Liddy, Deputy Director of Finance - 16 June 2017

### **Work Stream Summary** (to be completed by External Programme Assessment)

The work stream has made significant efforts to improve the assurance base since the previous sub-Committee review in June 2017. At that time only 1 project was able to be assessed and the rating was red. The latest position shows all 3 strategic level projects (it having been decided that the more granular work streams will be assured at the project level) have comprehensive evidence on SharePoint and are all green rated. This is an high standard of assurance evidence and the team should be commended.

Of current concern is the lack of evidenced financial contribution to the CIP programme.

Joe Gibson, External Programme Assessment – 19 September 2017

# Programme Assurance Framework Global Digital Exemplar (Completed by Assurance Team)



| Sub-Committee   | R&BD              | Report Date       | 19 September 2017         |
|-----------------|-------------------|-------------------|---------------------------|
| Workstream Name | Solid Foundations | Executive Sponsor | John Grinnell/ Steve Ryan |

## **Current Dashboard Rating:**

|                |                      | _  |  |                        |                      |                          |                                     |                                    |                      |  |                           |                   |   |
|----------------|----------------------|--|--|------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------|----------------------|--|---------------------------|-------------------|---|
| Project Ref    | Project Title        | Project Description  | Executive<br>Sponsor<br>Assures<br>the project | OVERALL<br>PROJECT RAG | An effective project | Scope and<br>Approach is | Targets / benefits defined/on track | Milestone plan is defined/on track | Stakeholders engaged | Risks are identified and being managed | Quality Impact Assessment | Equality Analysis | Comments for attention of the Project Team, Steering Group and sub-Committee  |
|                | Ţ                    |  | ¥  | Ţ                      | 4                    | Ţ                        |                                     | ,                                  |                      | ,                                      |                           |                   |   |
| 4.0. Global Di | gital Exemplar 17/18 | ETRC   |  |                        |                      |                          |                                     |                                    |                      |  |                           |                   |   |
| 4.0 Global Di  | gitai Exemplar 17/10 | EIBC   |  |                        |                      |                          |                                     |                                    |                      |  |                           |                   |   |
| R&BD 4.1       | GDE                  | Create exemplars that can inspire others by really showing how information technology can deliver both improved patient outcomes and enhanced business effectiveness | Steve Ryan/<br>John<br>Grinnell                |                        | •                    | •                        | •                                   | •                                  | •                    |  | •                         | •                 | Overall benefits profile and schedule still to be finalised. Further stakeholder evidence to be uploaded and register maintained. Risk protocols vis-à-vis national and Trust sytsems have been harmonised and are in the process of being finalised. Last updated 23 August 2017   |
| R&BD 4.1a      | Speciality Packages  | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways  | Steve Ryan/<br>John<br>Grinnell                |                        | •                    | •                        | •                                   | •                                  | •                    | •                                      |                           |                   | Overall benefits profile and schedule still to be finalised. Risk protocols vis-à-vis national and Trust sytsems to be harmonised and finalised. Last updated 21 August 2017. QIA/EA will be assured and assessed at project level.   |
| R&BD 4.10      | Voice Recognition    | Deploy voice recognition solution in<br>Medisec and Meditech   | Steve Ryan/<br>John<br>Grinnell                |                        | •                    | •                        | •                                   | •                                  | •                    | •                                      | •                         | •                 | PID and detailed project workbook on SharePoint. Details of financial benefits on separate document. Detailed milestone plan available, shows actions on track. Comms/engagement activities detailed in PID, evidence required where possible. Risks detailed in workbook. EA/QIA to be signed by Project Team and uploaded. Last updated 21 August 2017. |

## **Financial Reporting:**

| Project Title | RAG Rating | Budget £ | Forecast<br>£ | Variance<br>£ | Comments |
|---------------|------------|----------|---------------|---------------|----------|
| GDE           | Black      | 0        | 0             | 0             |          |
|               | Black      |          |               |               |          |
| Total         |            |          |               |               |          |

# **Programme Assurance Summary Park, Community Estate and Facilities**



Work Stream Summary (to be completed by Executive Sponsor of the assurance framework)

The workstream has mostly improved in terms of ratings, however more work needs to happen before the next committee to improve the ratings for red rated projects.

The International D&B consultancy needs to be financially appraised and included in the figures.

Claire Liddy, Deputy Director of Finance - 19 September 2017

### Work Stream Summary (to be completed by External Programme Assessment)

The work stream has made significant efforts to improve the assurance base since the previous sub-Committee review in June 2017. At that time only 3 projects were able to be assessed and the ratings were 3 red rated and one amber. The latest position shows all 8 projects having commenced, with evidence on SharePoint, and of those 2 green rated, 3 amber and 3 red. This positive trend should be commended and continued.

Of particular concern are the lack of an EA/QIA for the R&E 2 development and the overall lack of a financial contribution to the CIP programme.

The Executive Sponsor should work with all 'corporate leads 'of projects to attain green ratings as a matter of urgency.

Joe Gibson, External Programme Assessment – 19 September 2017

## Programme Assurance Framework



Park, Community Estate and Facilities (Completed by Assurance Team)

| Sub-Committee   | R&BD                                   | Report Date       | 19 September 2017 |
|-----------------|--|-------------------|-------------------|
| Workstream Name | Park, Community Estate and Facilities. | Executive Sponsor | David Powell      |

|                              |                    |   |  |   |                   |  |  |          |                          |                                     |                                    |                      |  |                           |                   | •   |
|------------------------------|--------------------|---|--|---|-------------------|--|--|----------|--------------------------|-------------------------------------|------------------------------------|----------------------|--|---------------------------|-------------------|---|
| Project Ref                  | Assurance<br>Group | Project Title                               | Proje  | ect Description   |                   | Executive<br>Sponsor<br>Assures<br>the project | OVERALL PROJECT RAG An effective project | .⊑<br>:: | Scope and<br>Approach is | Targets / benefits defined/on track | Milestone plan is defined/on track | Stakeholders engaged | Risks are identified and being managed | Quality Impact Assessment | Equality Analysis | Comments for attention of the Project Team, Steering Group and sub-Committee  |
| 5.0 Park, Com                | munity Estate &    | Facilities 17/18 £TB0                       | ;  |   |                   |  |  |          |                          |                                     |                                    |                      |  |                           |                   |   |
| R&BD 5.1                     | R&BD               | Decommission &<br>Demolition                |  | project is to move of<br>the old hospital red<br>demolition                                   |                   | David Powell                                   |  | •        | •                        | •                                   | •                                  | •                    | •                                      | •                         | •                 | PID available, however details of benefits requires review in line with revised/ updated dates. Milestone plan shows slippage (car park demolition). Details of communication/engagement activities to be confirmed and evidence provided where possible. Risks now on Ulysses, some require review. Last updated 2 August 2017   |
| R&BD 5.2                     | R&BD               | R&E 2                                       |  | project is to comple<br>E building to a worl<br>standard                                      |                   | David Powell                                   | (  |          |                          |                                     | •                                  | •                    | •                                      | •                         | •                 | Team action notes available to May. PID available, benefits to be confirmed. Milestone Plan shows some delays (space allocation & design). Details of comms/engagement activities to be confirmed and evidence provided where possible. Issues Log uploaded, risks to be entered on Ulysses. EA/QIA to be prepared and signed. Last updated 24 August 2017  |
| R&BD 5.3                     | R&BD               | Alder Centre                                |  | lop and construct to<br>e within the park se  |                   | David Powell                                   |  |          |                          |                                     | •                                  | •                    |  | •                         | •                 | Steering Group meeting notes available. Scope/approach defined in PID (revised recently). Benefits defined in PID. Milestone Plan has been revised recently - shows initial actions on track. Evidence of Comms/ Engagement activities. Risks to be confirmed on Ulysses. EA/QIA complete. Last updated 30 August 2017  |
| R&BD 5.4                     | R&BD               | Park  | community<br>Springfield Parl<br>value to the Ne | JV with LCC & the to create a world of the that complements aw Alder Hey in the he local area | class<br>s & adds | David Powell                                   |  |          |                          |                                     |                                    | •                    |  | •                         | •                 | Updated PID on SharePoint - confirmation of updates required/approval at Steering Group. Benefits defined in PID, tracking/reporting of delivery required. Milestone plan shows actions on track, however clarification required eg re LCC sign-off/financial contribution which shows as missed (August 2017). Risks on Ulysses - need confirmation these are up to date. EA/QIA complete. Last updated 26 August 2017 |
| R&BD 5.5                     | R&BD               | Residential<br>Development                  | that co-ordina                                   | n quality residential<br>ates with the theme<br>ithin the wider park                          | es and            | David Powell                                   |  |          | •                        | •                                   | •                                  | •                    |  | •                         | •                 | Scope/approach and benefits defined in PID. Plan shows delays - consultation pushed back to September. Evidence required of comms/engagement activities. Risks on Ulysses and require review (last review May 2017). EA/QIA complete. Last updated 8 August 2017  |
| R&BD 5.6                     | R&BD               | International Design &<br>Build Consultancy |  |   | ı                 | David Powell                                   | (  |          | •                        |                                     | •                                  | •                    |  | •                         | •                 | Work stream reports need to be augmented with evidence of notes/minutes of project meetings. Draft/outline PID on SharePoint. All project documentation to be fully developed. Last updated 24 August 2017  |
| R&BD 5.7                     | R&BD               | Reprovision of<br>Retained Estates          |  |   |                   | David Powell                                   |  |          |                          |                                     | •                                  | •                    |  | •                         | •                 | Some statistics available on numbers for whom estate/space is needed. A high level critical path has been uploaded as well as an option for external provision of space. All project documentation to be fully developed. Last updated 24 August 2017   |
| R&BD 5.8                     | R&BD               | Neuro-Developmental<br>Hub (TBC)            |  |   |                   | David Powell                                   |  |          |                          |                                     |                                    | •                    |  | •                         |                   | SOA' available. All project documentation to be fully developed. Last updated 24 August 2017  |
| Project Title                |                    | RAG Rating                                  | Budget £   | Forecast £  | Variance          | e Comn   | nents                                    |          |                          |                                     |                                    |                      |  |                           |                   |   |
|                              |                    |   |  |   | £                 |  |  |          |                          |                                     |                                    |                      |  |                           |                   |   |
| International<br>Consultancy | Design and B       | uild Black                                  | 0  | 0   | 0                 | No fin   | ancial sa                                | aving    | s ide                    | ntifie                              | d to d                             | ate                  |  |                           |                   |   |
| Total                        |                    |   |  |   |                   |  |  |          |                          |                                     |                                    |                      |  |                           |                   |   |
| . Jul                        |                    |   |  |   |                   |  |  |          |                          |                                     |                                    |                      |  |                           |                   |   |



# Corporate Report

## Corporate Report



### **Table of Contents**

| Executive Summary                   | 3  |
|-------------------------------------|----|
| Leading Metrics                     | 4  |
| Exceptions                          | 5  |
| Patient Safety - Section 1          | 6  |
| Patient Experience                  | 7  |
| Clinical Effectiveness              | 8  |
| Access                              | 9  |
| Accident and Emergency              | 10 |
| Productivity and Efficiency         | 11 |
| Facilities                          | 12 |
| CAHMS                               | 13 |
| External Regulation                 | 14 |
| Workforce                           | 15 |
| Performance by CBU                  | 16 |
| CBU Performance - Community         | 17 |
| CBU Performance - Medicine (Part 1) | 18 |
| CBU Performance - Surgery           | 20 |
| Financial Strength.                 | 21 |

## **Executive Summary**

Aug 2017





#### Highlights

The Trust is compliant with all NHSI standards following on from the challenge of delivering the ED 4hr standard in July. Winter Plan currently in development to support flow. Cancellations on the day reduced from 30 in July to 15 which will help with 28 day breach management. Activity has increased within the hospital against the same period last year, no patients waiting >52 weeks

#### Challenges

Lower levels of elective activity with higher levels of NEL demand and increased LOS have driven occupancy over 83%; the challenge is not the overall occupancy but how to manage the NEL surges that take place. 28 day relist breaches have increased from 1 to 9; analysis identifies HDU, management of emergency patients and list over-runs being the top 3 for failing to treat within the timescale. Surgical Division to review management of this cohort. OP actual utilisation has increased however DNA's have also increased. DQ issues persist notably with cashing up clinics which skews data. 18 week Backlog has increased slightly and needs input to manage.

#### Patient Centred Services

Improvement noted in metrics from July to August with the exception of CAMHS. This is due to increasing levels of DNA's for new & Follow Up patients. The division are currently investigating.4 core NHSI core standards achieved for August; key deterioration noted in July was the ED 4hr standard following high levels of NEL/ED attendance however strong performance noted for August. 28 day breaches have also deteriorated following cancellation in July (patients will now be treated FOC as the commissioner "fine" within the standard contract) which will require management action via the Division.

#### **Excellence in Quality**

The reduction of medication errors associated with harm continues with only 2 in the month of August. Reporting of pressure ulcers continues to increase with improved education. A deeper analysis of clinical incidents with harm is being undertaken.

All inpatient survey measures deteriorated in August. Friends and Family responses from A&E and Community still needs to be improved. The number of complaints remains similar to last year. The overall trend in PALS attendances is lower than last year, reflecting an improvement in addressing concerns locally.

There were 5 recorded hospital infections in August i.e. 20 year to date compared with 41 at this time last

There were 5 recorded hospital infections in August, i.e. 20 year to date compared with 41 at this time last year. MRSA and C difficile infections remain at zero. There were 7 in month readmissions of patients with long term conditions within 48 hours. For surgical patients with an Estimated Date of Discharge (EDD), 3.9% were discharged later than the EDD. This is an improvement against 5.4% last year and equates to 66 patients.

#### Financial, Growth & Mandatory Framework

For the month of August the Trust is reporting a trading deficit of £1.6m which is £0.1m ahead of plan.

Income is ahead of plan by £0.9m mainly due to income relating to non elective and outpatient activity. Elective activity is ahead of plan by 5%, non elective is ahead by 3% and outpatient activity is ahead by 8%.

Pay budgets are 0.3m overspent for the month relating to use of temporary staffing. The Trust is on plan with the CIP target to date. Cash in the Bank is £10.4m. Monitor Use of Resources rating of 3 in line with plan.

#### **Great Talented Teams**

The Trust position on sickness absence saw a small increase in August to 5.10%. Medical Appraisals continue to increase in line with the window to 81%. Mandatory Training remains at 75%, work on the OLM data cleanse in ongoing and the roll out of the ESR portal will see the Trust paperless with payslips at the end of September with all staff being able to access their own personal information, mandatory training compliance and payslip from their mobile device.

## Leading Metrics Aug 2017



#### **Patient Centered Services**

| Metric Name                                       | Goal   | Jul 2017 | Aug 2017 | Trend | Last 12 Months                         |
|---|--------|----------|----------|-------|--|
| ED: 95% Treated within 4 Hours                    | 95.0 % | 93.1 %   | 98.3 %   | _     | <b>\</b>                               |
| RTT: 90% Admitted within 18 weeks                 |        | 89.1 %   | 89.0 %   | •     |  |
| RTT: 95% Non-Admitted within 18 weeks             |        | 88.6 %   | 89.5 %   | _     | ·                                      |
| RTT: 92% Waiting within 18 weeks (open Pathways)  | 92.0 % | 92.0 %   | 92.0 %   |       |  |
| Diagnostics: Numbers waiting over 6 weeks         |        | 0        | 0        | _     | <b>√</b> √                             |
| Average LoS - Elective (Days)                     |        | 3.2      | 2.9      | •     | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| Average LoS - Non-Elective (Days)                 |        | 2.1      | 2.2      |       | ••                                     |
| Daycase Rate                                      | 0.0 %  | 70.9 %   | 70.3 %   | •     | **                                     |
| Theatre Utilisation - % of Session Utilised       | 90.0 % | 86.1 %   | 87.5 %   | _     | ~~~                                    |
| 28 Day Breaches                                   | 0.0    | 1        | 9        | _     | •~~~                                   |
| Clinic Session Utilisation                        | 90.0 % | 85.6 %   | 83.6 %   | •     | ,\\                                    |
| DNA Rate  | 12.0 % | 10.2 %   | 11.4 %   | _     | <b>\</b> \\\                           |
| Cancelled Operations - Non Clinical - On Same Day |        | 31       | 15       | •     | ~~\\                                   |

#### **Excellence in Quality**

| Metric Name   | Goal    | Jul 2017 | Aug 2017 | Trend | Last 12 Months                         |
|---|---------|----------|----------|-------|--|
| Never Events  | 0.0     | 0        | 0        | _     |  |
| IP Survey: % Received information enabling choices about their care | 90.0 %  | 95.7 %   | 92.1 %   | •     | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| IP Survey: % Treated with respect                                   | 100.0 % | 99.4 %   | 99.3 %   | •     | **                                     |
| IP Survey: % Know their planned date of discharge                   | 80.0 %  | 64.0 %   | 53.9 %   | •     | •                                      |
| IP Survey: % Know who is in charge of their care                    | 95.0 %  | 92.9 %   | 91.2 %   | •     | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| IP Survey: % Patients involved in play and learning                 | 80.0 %  | 74.0 %   | 65.7 %   | •     |  |
| Pressure Ulcers (Grade 2 and above) YTD                             |         | 20       | 23       | •     |  |
| Total Infections (YTD)  | 35.0    | 15       | 20       | _     |  |
| Medication errors resulting in harm (YTD)                           | 25.0    | 13       | 15       | •     | •                                      |
| Clinical Incidents resulting in harm (YTD)                          | 245.0   | 352      | 433      | •     |  |

#### **Great and Talented Teams**

| Metric Name                            | Goal    | Jul 2017 | Aug 2017 | Trend | Last 12 Months                         |
|--|---------|----------|----------|-------|--|
| Corporate Induction                    | 100.0 % | 100.0 %  | 55.6 %   | •     | <b>✓</b>                               |
| PDR                                    | 90.0 %  | 78.7 %   | 84.7 %   |       |  |
| Medical Appraisal                      | 100.0 % | 79.2 %   | 81.0 %   | _     |  |
| Sickness                               | 4.5 %   | 5.0 %    | 4.9 %    | •     | ~                                      |
| Mandatory Training                     | 90.0 %  | 78.2 %   | 77.2 %   | •     | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| Staff Survey (Recommend Place to Work) |         | 39.6 %   | 39.6 %   | _     | -                                      |
| Actual vs Planned Establishment (%)    |         | 97.4 %   | 92.9 %   | •     | ~~~                                    |
| Temporary Spend ('000s)                |         | 1092     | 1166     | _     | <b>~</b>                               |

### **Financial, Growth and Mandatory Framework**

| Metric Name                        | Jul 2017 | Aug 2017 | Last 12 Months |
|------------------------------------|----------|----------|----------------|
| CIP In Month Variance ('000s)      | -72      | 37       |                |
| Monitor Risk Ratings (YTD)         | 3        | 3        |                |
| Trading Surplus/(Deficit)          | -270     | -1691    | ~~\\           |
| Capital Expenditure YTD % Variance | 22.4 %   | -58.5 %  | ·              |
| Cash in Bank (£M)                  | 11.3     | 10.4     |                |

## **Exceptions**

Alder Hey Children's NHS Foundation Trust

Aug 2017

#### Positive (Top 5 based on % change) Metric Name Aug 2016 Sep 2016 Oct 2016 Nov 2016 Dec 2016 Jan 2017 Feb 2017 Mar 2017 Apr 2017 May 2017 Jun 2017 Jul 2017 Aug 2017 Last 12 Months RTT: 90% Admitted within 18 weeks 86.3% 88.9% 88.1% 89.2% 87.9% 87.5% 88.9% 87.9% 89.6% 90.3% 88.8% 89.1% 89.0% RTT: 95% Non-Admitted within 18 weeks 88.8% 87.5% 85.8% 87.2% 90.5% 86.7% 88.3% 88.7% 88.6% 89.5% 86.7% 89.5% 90.2% Cancelled Operations - Non Clinical - On Same Day 14 16 22 28 12 17 29 31 7 57 19 31 15 Never Events Cash in Bank (£M)

#### Early Warning (negative trend but not failing - Top 5 based on % change) Metric Name Aug 2016 Sep 2016 Oct 2016 Nov 2016 Dec 2016 Jan 2017 Feb 2017 Mar 2017 Apr 2017 May 2017 Jun 2017 Jul 2017 Aug 2017 Last 12 Months RTT: 92% Waiting within 18 weeks (open Pathways) 92.1% 92.4% Theatre Utilisation - % of Session Utilised 85.9% 87.8% 85.1% 85.1% 84.1% 86.6% 87.0% 86.8% 87.3% 88.2% 86.1% 87.2% 87.5% DNA Rate 12.7% 12.7% Actual vs Planned Establishment (%) 90.7% 91.8% 87.0% 91.8% 87.7% 89.0% 92.3% 95.1% 94.8% 94.9% 94.8% 97.4% 92.9% Trading Surplus/(Deficit) 1,104

| Challenge (Top 5 based on % change)                 |          |          |          |          |          |          |          |          |          |          |          |          |          |                |
|---|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------------|
| Metric Name   | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Last 12 Months |
| 28 Day Breaches                                     | 3        | 5        | 4        | 4        | 3        | 2        | 4        | 2        | 4        | 2        | 5        | 1        | 9        | ~~~~\/         |
| Corporate Induction                                 | 65.4%    | 85.5%    | 100.0%   | 74.1%    | 81.5%    | 77.8%    | 77.8%    | 82.4%    | 82.9%    | 85.7%    | 79.3%    | 100.0%   | 55.6%    | <b>*</b>       |
| Sickness  | 4.8%     | 5.1%     | 5.4%     | 5.4%     | 5.5%     | 5.4%     | 5.3%     | 4.7%     | 4.5%     | 4.6%     | 4.6%     | 5.0%     | 4.9%     | •              |
| IP Survey: % Know their planned date of discharge   | 69.0%    | 71.2%    | 71.6%    | 73.5%    | 73.1%    | 78.7%    | 72.0%    | 75.7%    | 79.4%    | 69.1%    | 65.5%    | 64.0%    | 53.9%    |                |
| IP Survey: % Patients involved in play and learning | 30.7%    | 31.0%    | 55.9%    | 55.1%    | 56.1%    | 55.6%    | 77.1%    | 75.7%    | 81.4%    | 75.8%    | 71.3%    | 74.0%    | 65.7%    |                |

Alder Hey Children's NHS Foundation Trust

#### Summary

Medication errors resulting in harm show continued improvement with only 2 in month. There were 3 pressure ulcers, increasing the year to date position to 23 compared to 11 last year. This is felt to be associated with improved education and reporting. There were revents in August. Clinical incidents with harm remains significantly higher at 433 compared to 234 last year. A deeper analysis is being undertaken to explore if this is simply improved reporting or if there are any trends or areas causing a real increase in harm caused. There were no incidents resulting in moderate or higher harm in August, and there were no Serious incidents Requiring Investigation (SIRIs) in month.



## Patient Experience

Aug 2017




#### Summary


There were 5 formal complaints in month, i.e. 27 year to date - very similar to last year's position. PALS attendances have reduced, with only 72 in August. The overall trend is lower than last year, reflecting an improvement in addressing concerns locally immediately and avoiding the need to refer to PALS.

Patients knowing their EDD has reduced from 64% to 53.9%, as has 'patients involved in play and learning', down from 74% to 65.7% in month. All other inpatient survey results have also deteriorated, and Friends and Family responses from A&E and Community still needs to be improved.

| npatient Survey  |         |          |          |       |                |
|--|---------|----------|----------|-------|----------------|
| Metric Name  | Goal    | Jul 2017 | Aug 2017 | Trend | Last 12 Months |
| % Know who is in charge of their care                    | 95.0 %  | 92.9 %   | 91.2 %   | •     | **             |
| % Patients involved in play and learning                 | 80.0 %  | 74.0 %   | 65.7 %   | •     | •              |
| % Know their planned date of discharge                   | 80.0 %  | 64.0 %   | 53.9 %   | •     | •              |
| % Received information enabling choices about their care | 90.0 %  | 95.7 %   | 92.1 %   | •     |                |
| % Treated with respect                                   | 100.0 % | 99.4 %   | 99.3 %   | •     |                |

| Metric Name                           | Required<br>Responses | Number of<br>Responses | Jul<br>2017 | Aug<br>2017 | Trend | Last 12<br>Months |
|---------------------------------------|-----------------------|------------------------|-------------|-------------|-------|-------------------|
| A&E - % Recommend the Trust           | 250                   | 26                     | 100.0 %     | 92.3 %      | •     | ••                |
| Community - % Recommend the Trust     | 29                    | 1                      | 100.0 %     | 100.0 %     | _     | **                |
| Inpatients - % Recommend the Trust    | 300                   | 517                    | 97.6 %      | 94.2 %      | •     | •                 |
| Mental Health - % Recommend the Trust | 27                    | 60                     | 93.3 %      | 96.7 %      | _     | · ^               |
| Outpatients - % Recommend the Trust   | 400                   | 490                    | 92.8 %      | 92.0 %      | _     | **                |






### Clinical Effectiveness


Aug 2017



#### Summary

There were 5 recorded hospital infections in August, resulting in 20 infections year to date compared with 41 at this time last year. MRSA and Clostridium difficile infections remain at zero year to date. There were 7 in month acute readmissions of patients with long term conditions within 48 hours of discharge, a slight increase on the previous month. For surgical patients with an Estimated Date of Discharge (EDD), 3.9% were actually discharged later than the EDD. This is an improvement against 5.4% last year and equates to 66 patients.







Alder Hey Patient Safety 19 Sep 2017





#### Summary

4 hour, Incomplete pathway, diagnostic & cancer standards achieved. Activity (spells) has increased against same period last year but reduced in line with seasonal variation. GP referrals have increased above 2016 levels and in line with seasonal trends with C&B available to meet current demand. Capacity continues to be monitored via Divisions & daily bed meetings. No patients waiting greater than 52 weeks











## **Emergency Department**


Alder Hey Children's NHS Foundation Trust


Aug 2017

#### Summary

Significant improvement in 4 hour target since last month when the Trust underachieved for the first time since December 2016. Fewer attendances (4031 compared with 5016 in July) and reduced vacant GP shifts have allowed for better flow through the Department. Conversion rate also slightly lower than last month (16.0%). Median time to treat this month has vastly improved on last month (July: 86 minutes).








## Productivity & Efficiency

Alder Hey Children's NHS Foundation Trust

Aug 2017

#### Summary


Planned activity levels have reduced in line with seasonal variation. Elective LOS has reduced and NEL LOS has increased accordingly impacting upon overall hospital occupancy. On the day cancellations have reduced however 28 day relist breaches have increased predominantly due to lack of HDU capacity and managing emergencies. Theatre utilisation has increased with general improvements noted across all areas. Out Patient utilisation has also decreased slightly spread across a number of specialties despite lower DNA rates that will require further analysis and action to address.








#### Theatres / Surgery










#### Outpatients












## Facilities Aug 2017



Summary












#### Summary

Waiting times for choice continue to raise due to lack of capacity. A remedial action plan has been produced and additional resource identity. DNAs for the CAMHS Service had increased, the service will undertaken a deep dive to identify the cause.









## **External Regulation**

Alder Hey Children's NHS Foundation Trust

Aug 2017


#### Summary


The Trust is currently rated as Good by CQC and remains registered without conditions. We are compliant with our Provider Licence and at the end of March continue to be placed in segment 2 under the new NHS Improvement Single Oversight Framework.




| Sep 16         Oct 16         Nov 16         Dec 16         Jan 17         Feb 17         Mar 17         Apr 17         May 17         Jun 17         Jul 17         Aug 17           2         3 | Monitor - Ri | sk Rating |        |        |        |        |        |        |        |        |        |        |
|---|--------------|-----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|   | Sep 16       | Oct 16    | Nov 16 | Dec 16 | Jan 17 | Feb 17 | Mar 17 | Apr 17 | May 17 | Jun 17 | Jul 17 | Aug 17 |
|   | 2            | 3         | 3      | 3      | 3      | 3      | 2      | 3      | 3      | 3      | 3      | 3      |

















#### Summary

The Trust position on sickness absence saw a small increase in August to 5.10%. Medical Appraisals continue to increase in line with the window to 81%. Mandatory Training remains at 75%, work on the OLM data cleanse in ongoing and the roll out of the ESR portal will see the Trust paperless with payslips at the end of September with all staff being able to access their own personal information, mandatory training compliance and payslip from their mobile device.

#### Staff Group Analysis

#### Sickness Absence (rolling 12 Months)

| Staff Group                      | Sep 16 | Oct 16 | Nov 16 | Dec 16 | Jan 17 | Feb 17 | Mar 17 | Apr 17 | May 17 | Jun 17 | Jul 17 | Aug 17 | Last 12 Months |
|----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|
| Add Prof Scientific and Technic  | 5.5%   | 5.0%   | 5.8%   | 5.2%   | 5.0%   | 5.9%   | 4.9%   | 3.6%   | 3.6%   | 3.9%   | 4.6%   | 4.4%   | ***            |
| Additional Clinical Services     | 6.1%   | 7.0%   | 6.9%   | 7.0%   | 6.6%   | 5.5%   | 5.7%   | 7.2%   | 7.4%   | 7.3%   | 7.7%   | 6.0%   |                |
| Administrative and Clerical      | 5.0%   | 5.2%   | 4.5%   | 4.7%   | 4.6%   | 5.0%   | 3.3%   | 2.9%   | 2.3%   | 2.4%   | 3.7%   | 4.1%   | **             |
| Allied Health Professionals      | 3.4%   | 3.1%   | 3.3%   | 4.3%   | 2.3%   | 2.2%   | 3.5%   | 2.9%   | 3.2%   | 3.8%   | 2.9%   | 2.8%   | •              |
| Estates and Ancillary            | 7.9%   | 8.4%   | 8.6%   | 10.9%  | 9.1%   | 7.4%   | 8.9%   | 10.7%  | 9.2%   | 9.1%   | 10.8%  | 14.3%  |                |
| Healthcare Scientists            | 2.8%   | 2.2%   | 1.9%   | 2.0%   | 1.7%   | 3.7%   | 2.3%   | 1.0%   | 3.3%   | 4.0%   | 4.6%   | 2.3%   |                |
| Medical and Dental               | 2.7%   | 2.7%   | 2.0%   | 1.6%   | 2.3%   | 2.4%   | 1.6%   | 1.1%   | 1.3%   | 1.3%   | 1.6%   | 1.6%   | **             |
| Nursing and Midwifery Registered | 5.1%   | 5.7%   | 6.2%   | 6.1%   | 6.4%   | 6.1%   | 5.5%   | 5.1%   | 5.5%   | 5.4%   | 5.2%   | 5.0%   | -              |
| Trust                            | 5.0%   | 5.4%   | 5.4%   | 5.6%   | 5.4%   | 5.2%   | 4.7%   | 4.5%   | 4.6%   | 4.6%   | 5.0%   | 4.9%   |                |

#### Staff in Post FTE (rolling 12 Months)

| Staff Group                      | Sep 16 | Oct 16 | Nov 16 | Dec 16 | Jan 17 | Feb 17 | Mar 17 | Apr 17 | May 17 | Jun 17 | Jul 17 | Aug 17 | Last 12 Months |
|----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|
| Add Prof Scientific and Technic  | 196    | 200    | 199    | 198    | 198    | 197    | 201    | 197    | 199    | 201    | 200    | 201    |                |
| Additional Clinical Services     | 369    | 365    | 368    | 367    | 370    | 373    | 376    | 391    | 393    | 392    | 400    | 397    | ••             |
| Administrative and Clerical      | 560    | 568    | 574    | 573    | 586    | 589    | 586    | 611    | 621    | 617    | 623    | 626    | •              |
| Allied Health Professionals      | 125    | 126    | 126    | 130    | 132    | 132    | 131    | 208    | 209    | 212    | 214    | 214    |                |
| Estates and Ancillary            | 192    | 192    | 190    | 190    | 189    | 189    | 189    | 187    | 185    | 184    | 184    | 183    | •              |
| Healthcare Scientists            | 105    | 105    | 106    | 108    | 107    | 107    | 107    | 107    | 107    | 109    | 110    | 110    | •              |
| Medical and Dental               | 248    | 245    | 246    | 245    | 245    | 246    | 243    | 243    | 242    | 246    | 241    | 245    | *              |
| Nursing and Midwifery Registered | 975    | 973    | 971    | 970    | 972    | 981    | 970    | 968    | 971    | 971    | 964    | 960    | *              |


#### Staff in Post Headcount (rolling 12 Months)

| Staff Group                      | Sep 16 | Oct 16 | Nov 16 | Dec 16 | Jan 17 | Feb 17 | Mar 17 | Apr 17 | May 17 | Jun 17 | Jul 17 | Aug 17 | Last 12 Months |
|----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|----------------|
| Add Prof Scientific and Technic  | 217    | 221    | 220    | 218    | 218    | 217    | 221    | 218    | 220    | 223    | 223    | 221    | ~~^            |
| Additional Clinical Services     | 431    | 430    | 431    | 430    | 434    | 439    | 442    | 469    | 470    | 468    | 477    | 473    |                |
| Administrative and Clerical      | 658    | 666    | 671    | 670    | 677    | 679    | 673    | 700    | 709    | 707    | 713    | 715    | •              |
| Allied Health Professionals      | 154    | 155    | 155    | 161    | 163    | 163    | 161    | 257    | 258    | 261    | 263    | 263    | •              |
| Estates and Ancillary            | 241    | 241    | 238    | 238    | 236    | 236    | 236    | 234    | 231    | 231    | 230    | 229    | •              |
| Healthcare Scientists            | 114    | 114    | 116    | 118    | 117    | 117    | 117    | 117    | 117    | 119    | 119    | 119    | •              |
| Medical and Dental               | 286    | 283    | 285    | 284    | 284    | 287    | 284    | 285    | 285    | 288    | 284    | 288    | *\^\^\         |
| Nursing and Midwifery Registered | 1,099  | 1,099  | 1,097  | 1,093  | 1,095  | 1,105  | 1,094  | 1,093  | 1,095  | 1,096  | 1,090  | 1,085  | •              |









| Operational  |           |          |         |
|--|-----------|----------|---------|
| Metric name  | COMMUNITY | MEDICINE | SURGERY |
| Clinic Session Utilisation                               | 64.6%     | 86.9%    | 84.8%   |
| Convenience and Choice: Slot Availability                | 100.0%    | 98.0%    | 100.0%  |
| DNA Rate (Followup Appts)                                | 15.9%     | 10.4%    | 10.0%   |
| DNA Rate (New Appts)                                     | 17.6%     | 13.0%    | 10.8%   |
| Referrals Received (GP)                                  | 228       | 641      | 977     |
| Temporary Spend ('000s)                                  | 169       | 326      | 554     |
| Theatre Utilisation - % of Session Utilised              |           | 81.8%    | 88.6%   |
| Trading Surplus/(Deficit)                                | 145       | -302     | 2,574   |
| Patient  |           |          |         |
| fletric name   | COMMUNITY | MEDICINE | SURGERY |
| Average LoS - Elective (Days)                            |           | 2.9      | 2.9     |
| Average LoS - Non-Elective (Days)                        |           | 1.5      | 3.0     |
| Cancelled Operations - Non Clinical - On Same Day        | 0         | 1        | 14      |
| Daycases (K1/SDCPREOP)                                   | 0         | 71       | 499     |
| Diagnostics: % Completed Within 6 Weeks                  |           | 100.0%   | 100.0%  |
| Hospital Initiated Clinic Cancellations < 6 weeks notice | 13        | 16       | 32      |
| OP Appointments Cancelled by Hospital %                  | 18.5%     | 13.9%    | 12.6%   |
| RTT: 90% Admitted within 18 weeks                        |           | 95.5%    | 87.8%   |
| RTT: 92% Waiting within 18 weeks (open Pathways)         | 96.5%     | 93.3%    | 91.2%   |
| RTT: 95% Non-Admitted within 18 weeks                    | 93.1%     | 87.3%    | 90.2%   |
| Quality  |           |          |         |
| letric name  | COMMUNITY | MEDICINE | SURGERY |
| Cleanliness Scores                                       |           |          |         |
| Hospital Acquired Organisms - C.difficile                | 0         | 0        | 0       |
| Hospital Acquired Organisms - MRSA (BSI)                 | 0         | 0        | 0       |
| Medication Errors (Incidents)                            | 17        | 139      | 243     |
| Workforce  |           |          |         |
| Metric name  | COMMUNITY | MEDICINE | SURGERY |
| Corporate Induction                                      | 57.1%     | 50.0%    | 60.0%   |
| Mandatory Training                                       | 75.3%     | 78.3%    | 77.0%   |
| PDR  | 82.8%     | 79.7%    | 91.1%   |
| Sickness   | 5.7%      | 4.0%     | 4.6%    |



Key Issues

Clinic utilisation is below required level despite increases in clinic booking rates. Increases in DNA rates have been observed and so further investigation is required to understand if there is a data reporting issue or real increase in DNA rates.

The division is reporting a deficit financial position at M5 related to increases in agency spend to cover medical staff vacancies and additional costs for services transferred from LCH which was not planned. The division has worked hard to increase rates of PDRs to above 80% and further work is planned during September to get to 90%.

### Support Required

Sickness rates are higher than the Trust average and so further work with local managers required to understand trends and what additional support is required to help bring rates down.

| Operational  |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--|
| Metric Name  | Aug-16 | Sep-16 | Oct-16 | Nov-16 | Dec-16 | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Last 12 Months   |
| Theatre Utilisation - % of Session Utilised              |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Clinic Session Utilisation                               | 75.9%  | 73.1%  | 78.4%  | 80.6%  | 74.1%  | 75.9%  | 80.3%  | 83.0%  | 79.0%  | 81.9%  | 79.8%  | 78.7%  | 64.6%  |  |
| DNA Rate (New Appts)                                     | 15.8%  | 12.9%  | 15.6%  | 12.8%  | 18.9%  | 15.3%  | 11.8%  | 11.8%  | 15.9%  | 16.4%  | 14.4%  | 14.6%  | 17.6%  | ~~~  |
| DNA Rate (Followup Appts)                                | 16.7%  | 15.9%  | 14.0%  | 12.3%  | 17.8%  | 16.5%  | 15.7%  | 13.3%  | 15.3%  | 14.4%  | 13.7%  | 11.2%  | 15.9%  | -  |
| Convenience and Choice: Slot Availability                | 92.1%  | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |        |        | 100.0% | /  |
| Referrals Received (GP)                                  | 200    | 313    | 307    | 393    | 298    | 268    | 336    | 385    | 229    | 387    | 322    | 319    | 228    | ~~~  |
| Temporary Spend ('000s)                                  | 149    | 144    | 37     | 60     | 47     | 77     | 72     | 150    | 67     | 103    | 116    | 146    | 169    | ~~~~   |
| Trading Surplus/(Deficit)                                | 371    | 244    | 355    | 341    | 415    | 410    | 256    | 442    | 343    | 414    | 299    | 224    | 145    | ~~~~   |
| Patient  |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Metric Name  | Aug-16 | Sep-16 | Oct-16 | Nov-16 | Dec-16 | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Last 12 Months   |
| RTT: 90% Admitted within 18 weeks                        |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| RTT: 95% Non-Admitted within 18 weeks                    | 80.9%  | 87.5%  | 77.4%  | 78.0%  | 80.2%  | 75.3%  | 73.1%  | 88.4%  | 87.9%  | 85.4%  | 91.8%  | 91.4%  | 93.1%  | - The state of the |
| RTT: 92% Waiting within 18 weeks (open Pathways)         | 89.6%  | 88.5%  | 82.5%  | 85.9%  | 92.3%  | 92.8%  | 93.1%  | 94.4%  | 94.0%  | 97.4%  | 94.3%  | 94.6%  | 96.5%  | -  |
| Average LoS - Elective (Days)                            |        |        |        | 22.00  |        |        |        |        |        |        |        |        |        |  |
| Average LoS - Non-Elective (Days)                        |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Hospital Initiated Clinic Cancellations < 6 weeks notice | 18     | 29     | 23     | 29     | 1      | 9      | 19     | 8      | 15     | 3      | 12     | 5      | 13     |  |
| Daycases (K1/SDCPREOP)                                   | 2      | 0      | 0      | 0      | 3      | 0      | 0      | 0      | 0      | 2      | 0      | 1      | 0      | \_\_\  |
| Cancelled Operations - Non Clinical - On Same Day        | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      |  |
| OP Appointments Cancelled by Hospital %                  | 23.2%  | 22.9%  | 22.3%  | 17.0%  | 15.4%  | 14.2%  | 20.3%  | 20.8%  | 23.1%  | 14.7%  | 19.4%  | 14.3%  | 18.5%  |  |
| Diagnostics: % Completed Within 6 Weeks                  | 100.0% |        |        |        |        |        |        |        |        |        |        |        |        | -  |
| Quality  |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Metric Name  | Aug-16 | Sep-16 | Oct-16 | Nov-16 | Dec-16 | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Last 12 Months   |
| Medication Errors (Incidents)                            | 19     | 20     | 24     | 26     | 27     | 29     | 30     | 31     | 3      | 5      | 8      | 10     | 17     |  |
| Cleanliness Scores                                       |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Hospital Acquired Organisms - MRSA (BSI)                 | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      |  |
| Hospital Acquired Organisms - C.difficile                | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      | 0      |  |
| Vorkforce  |        |        |        |        |        |        |        |        |        |        |        |        |        |  |
| Metric Name  | Aug-16 | Sep-16 | Oct-16 | Nov-16 | Dec-16 | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Last 12 Months   |
| Corporate Induction                                      | 60.0%  | 86.7%  | 100.0% | 72.7%  | 87.5%  | 87.5%  | 87.5%  | 100.0% | 82.9%  |        | 88.9%  | 100.0% | 57.1%  |  |
| PDR  | 68.3%  | 77.1%  | 82.1%  | 81.4%  | 75.4%  | 77.2%  | 76.4%  | 67.0%  | 0.0%   | 5.7%   | 26.5%  | 71.0%  | 82.8%  |  |
| Sickness   | 5.5%   | 6.2%   | 7.6%   | 8.8%   | 7.1%   | 7.1%   | 6.9%   | 5.9%   | 5.1%   | 5.6%   | 5.6%   | 6.0%   | 5.7%   |  |
| Mandatory Training                                       | 75.4%  | 73.2%  | 71.1%  | 70.9%  | 72.1%  | 75.8%  | 78.0%  | 57.1%  | 57.1%  | 56.1%  | 55.2%  | 74.5%  | 75.3%  |  |



Key Issues

Overall Month 5 was positive in terms of delivery of activity within Medicine where they were 4% ahead of plan; Daycase, A&E and Outpatients performed well. It was a better month for Nephrology where we had previously identified coding issues, and we saw an improved performance in month. Division is reviewing activity compared with 2016/17 and identifying in more detail where the challenged specialties any case mix opportunities.

Support Required

| Operational                                 |          |          |          |          |          |          |          |          |          |          |          |          |          |  |
|---|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|--|
| Metric Name                                 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Last 12 Months                         |
| Theatre Utilisation - % of Session Utilised | 75.8%    | 85.0%    | 80.1%    | 79.1%    | 80.1%    | 82.9%    | 79.1%    | 85.4%    | 81.1%    | 83.6%    | 84.6%    | 76.9%    | 81.8%    | \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| Clinic Session Utilisation                  | 81.0%    | 84.0%    | 86.6%    | 86.9%    | 83.8%    | 85.4%    | 86.9%    | 89.6%    | 86.8%    | 86.7%    | 84.7%    | 86.7%    | 86.9%    |  |
| DNA Rate (New Appts)                        | 17.5%    | 14.6%    | 14.8%    | 12.5%    | 14.6%    | 14.1%    | 12.4%    | 10.0%    | 15.0%    | 12.6%    | 12.6%    | 12.8%    | 13.0%    | ~~~~~                                  |
| DNA Rate (Followup Appts)                   | 18.7%    | 15.4%    | 13.6%    | 16.1%    | 18.5%    | 16.3%    | 16.8%    | 13.0%    | 16.6%    | 15.8%    | 11.4%    | 9.9%     | 10.4%    | -                                      |
| Convenience and Choice: Slot Availability   | 93.7%    | 99.4%    | 98.1%    | 100.0%   | 99.6%    | 96.1%    | 86.5%    | 99.4%    | 98.0%    | 96.3%    | 100.0%   | 100.0%   | 98.0%    |  |
| Referrals Received (GP)                     | 566      | 627      | 653      | 733      | 563      | 681      | 594      | 821      | 577      | 747      | 791      | 728      | 641      |  |
| Temporary Spend ('000s)                     | 272      | 272      | 230      | 229      | 164      | 499      | 341      | 302      | 290      | 322      | 222      | 323      | 326      |  |
| Trading Surplus/(Deficit)                   | -307     | 525      | 321      | 491      | 212      | 74       | -113     | 1,012    | -298     | 108      | -152     | -390     | -302     |  |

| Patient  |          |          |          |          |          |          |          |          |          |          |          |          |          |                |
|--|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------------|
| Metric Name  | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Last 12 Months |
| RTT: 90% Admitted within 18 weeks                        | 95.8%    | 100.0%   | 89.6%    | 93.1%    | 87.6%    | 92.6%    | 100.0%   | 91.5%    | 96.4%    |          | 95.7%    | 90.5%    | 95.5%    | ~~~~~          |
| RTT: 95% Non-Admitted within 18 weeks                    | 86.4%    | 85.4%    | 88.6%    | 83.2%    | 84.7%    | 92.4%    | 89.3%    | 90.9%    | 90.9%    | 86.2%    | 88.8%    | 89.1%    | 87.3%    | -              |
| RTT: 92% Waiting within 18 weeks (open Pathways)         | 93.3%    | 93.2%    | 95.1%    | 96.0%    | 96.7%    | 96.9%    | 96.0%    | 94.8%    | 94.9%    | 94.5%    | 94.0%    | 93.6%    | 93.3%    | 1              |
| Average LoS - Elective (Days)                            | 3.01     | 2.72     | 3.27     | 3.25     | 3.66     | 3.64     | 3.22     | 3.20     | 3.50     | 3.40     | 2.96     | 3.05     | 2.92     | ~~~            |
| Average LoS - Non-Elective (Days)                        | 1.28     | 1.34     | 1.29     | 1.54     | 1.53     | 1.44     | 1.69     | 1.57     | 1.62     | 1.60     | 1.51     | 1.65     | 1.49     | ~~~~           |
| Hospital Initiated Clinic Cancellations < 6 weeks notice | 14       | 27       | 22       | 41       | 29       | 41       | 37       | 27       | 20       | 18       | 23       | 17       | 16       | ~~~            |
| Daycases (K1/SDCPREOP)                                   | 68       | 86       | 52       | 46       | 65       | 68       | 63       | 70       | 58       | 70       | 103      | 70       | 71       | ~~~            |
| Cancelled Operations - Non Clinical - On Same Day        | 1        | 4        | 1        | 8        | 4        | 6        | 6        | 3        | 1        | 3        | 1        | 2        | 1        | ~~~            |
| OP Appointments Cancelled by Hospital %                  | 14.6%    | 13.4%    | 14.7%    | 13.6%    | 14.2%    | 14.6%    | 15.0%    | 14.1%    | 17.4%    | 11.3%    | 13.5%    | 14.8%    | 13.9%    | ~~~~           |
| Diagnostics: % Completed Within 6 Weeks                  | 99.5%    | 100.0%   | 76.9%    | 99.1%    | 99.5%    | 100.0%   | 99.7%    | 99.6%    | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | ~              |
|  |          |          |          |          |          |          |          |          |          |          |          |          |          |                |

| Quality                                   |          |          |          |          |          |          |          |          |          |          |          |          |          |                |
|---|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------------|
| Metric Name                               | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Last 12 Months |
| Medication Errors (Incidents)             | 114      | 146      | 168      | 198      | 228      | 251      | 270      | 305      | 25       | 58       | 84       | 109      | 139      |                |
| Cleanliness Scores                        | 95.0%    | 96.5%    | 95.8%    | 97.5%    | 97.0%    | 96.8%    | 96.8%    | 99.0%    |          |          |          |          |          | ~~             |
| Hospital Acquired Organisms - MRSA (BSI)  | 0        | 1        | 0        | 0        | 0        | 1        | 0        | 0        | 0        | 0        | 0        | 0        | 0        |                |
| Hospital Acquired Organisms - C.difficile | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        | 0        |                |

| Workforce           |          |          |          |          |          |          |          |          |          |          |          |          |          |                |
|---------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------------|
| Metric Name         | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Last 12 Months |
| Corporate Induction | 69.2%    | 80.0%    | 100.0%   | 85.0%    | 83.3%    | 75.0%    | 75.0%    | 68.8%    |          | 81.8%    | 61.5%    | 100.0%   | 50.0%    | ~~~            |
| PDR                 | 78.9%    | 81.6%    | 79.7%    | 79.4%    | 77.6%    | 76.7%    | 75.7%    | 69.7%    | 2.9%     | 15.4%    | 41.3%    | 73.8%    | 79.7%    |                |
| Sickness            | 4.5%     | 4.7%     | 4.9%     | 4.6%     | 4.8%     | 4.9%     | 5.3%     | 4.5%     | 4.0%     | 4.7%     | 4.3%     | 4.6%     | 4.0%     |                |
| Mandatory Training  | 80.1%    | 76.6%    | 76.9%    | 76.3%    | 76.4%    | 77.3%    | 79.2%    | 79.7%    | 80.1%    | 80.0%    | 80.5%    | 79.0%    | 78.3%    | 1              |

Alder Hey Children's NHS

Key Issues

All patient metrics are consistent or improved, with the exception of equipment availability, which will be investigated. MRI waiting time under 6 weeks at 77% and still a concern. Looking at possibility of extra MR sessions at weekends to reduce the MR waiting-list backlog.

All quality metrics consistent or improved.

#### Support Required

Metric Name

Pathology - % Tur

| Patient   |        |        |        |        |        |        |        |        |        |        |        |        |        |   |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---|
| Metric Name   | Aug-16 | Sep-16 | Oct-16 | Nov-16 | Dec-16 | Jan-17 | Feb-17 | Mar-17 | Apr-17 | May-17 | Jun-17 | Jul-17 | Aug-17 | Last 12 Months  |
| Imaging - % Report Turnaround times GP referrals < 24 hrs         | 91.0%  | 89.0%  | 96.0%  | 95.0%  | 93.0%  | 96.0%  | 97.0%  | 87.0%  | 96.0%  | 91.0%  | 92.0%  | 90.0%  | 90.0%  | ~~~~  |
| Imaging - % Reporting Turnaround Times - ED                       | 89.0%  | 89.0%  | 88.0%  | 87.0%  | 88.0%  | 88.0%  | 93.0%  | 90.0%  | 80.0%  | 64.0%  | 76.0%  | 83.0%  | 82.0%  |   |
| Imaging - % Reporting Turnaround Times - Inpatients               | 84.0%  | 85.0%  | 87.0%  | 76.0%  | 80.0%  | 86.0%  | 89.0%  | 90.0%  | 78.0%  | 74.0%  | 79.0%  | 85.0%  | 85.0%  |   |
| maging - % Reporting Turnaround Times - Outpatients               | 97.0%  | 89.0%  | 93.0%  | 93.0%  | 94.0%  | 97.0%  | 98.0%  | 94.0%  | 92.0%  | 90.0%  | 92.0%  | 98.0%  | 98.0%  | 1   |
| maging - Waiting Times - MRI % under 6 weeks                      | 94.0%  | 90.0%  | 88.0%  | 90.0%  | 92.0%  | 92.0%  | 86.0%  | 85.0%  | 71.0%  | 81.0%  | 67.0%  | 68.0%  | 77.0%  |   |
| Imaging - Waiting Times - CT % under 1 week                       | 92.0%  | 90.0%  | 86.0%  | 84.0%  | 81.0%  | 81.0%  | 77.0%  | 87.0%  | 95.0%  | 89.0%  | 87.0%  | 87.0%  | 89.0%  |   |
| maging - Waiting Times - Plain Film % under 24 hours              | 94.0%  | 95.0%  | 95.0%  | 94.0%  | 94.0%  | 94.0%  | 92.0%  | 93.0%  | 93.0%  | 94.0%  | 93.0%  | 94.0%  | 92.0%  |   |
| maging - Waiting Times - Ultrasound % under 2 weeks               | 89.0%  | 88.0%  | 86.0%  | 85.0%  | 83.0%  | 83.0%  | 81.0%  | 87.0%  | 84.0%  | 88.0%  | 90.0%  | 91.0%  | 90.0%  | - The same of the |
| maging - Waiting Times - Nuclear Medicine % under 2 weeks         | 81.0%  | 91.0%  | 85.0%  | 100.0% | 88.0%  | 88.0%  | 84.0%  | 93.0%  | 88.0%  | 95.0%  | 89.0%  | 100.0% | 93.0%  | ~~~~  |
| BME - High Risk Equipment PPM Compliance                          | 90.0%  | 90.0%  | 90.4%  | 89.7%  | 93.0%  | 91.0%  | 91.1%  | 88.0%  | 80.2%  | 91.7%  | 91.6%  | 91.2%  | 90.1%  |   |
| BME - Low Risk Equipment PPM Compliance                           | 80.0%  | 78.0%  | 77.0%  | 79.0%  | 80.0%  | 81.0%  | 80.8%  | 79.0%  | 100.0% | 82.0%  | 81.9%  | 80.4%  | 75.5%  |   |
| BME - Equipment Pool - Equipment Availability                     | 100.0% | 100.0% | 99.8%  | 100.0% | 100.0% | 99.8%  | 100.0% | 100.0% | 91.4%  | 99.8%  | 100.0% | 100.0% | 100.0% |   |
| Pharmacy - Dispensing for Out Patients - Routine                  | 64.0%  | 44.0%  | 45.0%  | 50.0%  | 51.0%  | 55.0%  | 50.0%  | 45.0%  | 57.0%  | 37.0%  | 60.0%  | 65.0%  | 63.0%  | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~  |
| Pharmacy - Dispensing for Out Patients - Complex                  | 100.0% | 100.0% | 100.0% | 97.7%  | 98.0%  | 100.0% | 98.0%  | 98.0%  | 98.0%  | 100.0% | 100.0% | 96.0%  | 97.0%  |   |
| Comm Therapy - % 1st Contact times following Pt opt in < 12 weeks | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 63.0%  | 63.0%  | 63.0%  | 54.3%  | 54.5%  | 80.0%  |   |

Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Last 12 Months

100.0%

Aug-16 Sep-16 Oct-16



Key Issues
We are delighted that more than 90% of staff have received a PDR this year. We are now turning our focus to supporting staff with access to mandatory training.

On a positive note, our theatre utilisation has improved and is near to the standard. Of concern is our persistent under-utilisation of clinics; in response Divisional Board will receive a report on clinic utilisation in neurosurgery and plastic surgery, which are the departments with the lowest utilisation.

#### Support Required

| Operational  |        |               |               |               |               |               |               |        |        |              |        |               |               |                |
|--|--------|---------------|---------------|---------------|---------------|---------------|---------------|--------|--------|--------------|--------|---------------|---------------|----------------|
| Metric Name  | Aug-16 | Sep-16        | Oct-16        | Nov-16        | Dec-16        | Jan-17        | Feb-17        | Mar-17 | Apr-17 | May-17       | Jun-17 | Jul-17        | Aug-17        | Last 12 Months |
| Theatre Utilisation - % of Session Utilised              | 87.6%  | 88.3%         | 86.0%         | 86.1%         | 84.8%         | 87.2%         | 88.5%         | 87.1%  | 88.3%  | 87.9%        | 88.9%  | 87.7%         | 88.6%         | ~~~~           |
| Clinic Session Utilisation                               | 84.3%  | 84.0%         | 86.6%         | 87.9%         | 84.2%         | 85.5%         | 85.3%         | 88.0%  | 87.7%  | 86.1%        | 85.9%  | 86.3%         | 84.8%         |                |
| DNA Rate (New Appts)                                     | 12.1%  | 11.3%         | 10.1%         | 11.7%         | 13.3%         | 12.4%         | 11.9%         | 9.8%   | 10.3%  | 11.7%        | 11.7%  | 9.6%          | 10.8%         | ~~~            |
| DNA Rate (Followup Appts)                                | 11.8%  | 10.5%         | 8.7%          | 9.0%          | 11.2%         | 8.7%          | 9.4%          | 8.3%   | 9.9%   | 10.1%        | 8.9%   | 9.3%          | 10.0%         | m              |
| Convenience and Choice: Slot Availability                | 99.6%  | 99.1%         | 97.4%         | 100.0%        | 98.7%         | 100.0%        | 99.8%         | 95.3%  | 98.2%  | 99.5%        | 96.0%  | 99.0%         | 100.0%        | ~~~            |
| Referrals Received (GP)                                  | 971    | 1,055         | 1,002         | 1,041         | 876           | 1,072         | 1,046         | 1,280  | 976    | 1,151        | 1,215  | 1,033         | 977           |                |
| Temporary Spend ('000s)                                  | 436    | 453           | 529           | 426           | 331           | 504           | 475           | 443    | 516    | 402          | 456    | 511           | 554           |                |
| Trading Surplus/(Deficit)                                | 1,992  | 1,921         | 1,806         | 2,721         | 1,539         | 2,008         | 2,181         | 2,821  | 1,826  | 2,930        | 3,321  | 2,980         | 2,574         |                |
| Patient  |        |               |               |               |               |               |               |        |        |              |        |               | ,             |                |
| Metric Name  | Aug-16 | Sep-16        | Oct-16        | Nov-16        | Dec-16        | Jan-17        | Feb-17        | Mar-17 | Apr-17 | May-17       | Jun-17 | Jul-17        | Aug-17        | Last 12 Months |
| RTT: 90% Admitted within 18 weeks                        | 85.4%  | 87.7%         | 87.9%         | 88.9%         | 88.0%         | 86.8%         | 87.0%         | 87.2%  | 86.9%  | 90.3%        | 87.8%  | 88.8%         | 87.8%         | Last 12 months |
| RTT: 95% Non-Admitted within 18 weeks                    | 90.8%  | 88.7%         | 87.0%         | 88.6%         | 89.7%         | 92.8%         | 88.1%         | 89.1%  | 90.1%  | 89.8%        | 88.2%  | 88.1%         | 90.2%         |                |
| RTT: 92% Waiting within 18 weeks (open Pathways)         | 91.9%  | 92.0%         | 92.1%         | 91.3%         | 90.4%         | 90.6%         | 90.6%         | 90.9%  | 90.9%  | 90.8%        | 91.3%  | 91.2%         | 91.2%         | -              |
| Average LoS - Elective (Days)                            | 2.93   | 2.43          | 2.87          | 2.88          | 2.73          | 2.17          | 3.26          | 2.62   | 2.58   | 3.57         | 2.57   | 3.10          | 2.90          | ~~~~           |
| Average LoS - Non-Elective (Days)                        | 2.58   | 2.27          | 2.65          | 2.64          | 2.55          | 3.02          | 2.78          | 2.64   | 2.84   | 3.06         | 2.57   | 2.86          | 2.96          |                |
| Hospital Initiated Clinic Cancellations < 6 weeks notice | 45     | 56            | 34            | 72            | 20            | 30            | 54            | 22     | 19     | 23           | 28     | 35            | 32            | ~~~            |
| Daycases (K1/SDCPREOP)                                   | 463    | 515           | 442           | 570           | 471           | 562           | 461           | 582    | 426    | 540          | 609    | 472           | 499           | ~~~~           |
| Cancelled Operations - Non Clinical - On Same Day        | 13     | 12            | 21            | 20            | 8             | 11            | 23            | 28     | 6      | 54           | 18     | 29            | 14            |                |
| OP Appointments Cancelled by Hospital %                  | 14.4%  | 13.8%         | 14.8%         | 14.6%         | 13.8%         | 14.0%         | 14.2%         | 13.7%  | 13.2%  | 11.2%        | 12.7%  | 12.0%         | 12.6%         |                |
| Diagnostics: % Completed Within 6 Weeks                  | 100.0% | 100.0%        | 100.0%        | 100.0%        | 100.0%        | 100.0%        | 100.0%        | 100.0% | 100.0% | 100.0%       | 100.0% | 100.0%        | 100.0%        |                |
| Quality  |        |               |               |               |               |               |               |        |        |              |        |               |               |                |
| ****   | A 40   | 0 40          | 0-140         | N 40          | D 40          | 1 m 42        | F-1-47        | May 47 | A 47   | Man. 47      | Lun 47 | to 1.47       | A 47          | Land 40 Marsha |
| Metric Name  Medication Errors (Incidents)               | Aug-16 | Sep-16<br>264 | Oct-16<br>295 | Nov-16<br>336 | Dec-16<br>367 | Jan-17<br>396 | Feb-17<br>430 | Mar-17 | Apr-17 | May-17<br>97 | Jun-17 | Jul-17<br>188 | Aug-17<br>243 | Last 12 Months |
| Cleanliness Scores                                       | 96.6%  | 96.6%         | 95.1%         | 97.9%         | 96.0%         | 96.1%         | 96.2%         | 97.7%  | 40     | 81           | 140    | 100           | 240           |                |
| Hospital Acquired Organisms - MRSA (BSI)                 | 0      | 0             | 0             | 0             | 0             | 0             | 0             | 0      | 0      | 0            | 0      | 0             | 0             |                |
| Hospital Acquired Organisms - C.difficile                | 0      | 0             | -             | 1             | 0             | -             | 0             | 0      | 0      | 0            | 0      | 0             | 0             | ^              |
|  |        |               |               |               |               |               |               |        |        |              |        |               |               |                |
| Workforce  |        |               |               |               |               |               |               |        |        |              |        |               |               |                |
| Metric Name  | Aug-16 | Sep-16        | Oct-16        | Nov-16        | Dec-16        | Jan-17        | Feb-17        | Mar-17 | Apr-17 | May-17       | Jun-17 | Jul-17        | Aug-17        | Last 12 Months |
| Corporate Induction                                      | 64.0%  | 85.7%         | 100.0%        | 65.2%         | 71.4%         | 71.4%         | 71.4%         | 94.1%  |        | 90.0%        | 100.0% | 100.0%        | 60.0%         |                |
| PDR  | 51.4%  | 64.2%         | 63.4%         | 63.3%         | 61.1%         | 63.4%         | 64.2%         | 45.1%  | 1.9%   | 11.2%        | 63.0%  | 87.6%         | 91.1%         |                |
| Sickness   | 5.2%   | 5.7%          | 5.7%          | 5.8%          | 5.5%          | 5.6%          | 4.9%          | 4.4%   | 4.5%   | 4.5%         | 4.8%   | 4.9%          | 4.6%          |                |
| Mandatory Training                                       | 78.5%  | 75.0%         | 75.3%         | 75.7%         |               | 77.5%         | 78.7%         | 79.3%  | 80.6%  | 80.7%        | 81.5%  | 79.1%         | 77.0%         | -              |

## 3. Financial Strength

| 2.1 Truct Incomo | 9. Evpanditura | Danart pariod a | ended August 2017 |
|------------------|----------------|-----------------|-------------------|
|                  |                |                 |                   |

|                                   |          | In Month |          | Y        | ear to Date | •        | Full Year |           |          |
|-----------------------------------|----------|----------|----------|----------|-------------|----------|-----------|-----------|----------|
|                                   | Budget   | Actual   | Variance | Budget   | Actual      | Variance | Budget    | Forecast  | Variance |
|                                   | £'000    | £'000    | £'000    | £'000    | £'000       | £'000    | £'000     | £'000     | £'000    |
| Clinical Income                   |          |          |          |          |             |          |           |           |          |
| Elective                          | 3,678    | 3,648    | (29)     | 19,771   | 18,749      | (1,023)  | 48,861    | 48,861    |          |
| Non Elective                      | 2,211    | 2,690    | 479      | 12,021   | 13,769      | 1,748    | 29,204    | 29,204    |          |
| Outpatients                       | 2,081    | 2,243    | 162      | 11,559   | 11,593      | 34       | 28,628    | 28,628    |          |
| A&E                               | 394      | 399      | 5        | 2,479    | 2,357       | (122)    | 6,036     | 6,036     |          |
| Critical Care                     | 2,003    | 2,114    | 111      | 10,314   | 10,851      | 537      | 25,222    | 25,222    |          |
| Non PbR Drugs & Devices           | 1,796    | 2,472    | 676      | 8,892    | 9,913       | 1,021    | 21,243    | 21,243    |          |
| Excess Bed Days                   | 388      | 221      | (167)    | 1,941    | 1,851       | (89)     | 4,658     | 4,658     |          |
| CQUIN                             | 261      | 179      | (82)     | 1,306    | 1,308       | 2        | 3,134     | 3,134     |          |
| Contract Sanctions                | (10)     | (4)      | 6        | (52)     | (36)        | 16       | (125)     | (125)     |          |
| Private Patients                  | 15       | 58       | 43       | 73       | 126         | 53       | 176       | 176       |          |
|                                   | 1        |          |          |          |             | 416      |           |           |          |
| Other Clinical Income             | 2,914    | 2,725    | (189)    | 14,862   | 15,278      | 416      | 37,489    | 37,489    |          |
| Non Clinical Income               |          |          |          |          |             |          |           |           |          |
| Other Non Clinical Income         | 2,033    | 1,961    | (72)     | 9,881    | 10,342      | 460      | 25,181    | 25,181    |          |
| Total Income                      | 17,763   | 18,706   | 943      | 93,046   | 96,100      | 3,053    | 229,707   | 229,707   |          |
| Expenditure                       |          |          |          |          |             |          |           |           |          |
| •                                 | (12.267) | (12 520) | (262)    | (61 126) | (62 022)    | (007)    | (144.005) | (144 005) |          |
| Pay Costs                         | (12,267) | (12,530) |          | (61,136) | (62,022)    | (887)    | (144,985) |           |          |
| Drugs                             | (1,638)  | (2,139)  | (501)    | (8,111)  | (9,511)     | (1,400)  | (19,368)  | (19,368)  |          |
| Clinical Supplies                 | (1,568)  | (1,564)  | 5        | (7,973)  | (8,044)     | (71)     | (18,524)  | (18,524)  |          |
| Other Non Pay                     | (2,203)  | (2,378)  | (175)    | (11,357) | (12,375)    | (1,018)  | (25,542)  | (25,542)  |          |
| PFI service costs                 | (329)    | (346)    | (17)     | (1,645)  | (1,540)     | 105      | (3,948)   | (3,948)   |          |
| Total Expenditure                 | (18,005) | (18,956) | (951)    | (90,222) | (93,493)    | (3,272)  | (212,367) | (212,367) |          |
| EBITDA                            | (242)    | (250)    | (8)      | 2,825    | 2,607       | (218)    | 17,340    | 17,340    |          |
| PDC Dividend                      | (114)    | (114)    | 0        | (569)    | (569)       | 0        | (1,365)   | (1,365)   |          |
| Depreciation                      | (548)    | (495)    | 53       | (2,677)  | (2,475)     | 202      | (6,409)   | (6,409)   |          |
| Finance Income                    | 0        | 2        | 2        | 2        | 9           | 7        | 5         | 5         |          |
| Interest Expense (non-PFI/LIFT)   | (92)     | (89)     | 2        | (445)    | (441)       | 4        | (1,087)   | (1,087)   |          |
| Interest Expense (PFI/LIFT)       | (675)    | (675)    | 0        | (3,374)  | (3,374)     | 0        | (8,098)   | (8,098)   |          |
| MASS/Restructuring                | (62)     | (62)     | 0        | (247)    | (284)       | (37)     | (247)     | (247)     |          |
| Gains/(Losses) on asset disposals | 0        | 65       | 65       | 0        | 71          | 71       | 0         | 7         |          |
| Control Total Surplus / (Deficit) | (1,732)  | (1,618)  | 114      | (4,486)  | (4,456)     | 30       | 138       | 145       |          |
| control rotal surpusy (School)    | (1,732)  | (1,010)  |          | (4,400)  | (4,430)     |          | 130       | 143       |          |
| One-off normalising items         |          |          |          |          |             |          |           |           |          |
| STF Funding                       | 0        | 0        | 0        | 0        | 93          | 93       | 0         | 93        | 9        |
| Government Grants/Donated Income  | 712      | 196      | (516)    | 5,101    | 1,970       | (3,131)  | 12,750    | 12,750    |          |
| Depreciation on Donated Assets    | (176)    | (172)    | 4        | (871)    | (853)       | 17       | (2,089)   | (2,089)   |          |
| Fixed Asset Impairment            | 0        | 0        | 0        | 0        | 0           | 0        | (1,536)   | (1,536)   |          |
| Reported Surplus/(Deficit)        | (1,196)  | (1,594)  | (398)    | (256)    | (3,246)     | (2,990)  | 9,263     | 9,363     | 10       |

| Key Metrics                          |          | In Month |          |          | ear to Date | :        | Full Year |           |          |  |
|--------------------------------------|----------|----------|----------|----------|-------------|----------|-----------|-----------|----------|--|
|                                      | Budget   | Actual   | Variance | Budget   | Actual      | Variance | Budget    | Forecast  | Variance |  |
| Income £000                          | 17,763   | 18,706   | 943      | 93,046   | 96,100      | 3,053    | 229,707   | 229,707   | 0        |  |
| Expenditure £000                     | (19,495) | (20,324) | (829)    | (97,532) | (100,556)   | (3,024)  | (229,569) | (229,562) | 7        |  |
| Control Total Surplus/(Deficit) £000 | (1,732)  | (1,618)  | 114      | (4,486)  | (4,456)     | 30       | 138       | 145       | 7        |  |
|                                      |          |          |          |          |             |          |           |           |          |  |
| WTE                                  | 3,223    | 3,191    | (32)     | 3,223    | 3,191       | (32)     |           |           |          |  |
| CIP £000                             | 428      | 465      | 37       | 1,696    | 1,839       | 143      | 8,000     | 6,067     | (1,933)  |  |
| Cash £000                            | 2,883    | 10,405   | 7,522    | 2,883    | 10,405      | 7,522    |           |           |          |  |
| CAPEX FCT £000                       | 1,344    | 558      | 786      | 9,112    | 4,015       | 5,097    | 28,972    | 28,972    | 0        |  |
| Use of Resources Risk Rating         | 3        | 3        | 0        | 3        | 3           | 0        | 3         | 3         | 0        |  |

| Activity Volumes | In Month |        |          | Ye     | ear to Date | •        | Full Year |          |          |  |
|------------------|----------|--------|----------|--------|-------------|----------|-----------|----------|----------|--|
|                  | Budget   | Actual | Variance | Budget | Actual      | Variance | Budget    | Forecast | Variance |  |
| Elective         | 2,116    | 2,223  | 107      | 11,904 | 11,213      | (691)    | 29,307    | 29,307   | 0        |  |
| Non Elective     | 1,026    | 1,056  | 30       | 5,600  | 6,025       | 425      | 13,769    | 13,769   | 0        |  |
| Outpatients      | 14,924   | 16,111 | 1,187    | 83,971 | 86,905      | 2,934    | 206,735   | 206,735  | 0        |  |
| A&E              | 3,697    | 4,011  | 314      | 23,197 | 23,645      | 448      | 56,463    | 56,463   | 0        |  |

## Alder Hey Children's NHS Foundation Trust CAPITAL PROGRAMME 2017/18

|  | IN MONTH<br>BUDGET | IN MONTH<br>ACTUAL | IN MONTH<br>VARIANCE | YEAR TO DATE<br>BUDGET | YEAR TO DATE<br>ACTUAL | YEAR TO DATE<br>VARIANCE | FULL YEAR<br>BUDGET | FULL YEAR FORECAST | ULL YEAR VAR<br>TO REV<br>BUDGET |
|--|--------------------|--------------------|----------------------|------------------------|------------------------|--------------------------|---------------------|--------------------|----------------------------------|
|  | £'000              | £'000              | £'000                | £'000                  | £'000                  | £'000                    | £'000               | £'000              | £'000                            |
| ESTATES                                    | 128                | 42                 | 86                   | 640                    | 655                    | (15)                     | 1,536               | 1,552              | (16)                             |
| RESEARCH & EDUCATION                       | 644                | 116                | 528                  | 4,532                  | 1,585                  | 2,947                    | 13,120              | 8,902              | 4,218                            |
| ESTATES TOTAL CAPITAL                      | 772                | 158                | 614                  | 5,172                  | 2,240                  | 2,932                    | 14,656              | 10,454             | 4,202                            |
| GDE, NETWORKING, INFRASTRUCTURE & OTHER IT | 250                | 249                | 1                    | 1,305                  | 948                    | 357                      | 3,431               | 2,828              | 603                              |
| ELECTRONIC PATIENT RECORD                  | 0                  | 39                 | (39)                 | 151                    | 174                    | (23)                     | 604                 | 539                | 65                               |
| IM & T TOTAL CAPITAL                       | 250                | 288                | (38)                 | 1,456                  | 1,121                  | 335                      | 4,035               | 3,367              | 668                              |
|  |                    | _                  |                      |                        |                        |                          |                     | _                  |                                  |
| MEDICAL EQUIPMENT                          | 104                | 86                 | 18                   | 821                    | 342                    | 479                      | 1,529               | 1,598              | (69)                             |
| NON-MEDICAL EQUIPMENT                      | 0                  | 5                  | (5)                  | 220                    | 109                    | 111                      | 220                 | 278                | (58)                             |
| CHILDRENS HEALTH PARK                      | 80                 | (22)               | 102                  | 743                    | 83                     | 660                      | 5,347               | 5,268              | 79                               |
| ALDER HEY IN THE PARK TOTAL                | 184                | 69                 | 115                  | 1,784                  | 534                    | 1,250                    | 7,096               | 7,144              | (48)                             |
| OTHER                                      | 138                | 43                 | 95                   | 700                    | 119                    | 581                      | 3,185               | 2,879              | 306                              |
| OTHER                                      | 138                | 43                 | 95                   | 700                    | 119                    | 581                      | 3,185               | 2,879              | 306                              |
|  |                    |                    |                      |                        |                        |                          |                     |                    |                                  |
| CAPITAL PROGRAMME 17/18                    | 1,344              | 558                | 786                  | 9,112                  | 4,015                  | 5,097                    | 28,972              | 23,844             | 5,128                            |

### In-Month

| Division | Specialty                        | POD                                 | Activity Plan       | Activity<br>Actual  | Activity<br>Variance | Income Plan                 | Income<br>Actual           | Income<br>Variance          | Income<br>Variance<br>(case-mix) | Income<br>Variance<br>(volume) |
|----------|----------------------------------|-------------------------------------|---------------------|---------------------|----------------------|-----------------------------|----------------------------|-----------------------------|----------------------------------|--------------------------------|
| Surgery  | Anaesthetics                     | Outpatient New Outpatient Follow-up | 3<br>102            | 2<br>56             | -1<br>-46            | £2,431<br>£12,487           | £1,476<br>£15,430          | -£955<br>£2,944             | £1<br>£8,601                     | -£956<br>-£5,657               |
|          | Anaesthetics Total               | Outpatient 1 oilow-up               | 106                 | <b>58</b>           | -48                  | £14,917                     | £16,906                    | £1,989                      | £8,602                           | -£6,613                        |
|          | Audiology                        | Daycase<br>Outpatient New           | 3<br>429            | 0<br>420            | -3<br>-9             | £2,930<br>£40,682           | £0<br>£39,834              | -£2,930<br>-£848            | £0<br>£5                         | -£2,930<br>-£853               |
|          |                                  | Outpatient Follow-up                | 316                 | 354                 | -9<br>38             | £40,682<br>£29,889          | £39,634<br>£33,490         | £3,601                      | £31                              | £3,570                         |
|          | Audiala m. Tatal                 | OP Procedure                        | 1                   | 1                   | 0                    | £108                        | £94                        | -£14                        | -£6                              | -£8                            |
|          | Audiology Total Burns Care       | Daycase                             | <b>750</b><br>4     | <b>775</b>          | <b>25</b><br>-2      | <b>£73,608</b><br>£4,750    | <b>£73,417</b><br>£809     | <b>-£191</b><br>-£3,941     | £30<br>-£1,390                   | <b>-£221</b><br>-£2,551        |
|          |                                  | Elective                            | 1                   | 0                   | -1                   | £4,919                      | £0                         | -£4,919                     | £0                               | -£4,919                        |
|          |                                  | Non Elective Outpatient New         | 21<br>13            | 26<br>14            | 5<br>1               | £135,874<br>£2,509          | £159,462<br>£2,777         | £23,588<br>£268             | -£11,535                         | £35,123<br>£266                |
|          |                                  | Outpatient Follow-up                | 59                  | 65                  | 6                    | £11,664                     | £12,892                    | £1,228                      | £11                              | £1,217                         |
|          |                                  | Ward Attender                       | 27                  | 22                  | -5                   | £5,286                      | £4,363                     | -£923                       | £4                               | -£926                          |
|          |                                  | Ward Based Outpatient OP Procedure  | 3<br>0              | 11                  | 8                    | £584<br>£4                  | £2,182<br>£0               | £1,598<br>-£4               | £2<br>£0                         | £1,596<br>-£4                  |
|          | Burns Care Total                 |                                     | 128                 | 140                 | 12                   | £165,591                    | £182,485                   | £16,895                     | -£12,906                         | £29,801                        |
|          | Cardiac Surgery                  | Elective<br>Non Elective            | 22<br>12            | 35<br>16            | 13<br>4              | £359,955<br>£317,289        | £442,559<br>£382,449       | £82,604<br>£65,160          | -£119,844<br>-£55,133            | £202,447<br>£120,294           |
|          |                                  | Excess Bed Days                     | 75                  | 29                  | -46                  | £38,217                     | £22,743                    | -£15,474                    | £8,031                           | -£23,505                       |
|          |                                  | Outpatient New                      | 8                   | 17                  | 9                    | £5,545                      | £12,252                    | £6,707                      | £11                              | £6,696                         |
|          |                                  | Outpatient Follow-up Ward Attender  | 39                  | 76<br>5             | 37<br>5              | £27,961<br>£0               | £54,774<br>£3,604          | £26,813<br>£3,604           | £49<br>£0                        | £26,763<br>£3,604              |
|          | Cardiac Surgery Total            |                                     | 156                 | 178                 | 22                   | £748,966                    | £918,380                   | £169,414                    | -£166,885                        | £336,299                       |
|          | Cardiology                       | Daycase<br>Elective                 | 18<br>18            | 26<br>16            | -2                   | £48,036<br>£59,529          | £73,530<br>£52,376         | £25,494<br>-£7,153          | £3,841<br>£685                   | £21,653<br>-£7,838             |
|          |                                  | Non Elective                        | 11                  | 16                  | 5                    | £43,114                     | £65,103                    | £21,990                     | £1,643                           | £20,347                        |
|          |                                  | Excess Bed Days                     | 20                  | 6                   | -14                  | £9,256                      | £3,217                     | -£6,039                     | £417                             | -£6,456                        |
|          |                                  | Outpatient New Outpatient Follow-up | 157<br>453          | 151<br>541          | -6<br>88             | £31,970<br>£56,696          | £30,619<br>£67,508         | -£1,352<br>£10,812          | -£34<br>-£222                    | -£1,317<br>£11,034             |
|          |                                  | Ward Attender                       | 43                  | 27                  | -16                  | £5,584                      | £3,369                     | -£2,215                     | -£112                            | -£2,102                        |
|          |                                  | Ward Based Outpatient               | 7                   | 0                   | -7                   | £924                        | £0                         | -£924                       | £0                               | -£924                          |
|          | Cardiology Total                 | OP Imaging                          | 610<br><b>1,338</b> | 622<br><b>1,405</b> | 12<br><b>67</b>      | £54,409<br><b>£309,518</b>  | £55,498<br><b>£351,221</b> | £1,089<br><b>£41,702</b>    | £18<br><b>£6,236</b>             | £1,070<br><b>£35,467</b>       |
|          | Dentistry                        | Daycase                             | 107                 | 118                 | 11                   | £64,853                     | £74,256                    | £9,404                      | £2,918                           | £6,486                         |
|          |                                  | Elective                            | <u>3</u>            | 1                   | -2<br>0              | £2,704<br>£981              | £653<br>£869               | -£2,051                     | -£408<br>-£0                     | -£1,642                        |
|          |                                  | Non Elective Outpatient New         | 108                 | 96                  | -12                  | £3,847                      | £3,418                     | -£112<br>-£428              | -£0<br>-£1                       | -£112<br>-£427                 |
|          |                                  | Outpatient Follow-up                | 100                 | 121                 | 21                   | £3,565                      | £4,308                     | £743                        | -£3                              | £746                           |
|          | Dentistry Total                  | OP Procedure                        | 27<br><b>346</b>    | 18<br><b>355</b>    | -9<br><b>9</b>       | £3,592<br><b>£79,541</b>    | £2,336<br>£85,841          | -£1,256<br>£6,300           | -£60<br>£2,445                   | -£1,196<br>£3,855              |
|          | ENT                              | Daycase                             | 109                 | 96                  | -13                  | £113,223                    | £104,616                   | -£8,607                     | £5,103                           | -£13,709                       |
|          |                                  | Elective                            | 82                  | 60                  | -22                  | £109,876                    | £80,548                    | -£29,328                    | -£1                              | -£29,327                       |
|          |                                  | Non Elective<br>Excess Bed Days     | 23<br>28            | 27<br>0             | -28                  | £32,359<br>£11,330          | £44,991<br>£0              | £12,632<br>-£11,330         | £7,404<br>£0                     | £5,228<br>-£11,330             |
|          |                                  | Outpatient New                      | 354                 | 327                 | -27                  | £43,334                     | £40,834                    | -£2,499                     | £797                             | -£3,297                        |
|          |                                  | Outpatient Follow-up                | 330<br>226          | 390<br>124          | 60                   | £20,727                     | £24,772                    | £4,045                      | £252                             | £3,793<br>-£12.593             |
|          | ENT Total                        | OP Procedure                        | 1,1 <b>52</b>       | 1,024               | -102<br><b>-128</b>  | £27,863<br><b>£358,712</b>  | £15,697<br><b>£311,458</b> | -£12,167<br><b>-£47,254</b> | £426<br><b>£13,981</b>           | -£12,593<br>- <b>£61,235</b>   |
|          | Gynaecology                      | Daycase                             | 2                   | 6                   | 4                    | £993                        | £3,797                     | £2,804                      | £235                             | £2,569                         |
|          |                                  | Elective<br>Outpatient New          | 1<br>31             | 0<br>20             | -1<br>-11            | £1,190<br>£5,189            | £0<br>£3,307               | -£1,190<br>-£1,882          | £0<br>-£0                        | -£1,190<br>-£1,882             |
|          |                                  | Outpatient Follow-up                | 44                  | 23                  | -21                  | £3,076                      | £1,626                     | -£1,450                     | £0                               | -£1,450                        |
|          | Gynaecology Total                |                                     | 78                  | 49                  | -29                  | £10,448                     | £8,730                     | -£1,719                     | £235                             | -£1,953                        |
|          | Intensive Care                   | Elective<br>Non Elective            | 0<br>17             | 9                   | -8                   | £0<br>£91,777               | £1,941<br>£21,463          | £1,941<br>-£70,314          | £0<br>-£28,051                   | £1,941<br>-£42,262             |
|          |                                  | Excess Bed Days                     | 18                  | 0                   | -18                  | £11,109                     | £0                         | -£11,109                    | £0                               | -£11,109                       |
|          |                                  | PICU<br>HDU                         | 554<br>382          | 519<br>369          | -35<br>-13           | £977,430<br>£454,931        | £936,620<br>£464,313       | -£40,810<br>£9,382          | £0                               | -£40,810<br>£9,382             |
|          |                                  | Cardiac HDU                         | 247                 | 242                 | -13                  | £238,388                    | £245,028                   | £6,641                      | £0                               | £6,641                         |
|          |                                  | Cardiac ECMO                        | 13                  | 34                  | 22                   | £45,104                     | £117,680                   | £72,576                     | £0                               | £72,576                        |
|          | Intensive Care Total             | Respiratory ECMO                    | 8<br><b>1,237</b>   | 0<br><b>1,175</b>   | -8<br><b>-62</b>     | £49,790<br>£1,868,527       | £21,944<br>£1,808,989      | -£27,846<br>-£59,539        | £0<br>- <b>£28,051</b>           | -£27,846<br><b>-£31,487</b>    |
|          | Maxillo-Facial                   | Outpatient New                      | 49                  | 62                  | 13                   | £7,468                      | £10,419                    | £2,951                      | £915                             | £2,037                         |
|          |                                  | Outpatient Follow-up                | 52                  | 82                  | 30                   | £9,459                      | £15,868                    | £6,409                      | £1,075                           | £5,335                         |
|          |                                  | Ward Attender OP Procedure          | 0                   | 0                   | -1                   | £5<br>£108                  | £0                         | -£5<br>-£108                | £0                               | -£5<br>-£108                   |
|          | Maxillo-Facial Total             |                                     | 102                 | 144                 | 42                   | £17,040                     | £26,288                    | £9,248                      | £1,990                           | £7,258                         |
|          | Neurosurgery                     | Daycase<br>Elective                 | 1<br>20             | 0<br>19             | -1<br>-1             | £1,623<br>£185,044          | £0<br>£198,910             | -£1,623<br>£13,865          | £0<br>£24,569                    | -£1,623<br>-£10,703            |
|          |                                  | Non Elective                        | 25                  | 27                  | 2                    |                             | £180,835                   | -£28,956                    | -£44,788                         | £15,832                        |
|          |                                  | Excess Bed Days                     | 25                  | 7                   | -18                  | £14,978                     | £4,254                     | -£10,724                    | £129                             | -£10,853                       |
|          |                                  | Outpatient New Outpatient Follow-up | 57<br>148           | 68<br>200           | 11<br>52             | £5,102<br>£13,207           | £6,057<br>£17,814          | £955<br>£4,607              | £5<br>£14                        | £950<br>£4,593                 |
|          |                                  | Ward Attender                       | 43                  | 20                  | -23                  | £3,818                      | £1,781                     | -£2,036                     | £1                               | -£2,038                        |
|          |                                  | Ward Based Outpatient               | 1                   | 0                   | -1                   | £131                        | £0                         | -£131                       | £0                               | -£131                          |
|          | Neurosurgery Total               | Neuro HDU                           | 217<br><b>539</b>   | 187<br><b>528</b>   | -30<br><b>-11</b>    | £195,356<br><b>£629,049</b> | £207,325<br>£616,976       | £11,970<br>-£12,073         | £0<br>- <b>£20,070</b>           | £11,970<br><b>£7,997</b>       |
|          | Ophthalmology                    | Daycase                             | 30                  | 31                  | 1                    | £36,877                     | £39,668                    | £2,790                      | £1,758                           | £1,032                         |
|          |                                  | Elective                            | 4                   | 4                   | 0                    | £8,289                      | £10,953                    | £2,664                      | £2,368                           | £296                           |
|          |                                  | Non Elective Outpatient New         | 2<br>265            | 1<br>296            | -1<br>31             | £3,253<br>£44,508           | £1,830<br>£42,784          | -£1,422<br>-£1,723          | -£165<br>-£6,968                 | -£1,257<br>£5,244              |
|          |                                  | Outpatient Follow-up                | 965                 | 1,275               | 310                  | £76,841                     | £83,527                    | £6,686                      | -£17,950                         | £24,636                        |
|          | Onhthalmalage Tatal              | OP Procedure                        | 17                  | 30<br>1 637         | 13<br>254            | £5,009                      | £4,754                     | -£254                       | -£3,923                          | £3,669                         |
|          | Ophthalmology Total Oral Surgery | Daycase                             | <b>1,283</b><br>22  | <b>1,637</b><br>24  | <b>354</b>           | <b>£174,776</b><br>£19,367  | £183,516<br>£16,927        | <b>£8,740</b> -£2,440       | <b>-£24,880</b><br>-£3,884       | <b>£33,620</b><br>£1,444       |
|          |                                  | Elective                            | 13                  | 13                  | 0                    | £47,421                     | £46,885                    | -£535                       | £154                             | -£690                          |
|          | Oral Surgery Total               | Non Elective                        | 10<br><b>45</b>     | 3<br><b>40</b>      | -7<br><b>-5</b>      | £10,230<br><b>£77,017</b>   | £3,390<br><b>£67,203</b>   | -£6,839<br><b>-£9,815</b>   | £209<br>-£3,521                  | -£7,048<br><b>-£6,294</b>      |
|          | Orthodontics                     | Outpatient New                      | <b>43</b><br>5      | 8                   | - <b>3</b>           | £806                        | £1,298                     | £492                        | <b>-£3,521</b><br>-£0            | £492                           |
|          |                                  | Outpatient Follow-up                | 25                  | 66                  | 41                   | £1,825                      | £4,736                     | £2,911                      | -£17                             | £2,928                         |
|          | Orthodontics Total               | OP Procedure                        | 19<br><b>49</b>     | 17<br><b>91</b>     | -2<br><b>42</b>      |                             | £1,857<br><b>£7,890</b>    | -£254<br>£3,149             | -£46<br><b>-£63</b>              | -£208<br>£3,212                |
|          | Paediatric Surgery               | Daycase                             | 122                 | 134                 | 12                   |                             | £147,361                   | £14,322                     | £1,760                           | £12,562                        |
|          |                                  |                                     |                     |                     |                      |                             |                            |                             |                                  |                                |

| n-Month       |   |   |   |  |   |  |   |   |   |  |
|---------------|---|---|---|--|---|--|---|---|---|--|
|               | Paediatric Surgery  | Elective  | 36  | 54   | 18  | £121,657   | £152,493  | £30,836   | -£30,699  | £61,536  |
|               | 3.,   | Non Elective  | 125   | 143  | 18  | £347,508   | £528,880  | £181,371  | £130,394  | £50,977  |
|               |   | Excess Bed Days   | 126   | 92   | -34   | £57,431  | £52,890   | -£4,542   | £10,797   | -£15,338   |
|               |   | Outpatient New  | 161   | 149  | -12   | £27,474  | £25,410   | -£2,064   | -£2   | -£2,062  |
|               |   | Outpatient Follow-up  | 253   | 195  | -58   | £29,107  | £22,555   | -£6,552   | £96   | -£6,649  |
|               |   | Ward Attender   | 71  | 65   | -6  | £8,077   | £7,435  | -£642   | -£5   | -£637  |
|               |   | Ward Based Outpatient   | 9   | 0  | -9  | £1,061   | £0  | -£1,061   | £0  | -£1,061  |
|               |   | OP Procedure  | 0   | 2  | 2   | -£0  | £458  | £458  | £459  | -£2  |
|               | I   | Neonatal HDU  | 11  | 17   | 6   | £132,920   | £143,933  | £11,013   | £0  | £11,013  |
|               | Paediatric Surgery Total  | _   | 913   | 851  | -62   | £858,274   | £1,081,413  | £223,139  | £112,801  | £110,338   |
|               | Plastic Surgery   | Daycase   | 72  | 76   | 4   | £79,738  | £87,372   | £7,633  | £3,344  | £4,290   |
|               |   | Elective  | 10  | 12   | 2   | £13,949  | £19,777   | £5,828  | £2,301  | £3,527   |
|               |   | Non Elective  | 85  | 116  | 31  | £139,497   | £173,026  | £33,529   | -£16,491  | £50,020  |
|               |   | Excess Bed Days   | 11  | 5  | -6  | £6,344   | £1,742  | -£4,602   | -£1,279   | -£3,323  |
|               |   | Outpatient New Outpatient Follow-up   | 212<br>362  | 339<br>473   | 127<br>111  | £28,835<br>£38,388   | £45,474   | £16,640<br>£11,782  | -£701<br>-£2  | £17,341<br>£11,784   |
|               |   | Ward Attender   | 9   | 10   | 1   | £909   | £50,169<br>£1,061   | £11,762<br>£152   | -£2<br>-£0  | £11,764<br>£152  |
|               |   | Ward Based Outpatient   | 2   | 4  | 2   | £187   | £424  | £238  | £0  | £238   |
|               |   | OP Procedure  | 105   | 188  | 83  | £13,120  | £23,795   | £10,675   | £372  | £10,303  |
|               | Plastic Surgery Total   |   | 867   | 1,223  | 356   | £320,966   | £402,840  | £81,875   | -£12,456  | £94,331  |
|               | Spinal Surgery  | Daycase   | 1   | 3  | 2   | £579   | £16,520   | £15,941   | £13,650   | £2,291   |
|               |   | Elective  | 11  | 8  | -3  | £328,044   | £193,563  | -£134,481   | -£40,928  | -£93,553   |
|               |   | Outpatient New  | 38  | 55   | 17  | £7,891   | £11,324   | £3,433  | -£0   | £3,434   |
|               |   | Outpatient Follow-up  | 83  | 87   | 4   | £6,326   | £6,604  | £278  | -£13  | £291   |
|               | Spinal Surgery Total  |   | 133   | 153  | 20  | £342,839   | £228,011  | -£114,828   | -£27,291  | -£87,537   |
|               | Trauma And Orthopaedio  | •   | 37  | 34   | -3  | £71,586  | £64,707   | -£6,879   | -£538   | -£6,341  |
|               |   | Elective  | 53  | 69   | 16  | £222,975   | £253,309  | £30,334   | -£37,177  | £67,511  |
|               |   | Non Elective  | 68  | 78   | 10  | £185,631   | £224,570  | £38,938   | £11,258   | £27,680  |
|               |   | Excess Bed Days   | 31  | 35   | 4   | £14,423  | £15,188   | £766  | -£1,139   | £1,905   |
|               |   | Outpatient New Outpatient Follow-up   | 623   | 729<br>1 301   | 106   | £99,292  | £114,533  | £15,241   | -£1,654<br>-£2,575  | £16,895  |
|               |   | Gait New  | 1,328<br>26   | 1,391<br>30  | 63<br>4   | £124,302<br>£30.666  | £127,622<br>£35,164   | £3,320<br>£4,498  | -£2,575<br>£0   | £5,896<br>£4,498   |
|               |   | Gait Follow-Up  | 26  | 20   | -3  | £30,666<br>£26,533   | £35,164<br>£23,442  | £4,498<br>-£3,090   | £0  | £4,498<br>-£3.090  |
|               |   | Ward Attender   | 23  | 20   | -3  | £20,533<br>£142  | £23,442<br>£179   | £37   | £0  | £37  |
|               |   | OP Procedure  | 190   | 207  | 17  | £23,408  | £25,613   | £2,204  | £50   | £2,154   |
|               | Trauma And Orthopaedic  |   | 2,380   | 2,595  | 215   | £798,957   | £884,327  | £85,370   | -£31,774  | £117,144   |
|               | Urology   | Daycase   | 169   | 219  | 50  | £152,397   | £225,981  | £73,583   | £28,572   | £45,012  |
|               | U,  | Elective  | 11  | 13   | 2   | £33,889  | £48,714   | £14,825   | £7,922  | £6,903   |
|               |   | Non Elective  | 3   | 6  | 3   | £7,716   | £25,184   | £17,467   | £10,417   | £7,050   |
|               |   | Excess Bed Days   | 13  | 35   | 22  | £6,748   | £13,750   | £7,002  | -£5,019   | £12,022  |
|               |   | Outpatient New  | 86  | 70   | -16   | £12,651  | £10,336   | -£2,315   | -£1   | -£2,314  |
|               |   | Outpatient Follow-up  | 174   | 208  | 34  | £16,988  | £20,331   | £3,344  | -£1   | £3,344   |
|               |   | Ward Attender   | 3   | 14   | 11  | £327   | £1,369  | £1,041  | £0  | £1,041   |
|               |   | Ward Based Outpatient   | 6   | 0  | -6  | £595   | 03<br>03  | -£595   | £0  | -£595  |
|               | Urology Total   | OP Procedure  | 15<br><b>479</b>  | 32<br><b>597</b>   | 17<br><b>118</b>  | £3,334<br><b>£234,646</b>  | £7,321<br><b>£352,986</b>   | £3,986<br>£118,340  | -£34<br>£41,856   | £4,020<br><b>£76,484</b>   |
| Surgery Total | Grology Total   |   | 12,080  | 13,018   | 938   | £7,088,135   | £7,608,877  | £520,742  | -£139,723   | £660,465   |
| Medicine      | Accident & Emergency  | Daycase   | 0   | 0  | 0   | £163   | £0  | -£163   | £0  | -£163  |
|               |   | Elective  | 0   | 0  | 0   | £98  | £0  | -£98  | £0  | -£98   |
|               |   |   |   |  |   |  |   |   |   |  |
|               |   | Non Elective  | 300   | 229  | -71   | £208,125   | £161,218  | -£46,907  | £2,308  | -£49,215   |
|               |   | Non Elective<br>Excess Bed Days   | 300<br>3  | 229<br>0   | -71<br>-3   | £208,125<br>£1,161   | £161,218<br>£0  | -£46,907<br>-£1,161   | £2,308<br>£0  | -£49,215<br>-£1,161  |
|               |   | Excess Bed Days<br>Outpatient New   | 3<br>183  | 0<br>132   | -3<br>-51   | £1,161<br>£61,640  | £0<br>£44,613   | -£1,161<br>-£17,026   | £0<br>£41   | -£1,161<br>-£17,067  |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up   | 3<br>183<br>19  | 0<br>132<br>9  | -3<br>-51<br>-10  | £1,161<br>£61,640<br>£6,464  | £0<br>£44,613<br>£3,042   | -£1,161<br>-£17,026<br>-£3,422  | £0<br>£41<br>£3   | -£1,161<br>-£17,067<br>-£3,425   |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient   | 3<br>183<br>19<br>1   | 0<br>132<br>9<br>0   | -3<br>-51<br>-10<br>-1  | £1,161<br>£61,640<br>£6,464<br>£197  | £0<br>£44,613<br>£3,042<br>£0   | -£1,161<br>-£17,026<br>-£3,422<br>-£197   | £0<br>£41<br>£3<br>£0   | -£1,161<br>-£17,067<br>-£3,425<br>-£197  |
|               | Assidant & Francesco T  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  | 3<br>183<br>19<br>1<br>3,697  | 0<br>132<br>9<br>0<br>4,011  | -3<br>-51<br>-10<br>-1<br>314   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173  | £0<br>£41<br>£3<br>£0<br>-£36,701   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528   |
|               | Accident & Emergency To   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b>  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b>  | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b>   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b>   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br><b>-£72,146</b>   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796   |
|               | Accident & Emergency To Allergy   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase   | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15  | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b><br>-19  | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>- <b>£72,146</b><br>-£11,826  | £0<br>£41<br>£3<br>£0<br>-£36,701<br><b>-£34,350</b><br>-£1,382   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444   |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15  | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b><br>-19  | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767   |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New   | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65   | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94   | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b><br>-19<br>2   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767<br>£6,392  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284   |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65   | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94   | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b><br>-19<br>2<br>29   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767<br>£6,392<br>£3,936  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£1,382<br>£0<br>£108<br>£206  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731   |
|               |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65   | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94   | -3<br>-51<br>-10<br>-1<br>314<br><b>178</b><br>-19<br>2   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767<br>£6,392  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731   |
|               | Allergy   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65<br>87<br>0  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94<br>114  | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27  | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767<br>£6,392<br>£3,936<br>£136  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731   |
|               | Allergy  Allergy Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Attender Ward Based Outpatient  | 3<br>183<br>19<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65<br>87<br>0  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94<br>114<br>1   | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27<br>1   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>-£35  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35   |
|               | Allergy   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Daycase  | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0   | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94<br>114<br>1<br>0<br>0<br><b>226</b>   | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27<br>1<br>0<br>0   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>£6,392<br>£3,936<br>£136<br>-£35<br>-£35   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£14,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>£0<br>£0<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136   |
|               | Allergy  Allergy Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New  | 3<br>183<br>19<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12   | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27<br>1<br>0<br>0<br>40   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>-£6,392<br>-£3,936<br>-£35<br>-£40<br>-£669<br>-£81,143<br>-£137   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>£0<br>£1,068<br>-£1,068<br>-£1,25<br>-£1,25   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136  |
|               | Allergy  Allergy Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up   | 3<br>183<br>19<br>1<br>1<br>3,697<br><b>4,203</b><br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>2<br>142<br>314  | 0<br>132<br>9<br>0<br>4,011<br><b>4,381</b><br>15<br>2<br>94<br>114<br>1<br>0<br>0<br><b>226</b><br>12<br>141<br>260   | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27<br>1<br>0<br>0<br>40<br>10<br>-1   | £1,161<br>£61,640<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35<br>£40<br><b>£44,515</b><br>£19,638<br>£28,148  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>£6,392<br>£3,936<br>£136<br>-£35<br>-£40<br>-£669<br>£8,143<br>-£137<br>-£4,897  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£125<br>-£125  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£136   |
|               | Allergy  Allergy Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Attender   | 3<br>183<br>19<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0  | -3<br>-51<br>-10<br>-1<br>314<br>178<br>-19<br>2<br>29<br>27<br>1<br>0<br>0<br>40<br>10<br>-1<br>1  | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35<br>£44<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£136<br>-£35<br>-£36<br>-£36<br>-£36<br>-£36<br>-£36<br>-£40<br>-£137<br>-£137<br>-£137<br>-£137<br>-£137<br>-£137   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£06<br>£0<br>£0<br>£0<br>£0<br>-£1,068<br>-£1,068<br>-£1,25<br>-£1  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£4,871  |
|               | Allergy  Allergy Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Ward Attender Ward Based Outpatient Follow-up Ward Attender Ward Based Outpatient   | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3   | -3 -51 -10 -1 314 178 -19 2 29 27 1 0 0 40 10 -1 -54 0 0 -1   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>-£6,392<br>-£3,936<br>-£35<br>-£40<br>-£669<br>-£61,43<br>-£137<br>-£4,897<br>-£3,434<br>-£137<br>-£4,897<br>-£3,434<br>-£3,434<br>-£3,434<br>-£3,434  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>£0<br>£1,068<br>-£1,25<br>-£1,25<br>-£1,26<br>£0<br>-£1,26<br>£0<br>-£1,26<br>£0<br>-£1,26<br>£0<br>-£1,26<br>£0<br>-£1,26<br>£0<br>-£1,26<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3  |
|               | Allergy Total Dermatology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Attender   | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3  | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 15  | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£13,951<br>£11,800<br>£0<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351<br>£29,532   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£28<br>£29,104  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£13,936<br>-£3,936<br>-£35<br>-£40<br>-£669<br>-£669<br>-£669<br>-£669<br>-£137<br>-£4,897<br>-£3<br>-£137<br>-£4,897<br>-£3<br>-£3<br>-£4,897<br>-£3<br>-£3<br>-£4,897<br>-£3   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£206<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>-£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871  |
|               | Allergy Total Dermatology  Dermatology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure   | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>2<br>142<br>314<br>0<br>4<br>4<br>253<br>715   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684                               | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 554 -31   | £1,161<br>£61,640<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35<br>£40<br><b>£44,515</b><br>£19,638<br>£28,148<br>£3<br>£29,532<br>£79,000  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595   | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£136<br>-£35<br>-£3936<br>-£136<br>-£35<br>-£40<br>-£669<br>-£8137<br>-£4,897<br>-£3<br>-£82<br>-£429<br>-£2,595   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£0<br>-£2,175<br>-£2,327  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-             |
|               | Allergy Total Dermatology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New   | 3<br>183<br>19<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1                               | -3 -51 -10 -1 314 178 -19 2 29 27 1 0 0 0 40 10 -1 -54 0 -1 155 -31 -25   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br><b>£44,515</b><br>£1,328<br>£19,638<br>£28,148<br>£35<br>£29,532<br><b>£79,000</b><br>£5,277  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£202  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>-£6,392<br>-£3,936<br>-£35<br>-£40<br>-£689<br>-£8,143<br>-£137<br>-£4,897<br>-£3<br>-£429<br>-£2,595<br>-£429<br>-£2,595  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£14,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,175<br>-£2,327<br>-£0   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£8,268<br>-£136<br>-£4,871<br>-£82<br>£1,746<br>£1,746<br>£4,922<br>-£5,075  |
|               | Allergy Total Dermatology  Dermatology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient New Outpatient New Outpatient New  | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>268<br>684<br>1<br>2                               | -3 -51 -10 -1 314 178 -19 2 29 27 1 0 0 40 -1 -54 0 -1 15 -31 -25 -1  | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£29,532<br>£79,000<br>£5,277<br>£458  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£767<br>-£6,392<br>-£3,936<br>-£35<br>-£40<br>-£669<br>-£8,143<br>-£137<br>-£4,897<br>-£3<br>-£82<br>-£259<br>-£259<br>-£259<br>-£2595<br>-£204  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>-£2,327   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,746<br>£1,7 |
|               | Allergy Total Dermatology  Dermatology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender   | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>1<br>2                     | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1   | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£29,104<br>£81,595<br>£29,104<br>£81,595  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£136<br>-£392<br>-£3,936<br>-£35<br>-£40<br>-£669<br>-£35<br>-£40<br>-£669<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£37<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,897<br>-£4,8 | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,175<br>-£2,327<br>-£0<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,871<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-£4,972<br>-                      |
|               | Allergy Total Dermatology  Dermatology Total Diabetes   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient New Outpatient New Outpatient New  | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>2                     | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -15 -31 -25 -1 0  | £1,161<br>£61,640<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35<br>£40<br><b>£44,515</b><br>£19,638<br>£28,148<br>£3<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458   | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br><b>£600,967</b><br>£6,863<br>£767<br>£20,343<br>£15,736<br>£136<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£202<br>£354   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£136 -£136 -£136 -£392 -£3,936 -£136 -£40 -£669 -£81,143 -£137 -£4,897 -£3 -£82 -£429 -£2,595 -£5,075 -£104 -£177 -£6   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>-£0<br>-£0<br>-£0<br>-£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£82<br>£1,746<br>£4,922<br>-£5,075<br>-£104  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient   | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0   | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>2                          | -3 -51 -10 -1 -314 178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -1 -55 -1 -1 -1 -25 -25   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£6  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£202<br>£354<br>£177<br>£0  | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£136<br>£235<br>£40<br>£8,143<br>£137<br>£4,897<br>£4,897<br>£2,595<br>£2,595<br>£104<br>£177<br>£2,595  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£14,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>£0<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£25<br>-£25<br>-£25<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Based Outpatient OP Ward Attender Ward Based Outpatient Daycase  | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>1<br>0                          | -3 -51 -10 -1 314 178 -19 2 29 27 1 1 0 0 40 -1 -54 0 -1 15 -31 -25 -1 1 0 -25 -37  | £1,161<br>£61,640<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£6<br>£6<br>£6<br>£6<br>£6<br>£7,41  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£29,104<br>£81,595<br>£177<br>£177<br>£202<br>£354<br>£177<br>£202<br>£354<br>£177<br>£202<br>£354<br>£177<br>£202<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£177<br>£203<br>£354<br>£354<br>£354<br>£354<br>£354<br>£354<br>£354<br>£35 | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£669 -£8,143 -£137 -£4,897 -£3 -£429 -£2,595 -£5,075 -£104 -£177 -£6 -£177 -£6 -£5,009  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>-£0<br>£0<br>£0   | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,871<br>-£3<br>-£4,922<br>-£1,746<br>£4,922<br>-£5,075<br>-£104<br>£177<br>-£6<br>-£1,009<br>£28,424   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient   | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>2                          | -3 -51 -10 -1 -314 178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -1 -55 -1 -1 -1 -25 -25   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£6  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,736<br>£0<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£202<br>£354<br>£177<br>£0  | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£136<br>£235<br>£40<br>£8,143<br>£137<br>£4,897<br>£4,897<br>£2,595<br>£2,595<br>£104<br>£177<br>£2,595  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£14,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>£0<br>£0  | -£1,161<br>-£17,067<br>-£3,425<br>-£197<br>£33,528<br>-£37,796<br>-£10,444<br>£767<br>£6,284<br>£3,731<br>£136<br>-£35<br>-£40<br>£399<br>£8,268<br>-£136<br>-£4,871<br>-£25<br>-£25<br>-£25<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£20,75<br>-£  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective   | 3<br>183<br>19<br>1<br>1,3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0  | 0<br>132<br>9<br>0<br>4,011<br>4,381<br>15<br>2<br>94<br>114<br>1<br>0<br>0<br>226<br>12<br>141<br>260<br>0<br>3<br>3<br>268<br>684<br>1<br>1<br>0<br>4<br>1<br>1<br>0 | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -1 -1 -1 -1 -1 -1 -25 -1 1 0 -25 -1 -1 -1 -25 -1 -1 -1 -25 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1   | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£13,951<br>£11,800<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£33<br>£28,148<br>£35<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£65,741<br>£62,331<br>£7,792   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£136 -£392 -£3,936 -£35 -£40 -£669 -£669 -£55,075 -£4,897 -£3,173 -£4,897 -£3,175 -£6,075 -£104 -£177 -£6 -£5,009 -£31,106 -£3,384  | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£34,350<br>-£1,382<br>£0<br>£108<br>£206<br>£0<br>£0<br>-£1,068<br>-£125<br>-£1<br>-£26<br>£0<br>-£2,175<br>-£2,175<br>-£2,327<br>-£0<br>£0<br>£0<br>£0<br>£0<br>£1,266<br>£1,275<br>-£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2,275<br>£2, | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective  | 3<br>183<br>19<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0<br>2   | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6   | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -1 -1 -5 -1 -1 -1 -2 -25 -7 -1 -1 -1 -1 -2   | £1,161<br>£61,640<br>£6,464<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br><b>£44,515</b><br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£62,331<br>£62,331<br>£62,331  | £0<br>£44,613<br>£3,042<br>£0<br>£392,093<br>£600,967<br>£6,863<br>£767<br>£20,343<br>£15,763<br>£0<br>£0<br>£43,845<br>£9,471<br>£19,501<br>£23,251<br>£0<br>£268<br>£29,104<br>£81,595<br>£202<br>£354<br>£177<br>£0<br>£3,436<br>£177<br>£0<br>£3,436  | -£1,161<br>-£17,026<br>-£3,422<br>-£197<br>-£3,173<br>-£72,146<br>-£11,826<br>-£13,936<br>-£35<br>-£40<br>-£669<br>£8,143<br>-£137<br>-£4,897<br>-£4,897<br>-£429<br>-£2,595<br>-£5,075<br>-£104<br>-£177<br>-£5,009<br>£31,106<br>-£3,384<br>-£5,748   | £0<br>£41<br>£3<br>£0<br>-£36,701<br>-£1,382<br>£108<br>£206<br>£0<br>£0<br>£0<br>-£1,668<br>-£125<br>-£1 -£26<br>£0<br>-£2,175<br>-£2,327<br>-£0<br>£0<br>£0<br>£0<br>£0<br>£0<br>£1,25<br>£1,25<br>£1,25<br>£1,25<br>£2,27<br>£2,27<br>£2,27<br>£2,27<br>£2,681<br>£2,681<br>£2,723<br>£2,681   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£66 -£5,009 £28,424 -£660 -£5,748  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up   | 3 183 19 1 1 3,697 4,203 34 0 65 87 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 0 4 118 6 0 0 5 73  | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -54 -0 -1 -15 -31 -25 -3 -3 -1 -2 -25 -37 -1 -2 -22   | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£0<br>£35<br>£40<br><b>£44,515</b><br>£1,328<br>£19,638<br>£28,148<br>£33<br>£28,148<br>£35<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £1177 £0 £732 £93,436 £4,408   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£136 -£136 -£392 -£3,936 -£136 -£35 -£40 -£669 -£31,136 -£137 -£4,897 -£3 -£29 -£2,595 -£5,075 -£104 -£177 -£6 -£5,009 -£31,106 -£3,384 -£5,748 -£9,896 -£3,384 -£5,748 -£9,896 -£4,810 -£4,810   | £0 £41 £3 £0 -£36,701 -£34,350 £1,382 £0 £108 £206 £0 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 £0 £0 £0 £1,668 £2,723 £0 £1,668  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender  | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0<br>2<br>9<br>142<br>253<br>14<br>253<br>14<br>253<br>15<br>16<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17<br>17 | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 0 5 73 363  | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -1 -25 -37 -1 -1 -2 -22 -16 -10 -5   | £1,161<br>£61,640<br>£64,646<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£5,748<br>£11,830<br>£17,432<br>£28,148   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £3,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408 £0 £1,934 £22,242  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£689 -£8,143 -£137 -£4,897 -£4,897 -£4,897 -£429 -£2,595 -£104 -£177 -£6 -£5,009 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£6,5481  | £0 £41 £3 £0 £36,701 £43,350 £1,382 £0 £108 £206 £0 £0 £0 £0 £0 £1,175 £2,175 £2,327 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 -£136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £1,746 £1,746 £1,746 -£5,009 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755 -£681  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up   | 3<br>183<br>19<br>1<br>1<br>3,697<br>4,203<br>34<br>0<br>65<br>87<br>0<br>0<br>0<br>186<br>2<br>142<br>314<br>0<br>4<br>253<br>715<br>26<br>3<br>0<br>0<br>0<br>2<br>2<br>142<br>253<br>715<br>265<br>715<br>715<br>715<br>715<br>715<br>715<br>715<br>715<br>715<br>71                             | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363   | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -54 -0 -1 -55 -1 -1 -25 -37 -1 -1 -22 -16 -10 -5 -1 -1 -5 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -1 -1 -25 -25 -1 -1 -25 -25 -25 -25 -25 -25 -25 -25 -25 -25   | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£669 -£8,143 -£137 -£4,897 -£3 -£82 -£259 -£5,075 -£104 -£77 -£6 -£5,009 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£16,153 -£681 -£681  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £108 £206 £0 £0 £0 £0 -£1,068 -£1,25 -£1 -£26 -£0 -£0 -£2,175 -£2,327 -£0 £0 £0 £0 £0 £0 £1,608 £1,608 £2,681 -£2,723 -£1 -£263 -£1 -£602  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £4,922 -£5,075 -£104 £777 -£6 £7,748 -£5,009 £28,424 -£660 -£5,748 £9,633 £4,810 £16,755 -£681 £634   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total                            | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient   | 3 183 199 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536   | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 1 0 4 118 6 0 0 5 73 363 12 97 674  | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 15 -31 -25 -1 -1 -2 -2 -22 -22 -22 -24 -24 -24 -38  | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£13,951<br>£11,800<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£6,231<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£2,491<br>£13,992<br>£160,279  | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273  | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£136<br>£235<br>£40<br>£669<br>£8,143<br>£137<br>£4,897<br>£2,595<br>£5,075<br>£104<br>£177<br>£6<br>£5,079<br>£31,106<br>£3,384<br>£5,748<br>£9,886<br>£4,810<br>£16,153<br>£681<br>£684<br>£634<br>£32,994   | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£1,25 -£1 -£26 £0 £0 £0 £2,175 -£2,327 -£0 £0 £0 £1 £2,681 -£2,723 £0 -£263 -£1 -£602 -£00 -£909   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,078 £177 -£6 -£5,748 £1,746 £4,922 -£5,748 £1,746 £4,922 -£5,075 -£104 £177 -£660 -£5,748 -£3,944 -£660 -£5,748 -£3,944 -£660 -£5,748 -£3,092  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient  | 3 183 19 1 1 3,697 4,203 34 0 65 87 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 0 4 118 6 0 0 5 73 363 12 97 674  | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -15 -31 -25 -1 1 0 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 -25 -1 1 1 1 1 2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -   | £1,161<br>£61,640<br>£1,97<br>£395,266<br><b>£673,113</b><br>£18,689<br>£13,951<br>£11,800<br>£0<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£33<br>£28,148<br>£33<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£6,331<br>£7,792<br>£5,744<br>£11,830<br>£17,432<br>£3,4864<br>£1,492<br>£13,992<br>£160,279<br>£2,529   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £136 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£136 -£136 -£392 -£3,936 -£136 -£35 -£40 -£669 -£81,143 -£137 -£4,897 -£3 -£429 -£2,595 -£5,075 -£104 -£177 -£6 -£5,009 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£6,153 -£681 -£634 -£634 -£634  | £0 £41 £3 £0 -£36,701 -£34,350 £1,382 £0 £108 £206 £0 £0 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £1,668  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755 -£681 £634 £33,902 £1,785  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy                   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient   | 3 183 193 19 1 1,3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 12 97 674  | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -0 -1 -1 -54 -0 -1 -1 -55 -1 -1 -25 -37 -1 -1 -25 -37 -1 -1 -25 -37 -1 -1 -25 -37 -1 -1 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -2 -25 -37 -1 -31 -31 -31   | £1,161<br>£61,640<br>£64,640<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£13,964<br>£11,830<br>£17,432<br>£13,964<br>£11,830<br>£17,432<br>£13,992<br>£160,279<br>£2,529<br>£4,595   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £1777 £0 £732 £93,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £4,986   | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£235<br>£40<br>£8,143<br>£137<br>£4,897<br>£2,595<br>£2,595<br>£5,075<br>£104<br>£177<br>£6,384<br>£177<br>£6,384<br>£177<br>£6,384<br>£177<br>£6,384<br>£177<br>£2,595  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 -£0 £0 £2,681 -£2,723 -£1 -£602 -£203 -£1 -£602 -£00 -£909   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £4,922 -£5,075 -£104 £1777 -£6,009 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755 -£681 £634 £33,902 £1,785 -£2,609   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Based Outpatient  | 3 183 193 19 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33   | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 363 12 97 674 17   | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -1 -54 -0 -1 -554 -0 -1 -1 -554 -0 -1 -1 -25 -37 -1 -1 -2 -25 -37 -1 -1 -2 -1 -37 -1 -1 -2 -1 -38 -7 -138 -7 -138 -6  | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£2,491<br>£13,992<br>£160,279<br>£2,529<br>£4,595<br>£4,595<br>£4,595   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £177 £0 £136 £44,618 £1,776 £1,809 £14,626 £193,273 £4,408   | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£136<br>£137<br>-£499<br>£8,143<br>-£137<br>-£4,897<br>-£3<br>£82<br>-£429<br>£2,595<br>-£104<br>£177<br>-£6<br>£3,384<br>£177<br>-£6<br>£1,075<br>-£104<br>£1,776<br>£2,748<br>£3,848<br>£1,784<br>£2,994<br>£1,784<br>£1,784<br>£2,699<br>£2,699<br>£31,106  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 £0 £2,681 -£2,723 £0 -£263 -£1 -£602 -£0 -£0 -£263 -£1 -£602 -£0 -£0 -£0 -£0 -£0 -£0 -£0 -£0 -£0  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,099 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755 -£881 £634 £33,902 £1,785 -£2,609 -£825  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy                   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient DP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient  | 3 183 199 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33 126  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 0 4 118 6 0 0 4,011 7 10 0 7 145  | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -1 -1 -5 -31 -2 -2 -2 -2 -2 -2 -2 -2 -2 -3 -6 -110 -5 -5 -13 -6 -6 -19  | £1,161 £61,640 £64,640 £197 £395,266 £673,113 £18,689 £13,951 £11,800 £35 £40 £44,515 £1,328 £19,638 £28,148 £3 £351 £29,532 £79,000 £5,277 £458 £0 £6 £5,741 £62,331 £7,792 £5,748 £11,830 £17,432 £38,664 £2,491 £13,992 £160,279 £2,529 £4,595  | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £20,2534 £177 £0 £23,254 £177 £0 £19,501 £3,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£13,936 -£3936 -£35 -£40 -£669 -£689 -£31,136 -£137 -£4,897 -£3 -£429 -£2,595 -£5,075 -£104 -£177 -£6 -£5,009 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£16,153 -£681 -£634 -£2,609 -£25,694  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 -£2,273 £0 -£2681 -£2,723 £0 -£263 -£1 -£602 -£0 -£0 -£263 -£1 -£002 -£0 -£0 -£263 -£1 -£263 -£1 -£263 -£1 -£263 -£1 -£263 -£1 -£263 -£1 -£263 -£263 -£263 -£263 -£263 -£263 -£3255   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£4,871 -£3 -£1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660 -£5,748 -£9,633 £4,810 £16,755 -£681 £33,902 £1,785 -£2,609 -£25,563   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Daycase Elective Daycase Elective Daycase Elective   | 3 183 183 19 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33 126 36  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 12 97 674 17 10 27   | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -1 -25 -1 -1 -25 -37 -1 -1 -2 -22 -22 -24 -37 -1 -1 -38 -4 -4 -38 -7 -13 -6 -9 -22   | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£6,331<br>£7,792<br>£5,748<br>£11,830<br>£11,830<br>£17,432<br>£17,432<br>£18,634<br>£11,830<br>£17,432<br>£38,664<br>£2,491<br>£13,992<br>£38,664<br>£2,491<br>£13,992<br>£38,664<br>£2,491<br>£13,992<br>£160,279<br>£2,529<br>£4,595  | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £1777 £0 £732 £93,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£11,826 -£3,936 -£3,936 -£35 -£40 -£689 -£8,143 -£137 -£4,897 -£3,255 -£404 -£177 -£66 -£5,075 -£104 -£177 -£66 -£5,075 -£104 -£177 -£66 -£3,384 -£5,748 -£9,896 -£4,810 -£1,7784 -£9,896 -£3,11,06 -£3,384 -£5,748 -£9,896 -£1,748 -£1,7784 -£2,609 -£3,186,840 -£32,164   | £0 £41 £3 £0 £43,50 -£36,701 -£34,350 -£1,382 £108 £206 £0 £0 £0 £0 £0 -£1,668 -£125 -£1 -£26 £0 -£2,175 -£2,327 -£0 £0 £0 £0 £0 £0 £0 £1,723 £0 -£2,681 -£2,723 £0 -£263 -£1 -£602 -£0 -£909 -£0 -£0 -£1,968   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £8,268 -£136 -£4,871 -£82 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,748 -£2,609 £28,424 £660 -£5,748 -£9,633 £4,810 £16,755 -£681 £634 £33,902 £1,785 -£2,609 -£825 £13,585 -£2,609   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Daycase Elective Non Elective Non Elective   | 3 183 183 19 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 253 715 26 3 0 0 29 81 7 27 57 253 17 93 536 10 23 33 126 36 9  | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 12 97 674 17 10 27 145 14 12   | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -1 -54 -0 -1 -1 -55 -31 -1 -2 -25 -37 -1 -1 -1 -54 -1 -1 -1 -55 -37 -1 -1 -2 -2 -2 -2 -2 -2 -3 -3 -6 -9 -9 -2 -3 -3 -6 -9 -9 -2 -3 -3 -3 -6 -9 -9 -2 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3   | £1,161<br>£61,640<br>£64,640<br>£197<br>£395,266<br>£673,113<br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£35,748<br>£11,830<br>£17,432<br>£25,249<br>£1,432<br>£13,992<br>£160,279<br>£4,595<br>£4,491<br>£13,992<br>£4,595<br>£4,595<br>£4,494<br>£27,788   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £1177 £0 £732 £93,436 £4,408 £0,1934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282  | £1,161<br>£17,026<br>£3,422<br>£197<br>£3,173<br>£72,146<br>£11,826<br>£767<br>£6,392<br>£3,936<br>£136<br>£35<br>£40<br>£8,143<br>£137<br>£4,897<br>£4,897<br>£2,595<br>£5,075<br>£104<br>£177<br>£177<br>£2,595<br>£31,106<br>£33,844<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£177<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178<br>£178   | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,688 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 -£0 -£2,681 -£1,723 -£1 -£602 -£0 -£00 -£203 -£1,680 -£1,680 -£2,723   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £33,92 £8,268 -£136 -£4,871 -£36 -£4,871 -£660 £4,922 -£5,075 -£104 £1777 -£6,284 -£33,902 £8,424 -£660 £16,755 -£681 £634 £33,902 £1,785  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Follow-up Daycase Elective Non Elective Excess Bed Days   | 3 183 193 19 1 1,3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 22 7 57 253 17 93 536 10 10 23 33 126 36 9   | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 363 12 97 674 17 10 27 145 14   | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 -1 -54 0 -1 -55 -1 -1 -25 -37 -1 -1 -22 -16 -110 -5 -4 -138 -7 -138 -7 -138 -6 -19 -22 -3 -100   | £1,161 £61,640 £64,646 £197 £395,266 £673,113 £18,689 £0 £13,951 £11,800 £35 £40 £44,515 £1,328 £19,638 £28,148 £3 £351 £29,532 £79,000 £5,747 £458 £0 £6 £5,741 £62,331 £7,792 £5,748 £11,830 £17,432 £38,664 £21,491 £13,992 £160,279 £2,529 £4,595 £7,124 £90,132 £49,446 £27,788 £48,527   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £292 £354 £1777 £0 £93,436 £4,408 £0,90 £1,4626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282 £36,850 £1,755  | £1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£6392 -£3,936 -£136 -£35 -£40 -£669 -£8,143 -£137 -£4,897 -£3 -£82 -£429 -£2,595 -£0,075 -£104 -£177 -£6 -£5,748 -£3,384 -£5,748 -£3,384 -£5,748 -£1,784 -£1,784 -£2,699 -£1,784 -£2,699 -£1,784 -£2,699 -£22,695 -£16,840 -£32,164 -£23,164 -£3,062 -£46,772  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 £2,681 -£2,723 £0 -£263 -£11 -£602 -£0 -£0 -£263 -£11 -£002 -£1,968   | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 £4,922 -£5,075 -£104 £177 -£6 £4,922 £1,785 -£3 £4,810 £16,755 -£681 £634 £33,902 £1,785 -£2,609 -£825 £13,585 -£2,609 -£8327 -£46,662  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance otal Daycase Elective Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New  | 3 183 193 19 1 1,3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 0 4 253 715 26 3 0 0 29 81 7 2 27 57 253 17 253 17 253 17 26 33 3 33 33 33 126 36 9 104   | 0 132 9 0 4,011 4,381 15 2 94 114 1 0 0 226 12 141 260 0 3 268 684 1 0 4 118 6 0 0 4 118 6 73 363 12 77 10 77 145 14 12 4 140  | -3 -51 -10 -1 314 178 -19 2 29 27 -1 0 0 40 -1 -54 0 -1 -1 -1 -5 -1 -1 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2   | £1,161 £61,640 £64,646 £197 £395,266 £673,113 £18,689 £00 £13,951 £11,800 £00 £35 £44,515 £1,328 £19,638 £28,148 £33 £351 £29,532 £79,000 £5,277 £458 £0 £6 £5,741 £62,331 £7,792 £5,748 £11,830 £17,432 £38,664 £2,491 £13,992 £160,279 £2,529 £4,595 £7,124 £90,132 £49,446 £27,788 £48,527  | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £20,242 £34,408 £0 £14,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,866 £6,299 £106,972 £17,282 £36,850 £1,755   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£13,936 -£3,936 -£35 -£40 -£669 -£689 -£3,143 -£137 -£4,897 -£3,173 -£4,897 -£3,075 -£104 -£177 -£6 -£5,075 -£104 -£177 -£6 -£5,099 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£16,153 -£681 -£684 -£2,609   | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 -£0 -£2,175 -£2,327 -£0 £0 £0 -£0 -£2,175 -£2,327 -£0 -£0 -£0 -£2,681 -£2,723 £0 -£263 -£11 -£602 -£0 -£0 -£0 -£1,968 £7,355 -£1,968 £7,735 -£1,968  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£4,871 -£3 -£4,922 -£5,075 -£104 £177 -£6 -£5,049 £177 -£6 -£5,748 -£9,633 £4,810 £16,755 -£881 £1,785 -£2,609 £28,424 -£634 £33,902 £1,785 -£2,609 £28,424 -£660 £5,748 -£9,633 £4,810 £16,755 -£881 £3,902 £1,785 -£2,609 £28,424 -£664 £33,902 £1,785 -£2,609  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  Total Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up  Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up | 3 183 183 19 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33 126 36 9 104 90 281   | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 12 97 674 17 10 27 145 14 12 4 140 246                                  | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -0 -1 -1 -54 -1 -2 -25 -37 -1 -1 -2 -22 -16 -10 -5 -4 -138 -6 -19 -22 -3 -10 -5 -6 -19 -35 -10 -5 -6 -19 -35 -6 -19 -35 -6 -19 -35 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -19 -35 -6 -6 -6 -19 -35 -6 -6 -6 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -13 -6 -6 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br><b>£79,000</b><br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£11,830<br>£17,432<br>£2,491<br>£13,992<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£2,491<br>£13,992<br>£160,279<br>£2,529<br>£4,595<br>£2,7788<br>£14,830<br>£17,792<br>£3,748<br>£11,830<br>£17,792<br>£5,748<br>£11,830<br>£17,792<br>£5,748<br>£11,830<br>£17,792<br>£5,748<br>£11,830<br>£17,792<br>£5,748<br>£11,830<br>£17,792<br>£160,279<br>£2,529<br>£4,595<br>£2,529<br>£4,595<br>£4,595<br>£7,124<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132<br>£90,132  | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £202 £354 £177 £0 £732 £93,436 £4,408 £0 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282 £36,880 £1,755 £32,553 £35,813  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£689 -£8,143 -£137 -£4,897 -£3,255 -£104 -£177 -£6,009 -£31,106 -£3,384 -£5,748 -£9,896 -£4,810 -£16,153 -£681 -£634 -£632,994 -£1,784 -£2,609 -£22,164 -£32,164 -£32,164 -£9,062 -£46,772 -£11,881 -£5,040   | £0 £41 £3 £0 £44,350 £3,6,701 £34,350 £1,382 £108 £206 £0 £0 £0 £0 £0 £1,688 £2,175 £2,175 £2,327 £0 £0 £0 £0 £0 £2,681 £2,723 £11 £602 £2,681 £2,723 £11 £602 £2,681 £2,723  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £339 £8,268 -£136 -£4,871 -£82 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,746 £1,748 -£1,748   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 3 183 183 19 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33 126 36 9 104 90 281   | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 363 12 97 674 17 10 27 145 14 12 4 140 246 1                            | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -54 -0 -1 -15 -31 -25 -37 -1 -1 -25 -37 -1 -1 -2 -22 -3 -6 -19 -23 -100 -55 -51 -138 -6 -19 -22 -23 -100 -55 -55 -51 -100 -55 -55 -51 -100 -55 -55 -51 -52 -55 -55 -51 -52 -53 -60 -60 -60 -60 -60 -60 -60 -60 -60 -60  | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£22,491<br>£13,992<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,59 | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £31,595 £202 £354 £1177 £0 £732 £93,436 £4,408 £0,11,736 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282 £36,850 £1,755 £32,553 £35,813 £1466   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£669 -£8,143 -£137 -£4,897 -£3,255 -£409 -£3,075 -£104 -£777 -£6 -£5,009 -£31,106 -£3,384 -£3,099 -£825 -£16,840 -£3,088  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£1,25 -£1 -£26 -£0 -£2,175 -£2,327 -£0 £0 -£0 -£2,681 -£2,723 -£1 -£602 -£0 -£263 -£1 -£602 -£0 -£0 -£0 -£0 -£1,968 £73,55 -£1,968 £735 -£110 -£7  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660 £16,755 -£681 £634 £33,902 £1,785 -£2,609 -£825 £13,585 -£30,196 £8,327 -£46,662 £11,687 -£5,037 -£3,088  |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology Total Epilepsy  Epilepsy Total Gastroenterology | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance  Total Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up  Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up | 3 183 193 19 1 1,3,697 4,203 34 0 65 87 0 0 0 186 22 142 314 0 4 253 715 26 3 0 0 29 81 7 22 77 57 253 17 93 536 10 23 33 126 36 9 104 90 281 90 22 77  | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 0 4 118 6 0 0 5 73 363 12 97 674 17 10 27 145 14 140 246 119 4                                     | -3 -51 -10 -1 314 -178 -19 -2 -29 -27 -1 -1 -0 -0 -1 -54 -0 -1 -15 -31 -25 -1 -1 -2 -2 -22 -22 -22 -26 -10 -10 -54 -11 -25 -1 -1 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2   | £1,161<br>£61,640<br>£64,644<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£3<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£60<br>£6,741<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£21,491<br>£13,992<br>£160,279<br>£2,529<br>£4,595<br>£7,124<br>£90,132<br>£49,444<br>£90,132<br>£49,444<br>£27,788<br>£48,527<br>£20,872<br>£40,852<br>£20,872<br>£40,852<br>£21,234   | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £81,595 £177 £0 £13,641 £13,641 £13,685  | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£669 -£81,143 -£137 -£4,897 -£3 -£429 -£2,595 -£5,075 -£104 -£177 -£6 -£5,078 -£177 -£6 -£5,488 -£1,784 -£2,898 -£32,94 -£1,784 -£2,609 -£25,168 -£32,164 -£32,164 -£32,164 -£32,164 -£32,164 -£32,164 -£32,164 -£32,164 -£32,164 -£5,040 -£32,164  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 £0 -£1,068 -£125 -£1 -£26 £0 £0 £0 £0 £0 £1,068 -£125 -£1 -£2,327 -£0 £0 £0 £2,681 -£2,723 £0 -£263 -£1,668 -£1,968 £2,681 -£2,723 £0 -£263 -£1,7660 -£263 -£2  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 -£35 -£40 £399 £8,268 -£136 -£4,871 -£3 -£1,746 £4,922 -£5,075 -£104 £177 -£6 25,748 £1,785 -£681 £1,785 -£681 £1,785 -£681 £33,902 £1,785 -£2,609   |
|               | Allergy Total Dermatology  Dermatology Total Diabetes  Diabetes Total Endocrinology  Endocrinology Total Epilepsy  Epilepsy Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Based Outpatient A&E Attendance Otal Daycase Elective Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Outpatient Follow-up  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 3 183 183 19 1 1 3,697 4,203 34 0 65 87 0 0 0 186 2 142 314 253 715 26 3 0 0 29 81 7 2 27 57 253 17 93 536 10 23 33 126 36 9 104 90 281   | 0 132 9 0 4,011 4,381 15 2 94 114 10 0 226 12 141 260 0 3 268 684 1 2 1 1 0 4 118 6 0 5 73 363 363 12 97 674 17 10 27 145 14 12 4 140 246 1                            | -3 -51 -10 -1 -314 -178 -19 -2 -29 -27 -1 -0 -0 -0 -1 -54 -0 -1 -15 -31 -25 -37 -1 -1 -25 -37 -1 -1 -2 -22 -3 -6 -19 -23 -100 -55 -51 -138 -6 -19 -22 -23 -100 -55 -55 -51 -100 -55 -55 -51 -100 -55 -55 -51 -52 -55 -55 -51 -52 -53 -60 -60 -60 -60 -60 -60 -60 -60 -60 -60  | £1,161<br>£61,640<br>£64,64<br>£197<br>£395,266<br><b>£673,113</b><br>£18,689<br>£0<br>£13,951<br>£11,800<br>£35<br>£40<br>£44,515<br>£1,328<br>£19,638<br>£28,148<br>£351<br>£29,532<br>£79,000<br>£5,277<br>£458<br>£0<br>£62,331<br>£7,792<br>£5,748<br>£11,830<br>£17,432<br>£38,664<br>£11,830<br>£17,432<br>£38,664<br>£22,491<br>£13,992<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,595<br>£4,59 | £0 £44,613 £3,042 £0 £392,093 £600,967 £6,863 £767 £20,343 £15,736 £0 £0 £0 £43,845 £9,471 £19,501 £23,251 £0 £268 £29,104 £31,595 £202 £354 £1177 £0 £732 £93,436 £4,408 £0,11,736 £1,934 £22,242 £54,817 £1,809 £14,626 £193,273 £4,313 £1,986 £6,299 £106,972 £17,282 £36,850 £1,755 £32,553 £35,813 £1466   | -£1,161 -£17,026 -£3,422 -£197 -£3,173 -£72,146 -£11,826 -£767 -£6,392 -£3,936 -£35 -£40 -£669 -£8,143 -£137 -£4,897 -£3,255 -£409 -£3,075 -£104 -£777 -£6 -£5,009 -£31,106 -£3,384 -£3,099 -£825 -£16,840 -£3,088  | £0 £41 £3 £0 -£36,701 -£34,350 -£1,382 £0 £108 £206 £0 £0 £0 £0 -£1,068 -£1,25 -£1 -£26 -£0 -£2,175 -£2,327 -£0 £0 -£0 -£2,681 -£2,723 -£1 -£602 -£0 -£263 -£1 -£602 -£0 -£0 -£0 -£0 -£1,968 £73,55 -£1,968 £735 -£110 -£7  | -£1,161 -£17,067 -£3,425 -£197 £33,528 -£37,796 -£10,444 £767 £6,284 £3,731 £136 -£35 -£40 £399 £8,268 -£136 -£4,871 -£82 £1,746 £4,922 -£5,075 -£104 £177 -£6 -£5,009 £28,424 -£660 £16,755 -£681 £634 £33,902 £1,785 -£2,609 -£825 £13,585 -£30,196 £8,327 -£46,662 £11,687 -£5,037 -£3,088  |

| In- | RЛ | - | - | 4 | ᄂ |
|-----|----|---|---|---|---|
|     |    |   |   |   |   |

|                          | Haematology   | Elective   | 3  | 8   | 5  | £11,976   | £35,512  | £23,536  | -£1,054  | £24,590  |
|--------------------------|---|--|--|---|--|---|--|--|--|--|
|                          | 1 identificacy  | Non Elective   | 11   | 14  | 3  |   | £15,117  | £1,137   | -£2,517  | £3,654   |
|                          |   |  |  |   |  | £13,981   |  |  |  |  |
|                          |   | Excess Bed Days  | 3  | 3   | 0  | £879  | £1,160   | £281   | £256   | £25  |
|                          |   | Outpatient New   | 19   | 34  | 15   | £8,636  | £15,309  | £6,673   | -£1  | £6,674   |
|                          |   | Outpatient Follow-up   | 53   | 82  | 29   | £11,126   | £17,310  | £6,183   | -£1  | £6,184   |
|                          |   | Ward Attender  | 150  | 192   | 42   | £31,645   | £40,531  | £8,886   | -£0  | £8,886   |
|                          |   | Ward Based Outpatient  |  |   | 0  |   |  |  | £0   |  |
|                          |   |  | 0  | 0   |  | £53   | £0   | -£53   |  | -£53   |
|                          |   | OP Procedure   | 0  | 0   | 0  | £22   | £0   | -£22   | £0   | -£22   |
|                          | Haematology Total   |  | 260  | 377   | 117  | £94,746   | £157,294   | £62,548  | -£5,607  | £68,155  |
|                          | Immunology  | Daycase  | 4  | 0   | -4   | £1,924  | £0   | -£1,924  | £0   | -£1,924  |
|                          | minunology  |  |  |   |  |   |  |  |  |  |
|                          |   | Outpatient New   | 11   | 26  | 15   | £2,417  | £5,624   | £3,207   | £27  | £3,180   |
|                          |   | Outpatient Follow-up   | 8  | 25  | 17   | £1,157  | £3,424   | £2,267   | £19  | £2,248   |
|                          |   | Ward Attender  | 4  | 5   | 1  | £581  | £681   | £100   | -£0  | £100   |
|                          |   | Ward Based Outpatient  | 14   | 35  | 21   | £1,856  | £4,768   | £2,912   | £0   | £2,912   |
|                          | Immun alamu Tatal   | Traia Bassa Salpalisin   |  |   | 50   |   |  |  | £46  |  |
|                          | Immunology Total  |  | 41   | 91  |  | £7,934  | £14,497  | £6,563   |  | £6,517   |
|                          | LTV   | Outpatient New   | 10   | 6   | -4   | £6,736  | £4,428   | -£2,308  | £174   | -£2,482  |
|                          |   | Outpatient Follow-up   | 42   | 50  | 8  | £29,119   | £36,898  | £7,779   | £1,955   | £5,824   |
|                          | LTV Total   | _  | 51   | 56  | 5  | £35,855   | £41,326  | £5,471   | £2,129   | £3,342   |
|                          | Metabolic Disease   | Outpatient New   | 4  | 9   | 5  | £1,686  | £3,459   | £1,774   | £3   | £1,770   |
|                          | Wictabolic Disease  |  |  |   |  |   |  |  |  |  |
|                          |   | Outpatient Follow-up   | 24   | 45  | 21   | £9,258  | £17,297  | £8,039   | £15  | £8,024   |
|                          |   | Ward Based Outpatient  | 3  | 5   | 2  | £1,056  | £1,922   | £866   | £2   | £864   |
|                          | Metabolic Disease Total   |  | 31   | 59  | 28   | £12,000   | £22,678  | £10,678  | £20  | £10,658  |
|                          | Nephrology  | Daycase  | 119  | 161   | 42   | £212,418  | £236,828   | £24,411  | -£50,608   | £75,019  |
|                          | rtopinology   | Elective   |  | 30  | 3  |   |  |  |  |  |
|                          |   |  | 27   |   |  | £29,102   | £19,842  | -£9,260  | -£11,968   | £2,708   |
|                          |   | Non Elective   | 4  | 1   | -3   | £12,337   | £2,176   | -£10,161   | -£899  | -£9,263  |
|                          |   | Excess Bed Days  | 17   | 0   | -17  | £8,513  | £0   | -£8,513  | £0   | -£8,513  |
|                          |   | Outpatient New   | 14   | 21  | 7  | £1,635  | £2,481   | £846   | £2   | £844   |
|                          |   | Outpatient Follow-up   | 124  | 160   | 36   | £14,694   | £18,906  | £4,212   | £18  | £4,194   |
|                          |   |  |  |   |  |   |  |  |  |  |
|                          |   | Ward Attender  | 59   | 15  | -44  | £6,974  | £1,654   | -£5,320  | -£117  | -£5,203  |
|                          |   | Ward Based Outpatient  | 47   | 50  | 3  | £5,492  | £5,908   | £416   | £6   | £410   |
|                          | Nephrology Total  |  | 411  | 438   | 27   | £291,165  | £287,795   | -£3,370  | -£63,566   | £60,196  |
|                          | Neurology   | Daycase  | 23   | 9   | -14  | £25,240   | £11,555  | -£13,686   | £1,663   | -£15,349   |
|                          | rectional   |  |  |   |  |   |  |  |  |  |
|                          |   | Elective   | 5  | 14  | 9  | £9,776  | £30,038  | £20,261  | £4,480   | £15,781  |
|                          |   | Non Elective   | 9  | 10  | 1  | £46,325   | £55,553  | £9,228   | £1,230   | £7,999   |
|                          |   | Excess Bed Days  | 81   | 43  | -38  | £49,084   | £27,282  | -£21,802   | £1,251   | -£23,054   |
|                          |   | Outpatient New   | 79   | 67  | -12  | £21,917   | £18,593  | -£3,324  | £18  | -£3,342  |
|                          |   |  |  |   |  |   |  |  |  |  |
|                          |   | Outpatient Follow-up   | 209  | 193   | -16  | £57,892   | £53,559  | -£4,333  | £49  | -£4,382  |
|                          |   | Ward Attender  | 12   | 9   | -3   | £3,373  | £2,498   | -£876  | £2   | -£878  |
|                          |   | Ward Based Outpatient  | 16   | 0   | -16  | £4,349  | £0   | -£4,349  | £0   | -£4,349  |
|                          | Neurology Total   | Traia Bassa Salpalisin   | 434  | 345   | -89  |   |  |  | £8,694   |  |
|                          |   | _  |  |   |  | £217,957  | £199,077   | -£18,880   |  | -£27,573   |
|                          | Oncology  | Daycase  | 159  | 71  | -88  | £150,947  | £58,097  | -£92,850   | -£9,414  | -£83,437   |
|                          |   | DCHEMO   | 121  | 168   | 47   | £40,387   | £55,862  | £15,475  | -£0  | £15,475  |
|                          |   | Elective   | 26   | 25  | -1   | £97,702   | £119,357   | £21,654  | £24,705  | -£3,050  |
|                          |   | Non Elective   | 50   | 23  | -27  | £101,799  | £61,797  | -£40,002   | £14,982  | -£54,984   |
|                          |   |  |  |   |  |   |  |  |  |  |
|                          |   | Excess Bed Days  | 58   | 9   | -49  | £26,779   | £3,327   | -£23,452   | -£853  | -£22,600   |
|                          |   | Outpatient New   | 9  | 7   | -2   | £2,302  | £1,814   | -£487  | £2   | -£489  |
|                          |   | Outpatient Follow-up   | 196  | 276   | 80   | £50,865   | £71,280  | £20,415  | -£234  | £20,649  |
|                          |   | Ward Attender  | 44   | 46  | 2  |   | £11,923  |  | £11  | £531   |
|                          |   |  |  |   |  | £11,382   |  | £541   |  |  |
|                          |   | Ward Based Outpatient  | 8  | 0   | -8   | £2,105  | £0   | -£2,105  | £0   | -£2,105  |
|                          | Oncology Total  |  | 671  | 625   | -46  | £484,268  | £383,457   | -£100,811  | £29,198  | -£130,009  |
|                          | Paediatrics   | Daycase  | 13   | 8   | -5   | £7,324  | £5,427   | -£1,896  | £1,030   | -£2,926  |
|                          |   | Elective   | 1  | 5   | 4  | £619  | £7,369   | £6,750   | £3,205   | £3,545   |
|                          |   |  |  |   |  |   |  |  |  | 13,343   |
|                          |   |  |  |   |  |   |  |  |  |  |
|                          |   | Non Elective   | 220  | 287   | 67   | £255,359  | £340,148   | £84,789  | £7,137   | £77,653  |
|                          |   | Excess Bed Days  | 220<br>72  | 287<br>16   | -56  | £255,359<br>£29,670   | £340,148<br>£6,826   | £84,789<br>-£22,844  | £7,137<br>£272   | £77,653<br>-£23,116  |
|                          |   | Excess Bed Days  | 72   | 16  | -56  | £29,670   | £6,826   | -£22,844   | £272   | -£23,116   |
|                          |   | Excess Bed Days<br>Outpatient New  | 72<br>271  | 16<br>258   | -56<br>-13   | £29,670<br>£58,397  | £6,826<br>£55,535  | -£22,844<br>-£2,862  | £272<br>-£2  | -£23,116<br>-£2,860  |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up  | 72<br>271<br>446   | 16<br>258<br>408  | -56<br>-13<br>-38  | £29,670<br>£58,397<br>£60,766   | £6,826<br>£55,535<br>£55,579   | -£22,844<br>-£2,862<br>-£5,187   | £272<br>-£2<br>-£3   | -£23,116<br>-£2,860<br>-£5,184   |
|                          |   | Excess Bed Days<br>Outpatient New  | 72<br>271<br>446<br>8  | 16<br>258<br>408<br>5   | -56<br>-13<br>-38<br>-3  | £29,670<br>£58,397<br>£60,766<br>£1,112   | £6,826<br>£55,535<br>£55,579<br>£681   | -£22,844<br>-£2,862<br>-£5,187<br>-£431  | £272<br>-£2<br>-£3<br>-£0  | -£23,116<br>-£2,860<br>-£5,184<br>-£431  |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72<br>271<br>446   | 16<br>258<br>408  | -56<br>-13<br>-38  | £29,670<br>£58,397<br>£60,766   | £6,826<br>£55,535<br>£55,579<br>£681   | -£22,844<br>-£2,862<br>-£5,187   | £272<br>-£2<br>-£3   | -£23,116<br>-£2,860<br>-£5,184   |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  | 72<br>271<br>446<br>8<br>36  | 16<br>258<br>408<br>5<br>11   | -56<br>-13<br>-38<br>-3<br>-25   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450   | £272<br>-£2<br>-£3<br>-£0<br>-£0   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450   |
|                          | Deadlistrice Tatal  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72<br>271<br>446<br>8<br>36<br>0   | 16<br>258<br>408<br>5<br>11   | -56<br>-13<br>-38<br>-3<br>-25   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27   | £272<br>-£2<br>-£3<br>-£0<br>-£0   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27   |
|                          | Paediatrics Total   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069  | 16<br>258<br>408<br>5<br>11<br>0  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b>   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b>   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£0<br>£11,638  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b>   |
|                          | Paediatrics Total<br>Radiology  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  | 72<br>271<br>446<br>8<br>36<br>0   | 16<br>258<br>408<br>5<br>11   | -56<br>-13<br>-38<br>-3<br>-25   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27   | £272<br>-£2<br>-£3<br>-£0<br>-£0   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27   |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure   | 72<br>271<br>446<br>8<br>36<br>0<br><b>1,069</b><br>99   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126   | -56<br>-13<br>-38<br>-3<br>-25<br>0<br><b>-71</b><br>27  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b><br>£129,103   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£0<br>£11,638<br>-£29,483  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726   |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective   | 72<br>271<br>446<br>8<br>36<br>0<br><b>1,069</b><br>99   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126   | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b><br>£129,103<br>£31,126  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br><b>£473,064</b><br>£134,346<br>£17,167   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243<br>-£13,959   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£0<br>£11,638<br>-£29,483<br>£4,112  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071  |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective  | 72<br>271<br>446<br>8<br>36<br>0<br><b>1,069</b><br>99<br>17   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b><br>£129,103<br>£31,126<br>£25,224   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br><b>£473,064</b><br>£134,346<br>£17,167<br>£32,480  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243<br>-£13,959<br>£7,256   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£14,991  |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10<br>-1  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b><br>£129,103<br>£31,126<br>£25,224<br>£11,551  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br><b>£473,064</b><br>£134,346<br>£17,167<br>£32,480  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243<br>-£13,959<br>£7,256<br>-£11,551   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551  |
|                          | Radiology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>-71<br>-10<br>-1<br>-24<br>309   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947   |
|                          |   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10<br>-1  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br><b>£418,222</b><br>£129,103<br>£31,126<br>£25,224<br>£11,551  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br><b>£473,064</b><br>£134,346<br>£17,167<br>£32,480  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br><b>£54,842</b><br>£5,243<br>-£13,959<br>£7,256<br>-£11,551   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551  |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b>   | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>-71<br>-10<br>-1<br>-24<br>309<br>300  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>£11,551<br>£40,947<br>£31,060  |
|                          | Radiology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084   | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b>   | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10<br>-1<br>-24<br>309<br>300   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850  | £272<br>-£2<br>-£3<br>-£0<br>£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,840<br>-£7,714   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564  |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9  | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b><br>29<br>7  | -56 -13 -38 -3 -25 0 -71 27 -10 -1 -24 309 300 -3  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£5,484<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,840<br>-£7,714  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222   |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Non Elective   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9  | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b><br>29<br>7  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10<br>-1<br>-24<br>309<br>300<br>20<br>-3<br>-9   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,463<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>£41,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016  |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9  | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b><br>29<br>7  | -56 -13 -38 -3 -25 0 -71 27 -10 -1 -24 309 300 -3  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£5,484<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,840<br>-£7,714  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222   |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Non Elective   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9  | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b><br>29<br>7  | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>27<br>-10<br>-1<br>-24<br>309<br>300<br>20<br>-3<br>-9   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,463<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464   |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days OUtpatient New   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66  | 16<br>258<br>408<br>5<br>11<br>0<br><b>998</b><br>126<br>7<br>1<br>0<br>1,250<br><b>1,384</b><br>29<br>7<br>7   | -56<br>-13<br>-38<br>-3<br>-25<br>0<br>-71<br>-77<br>-10<br>-1<br>-24<br>-300<br>20<br>-3<br>-9<br>10<br>7   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,63<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909   |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Ovapatient New Outpatient New Outpatient Follow-up   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218                                 | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>73  | -56 -13 -38 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 10 7 -88   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660  |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218                                 | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>7<br>33<br>73<br>306<br>3                             | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -9 -8 -8 -8 -8 -8 -56 -70 -71 -71 -71 -71 -71 -71 -71 -71 -71 -71   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,463<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£11,551<br>£40,947<br><b>£31,060</b><br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£1,660<br>-£29   |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Ward Attender Ward Based Outpatient   | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218<br>3                            | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>73<br>306<br>3<br>8                             | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 10 -7 -88 0 0 -113  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£431   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£16,171  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£3   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£14,991<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171  |
|                          | Radiology  Radiology Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218                                 | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>7<br>33<br>73<br>306<br>3                             | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -9 -8 -8 -8 -8 -8 -56 -70 -71 -71 -71 -71 -71 -71 -71 -71 -71 -71   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,463<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£11,551<br>£40,947<br><b>£31,060</b><br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£1,660<br>-£29   |
|                          | Radiology Total Respiratory Medicine  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Over Daycase Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218<br>3<br>121<br>52               | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>73<br>306<br>3<br>8                             | -56 -13 -38 -38 -39 -25 0 -71 -27 -10 -1 -1 -24 -309 -30 -3 -9 10 7 -88 0 -113 -51   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£29<br>-£21,571<br>£12,658   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£3<br>-£0<br>-£0<br>-£136  | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  | 72<br>271<br>446<br>8<br>36<br>0<br>1,069<br>99<br>17<br>2<br>24<br>942<br>1,084<br>9<br>10<br>16<br>23<br>66<br>218<br>3<br>121<br>52<br>52         | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>33<br>73<br>306<br>3<br>8<br>1<br>467           | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -3 -9 -9 10 7 -88 0 -113 -51  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220  | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£5,484<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£16,171<br>-£10,973<br>£35,651  | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£3<br>-£0<br>-£0<br>-£13<br>-£25,229   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>£21,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677   |
|                          | Radiology Total Respiratory Medicine  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517  | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>73<br>306<br>3<br>8<br>1<br>467<br>105          | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -10 -7 -113 -51 -50 -46   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>£5,243<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£16,171<br>-£10,973<br>£35,651<br>-£27,152   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,463 -£4,112 £22,247 -£36,716 -£39,840 -£7,714 £17,564 £25,229 £4,456 -£68 -£63 -£0 -£136 -£90 -£136   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br><b>£43,204</b><br>£34,726<br>-£18,071<br>-£11,551<br>£40,947<br><b>£31,060</b><br>£26,564<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677<br>-£29,022  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517  | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 73 306 3 8 1 467 105 2  | -56 -13 -38 -3 -25 0 -71 -17 -17 -19 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£16,171<br>-£10,973<br>£35,651<br>-£27,152<br>-£21,069   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,746<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£3<br>-£0<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18   | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>73<br>306<br>3<br>8<br>1<br>467<br>105          | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -10 -7 -113 -51 -50 -46   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333   | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722  | £272<br>-£2<br>-£3<br>-£0<br>£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,840<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£9<br>-£0<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136<br>-£136  | -£23,116<br>-£2,860<br>-£5,184<br>-£3,450<br>-£3,450<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677<br>-£29,022<br>-£29,022<br>-£29,022  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517  | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 73 306 3 8 1 467 105 2  | -56 -13 -38 -3 -25 0 -71 -17 -17 -19 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£418,222<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£0<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891   | -£22,844<br>-£2,862<br>-£5,187<br>-£431<br>-£3,450<br>-£27<br>£54,842<br>-£13,959<br>£7,256<br>-£11,551<br>£4,231<br>-£8,779<br>£18,850<br>£13,342<br>£6,213<br>£9,920<br>£1,841<br>£12,658<br>-£29<br>-£16,171<br>-£10,973<br>£35,651<br>-£27,152<br>-£21,069   | £272<br>-£2<br>-£3<br>-£0<br>-£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£38,746<br>-£7,714<br>£17,564<br>£25,229<br>£4,456<br>-£68<br>-£3<br>-£0<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136<br>£3,716<br>-£136   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days  | 72 271 446 8 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 618 3 121 18 18 2 26  | 16<br>258<br>408<br>5<br>11<br>0<br>998<br>126<br>7<br>1<br>0<br>1,250<br>1,384<br>29<br>7<br>7<br>7<br>33<br>306<br>3<br>8<br>1<br>467<br>105<br>2<br>3<br>0 | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -3 -9 -9 -10 -113 -51 -46 -16 -1 -26  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568<br>£95,709<br>£22,959<br>£22,959<br>£2610<br>£10,695  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£777<br>£187,220<br>£68,557<br>£1,891<br>£5,333  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£39,840 -£7,714 -£17,564 -£68 -£39,229 -£4,456 -£68 -£13 -£0 -£10 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136,716 -£136   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£27 £43,204 £34,726 -£18,071 -£14,991 £41,991 £23,1060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient New  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49   | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 73 306 3 8 1 467 105 2 3 0 61  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -24 -309 -300 -3 -9 -10 -7 -8 -8 0 -113 -51 -46 -16 -16 -16 -16 -16 -16 -16 -16 -16 -1  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568<br>£95,709<br>£22,959<br>£22,959<br>£26,10<br>£10,695<br>£7,307  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£23,271<br>£18,940<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,183  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 -£13,959 £7,256 -£11,551 -£4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,463 -£4,112 £22,247 -£36,716 -£39,840 -£7,714 -£17,564 £25,229 £4,456 -£68 -£68 -£39,228 £1,871 -£726 £130 £0 £8  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£27 <b>£43,204</b> £34,726 -£18,071 -£14,991 -£11,551 £40,947 <b>£31,060</b> £26,564 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 £10,695 £1,868   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Ron Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49   | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61  | -56 -13 -38 -38 -38 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -3 -9 10 7 -88 0 -113 -51 -50 -46 -16 -16 -16 -16 -12 -23  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0   | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 £10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042   | £272 -£2 -£3 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,56 -£68 -£3 -£0 -£136 -£39,328 -£1,871 -£726 -£130 -£0 -£8   | -£23,116<br>-£2,860<br>-£5,184<br>-£3,450<br>-£3,450<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677<br>-£29,022<br>-£20,343<br>£2,593<br>-£10,695<br>£1,868<br>£4,957                                      |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172   | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,709<br>£21,956<br>£2,610<br>£17,309<br>£2,610<br>£2,959<br>£2,610<br>£10,695<br>£7,307<br>£2,610<br>£10,695<br>£7,307   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£777<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,861<br>£903  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,7722 -£10,695 £1,876 £5,042 -£1,136  | £272<br>-£2<br>-£3<br>-£0<br>£0<br>£11,638<br>-£29,483<br>£4,112<br>£22,247<br>£0<br>-£36,716<br>-£39,840<br>-£7,564<br>£25,229<br>£4,456<br>-£68<br>-£3<br>-£0<br>-£136<br>-£39,328<br>£1,871<br>-£726<br>£130<br>£130<br>£25,229   | -£23,116<br>-£2,860<br>-£5,184<br>-£431<br>-£3,450<br>-£27<br>£43,204<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677<br>-£29,022<br>-£20,343<br>£2,593<br>-£10,695<br>£1,868<br>£4,957<br>-£1,137          |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Ron Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient New   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49   | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61  | -56 -13 -38 -38 -38 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -3 -9 10 7 -88 0 -113 -51 -50 -46 -16 -16 -16 -16 -12 -23  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0   | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 £10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042   | £272 -£2 -£3 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,56 -£68 -£3 -£0 -£136 -£39,328 -£1,871 -£726 -£130 -£0 -£8   | -£23,116<br>-£2,860<br>-£5,184<br>-£3,450<br>-£3,450<br>£34,726<br>-£18,071<br>-£14,991<br>-£11,551<br>£40,947<br>£31,060<br>£26,564<br>-£4,222<br>-£19,016<br>£5,464<br>£1,909<br>£12,660<br>-£29<br>-£16,171<br>-£10,837<br>-£3,677<br>-£29,022<br>-£20,343<br>£2,593<br>-£10,695<br>£1,868<br>£4,957                                      |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 151 18 2 26 49 172 14 9   | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 73 306 3 8 1 467 105 2 3 0 61 205 6 10   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -10 -7 -88 0 -113 -51 -46 -16 -16 -26 -12 -33 -8 -8 -1   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,055<br>£15,588<br>£95,709<br>£22,959<br>£21,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£1,385   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,861<br>£9,183<br>£30,861  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £18,41 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £1,876 £5,042 -£1,876 £5,042 -£1,136  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£39,328 -£1,871 -£726 -£136  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£43,204 £34,726 -£18,071 -£14,991 £41,991 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137  |
|                          | Radiology  Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14  | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 73 306 3 8 1 467 105 2 3 0 61 205 6  | -56 -13 -38 -3 -25 -0 -71 -17 -17 -19 -19 -19 -10 -17 -19 -10 -17 -19 -10 -10 -10 -10 -10 -10 -10 -10 -10 -10  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£11,551<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568<br>£95,709<br>£22,959<br>£22,959<br>£22,959<br>£22,959<br>£22,959<br>£22,819<br>£20,40<br>£13,385  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,661<br>£903<br>£1,505<br>£0   | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 -£13,959 £7,256 -£11,551 -£4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£68 -£39,328 -£1,871 -£726 -£136 -£0 -£36,716 -£39,840 -£1,640 -£36,716 -£25,229 -£1,456 -£68 -£39,288 -£1,871 -£726 -£136 -£130 -£14 -£15,640 -£15 | -£23,116 -£2,860 -£5,184 -£43,204 -£3,450 -£27 -£18,071 -£14,991 -£11,551 -£40,947 -£31,060 -£26,564 -£19,016 -£5,464 -£1,909 -£12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£2,593 -£10,695 -£1,688 -£4,957 -£1,137 -£11,157  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  I Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Vard Based Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439  | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 -27  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£11,385   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,03<br>£1,505  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136 £120  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£33,840 -£7,714 £17,564 £25,229 £4,456 -£68 -£68 -£3 -£0 -£136 £39,328 £1,871 -£726 £130 -£0 £8 £85 £1 £0 £1,370   | -£23,116 -£2,860 -£5,184 -£4,311 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 £14   |
|                          | Radiology  Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology  | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase   | 72 271 446 8 36 0 1,069 99 17 2 44 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439  | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 33 8 1 467 105 2 3 0 61 205 6 10 0 392  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 -0 -7 -7 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568<br>£95,709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£1,385<br>£14,605<br>£15,381<br>£2,040<br>£13,885<br>£14   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£777<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,863<br>£90,3861<br>£90,3861<br>£903<br>£1,505<br>£0<br>£118,233<br>£0,554  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,0695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£39,840 -£7,714 -£17,564 -£68 -£3 -£0 -£0 -£136,716 -£88 -£13 -£0 -£10 -£136,716 -£136 -£136 -£136 -£136 -£136 -£136 -£1370 -£130  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  I Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Vard Based Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439  | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 -27  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£11,385   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,3861<br>£903<br>£1,505  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136 £120  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£33,840 -£7,714 £17,564 £25,229 £4,456 -£68 -£68 -£3 -£0 -£136 £39,328 £1,871 -£726 £130 -£0 £8 £85 £1 £0 £1,370   | -£23,116 -£2,860 -£5,184 -£4,311 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 £14   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology  Rheumatology Total Sleep Studies   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22                                       | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 8 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -10 -7 -88 0 -113 -51 -46 -16 -1 -26 -12 -33 -8 -8 -8 -1 -0 -47 -1 -6  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,556<br>£95,709<br>£22,959<br>£22,959<br>£26,100<br>£10,695<br>£7,307<br>£25,819<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£11,385<br>£14<br>£168,539   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,661<br>£99,183<br>£30,861<br>£99,381<br>£1,505<br>£0<br>£118,233<br>£0<br>£15,505   | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £1,876 £5,042 -£1,136 £1,876  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£68 -£136 -£136 -£39,328 -£1,871 -£726 -£130 -£8 -£85 -£1 -£1 -£0 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 -£130 -£14,456 - | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£43,204 £34,726 -£18,071 -£14,991 £31,060 £26,564 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675   |
| Madicina Tatal           | Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 22                                    | 16 258 408 5 11 0 998 126 7 1 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -3 -9 -9 10 7 -88 0 -113 -51 -50 -46 -16 -16 -16 -12 -23 -8 -1 -26 -3 -47 -47 -47 -55   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,126<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£151,568<br>£95,709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£20,400<br>£1,385<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£26,465   | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£473,064<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,03<br>£1,505<br>£0<br>£118,233<br>£654<br>£23,630<br>£24,284  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2834 -£2,834  | £272 -£2 -£3 -£0 -£0 -£0, £11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£3 -£0 -£136 -£39,328 -£1,871 -£726 -£130 -£0 -£8,85 -£1 -£1 -£1 -£1 -£1 -£1 -£1 -£1 -£1 -£1   | -£23,116 -£2,860 -£5,184 -£4,31 -£3,450 -£5,184 -£431 -£3,450 -£34,726 -£18,071 -£14,991 -£11,551 -£40,947 -£31,060 -£26,564 -£4,222 -£19,016 -£5,464 -£1,909 -£12,660 -£29,022 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£2,593 -£10,695 -£1,868 -£4,957 -£1,137 -£119 -£14 -£51,675 -£6841 -£6,207                                      |
| Medicine Total           | Radiology Total Respiratory Medicine  Respiratory Medicine Total  Respiratory Medicine Total  Rheumatology Total Sleep Studies  Sleep Studies Total                   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Daycase Elective Daycase Elective Daycase Elective Daycase Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 0 439 0 0 22 211,476                           | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -9 -10 -7 -88 0 -7 -11 -50 -46 -16 -1 -26 -12 -33 -8 -1 -0 -47 -1 -5 -55 -425   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£1,385<br>£26,465<br>£20,40<br>£1,385<br>£26,465  | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,183<br>£30,861<br>£903<br>£1,505<br>£118,233<br>£654<br>£23,630<br>£24,284<br>£3,393,884  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,772 -£10,695 £1,876 £12,054 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£38,840 -£7,714 £17,564 -£25,229 -£4,456 -£68 -£9 -£0 -£136 -£136 -£39,328 -£1,871 -£726 -£130 -£0 -£36,716 -£39,328 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£4,027 -£449,316   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £6861 -£6,861 -£6,867 -£29,0347  |
| Medicine Total Community | Radiology Total Respiratory Medicine  Respiratory Medicine Total Rheumatology  Rheumatology Total Sleep Studies   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective  Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 21 1,476                                     | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 0 -47 -6 -5 -55 -50 -6 -55 -50 -6 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7               | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £418,222 £129,103 £31,126 £25,224 £11,551 £124,966 £321,970 £11,356 £15,927 £33,753 £13,351 £17,099 £31,254 £460 £17,319 £11,050 £151,568 £95,709 £22,959 £22,959 £22,610 £10,695 £7,307 £25,819 £20,440 £1,385 £14 £168,539 £0 £26,465 £24,6465 £3,492,547 £259  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,861<br>£9,183<br>£30,861<br>£903<br>£1,505<br>£0<br>£118,233<br>£654<br>£23,630<br>£24,284<br>£3,393,884<br>£3,393,884  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834 -£2,834 -£2,834   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£3 -£0 -£0 -£136,716 -£88 -£33 -£0 -£136 -£139,328 -£1,871 -£726 -£130 -£130 -£1,370 -£4,027 -£49,316  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£14,991 -£21,060 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£2,593 -£10,695 -£1,868 £4,957 -£1,137 -£119 -£14 -£51,675 -£6,861 -£6,207 -£49,347 -£259   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  Respiratory Medicine Total  Rheumatology Total Sleep Studies  Sleep Studies Total                   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Daycase Elective Daycase Elective Daycase Elective Daycase Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 0 439 0 0 22 211,476                           | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901  | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -1 -24 -309 -300 -20 -3 -9 -9 -10 -7 -88 0 -7 -11 -50 -46 -16 -1 -26 -12 -33 -8 -1 -0 -47 -1 -5 -55 -425   | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£129,103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£15,5709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£2,040<br>£1,385<br>£26,465<br>£20,40<br>£1,385<br>£26,465  | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,183<br>£30,861<br>£903<br>£1,505<br>£118,233<br>£654<br>£23,630<br>£24,284<br>£3,393,884  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,772 -£10,695 £1,876 £12,054 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£38,840 -£7,714 £17,564 -£25,229 -£4,456 -£68 -£9 -£0 -£136 -£136 -£39,328 -£1,871 -£726 -£130 -£0 -£36,716 -£39,328 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£1,871 -£726 -£130 -£0 -£4,027 -£449,316   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £6861 -£6,861 -£6,867 -£29,0347  |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total  Respiratory Medicine Total  Rheumatology Total Sleep Studies  Sleep Studies Total                   | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Top Procedure  al Daycase Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective Outpatient New  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 22 11,476                             | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901 0 104                                       | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -10 -7 -88 0 -113 -51 -46 -16 -1 -26 -12 -33 -8 -8 -1 -0 -47 -1 -6 -5 -55 -50 -66  | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,555<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,055<br>£151,568<br>£95,709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£20,465<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£26,465<br>£26,465<br>£26,465<br>£259,509<br>£259,500   | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,894<br>£0,861<br>£0,9183<br>£0,861<br>£0,9183<br>£30,861<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184<br>£0,5184  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £7,722 -£10,695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,180   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,463 -£4,112 -£22,247 -£39,840 -£7,714 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£68 -£39,328 -£1,871 -£726 -£130 -£8 -£85 -£1 -£0 -£1,370 -£44,027 -£44,027 -£49,316   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 £41,951 £40,947 £31,060 £26,564 £1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £654 -£6,861 -£6,207 -£9,022   |
|                          | Radiology  Radiology Total Respiratory Medicine  Respiratory Medicine Total  Rheumatology  Rheumatology Total Sleep Studies  Sleep Studies Total  CAMHS               | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective  Elective  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 0 22 22 11,476 0 170 846                 | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 1 11,901 0 11,294   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -30 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 -26 -15 -47 -1 -5 -55 -66 -66 -66 -66 -66 -66 -66 -66                                   | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £418,222 £129,103 £31,126 £255,224 £11,551 £124,966 £321,970 £11,356 £15,927 £33,753 £13,351 £17,099 £31,254 £460 £17,319 £11,050 £151,568 £95,709 £22,959 £2,610 £10,695 £7,307 £25,819 £2,040 £1,385 £0,040 £1,385 £14 £168,539 £0 £26,465 £26,465 £3,492,547 £2599   | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,03<br>£1,505<br>£0<br>£118,233<br>£654<br>£23,630<br>£24,284<br>£3,933,884<br>£0<br>£0<br>£2,630<br>£2,630<br>£2,640<br>£2,630<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,64 | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 £10,973 £35,651 -£27,152 -£10,695 £1,876 £10,695 £1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 £17,564 £25,229 £4,456 -£68 -£3 -£0 -£136 £39,328 £1,871 -£726 £130 £0 £8 £85 £1 £1 £0 £1,877 -£726 £130 £0 £4,027 £4,027 £4,027 -£49,316 £0 £0 -£12,596   | -£23,116 -£2,860 -£5,184 -£4,311 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 -£31,060 -£26,564 -£4,222 -£19,016 -£5,464 -£1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£2,593 -£10,695 -£1,137 -£119 -£14 -£51,675 -£6,861 -£6,207 -£49,347 -£259 -£0,695                      |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Respiratory Medicine Total Respiratory Medicine Total  Respiratory Medicine Total  CAMHS CAMHS Total | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective  Daycase Elective  Elective  Daycase Elective  Daycase Elective   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 21,476 0 170 846 1,016                | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901 0 104 1,294 1,398                              | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 10 -7 -88 0 -46 -16 1 -26 -12 -33 -8 1 0 -47 -11 -55 -48 -48 -48 -48 -48 -48 -48 -48 -48  | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £418,222 £129,103 £31,126 £255,224 £11,551 £124,966 £321,970 £11,356 £15,927 £33,753 £13,351 £17,099 £31,254 £460 £17,319 £11,050 £151,568 £95,709 £22,610 £10,695 £7,307 £25,819 £2,040 £1,385 £14 £168,539 £0 £26,465 £3,492,547 £259 £0 £11,358 £11,617  | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£777<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,269<br>£19,183<br>£1,505<br>£105<br>£105<br>£105<br>£105<br>£105<br>£105<br>£105<br>£  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,7722 -£10,695 £1,876 £120 -£14 -£50,305 £120 -£14 -£50,305 £654 -£2,834 -£2,180 -£98,663 -£259 £0 -£6,582 -£6,841  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£38,840 -£7,714 £17,564 -£25,229 -£4,456 -£68 -£0 -£0 -£136 -£139,328 -£1,871 -£726 -£130 -£0 -£130 -£0 -£12,596 -£12,596 -£12,596 -£12,596  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 -£29 -£16,5464 -£4,222 -£19,016 -£5,464 -£1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£0,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £654 -£6,861 -£6,207 -£49,347 -£259 £0 £0,014 |
|                          | Radiology  Radiology Total Respiratory Medicine  Respiratory Medicine Total  Rheumatology  Rheumatology Total Sleep Studies  Sleep Studies Total  CAMHS               | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Top Procedure  al Daycase Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective Outpatient New  | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 0 22 22 11,476 0 170 846                 | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 1 11,901 0 11,294   | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -30 -3 -9 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -1 -26 -15 -47 -1 -5 -55 -66 -66 -66 -66 -66 -66 -66 -66                                   | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £418,222 £129,103 £31,126 £255,224 £11,551 £124,966 £321,970 £11,356 £15,927 £33,753 £13,351 £17,099 £31,254 £460 £17,319 £11,050 £151,568 £95,709 £22,959 £2,610 £10,695 £7,307 £25,819 £2,040 £1,385 £0,040 £1,385 £14 £168,539 £0 £26,465 £26,465 £3,492,547 £2599   | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,03<br>£1,505<br>£0<br>£118,233<br>£654<br>£23,630<br>£24,284<br>£3,933,884<br>£0<br>£0<br>£2,630<br>£2,630<br>£2,640<br>£2,630<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,640<br>£2,64 | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 £10,973 £35,651 -£27,152 -£10,695 £1,876 £10,695 £1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 £17,564 £25,229 £4,456 -£68 -£3 -£0 -£136 £39,328 £1,871 -£726 £130 £0 £8 £85 £1 £1 £0 £1,877 -£726 £130 £0 £4,027 £4,027 £4,027 -£49,316 £0 £0 -£12,596   | -£23,116 -£2,860 -£5,184 -£4,311 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 -£31,060 -£26,564 -£4,222 -£19,016 -£5,464 -£1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£2,593 -£10,695 -£1,137 -£119 -£14 -£51,675 -£6,861 -£6,207 -£49,347 -£259 -£0,695                      |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Respiratory Medicine Total Respiratory Medicine Total  Respiratory Medicine Total  CAMHS CAMHS Total | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective  Elective  Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective   | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 22 11,476 0 170 846 1,016 322         | 16 258 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901 0 104 1,294 1,398 236                        | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -9 -10 -113 -51 -46 -16 -1 -26 -12 -33 -8 -1 -0 -6 -5 -5 -5 -5 -5 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 -8 | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £129,103 £31,126 £25,224 £11,551 £124,966 £321,970 £11,356 £15,927 £33,753 £13,351 £17,099 £31,254 £460 £17,319 £11,050 £151,568 £95,709 £22,959 £2,610 £10,695 £7,307 £25,819 £20,440 £1,385 £14 £168,539 £0 £26,465 £3,492,547 £259 £0 £11,358  | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£777<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0,861<br>£9,183<br>£30,861<br>£9,93<br>£1,505<br>£0<br>£14,234<br>£23,630<br>£1,505<br>£0<br>£14,776<br>£28,826  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,834 -£2,834 -£2,834 -£2,834 -£2,8681 -£259 £0 -£6,582 £0 -£6,582 -£6,841 £2,747   | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£36,716 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£3 -£0 -£0 -£136,716 -£39,328 -£1,871 -£726 -£130 -£130 -£130 -£12,596 -£12,596 -£0 -£0 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596  | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£43,204 £34,726 -£18,071 -£14,991 -£14,991 -£23,1,060 -£26,564 -£4,222 -£19,016 -£5,464 -£1,909 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£10,695 -£1,868 -£4,957 -£1,137 -£119 -£14 -£51,675 -£6,861 -£6,207 -£49,347 -£259 -£0 -£6,014 -£5,755 -£6,964               |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Respiratory Medicine Total Respiratory Medicine Total  Respiratory Medicine Total  CAMHS CAMHS Total | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective Outpatient Follow-up Outpatient Follow-up Outpatient Follow-up Outpatient Follow-up                                | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 22 11,476 0 170 846 1,016 1,016       | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 73 306 3 8 1 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901 0 104 1,294 1,398 236 410              | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -8 -1 -0 -47 -1 -6 -5 -5 -66 -68 -68 -68 -68 -68 -68 -68                                 | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£51,568<br>£95,709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£20,465<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£11,358<br>£14<br>£168,539<br>£11,358<br>£26,465<br>£26,465<br>£3,492,547<br>£259<br>£0<br>£11,358<br>£11,617<br>£259<br>£26,080<br>£11,358<br>£11,617<br>£26,080<br>£31,91 | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,894<br>£0,861<br>£903<br>£1,505<br>£0<br>£1,894<br>£1,894<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665     | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,0695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,180 -£98,663 -£259 £0 -£6,582 -£6,841 £2,747 £256  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£68 -£39,328 -£1,871 -£726 -£136 -£39,328 -£1,871 -£726 -£130 -£8 -£85 -£1 -£0 -£1,370 -£44,027 -£44,027 -£49,316 -£0 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£5,184 -£431 -£3,450 -£27 -£18,071 -£14,991 -£11,551 -£40,947 -£31,060 -£29 -£16,564 -£1,909 -£12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 -£10,695 -£1,868 -£4,957 -£1,137 -£119 -£14 -£51,675 -£6,861 -£6,207 -£9,347 -£259 -£0,014 -£5,755 -£6,064 -£1,122                            |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Respiratory Medicine Total Respiratory Medicine Total  Respiratory Medicine Total  CAMHS CAMHS Total | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Outpatient Follow-up Ward Attender  Daycase Elective Outpatient Follow-up Outpatient New Outpatient Follow-up Outpatient Follow-up Ward Attender | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 177 2 14 9 0 439 0 22 22 11,476 0 170 846 1,016 322 632 2 | 16 258 408 408 408 5 11 0 998 126 7 1 0 1,250 1,384 29 7 7 33 306 3 8 1 467 105 2 3 0 61 205 6 10 0 392 1 1 16 17 11,901 0 104 1,294 1,398 236 410 0          | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -3 -9 -9 -10 -7 -88 0 -7 -11 -50 -46 -16 -16 -1 -26 -12 -3 -3 -8 -1 -26 -12 -3 -3 -8 -4 -4 -4 -4 -5 -5 -4 -4 -5 -5 -4 -2 -2 -2 -2 -2                   | £29,670 £58,397 £60,766 £1,112 £4,949 £27 £418,222 £129,103 £31,126 £25,224 £11,551 £124,966 £321,970 £11,356 £11,356 £17,099 £31,254 £460 £17,319 £21,959 £2,610 £10,695 £7,307 £25,819 £2,040 £1,385 £0,465 £26,465 £26,465 £3,492,547 £259 £0 £11,358 £11,617 £26,080 £31,911 £0   | £6,826<br>£55,535<br>£55,539<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,891<br>£5,333<br>£0<br>£9,183<br>£30,861<br>£903<br>£1,505<br>£1,505<br>£24,284<br>£23,630<br>£24,284<br>£23,630<br>£24,284<br>£23,630<br>£24,776<br>£28,826<br>£3,826<br>£24,776<br>£4,776<br>£28,826<br>£3,44776<br>£28,826<br>£3,44776<br>£28,826<br>£3,44776  | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,069 £2,722 -£10,695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£0 -£36,716 -£33,840 -£7,714 £17,564 -£25,229 -£4,456 -£68 -£3 -£0 -£136 -£130 -£0 -£130 -£130 -£0 -£130 -£130 -£130 -£130 -£12,596 -£1370 -£0 -£1370 -£0 -£1370 -£0 -£1370 -£0 -£1370 -£0 -£13,370 -£0 -£13,370 -£0 -£12,596 -£12,596 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£0 -£13,770 -£13,7 | -£23,116 -£2,860 -£5,184 -£4,311 -£3,450 -£5,184 -£4,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£4,222 -£19,016 £5,464 £1,909 £12,660 -£29 £10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £654 -£6,861 -£6,207 -£49,347 -£259 £0,114 £5,755 -£6,964 -£1,122   |
|                          | Radiology Total Respiratory Medicine  Respiratory Medicine Total Respiratory Medicine Total Respiratory Medicine Total  Respiratory Medicine Total  CAMHS CAMHS Total | Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective Non Elective Excess Bed Days OP Imaging  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  al Daycase Elective Non Elective Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Excess Bed Days Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure  Daycase Elective  Elective Outpatient Follow-up Outpatient Follow-up Outpatient Follow-up Outpatient Follow-up                                | 72 271 446 8 36 0 1,069 99 17 2 24 942 1,084 9 10 16 23 66 218 3 121 52 517 151 18 2 26 49 172 14 9 0 439 0 22 22 11,476 0 170 846 1,016 1,016       | 16 258 408 5 111 0 998 126 7 1 0 1,250 1,384 29 7 7 7 33 73 306 3 8 1 1 467 105 2 3 0 61 205 6 10 0 392 1 16 17 11,901 0 104 1,294 1,398 236 410              | -56 -13 -38 -3 -25 0 -71 -27 -10 -1 -24 -309 -300 -20 -3 -9 -10 -7 -88 0 -113 -51 -50 -46 -16 -1 -26 -12 -33 -8 -8 -1 -0 -47 -1 -6 -5 -5 -66 -68 -68 -68 -68 -68 -68 -68                                 | £29,670<br>£58,397<br>£60,766<br>£1,112<br>£4,949<br>£27<br>£12,9103<br>£31,126<br>£25,224<br>£11,551<br>£124,966<br>£321,970<br>£11,356<br>£15,927<br>£33,753<br>£13,351<br>£17,099<br>£31,254<br>£460<br>£17,319<br>£11,050<br>£51,568<br>£95,709<br>£22,959<br>£2,610<br>£10,695<br>£7,307<br>£25,819<br>£20,465<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£14<br>£168,539<br>£11,358<br>£14<br>£168,539<br>£11,358<br>£26,465<br>£26,465<br>£3,492,547<br>£259<br>£0<br>£11,358<br>£11,617<br>£259<br>£26,080<br>£11,358<br>£11,617<br>£26,080<br>£31,91 | £6,826<br>£55,535<br>£55,579<br>£681<br>£1,499<br>£0<br>£134,346<br>£17,167<br>£32,480<br>£129,197<br>£313,191<br>£30,206<br>£29,269<br>£39,966<br>£23,271<br>£18,940<br>£43,911<br>£431<br>£1,148<br>£77<br>£187,220<br>£68,557<br>£1,894<br>£0,861<br>£903<br>£1,505<br>£0<br>£1,894<br>£1,894<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,364<br>£2,363<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,363<br>£2,465<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665<br>£2,665     | -£22,844 -£2,862 -£5,187 -£431 -£3,450 -£27 £54,842 £5,243 -£13,959 £7,256 -£11,551 £4,231 -£8,779 £18,850 £13,342 £6,213 £9,920 £1,841 £12,658 -£29 -£16,171 -£10,973 £35,651 -£27,152 -£21,0695 £1,876 £5,042 -£1,136 £120 -£14 -£50,305 £654 -£2,834 -£2,180 -£98,663 -£259 £0 -£6,582 -£6,841 £2,747 £256  | £272 -£2 -£3 -£0 -£0 -£0 -£0 -£0 -£0 -£11,638 -£29,483 -£4,112 -£22,247 -£39,840 -£7,714 -£17,564 -£25,229 -£4,456 -£68 -£68 -£39,328 -£1,871 -£726 -£136 -£39,328 -£1,871 -£726 -£130 -£8 -£85 -£1 -£0 -£1,370 -£44,027 -£44,027 -£49,316 -£0 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596 -£12,596   | -£23,116 -£2,860 -£5,184 -£431 -£3,450 -£7,843,204 £34,726 -£18,071 -£14,991 -£11,551 £40,947 £31,060 £26,564 -£1,909 £12,660 -£29 -£16,171 -£10,837 -£3,677 -£29,022 -£20,343 £2,593 -£10,695 £1,868 £4,957 -£1,137 £119 -£14 -£51,675 £654 -£6,861 -£6,207 -£49,347 -£259 £0 £6,014 £5,755 £6,064  |

In-Month

| Community Medicine Total | 957    | 646    | -311    | £29,283       | £32,274    | £2,990   | £11,088  | -£8,098  |
|--------------------------|--------|--------|---------|---------------|------------|----------|----------|----------|
| Community Total          | 1,973  | 2,044  | 71      | £40,900       | £37,049    | -£3,851  | -£1,508  | -£2,343  |
| Grand Total              | 25 520 | 26.062 | 1 424 0 | 210 621 602 0 | 11 020 011 | £440 220 | C100 E47 | CC00 77E |

# Year to Date

| Ar    | Anaesthetics  naesthetics Total  Audiology | Outpatient New Outpatient Follow-up  Daycase Outpatient New | 16<br>512<br><b>528</b><br>17<br>2,419  | 21<br>226<br><b>247</b><br>12         | 5<br>-286<br><b>-281</b><br>-5       | £12,153<br>£62,433<br><b>£74,586</b>         | £14,884<br>£55,371<br><b>£70,255</b>        | £2,731<br>-£7,063<br>- <b>£4,332</b>              | -£599<br>£27,808<br>£27,209                             | £3,330<br>-£34,871<br><b>-£31,541</b>      |
|-------|--|---|---|---------------------------------------|--------------------------------------|--|---|---|---|--|
| A     |  | Daycase<br>Outpatient New                                   | <b>528</b><br>17                        | 247                                   | -281                                 | £74,586                                      | £70,255                                     | -£4,332   | £27,209   |  |
| A     |  | Outpatient New  | 17                                      |                                       |                                      |  |   |   |   | -231,341                                   |
| A     | , tad.o.ogy                                | Outpatient New  |   |                                       |                                      | £14,650                                      | £9,525                                      | -£5,125   | -£1,023   | -£4,102                                    |
|       |  |   | 2,419                                   | 3,260                                 | 841                                  | £229,399                                     | £309,367                                    | £79,968   | £221  | £79,747                                    |
|       |  | Outpatient Follow-up  | 1,783                                   | 1,554                                 | -229                                 | £168,538                                     | £147,015                                    | -£21,523  | £138  | -£21,661                                   |
|       | T - ( - )                                  | OP Procedure  | 6                                       | 7                                     | 1                                    | £607   | £673  | £66   | -£25  | £91  |
|       | udiology Total<br>Burns Care               | Daycase   | <b>4,225</b> 24                         | <b>4,833</b>                          | <b>608</b><br>-11                    | <b>£413,194</b> £26,785                      | £466,580<br>£13,729                         | £53,386<br>-£13,056                               | <b>-£689</b><br>-£565                                   | £54,075<br>-£12,491                        |
|       | Dunio Carc                                 | Elective  | 8                                       | 5                                     | -3                                   | £27,738                                      | £8,262                                      | -£19,476  | -£8,337   | -£11,139                                   |
|       |  | Non Elective  | 127                                     | 96                                    | -31                                  | £837,336                                     | £608,992                                    | -£228,344   | -£22,382  | -£205,962                                  |
|       |  | Outpatient New  | 71                                      | 64                                    | -7                                   | £14,146                                      | £12,694                                     | -£1,452   | £11   | -£1,463                                    |
|       |  | Outpatient Follow-up  | 332                                     | 297                                   | -35                                  | £65,774                                      | £58,709                                     | -£7,065   | -£148   | -£6,918                                    |
|       |  | Ward Attender Ward Based Outpatient                         | 150<br>17                               | 168<br>67                             | 18<br>50                             | £29,807<br>£3,293                            | £33,321<br>£13,289                          | £3,514<br>£9,996                                  | £29<br>£11  | £3,485<br>£9,984                           |
|       |  | OP Procedure  | 0                                       | 31                                    | 31                                   | £25  | £3,809                                      | £3,784  | -£59  | £3,843                                     |
| Br    | urns Care Total                            |   | 731                                     | 741                                   | 10                                   | £1,004,905                                   | £752,804                                    | -£252,101   | -£31,440  | -£220,661                                  |
|       | Cardiac Surgery                            | Elective  | 126                                     | 145                                   | 19                                   | £2,029,747                                   | £2,257,345                                  | £227,598  | -£72,608  | £300,206                                   |
|       |  | Non Elective  | 58                                      | 60                                    | 2                                    |  | £1,560,572                                  | -£28,141  | -£80,363  | £52,222                                    |
|       |  | Excess Bed Days Outpatient New                              | 377<br>43                               | 127<br>61                             | -250<br>18                           | £191,083<br>£31,266                          | £94,163<br>£43,963                          | -£96,920<br>£12,698                               | £29,736<br>£40  | -£126,656<br>£12,658                       |
|       |  | Outpatient Follow-up  | 219                                     | 264                                   | 45                                   | £157,671                                     | £190,267                                    | £32,597   | £172  | £32,425                                    |
|       |  | Ward Attender   | 0                                       | 21                                    | 21                                   | £0   | £15,135                                     | £15,135   | £0  | £15,135                                    |
|       | ardiac Surgery Total                       | _   | 823                                     | 678                                   | -145                                 | £3,998,479                                   | £4,161,446                                  |   | -£123,023   | £285,990                                   |
|       | Cardiology                                 | Daycase   | 101                                     | 93                                    | -8                                   | £270,870                                     | £254,276                                    | -£16,594  | £5,003  | -£21,597                                   |
|       |  | Elective<br>Non Elective                                    | 104<br>54                               | 87<br>75                              | -17<br>21                            | £335,679<br>£215,876                         | £323,221<br>£456,988                        | -£12,458<br>£241,112                              | £42,151<br>£159,519                                     | -£54,610<br>£81,593                        |
|       |  | Excess Bed Days   | 99                                      | 42                                    | -57                                  | £215,876<br>£46,280                          | £456,988<br>£19,426                         | £241,112<br>-£26,854                              | £159,519<br>-£175                                       | £81,593<br>-£26,679                        |
| •     |  | Outpatient New  | 888                                     | 786                                   | -102                                 | £180,278                                     | £159,380                                    | -£20,898  | -£179   | -£20,719                                   |
|       |  | Outpatient Follow-up  | 2,554                                   | 2,901                                 | 347                                  | £319,702                                     | £361,997                                    | £42,295   | -£1,192   | £43,487                                    |
|       |  | Ward Attender   | 244                                     | 167                                   | -77                                  | £31,487                                      | £20,840                                     | -£10,647  | -£695   | -£9,953                                    |
|       |  | Ward Based Outpatient                                       | 42                                      | 36                                    | -6                                   | £5,210                                       | £4,492                                      | -£717   | -£0   | -£717                                      |
|       |  | OP Procedure OP Imaging                                     | 3,050                                   | 3,389                                 | 339                                  | £0<br>£272,047                               | £185<br>£287,767                            | £185<br>£15,720                                   | £0<br>-£14,517  | £185<br>£30,237                            |
| C     | ardiology Total                            | Or imaging  | 7,136                                   | 7,577                                 | 441                                  | £1,677,429                                   | £1,888,572                                  | £211,143  | £189,915  | £21,228                                    |
|       | Dentistry                                  | Daycase   | 605                                     | 517                                   | -88                                  | £365,697                                     | £324,051                                    | -£41,646  | £11,493   | -£53,138                                   |
|       |  | Elective  | 14                                      | 6                                     | -8                                   | £15,246                                      | £5,954                                      | -£9,293   | -£415   | -£8,878                                    |
|       |  | Non Elective  | 6                                       | 5                                     | -1                                   | £4,912                                       | £12,034                                     | £7,121  | £7,687  | -£565                                      |
|       |  | Outpatient New Outpatient Follow-up                         | 609<br>564                              | 522<br>514                            | -87<br>-50                           | £21,690<br>£20,103                           | £18,586<br>£18,301                          | -£3,104<br>-£1,802                                | -£8<br>-£13   | -£3,097<br>-£1,789                         |
|       |  | OP Procedure  | 152                                     | 164                                   | 12                                   | £20,103                                      | £20,981                                     | £728  | -£845   | £1,703                                     |
| De    | entistry Total                             |   | 1,950                                   | 1,728                                 | -222                                 | £447,901                                     | £399,907                                    | -£47,994  | £17,899   | -£65,893                                   |
|       | ENT  | Daycase   | 616                                     | 535                                   | -81                                  | £638,450                                     | £573,218                                    | -£65,231  | £18,640   | -£83,871                                   |
|       |  | Elective  | 462                                     | 352                                   | -110                                 | £619,581                                     | £478,449                                    | -£141,132   | £5,893  | -£147,025                                  |
|       |  | Non Elective<br>Excess Bed Days                             | 116<br>139                              | 128<br>136                            | 12<br>-3                             | £162,027<br>£56,652                          | £217,491<br>£56,729                         | £55,464<br>£78                                    | £39,300<br>£1,200                                       | £16,164<br>-£1,123                         |
| •     |  | Outpatient New  | 1,996                                   | 1,540                                 | -456                                 | £30,032                                      | £192,257                                    | -£52,097  | £3,703  | -£1,123                                    |
|       |  | Outpatient Follow-up  | 1,859                                   | 1,873                                 | 14                                   | £116,875                                     | £118,957                                    | £2,082  | £1,200  | £882                                       |
| _     |  | OP Procedure  | 1,276                                   | 1,430                                 | 154                                  | £157,119                                     | £177,608                                    | £20,489   | £1,503  | £18,985                                    |
|       | NT Total                                   | Davis   | 6,463                                   | 5,994                                 | -469                                 | £1,995,058                                   | £1,814,710                                  | -£180,348   | £71,439   | -£251,787                                  |
|       | Gynaecology                                | Daycase<br>Elective   | 9                                       | 16<br>5                               | 7<br>-1                              | £5,599<br>£6,712                             | £9,232<br>£7,240                            | £3,633<br>£528                                    | -£266<br>£1,914   | £3,899<br>-£1,386                          |
| •     |  | Outpatient New  | 177                                     | 143                                   | -34                                  | £29,258                                      | £23,643                                     | -£5,615   | -£0   | -£5,615                                    |
|       |  | Outpatient Follow-up  | 245                                     | 206                                   | -39                                  | £17,347                                      | £14,566                                     | -£2,781   | £0  | -£2,781                                    |
|       | ynaecology Total                           |   | 438                                     | 370                                   | -68                                  | £58,917                                      | £54,681                                     | -£4,235   | £1,647  | -£5,882                                    |
|       | Intensive Care                             | Elective  | 0                                       | 5                                     | 5                                    | £0   | £17,979                                     | £17,979   | £0  | £17,979                                    |
|       |  | Non Elective<br>Excess Bed Days                             | 84<br>101                               | 65<br>242                             | -19<br>141                           | £459,539<br>£62,643                          | £431,368<br>£102,470                        | -£28,171<br>£39,827                               | £73,765<br>-£48,090                                     | -£101,936<br>£87,917                       |
|       |  | PICU PICU   | 2,769                                   | 2,808                                 | 39                                   | £4,887,151                                   | £4,948,740                                  | £61,589   | £0  | £61,589                                    |
|       |  | HDU   | 1,910                                   | 2,050                                 | 140                                  |  | £2,404,519                                  | £129,866  | £0  | £129,866                                   |
|       |  | Cardiac HDU   | 1,233                                   | 1,220                                 | -13                                  | £1,191,938                                   | £1,206,591                                  | £14,654   | £0  | £14,654                                    |
|       |  | Cardiac ECMO  | 63                                      | 74                                    | 12                                   | £225,518                                     | £302,472                                    | £76,954   | £0  | £76,954                                    |
| ln ln | tensive Care Total                         | Respiratory ECMO  | 38<br><b>6,197</b>                      | 47<br><b>6,511</b>                    | 10<br><b>314</b>                     | £248,949<br><b>£9,350,391</b>                | £286,661<br>£9,700,801                      | £37,712   | £0<br><b>£25,675</b>                                    | £37,712<br>£324,735                        |
|       | Maxillo-Facial                             | Outpatient New  | 275                                     | 302                                   | 27                                   | £42,111                                      | £49,005                                     | £350,410<br>£6,894                                | £2,708  | £4,186                                     |
| •     | iviaxino i uolai                           | Outpatient Follow-up  | 296                                     | 432                                   | 136                                  | £53,338                                      | £83,709                                     | £30,371   | £5,772  | £24,599                                    |
|       |  | Ward Attender   | 0                                       | 2                                     | 2                                    | £30  | £291  | £262  | -£0   | £262                                       |
|       |  | OP Procedure  | 5                                       | 1                                     | -4                                   |  | £105  | -£505   | -£10  | -£494                                      |
|       | axillo-Facial Total                        | Daycass   | 576                                     | 737                                   | 161                                  | £96,088                                      | £133,110                                    | £37,022   | £8,469  | £28,553                                    |
|       | Neurosurgery                               | Daycase<br>Elective   | 5<br>114                                | 14<br>124                             | 9                                    | £9,152<br>£1,043,444                         | £31,310<br>£1,058,921                       | £22,158<br>£15,478                                | £6,538<br>-£78,881                                      | £15,620<br>£94,359                         |
|       |  | Non Elective  | 126                                     | 140                                   | 14                                   | £1,043,444<br>£1,050,457                     | £849,675                                    | -£200,782   | -£70,001  | £119,442                                   |
|       |  | Excess Bed Days   | 127                                     | 92                                    | -35                                  | £74,889                                      | £36,736                                     | -£38,153  | -£17,479  | -£20,674                                   |
|       |  | Outpatient New  | 323                                     | 347                                   | 24                                   | £28,767                                      | £30,907                                     | £2,140  | £24   | £2,116                                     |
|       |  | Outpatient Follow-up  | 837                                     | 931                                   | 94                                   | £74,471                                      | £82,924                                     | £8,454  | £65   | £8,388                                     |
|       |  | Ward Attender   | 242                                     | 141                                   | -101                                 | £21,527                                      | £12,559                                     | -£8,968   | £10   | -£8,978                                    |
|       |  |   |   | ()                                    | -8                                   | £741   | £0  | -£741   | £0  | -£741                                      |
|       |  | Ward Based Outpatient                                       |   |                                       |                                      | £976 779                                     | £960 750                                    | -£16 029  | €U  | -£16 029                                   |
| Ne    | eurosurgery Total                          | Ward Based Outpatient Neuro HDU                             | 1,085<br><b>2,867</b>                   | 979<br><b>2,768</b>                   | -106<br><b>-99</b>                   | £976,778<br><b>£3,280,225</b>                | £960,750<br>£3,063,783                      | -£16,028<br>- <b>£216,442</b>                     | £0<br>- <b>£409,947</b>                                 | -£16,028<br>£193,505                       |
|       | eurosurgery Total Ophthalmology            |   | 1,085                                   | 979                                   | -106                                 |  |   |   |   |  |
|       |  | Neuro HDU  Daycase Elective                                 | 1,085<br><b>2,867</b><br>170<br>22      | 979<br><b>2,768</b><br>166<br>16      | -106<br><b>-99</b><br>-4<br>-6       | £3,280,225<br>£207,947<br>£46,742            | £3,063,783<br>£217,425<br>£41,800           | <b>-£216,442</b><br>£9,478<br><b>-£4,942</b>      | <b>-£409,947</b><br>£14,424<br>£7,459                   | £193,505<br>-£4,947<br>-£12,401            |
|       |  | Neuro HDU  Daycase Elective Non Elective                    | 1,085<br><b>2,867</b><br>170<br>22<br>8 | 979<br><b>2,768</b><br>166<br>16<br>5 | -106<br><b>-99</b><br>-4<br>-6<br>-3 | £3,280,225<br>£207,947<br>£46,742<br>£16,286 | £3,063,783<br>£217,425<br>£41,800<br>£5,523 | <b>-£216,442</b><br>£9,478<br>-£4,942<br>-£10,763 | <b>-£409,947</b><br>£14,424<br>£7,459<br><b>-£4,453</b> | £193,505<br>-£4,947<br>-£12,401<br>-£6,310 |
|       |  | Neuro HDU  Daycase Elective                                 | 1,085<br><b>2,867</b><br>170<br>22      | 979<br><b>2,768</b><br>166<br>16      | -106<br><b>-99</b><br>-4<br>-6       | £3,280,225<br>£207,947<br>£46,742            | £3,063,783<br>£217,425<br>£41,800           | <b>-£216,442</b><br>£9,478<br><b>-£4,942</b>      | <b>-£409,947</b><br>£14,424<br>£7,459                   | £193,505<br>-£4,947<br>-£12,401            |

| Year | to | Date |
|------|----|------|
|------|----|------|

| ırgery                                  | Ophthalmology                         | OP Procedure                       | 98              | 333             | 235          | £28,243                   | £57,999                   | £29,756             | -£38,321             | £68,0            |
|---|---------------------------------------|------------------------------------|-----------------|-----------------|--------------|---------------------------|---------------------------|---------------------|----------------------|------------------|
|   | Ophthalmology Total                   |                                    | 7,235           | 8,155           | 920          | £983,488                  | £937,752                  |                     |                      | £95,0            |
|   | Oral Surgery                          | Daycase                            | 126             | 132             | 6            | £109,208                  | £95,574                   |                     | -£18,884             | £5,2             |
|   |                                       | Elective<br>Non Elective           | 74<br>48        | 62<br>36        | -12<br>-12   | £267,400<br>£51,221       | £202,738<br>£42,978       | -£64,662<br>-£8,243 | -£20,134             | -£44,5<br>-£13,0 |
|   | Oral Surgery Total                    | Non Elective                       | 249             | 230             | -12<br>-19   | £427,829                  | £341,290                  |                     | £4,800<br>-£34,218   | -£13,0           |
|   | Orthodontics                          | Elective                           | 0               | 1               | 1            | £0                        | £1,314                    |                     | £0                   | £1,3             |
|   | Grandadinada                          | Outpatient New                     | 28              | 36              | 8            | £4,542                    | £5,840                    | £1,298              | -£0                  | £1,2             |
|   |                                       | Outpatient Follow-up               | 143             | 313             | 170          | £10,288                   | £22,557                   | £12,269             | £18                  | £12,2            |
|   |                                       | OP Procedure                       | 106             | 71              | -35          | £11,906                   | £7,800                    | -£4,106             | -£149                | -£3,9            |
|   | Orthodontics Total                    | _                                  | 277             | 421             | 144          | £26,736                   | £37,511                   | £10,775             | -£132                | £10,9            |
|   | Paediatric Surgery                    | Daycase                            | 690             | 696             | 6            | £750,187                  | £750,215                  | £28                 | -£6,036              | £6,0             |
|   |                                       | Elective                           | 202             | 240             | 38           | £686,009                  | £930,826                  | £244,817            | £116,638             | £128,1           |
|   |                                       | Non Elective                       | 624             | 684             | 60           | £1,740,028                | £2,504,501                | £764,474            | £598,458             | £166,0           |
|   |                                       | Excess Bed Days                    | 628             | 663             | 35           | £287,156                  | £311,954                  | £24,798             | £8,612               | £16,1            |
|   |                                       | Outpatient New                     | 908             | 818             | -90          | £154,923                  | £139,503                  | -£15,421            | -£7                  | -£15,4           |
|   |                                       | Outpatient Follow-up               | 1,425           | 1,202           | -223         | £164,132                  | £138,739                  | -£25,393            | £304                 | -£25,6           |
|   |                                       | Ward Attender                      | 398<br>52       | 334<br>22       | -64<br>-30   | £45,545                   | £38,206                   |                     | -£24<br>-£0          | -£7,3<br>-£3,4   |
|   |                                       | Ward Based Outpatient OP Procedure | 0               | 3               | 3            | £5,982<br>-£0             | £2,517<br>£686            | -£3,466<br>£686     | £689                 | -£3,²            |
|   |                                       | Neonatal HDU                       | 55              | 262             | 207          | £664,602                  | £792,498                  | £127,896            | £003                 | £127,8           |
|   | Paediatric Surgery Total              | Neonatarribo                       | 4,983           | 4,924           | -59          | £4,498,564                |                           | £1,111,081          | £718,633             | £392,4           |
|   | Plastic Surgery                       | Daycase                            | 407             | 486             | 79           | £449,635                  | £611,146                  | £161,511            | £73,810              | £87,7            |
|   | · · · · · · · · · · · · · · · · · · · | Elective                           | 54              | 41              | -13          | £78,658                   | £106,739                  | £28,080             | £47,028              | -£18,            |
|   |                                       | Non Elective                       | 428             | 538             | 110          | £698,480                  | £984,401                  | £285,920            | £105,434             | £180,            |
|   |                                       | Excess Bed Days                    | 53              | 35              | -18          | £31,719                   | £17,014                   | -£14,706            | -£4,133              | -£10,            |
|   |                                       | Outpatient New                     | 1,194           | 1,525           | 331          | £162,595                  | £204,773                  | £42,178             | -£2,947              | £45,             |
|   |                                       | Outpatient Follow-up               | 2,041           | 2,191           | 150          | £216,463                  | £232,391                  | £15,927             | -£9                  | £15,             |
|   |                                       | Ward Attender                      | 48              | 105             | 57           | £5,124                    | £11,137                   | £6,013              | -£0                  | £6,              |
|   |                                       | Ward Based Outpatient              | 10              | 42              | 32           | £1,052                    | £4,243                    |                     | -£212                | £3,              |
|   |                                       | OP Procedure                       | 594             | 1,123           | 529          | £73,984                   | £142,835                  |                     | £2,920               | £65,             |
|   | Plastic Surgery Total                 |                                    | 4,827           | 6,086           | 1,259        | £1,717,712                |                           |                     | £221,891             | £375,            |
|   | Spinal Surgery                        | Daycase                            | 3               | 34              | 31           | £3,266                    | £257,212                  | ,                   | £224,689             | £29,             |
|   |                                       | Elective<br>Non Elective           | 63              | 60              | -3<br>3      | £1,849,801<br>£0          | £1,399,059                |                     | -£359,624<br>£0      | -£91,            |
|   |                                       | Non Elective<br>Excess Bed Days    | 0               | 10              | 10           | £0                        | £52,120<br>£5,014         | £52,120<br>£5,014   | £0                   | £52,<br>£5,      |
|   |                                       | Outpatient New                     | 192             | 255             | 63           | £39,453                   | £52,503                   | £13,049             | -£2                  | £13,             |
|   |                                       | Outpatient Follow-up               | 416             | 436             | 20           | £31,630                   | £33,293                   |                     | £131                 | £13,             |
|   |                                       | Ward Attender                      | 0               | 5               | 5            | £0                        | £380                      | £380                | £0                   | £                |
| Spinal Surgery Total Trauma And Orthopa | Spinal Surgery Total                  |                                    | 674             | 803             | 129          | £1,924,151                | £1,799,581                | -£124,570           | -£134,806            | £10              |
|   | Trauma And Orthopaedic                | s Daycase                          | 210             | 196             | -14          | £403,664                  | £376,182                  |                     | £68                  | -£27             |
|   | · ·                                   | Elective                           | 299             | 318             | 19           | £1,257,331                | £1,248,157                | -£9,174             | -£90,604             | £81              |
|   |                                       | Non Elective                       | 339             | 335             | -4           | £926,258                  | £1,038,149                | £111,891            | £122,004             | -£10             |
|   |                                       | Excess Bed Days                    | 155             | 183             | 28           | £72,115                   | £80,977                   | £8,863              | -£4,394              | £13              |
|   |                                       | Outpatient New                     | 3,513           | 3,840           | 327          | £559,895                  | £603,450                  | £43,555             | -£8,563              | £52              |
|   |                                       | Outpatient Follow-up               | 7,489           | 6,641           | -848         | £700,925                  | £609,100                  | -£91,826            | -£12,498             | -£79             |
|   |                                       | Gait New                           | 148             | 147             | -1           | £172,921                  | £172,302                  |                     | £1                   | -£               |
|   |                                       | Gait Follow-Up                     | 128             | 113             | -15          | £149,614                  | £132,450                  | -£17,164            | £1                   | -£17             |
|   |                                       | Ward Attender                      | 9               | 3<br>1          | -6<br>1      | £799<br>£0                | £179<br>£0                | -£620<br>£0         | £89<br>£0            | -£               |
|   |                                       | Ward Based Outpatient OP Procedure | 1,069           | 1,622           | 553          | £131,998                  | £202,979                  | £70,981             | £2,678               | £68              |
|   | Trauma And Orthopaedic                |                                    | 13,357          | 13,399          | 42           | £4,375,519                | £4,463,924                |                     | £8,604               | £79              |
|   | Urology                               | Daycase                            | 953             | 1,088           | 135          | £859,351                  | £1,030,624                |                     | £49,890              | £121             |
|   |                                       | Elective                           | 61              | 63              | 2            | £191,098                  | £294,471                  | £103,373            | £96,783              | £6               |
|   |                                       | Non Elective                       | 16              | 30              | 14           | £38,637                   | £72,130                   |                     | -£1,704              | £35              |
|   |                                       | Excess Bed Days                    | 63              | 107             | 44           | £33,741                   | £48,895                   | £15,154             | -£8,487              | £23              |
|   |                                       | Outpatient New                     | 483             | 449             | -34          | £71,338                   | £66,300                   | -£5,038             | -£4                  | -£5              |
|   |                                       | Outpatient Follow-up               | 980             | 927             | -53          | £95,791                   | £90,612                   |                     | -£3                  | -£5              |
|   |                                       | Ward Attender                      | 19              | 90              | 71           | £1,845                    | £8,798                    |                     | £0                   | £6               |
|   |                                       | Ward Based Outpatient              | 34              | 20              | -14          | £3,353                    | £1,955                    |                     | £0                   | -£1              |
|   |                                       | OP Procedure                       | 82              | 205             | 123          | £18,801                   | £46,898                   |                     | -£215                | £28              |
| ry Total                                | Urology Total                         |                                    | 2,691<br>66,228 | 2,979<br>69,181 | 288<br>2,953 | £1,313,956<br>£37,665,129 | £1,660,682<br>£39,671,710 |                     | £136,261<br>£552,620 | £210             |
| licine                                  | Accident & Emergency                  | Daycase                            | 1               | 03,101          | -1           | £917                      | £0                        |                     | £0                   | -£1,433          |
|   | Accident a Emergency                  | Elective                           | 1               | 1               | 0            | £551                      | £947                      |                     | £269                 | £                |
|   |                                       | Non Elective                       | 1,502           | 1,418           | -84          | £1,042,114                | £1,024,879                |                     | £40,887              | -£58             |
|   |                                       | Excess Bed Days                    | 15              | 0               | -15          | £5,803                    | £0                        |                     | £0                   | -£5              |
|   |                                       | Outpatient New                     | 1,029           | 778             | -251         | £347,578                  | £262,947                  | -£84,632            | £239                 | -£84             |
|   |                                       | Outpatient Follow-up               | 108             | 46              | -62          | £36,449                   | £15,547                   | -£20,902            | £14                  | -£20             |
|   |                                       | Ward Based Outpatient              | 3               | 0               | -3           | £985                      | £0                        | -£985               | £0                   | -£               |
|   |                                       | A&E Attendance                     | 23,197          |                 | 448          | £2,479,903                |                           |                     | -£170,922            | £47              |
|   | Accident & Emergency To               |                                    | 25,856          |                 | 32           | £3,914,299                | £3,661,160                |                     | -£129,513            |                  |
|   | Allergy                               | Daycase                            | 170             | 86              | -84          | £93,444                   | £36,643                   |                     | -£10,629             | -£46             |
|   |                                       | Elective                           | 0               | 2               | 2            | £0                        | £767                      |                     | 0£0                  | £                |
|   |                                       | Outpatient New                     | 365             | 381             | 16           | £78,666                   | £81,992                   |                     | -£22                 | £3               |
|   |                                       | Outpatient Follow-up Ward Attender | 488             | 483<br>1        | -5<br>1      | £66,537<br>£0             | £66,332<br>£136           |                     | £532<br>£0           | -£               |
|   |                                       | Ward Based Outpatient              | 1               | 2               | 1            | £198                      | £136                      |                     | £0                   | I                |
|   |                                       | OP Procedure                       | 2               | 5               | 3            | £228                      | £733                      |                     | £109                 | £                |
|   | Allergy Total                         | _ CT T TOOCUUTO                    | 1,027           | 960             | -67          | £239,074                  | £186,876                  | -£52,198            | -£10,009             | -£42             |
|   | Dermatology                           | Daycase                            | 9               | 46              | 37           | £7,487                    | £33,124                   |                     | -£3,662              | £29              |
|   |                                       | Outpatient New                     | 801             | 713             | -88          | £110,735                  | £98,609                   |                     | -£6                  | -£12             |
|   |                                       | Outpatient Follow-up               | 1,773           | 1,451           | -322         | £158,726                  | £129,937                  |                     | £29                  | -£28             |
|   |                                       | Ward Attender                      | 0               | 0               | 0            | £18                       | £0                        |                     | £0                   | ~                |
|   |                                       | Ward Based Outpatient              | 22              | 38              | 16           | £1,977                    | £3,398                    |                     | £0                   | £1               |
|   |                                       |                                    |                 |                 |              |                           |                           |                     |                      | £41.             |
|   |                                       | OP Procedure                       | 1,427           | 1,786           | 359          | £166,530                  | £196,723                  | £30,193             | -£11,721             | ۸,               |
|   | Dermatology Total                     | OP Procedure                       | 4,032           | 4,034           | 2            | £445,473                  | £461,792                  | £16,319             | -£11,721             | £31,<br>-£28,    |
|   | Dermatology Total Diabetes            |                                    | ,               |                 |              |                           |                           | £16,319             |                      |                  |

# Year to Date Medicine

| Diabetes                                      | Ward Attender   | 0   | 6  | 6  | £0  | £1,061   | £1,061   | £0  | £1,061  |
|---|---|---|--|--|---|--|--|---|---|
|   | Ward Based Outpatient   | 0   | 0  | 0  | £34   | £0   | -£34   | £0  | -£34  |
| Diabetes Total                                | Davisass  | 162   | 24   | -138   | £32,371   | £4,392   | -£27,978   | -£0   | -£27,978  |
| Endocrinology                                 | Daycase<br>Elective   | 457<br>37   | 516<br>23  | 59<br>-14  | £351,475<br>£43,936   | £392,293<br>£21,685  | £40,817<br>-£22,251  | -£4,568<br>-£5,651  | £45,386   |
|   | Non Elective  | 8   | 7  | -1   | £28,780   | £26,848  | -£1,932  | £2,750  | -£4,682   |
|   | Excess Bed Days   | 135   | 211  | 76   | £59,151   | £93,128  | £33,977  | £391  | £33,586   |
|   | Outpatient New  | 323   | 279  | -44  | £98,296   | £85,006  | -£13,291   | -£3   | -£13,288  |
|   | Outpatient Follow-up  | 1,428   | 1,655  | 227  | £218,024  | £250,776   | £32,753  | -£1,892   | £34,645   |
|   | Ward Attender Ward Based Outpatient   | 93<br>523   | 43<br>392  | -50<br>-131  | £14,044<br>£78,901  | £6,484<br>£59,108  | -£7,560<br>-£19,793  | -£0<br>-£2  | -£7,560<br>-£19,792   |
| Endocrinology Total                           | Ward based Odipatient   | 3,004   | 3,126  | 122  | £892,608  | £935,328   | £42,720  | -£8,975   | £51,695   |
| Epilepsy                                      | Outpatient New  | 56  | 61   | 5  | £14,261   | £15,477  | £1,216   | -£1   | £1,217  |
|   | Outpatient Follow-up  | 130   | 49   | -81  | £25,913   | £9,732   | -£16,181   | -£0   | -£16,181  |
| Epilepsy Total                                | _   | 187   | 110  | -77  | £40,174   | £25,209  | -£14,965   | -£1   | -£14,963  |
| Gastroenterology                              | Daycase<br>Elective   | 711<br>203  | 741<br>92  | -111   | £508,245  | £567,216   | £58,971  | £37,187   | £21,784<br>-£152,318  |
|   | Non Elective  | 46  | 43   | -111   | £278,818<br>£139,139  | £123,487<br>£156,160   | -£155,331<br>£17,022   | -£3,013<br>£26,748  | -£152,316   |
|   | Excess Bed Days   | 520   | 143  | -377   | £242,634  | £66,621  | -£176,013  | -£50  | -£175,963   |
|   | Outpatient New  | 506   | 465  | -41  | £117,697  | £108,288   | -£9,409  | £143  | -£9,552   |
|   | Outpatient Follow-up  | 1,582   | 1,180  | -402   | £230,362  | £171,785   | -£58,577   | -£11  | -£58,566  |
|   | Ward Attender   | 125   | 23   | -102   | £18,233   | £3,348   | -£14,885   | -£0   | -£14,885  |
| Gastroenterology Total                        | Ward Based Outpatient   | 435<br><b>4,129</b>   | 483<br><b>3,170</b>  | 48<br><b>-959</b>  | £63,349<br>£1,598,477   | £70,318<br>£1,267,224  | £6,969<br>-£331,253  | -£2<br>£61,003  | £6,971<br><b>-£392,255</b>  |
| Haematology                                   | Daycase   | 118   | 235  | 117  | £92,636   | £175,628   | £82,991  | -£9,414   | £92,405   |
| r idomatorogy                                 | Elective  | 15  | 32   | 17   | £67,530   | £145,743   | £78,213  | -£521   | £78,734   |
|   | Non Elective  | 56  | 81   | 25   | £70,003   | £179,785   | £109,782   | £77,756   | £32,026   |
|   | Excess Bed Days   | 15  | 5  | -10  | £4,396  | £2,116   | -£2,280  | £609  | -£2,889   |
|   | Outpatient New  | 108   | 128  | 20   | £48,696   | £57,633  | £8,938   | -£2   | £8,940  |
|   | Outpatient Follow-up Ward Attender  | 297<br>845  | 310<br>970   | 13<br>125  | £62,741<br>£178,443   | £65,439<br>£204,767  | £2,698<br>£26,324  | -£2<br>-£0  | £2,700<br>£26,324   |
|   | Ward Based Outpatient   | 1   | 1  | 0  | £176,443  | £204,707   | £20,324<br>-£89  | -£0   | £20,324   |
|   | OP Procedure  | 1   | 0  | -1   | £127  | £0   | -£127  | £0  | -£127   |
| Haematology Total                             |   | 1,456   | 1,762  | 306  | £524,871  | £831,321   | £306,450   | £68,425   | £238,025  |
| Immunology                                    | Daycase   | 18  | 17   | -1   | £9,619  | £9,441   | -£178  | £97   | -£275   |
|   | Non Elective  | 0   | 1  | 1  | £0  | £1,416   | £1,416   | £0  | £1,416  |
|   | Outpatient New Outpatient Follow-up   | 63<br>48  | 111<br>197   | 48<br>149  | £13,627<br>£6,527   | £24,083<br>£27,335   | £10,456<br>£20,809   | £189<br>£498  | £10,267<br>£20,311  |
|   | Ward Attender   | 24  | 46   | 22   | £3,275  | £6,267   | £2,991   | £0  | £2,991  |
|   | Ward Based Outpatient   | 77  | 250  | 173  | £10,465   | £34,058  | £23,593  | £0  | £23,593   |
| Immunology Total                              |   | 230   | 622  | 392  | £43,512   | £102,600   | £59,088  | £785  | £58,304   |
| LTV   | Outpatient New  | 48  | 42   | -6   | £33,679   | £30,994  | -£2,684  | £1,215  | -£3,900   |
| LTV Total                                     | Outpatient Follow-up  | 208<br><b>256</b>   | 305<br><b>347</b>  | 97<br><b>91</b>  | £145,596<br><b>£179,275</b>   | £226,554<br>£257,548   | £79,482<br><b>£76,798</b>  | £11,926<br>£13,141  | £67,556<br><b>£63,657</b>   |
|   | Outpatient New  | 25  | 18   | -7   | £9,506  | £6,919   | -£2,588  | £13,141   | -£2,594   |
| Metabolic Disease                             | Outpatient Follow-up  | 136   | 139  | 3  | £52,205   | £53,429  | £1,224   | £47   | £1,176  |
|   | Ward Attender   | 0   | 1  | 1  | £0  | £384   | £384   | £0  | £384  |
|   | Ward Based Outpatient   | 14  | 19   | 5  | £5,281  | £7,303   | £2,023   | £6  | £2,016  |
| Metabolic Disease Total                       | Davissa   | 174   | 177  | 3  | £66,992   | £68,035  | £1,043   | £60   | £983  |
| Nephrology                                    | Daycase<br>Elective   | 671<br>155  | 714<br>158   | 43   | £1,197,799<br>£164,102  | £1,163,414<br>£94,462  | -£34,385<br>-£69,639   | -£111,304<br>-£73,072   | £76,920<br>£3,432   |
|   | Non Elective  | 20  | 18   | -2   | £61,773   | £57,870  | -£3,903  | £2,533  | -£6,436   |
|   | Excess Bed Days   | 84  | 57   | -27  | £42,567   | £20,836  | -£21,731   | -£8,135   | -£13,596  |
|   | Outpatient New  | 78  | 159  | 81   | £9,222  | £18,787  | £9,566   | £17   | £9,548  |
|   | Outpatient Follow-up  | 702   | 919  | 217  | £82,856   | £108,589   | £25,733  | £101  | £25,632   |
|   | Ward Attender Ward Based Outpatient   | 333<br>262  | 56<br>285  | -277<br>23   | £39,326   | £6,262<br>£33,676  | -£33,063<br>£2,707   | -£348<br>£31  | -£32,715<br>£2,675  |
| Nephrology Total                              | waru baseu Outpatierit  | 2,305   | 2,366  | 61   | £30,969<br>£1,628,613   | £1,503,897   | £2,707   | -£190,177   | £65,460   |
| Neurology                                     | Daycase   | 129   | 73   | -56  | £142,326  | £98,196  | -£44,130   | £17,964   | -£62,095  |
| υ,  | Elective  | 30  | 55   | 25   | £55,128   | £137,541   | £82,413  | £37,137   | £45,276   |
|   | Non Elective  | 43  | 38   | -5   | £231,956  | £183,853   | -£48,103   | -£22,577  | -£25,526  |
|   | Excess Bed Days   | 405   | 257  | -148   | £245,419  | £151,818   | -£93,601   | -£3,757   | -£89,844  |
|   | Outpatient New Outpatient Follow-up   | 446<br>1,177  | 421<br>1,123   | -25<br>-54   | £123,590<br>£326,448  | £116,832<br>£311,644   | -£6,758<br>-£14,804  | £114<br>£283  | -£6,872<br>-£15,088   |
|   | Ward Attender   | 69  | 67   | -2   | £320,446  | £18,593  | -£14,804<br>-£428  | £203  | -£15,086  |
|   |   |   |  |  |   |  |  |   |   |
|   | Ward Based Outpatient   | 88  | 122  | 34   | £24,522   | £33,856  | £9,335   | £33   | £9,302  |
| Neurology Total                               |   |   | 122<br><b>2,156</b>  | 34<br><b>-232</b>  | £24,522<br>£1,168,409   | £33,856<br>£1,052,333  | £9,335<br>-£116,077  | £29,216   |   |
| Neurology Total Oncology                      | Ward Based Outpatient  Daycase  | 88<br><b>2,388</b><br>895   | <b>2,156</b> 326   | <b>-232</b><br>-569  | <b>£1,168,409</b> £851,174  | <b>£1,052,333</b> £259,448   | <b>-£116,077</b><br>-£591,725  | <b>£29,216</b> -£50,529   | <b>-£145,292</b><br>-£541,196   |
|   | Ward Based Outpatient  Daycase DCHEMO   | 88<br><b>2,388</b><br>895<br>685  | <b>2,156</b><br>326<br>852   | <b>-232</b><br>-569<br>167   | £1,168,409<br>£851,174<br>£227,735  | £1,052,333<br>£259,448<br>£283,299   | -£116,077<br>-£591,725<br>£55,563  | <b>£29,216</b><br>-£50,529<br>£0  | -£145,292<br>-£541,196<br>£55,563   |
|   | Ward Based Outpatient  Daycase DCHEMO Elective  | 88<br><b>2,388</b><br>895<br>685<br>146   | <b>2,156</b> 326 852 116   | -232<br>-569<br>167<br>-30   | £1,168,409<br>£851,174<br>£227,735<br>£550,933  | £1,052,333<br>£259,448<br>£283,299<br>£524,560   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372  | £29,216<br>-£50,529<br>£0<br>£85,374  | -£145,292<br>-£541,196<br>£55,563<br>-£111,746  |
|   | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective   | 88<br><b>2,388</b><br>895<br>685<br>146<br>250  | 2,156<br>326<br>852<br>116<br>216  | -232<br>-569<br>167<br>-30<br>-34  | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724  | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680  | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069  |
|   | Ward Based Outpatient  Daycase DCHEMO Elective  | 88<br><b>2,388</b><br>895<br>685<br>146   | <b>2,156</b> 326 852 116   | -232<br>-569<br>167<br>-30   | £1,168,409<br>£851,174<br>£227,735<br>£550,933  | £1,052,333<br>£259,448<br>£283,299<br>£524,560   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372  | £29,216<br>-£50,529<br>£0<br>£85,374  | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070   |
|   | Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up  | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107   | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303   | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196   | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654   | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796   |
|   | Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender  | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248  | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336  | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88   | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180  | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091  | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911  | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£77  | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834  |
| Oncology                                      | Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up  | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46  | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54  | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8  | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127  | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£77<br>£12   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115  |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient   | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46<br>3,715   | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291   | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8  | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857   | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115  |
| Oncology                                      | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Daycase   | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46  | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20   | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55   | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£550,9724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027  | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109   | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£777<br>£12<br>£113,277<br>£2,033  | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115<br>-£706,134<br>-£30,142   |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient   | 88 2,388 895 685 146 250 288 50 1,107 248 46 3,715  | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291   | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8  | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857   | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,068<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>-£31,15<br>-£706,134<br>-£30,142<br>£16,512   |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective   | 88 2,388 895 685 146 250 288 50 1,107 248 46 3,715 75   | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20   | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55   | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135  | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879  | £29,216<br>-£50,529<br>£0<br>£85,374<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277<br>£2,033<br>£22,367   | -£145,292<br>-£541,196<br>-£55,563<br>-£111,746<br>-£70,068<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115<br>-£706,134<br>-£30,142<br>£16,512   |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New   | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46<br>3,715<br>75<br>4<br>1,448<br>408<br>1,530                       | 2,156<br>326<br>852<br>116<br>27<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336                     | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194                              | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293  | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,576   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716   | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£777<br>£12,033<br>£22,367<br>£156,713<br>£36,893<br>-£11                                  | -£145,292<br>-£541,196<br>-£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>-£50,796<br>-£2,834<br>-£2,115<br>-£706,134<br>-£30,142<br>£16,512<br>£577,556<br>-£8,014<br>-£41,705  |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up   | 88 2,388 895 685 146 250 288 50 1,107 248 46 3,715 75 4 1,448 408 1,530 2,515   | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336<br>2,086           | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194<br>-429                      | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£550,9724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£342,653                             | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,576<br>£284,159   | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494   | £29,216<br>-£50,529<br>£00<br>£85,374<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17                   | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115<br>-£706,134<br>-£30,142<br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£58,477  |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender                              | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46<br>3,715<br>75<br>4<br>1,448<br>408<br>1,530<br>2,515<br>46        | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>4<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336<br>2,086<br>17      | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194<br>-429<br>-29               | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£329,293<br>£342,653<br>£6,272                   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,552<br>£284,159<br>£2,316                                     | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494<br>-£3,956   | £29,216<br>-£50,529<br>£0<br>£85,374<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17<br>-£0             | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>-£30,142<br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£41,705   |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46<br>3,715<br>75<br>4<br>1,448<br>408<br>1,530<br>2,515<br>46<br>205 | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336<br>2,086<br>17     | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194<br>-429<br>-113              | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£342,653<br>£6,272<br>£27,904         | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,576<br>£284,159<br>£2,316<br>£2,316<br>£12,533                | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494<br>-£3,956<br>-£15,371                      | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£777<br>£12<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17<br>-£0 | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>-£30,142<br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£58,477<br>-£3,956<br>-£15,371  |
| Oncology Oncology Total                       | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient New Outpatient Follow-up Ward Attender                              | 88<br>2,388<br>895<br>685<br>146<br>250<br>288<br>50<br>1,107<br>248<br>46<br>3,715<br>75<br>4<br>1,448<br>408<br>1,530<br>2,515<br>46        | 2,156<br>326<br>852<br>116<br>216<br>47<br>41<br>1,303<br>336<br>4<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336<br>2,086<br>17      | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194<br>-429<br>-29               | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£329,293<br>£342,653<br>£6,272                   | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,552<br>£284,159<br>£2,316                                     | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494<br>-£3,956   | £29,216<br>-£50,529<br>£0<br>£85,374<br>-£1,274<br>£9<br>-£142<br>£77<br>£12<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17<br>-£0             | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115<br>-£706,134<br>-£30,142<br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£58,477<br>-£3,956<br>-£15,371<br>-£152                      |
| Oncology  Oncology Total  Paediatrics         | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient Ward Based Outpatient | 88 2,388 895 685 146 250 288 50 1,107 248 46 3,715 75 4 1,448 408 1,530 2,515 46 205  | 2,156<br>326<br>852<br>116<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20<br>24<br>428<br>1,336<br>2,086<br>17<br>92               | -232<br>-569<br>167<br>-30<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>-194<br>-429<br>-29<br>-213<br>-1                     | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£342,653<br>£6,272<br>£27,904<br>£152 | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£24,356<br>£2,414,696<br>£212,214<br>£287,576<br>£284,159<br>£2,316<br>£12,533                          | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494<br>-£15,371<br>-£152                        | £29,216<br>-£50,529<br>£05,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17<br>-£0<br>£0                | £50,796<br>£22,834<br>£2,115<br><b>-£706,134</b><br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£58,477<br>-£3,956<br>-£15,371  |
| Oncology Total Paediatrics  Paediatrics Total | Ward Based Outpatient  Daycase DCHEMO Elective Non Elective Excess Bed Days Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient  Daycase Elective Non Elective Excess Bed Days Outpatient New Outpatient New Outpatient Follow-up Ward Attender Ward Based Outpatient OP Procedure          | 88 2,388 895 685 146 250 288 50 1,107 248 46 3,715 75 4 1,448 408 1,530 2,515 46 205 1 6,233  | 2,156<br>326<br>852<br>116<br>47<br>41<br>1,303<br>336<br>54<br>3,291<br>20<br>24<br>1,946<br>428<br>1,336<br>2,086<br>17<br>92<br>0 | -232<br>-569<br>167<br>-30<br>-34<br>-241<br>-9<br>196<br>88<br>8<br>-424<br>-55<br>20<br>498<br>20<br>-194<br>-429<br>-29<br>-113<br>-1 | £1,168,409<br>£851,174<br>£227,735<br>£550,933<br>£509,724<br>£133,896<br>£12,979<br>£286,824<br>£64,180<br>£11,869<br>£2,649,314<br>£41,135<br>£3,477<br>£1,680,427<br>£167,308<br>£329,293<br>£342,653<br>£6,272<br>£27,904<br>£152 | £1,052,333<br>£259,448<br>£283,299<br>£524,560<br>£519,404<br>£20,552<br>£10,627<br>£337,478<br>£87,091<br>£13,997<br>£2,056,457<br>£13,027<br>£42,356<br>£2,414,696<br>£212,214<br>£287,576<br>£2,316<br>£12,533<br>£0<br>£12,533<br>£0<br>£3,268,877 | -£116,077<br>-£591,725<br>£55,563<br>-£26,372<br>£9,680<br>-£113,344<br>-£2,351<br>£50,654<br>£22,911<br>£2,127<br>-£592,857<br>-£28,109<br>£38,879<br>£734,269<br>£44,907<br>-£41,716<br>-£58,494<br>-£3,956<br>-£15,371<br>-£152<br>£670,257 | £29,216<br>-£50,529<br>£0<br>£85,374<br>£79,749<br>-£1,274<br>£9<br>-£142<br>£113,277<br>£2,033<br>£22,367<br>£156,713<br>£36,893<br>-£11<br>-£17<br>-£0<br>£0          | -£145,292<br>-£541,196<br>£55,563<br>-£111,746<br>-£70,069<br>-£112,070<br>-£2,361<br>£50,796<br>£22,834<br>£2,115<br>- <b>£706,134</b><br>-£30,142<br>£16,512<br>£577,556<br>£8,014<br>-£41,705<br>-£58,477<br>-£58,477<br>-£15,371<br>-£152<br>£452,279 |

| Year to Date    |                         |                       |         |         |       |             |             |            |           |           |
|-----------------|-------------------------|-----------------------|---------|---------|-------|-------------|-------------|------------|-----------|-----------|
| Medicine        | Radiology               | Non Elective          | 12      | 7       | -5    | £126,301    | £69,548     | -£56,753   | -£2,083   | -£54,670  |
|                 |                         | Excess Bed Days       | 122     | 47      | -75   | £57,755     | £26,856     | -£30,900   | £4,545    | -£35,444  |
|                 |                         | OP Imaging            | 4,708   | 5,822   | 1,115 | £624,831    | £566,751    | -£58,080   | -£206,009 | £147,929  |
|                 | Radiology Total         |                       | 5,496   | 6,550   | 1,054 | £1,712,401  | £1,535,624  | -£176,777  | -£229,460 | £52,682   |
|                 | Respiratory Medicine    | Daycase               | 49      | 115     | 66    | £64,035     | £135,701    | £71,665    | -£14,673  | £86,339   |
|                 |                         | Elective              | 54      | 25      | -29   | £89,809     | £67,753     | -£22,056   | £25,950   | -£48,006  |
|                 |                         | Non Elective          | 173     | 37      | -136  | £363,314    | £267,515    | -£95,799   | £189,617  | -£285,416 |
|                 |                         | Excess Bed Days       | 117     | 815     | 698   | £66,755     | £416,139    | £349,384   | -£48,533  | £397,917  |
|                 |                         | Outpatient New        | 370     | 386     | 16    | £96,422     | £100,022    | £3,601     | -£488     | £4,089    |
|                 |                         | Outpatient Follow-up  | 1,228   | 1,432   | 204   | £176,236    | £205,494    | £29,258    | -£13      | £29,270   |
|                 |                         | Ward Attender         | 18      | 9       | -9    | £2,592      | £1,292      | -£1,301    | -£0       | -£1,301   |
|                 |                         | Ward Based Outpatient | 681     | 170     | -511  | £97,662     | £24,396     | -£73,266   | -£1       | -£73,265  |
|                 |                         | OP Procedure          | 293     | 3       | -290  | £62,307     | £452        | -£61,855   | -£186     | -£61,669  |
|                 | Respiratory Medicine To | tal                   | 2,982   | 2,992   | 10    | £1,019,132  | £1,218,763  | £199,631   | £151,672  | £47,958   |
|                 | Rheumatology            | Daycase               | 850     | 635     | -215  | £539,692    | £408,094    | -£131,599  | £4,799    | -£136,398 |
|                 |                         | Elective              | 99      | 17      | -82   | £129,466    | £24,868     | -£104,597  | £2,626    | -£107,223 |
|                 |                         | Non Elective          | 8       | 13      | 5     | £13,071     | £30,009     | £16,937    | £7,462    | £9,475    |
|                 |                         | Excess Bed Days       | 128     | 174     | 47    | £53,476     | £67,164     | £13,688    | -£5,815   | £19,503   |
|                 |                         | Outpatient New        | 274     | 333     | 59    | £41,202     | £50,130     | £8,928     | £43       | £8,885    |
|                 |                         | Outpatient Follow-up  | 970     | 1,066   | 96    | £145,588    | £160,476    | £14,887    | £444      | £14,444   |
|                 |                         | Ward Attender         | 76      | 31      | -45   | £11,502     | £4,667      | -£6,835    | £4        | -£6,839   |
|                 |                         | Ward Based Outpatient | 52      | 43      | -9    | £7,812      | £6,473      | -£1,339    | £6        | -£1,344   |
|                 |                         | OP Procedure          | 1       | 0       | -1    | £80         | £0          | -£80       | £0        | -£80      |
|                 | Rheumatology Total      |                       | 2,456   | 2,312   | -144  | £941,889    | £751,880    | -£190,008  | £9,568    | -£199,577 |
|                 | Sleep Studies           | Daycase               | 0       | 1       | 1     | £0          | £654        | £654       | £0        | £654      |
|                 |                         | Elective              | 122     | 89      | -33   | £149,231    | £110,754    | -£38,477   | £1,710    | -£40,187  |
|                 | Sleep Studies Total     |                       | 122     | 90      | -32   | £149,231    | £111,408    | -£37,823   | £1,710    | -£39,533  |
| Medicine Total  |                         |                       | 66,209  | 65,926  | -283  | £19,844,734 |             | -£545,487  | £83,340   | -£628,827 |
| Community       | CAMHS                   | Elective              | 1       | 0       | -1    | £1,461      | £0          | -£1,461    | £0        | -£1,461   |
|                 |                         | Outpatient New        | 957     | 764     | -193  | £0          | £0          | £0         | £0        | £0        |
|                 |                         | Outpatient Follow-up  | 4,771   | 7,473   | 2,702 | £64,046     | £33,063     | -£30,983   | -£67,260  | £36,277   |
|                 |                         | Ward Based Outpatient | 0       | 1       | 1     | £0          | £0          | £0         | £0        | £0        |
|                 | CAMHS Total             |                       | 5,729   | 8,238   | 2,509 | £65,507     | £33,063     | -£32,444   | -£67,260  | £34,816   |
|                 | Community Medicine      | Outpatient New        | 1,816   | 1,452   | -364  | £147,061    | £131,777    | -£15,283   | £14,166   | -£29,449  |
|                 |                         | Outpatient Follow-up  | 3,565   | 3,460   | -105  | £17,996     | £16,375     | -£1,620    | -£1,091   | -£530     |
|                 |                         | Ward Attender         | 11      | 4       | -7    | £0          | £0          | £0         | £0        | £0        |
|                 |                         | OP Procedure          | 1       | 0       | -1    | £69         | £0          | -£69       | £0        | -£69      |
|                 | Community Medicine To   | tal                   | 5,392   | 4,916   | -476  | £165,126    | £148,153    | -£16,973   | £13,075   | -£30,048  |
| Community Total |                         |                       | 11,122  | 13,154  | 2,032 | £230,633    | £181,216    | -£49,417   | -£54,185  | £4,768    |
| Grand Total     |                         |                       | 143,559 | 148,261 | 4,702 | £57,740,496 | £59,153,648 | £1,411,677 | £581,775  | £829,902  |



# Board of Directors Thursday 28<sup>th</sup> September 2017

| Report of  | Director of Corporate Affairs   |  |  |  |
|--|---|--|--|--|
| Paper prepared by  | Executive Team, and Quality Assurance Officer   |  |  |  |
| Subject/Title  | 2017/18 BAF Report  |  |  |  |
| Background papers  | Monthly BAF updates/reports   |  |  |  |
| Purpose of Paper   | To provide the Board with the BAF August report   |  |  |  |
| Action/Decision required                                       | The Board is asked to note the June position relating to the Board Assurance Framework  |  |  |  |
| Link to:  > Trust's Strategic Direction > Strategic Objectives | By 2020, we will:  be internationally recognised for the quality of our care (Excellence in Quality)  be recognised for the exceptional care we provide to our children, that is technologically enabled and matched by exceptional facilities (Patient Centred Services)  have a fully engaged workforce that is actively driving quality improvement (Great Talented Teams)  be a world class, child focussed centre of research & innovation expertise to improve the health and wellbeing outcomes for babies, children & young people (International Research, Innovation & Education)  have secured sustainable long term financial and service growth supported by a strong international business (Growing our Services and Safeguarding Core Business) |  |  |  |
| Resource Impact  | Non achievement of the Trust's objectives could have a negative impact on the services provided by the Trust.   |  |  |  |



# 1. Purpose

This report is a summary of the current Board Assurance Framework (BAF) for review and discussion.

#### 2. Review of the BAF

The diagram below gives a high level view of the current version, followed by a summary and a brief on the changes since the last Board meeting. The full document is included as Appendix A.

```
BAF Risk Register - Overview at 28 September 2017

2.4: Financial Environment (S)

2.3: IT Strategic Development (S)

1.3: Management Contract arrangement with Liverpool Community Health Trust (S)

2.2: Failure to fully realise the Trust's Vision for the Park (S)

3.2: Business Development and Growth. (S)

3.3: Developing the Paediatric Service Offer (S)

4.1: Workforce Sustainability & Capability (S)

4.2: Staff Engagement (S)

4.3: Workforce Diversity & Inclusion (S)

1.1: Maintain care quality in a cost constrained environment (S)

2.1: New Hospital Environment (S)

5.1: Research, Education & Innovation (S)

1.2: Mandatory & compliance standards (S)
```



| Ref,<br>Owner | Risk Title   | Risk R                                  | •      | Monthl | y Trend |  |  |
|---------------|--|---|--------|--------|---------|--|--|
|               |  | Current                                 | Target | Last   | Now     |  |  |
| STRATEG       | IC PILLAR: Delivery of Outstanding Care                  |   |        |        |         |  |  |
| 1.1 HG        | Maintain care quality in a cost constrained environment  | 4-2                                     | 4-2    | STATIC | STATIC  |  |  |
| 1.2 ES        | Mandatory & Compliance Standards                         | andatory & Compliance Standards 5-1 3-1 |        |        |         |  |  |
| 1.3 LS        | Management Contract Arrangement with LCH Trust           | STATIC                                  | STATIC |        |         |  |  |
| STRATEG       | STRATEGIC PILLAR: Strong Foundations                     |   |        |        |         |  |  |
| 2.1 DP        | New Hospital Environment                                 | 4-2                                     | 4-1    | STATIC | STATIC  |  |  |
| 2.2 DP        | Failure to fully realise the Trust's Vision for the Park | 4-3                                     | 4-2    | STATIC | STATIC  |  |  |
| 2.3 JG        | IT Strategic Development                                 | 3-4                                     | 3-3    | STATIC | STATIC  |  |  |
| 2.4 JG        | Financial Environment                                    | 5-4                                     | 3-4    | STATIC | STATIC  |  |  |
| STRATEG       | IC PILLAR: Sustainability Through External Partnerships  |   |        |        |         |  |  |
| 3.2 MB        | Business Development & Growth                            | 4-3                                     | 4-2    | STATIC | STATIC  |  |  |
| 3.3 MB        | Developing the Paediatric Service Offer                  | 4-3                                     | 4-2    | STATIC | STATIC  |  |  |
| STRATEG       | IC PILLAR: The Best People Doing Their Best Work         |   |        |        |         |  |  |
| 4.1 MS        | Workforce Sustainability & Capability                    | 4-3                                     | 4-2    | STATIC | STATIC  |  |  |
| 4.2 MS        | Staff Engagement   | 3-3                                     | 3-2    | STATIC | STATIC  |  |  |
| 4.3 MS        | Workforce Diversity & Inclusion                          | 3-3                                     | 3-1    | STATIC | STATIC  |  |  |
| STRATEG       | IC PILLAR: Game-Changing Research And Innovation         |   |        |        |         |  |  |
| 5.1 DP        | Research, Education & Innovation                         | 4-2                                     | 4-1    | STATIC | STATIC  |  |  |

**Changes since 30 May 2017 Board meeting** 



The diagram above shows that the majority of the risks on the BAF remained broadly static.

#### **External risks**

# Business development and growth (MB)

- 1) AH were awarded the Management Contract for Liverpool Community Health, (Liverpool Bundle) for May 2017. Future organisational structure being developed with NHSi, the 3 Acute Trusts, local authority, LCCG and local GP's. Opportunities for all to rationalise patient pathways.
- 2) Partnership with Al Jalia now entering Phase 2. Specific deliverables identified and agreed. Work due to commence in Q2. Non NHS patient stretch target agreed and Q1 activity delivered.
- 3) MOUs signed with two hospitals in China and work in progress to identifying workstreams and benefits.
- 4) AH awarded contract for Design and Build Consultancy for Children's Hospital in Xian.

# • Mandatory and compliance standards (ES)

Complaint with all national targets in month. Registration of community services with CQC is resolved.

# Developing the Paediatric Service Offer (MB)

Work commencing on the Implementation of the single service, two site model;

- 1) Neonatal service model with NHS England and LWH on 6/7/17
- 2) CHD Public Consultation closes in July. Results not expected to be released until January 2018. In the meantime AHCH and LCH are providing support to deliver services for patients due to the collapse of the Manchester service following the departure of their last remaining surgeon in June.
- 3) Out of Hours group has been merged with the other workstreams to design a sustainable 24/7 paediatric service in light of further reductions and gaps in rotation. This workstream is named best in Acute Care and is led by the MD and Chief Nurse.

### Internal risks:

• Maintain care quality in a cost constrained environment (HG)

All nursing staff now trained in Sepsis triggers; medical staff training to take place in August & September. Re-introduction of matron role across the Trust over next three months.

Management Contract arrangement with Liverpool Community Health Trust (LS)

Stock take report compiled for NHS I. Plans in place to ensure services at both AH & LCH are managed safely and effectively. Senior Roles and associated back fill confirmed and communicated to all AH staff.



# • New Hospital Environment (DP)

Probation period ended. Main outstanding issue – energy.

# • Financial Environment (JG)

£0.3m behind control total at month 2. Residual Forecast financial risk of circa £5m identified by Divisions. Action Plan Produced and delivery tracked via Internal Recovery and RABD.

# • Failure to fully realise the Trust's Vision for the Park (DP)

Consultation strategy presented at July board.

# • IT Strategic Development (JG)

GDE funding confirmed and agreements signed / returned by DoF. Cash not received 27.06.17. Overall GDE programme milestones have slipped but on track to deliver objectives.

# • Workforce Sustainability & Capability (MS)

Temporary Staffing Project initiated

# • Staff Engagement (MS)

Launch of the Big Conversations with staff from across the Trust. Executive Visibility Programme commenced

# Workforce Diversity & Inclusion (MS)

First BME Network meeting. HRD as Exec sponsor.

# • Research, Education & Innovation (DP)

Academy model agreed.

Erica Saunders Director of Corporate Affairs September 2017



| Related CQC Themes: Safe, Caring, Effective, Responsive, Well Led  Exec Lead: Hilda Gwilliams  Type: Internal, Known  Risk Desc  Failure to maintain appropriate levels of care quality in a cost constrained envi | Current IxL:   | environment  |  |  |  |  |
|--|--|--|--|--|--|--|
| Exec Lead: Hilda Gwilliams  Type: Internal, Known  Risk Desc   |  | Township   |  |  |  |  |
|  |  | Target lxL:<br>4-2   | Trend: STATIC                                    |  |  |  |
| Failure to maintain appropriate levels of care quality in a cost constrained envi  | ription  |  |  |  |  |  |
| Tallate to maintain appropriate levels of care quality in a cost constrained envi  | ironment.  |  |  |  |  |  |
| Existing Control   | ol Measures  |  |  |  |  |  |
|  | Risk assessment and utilis nd other drivers.   | ation of risk registers  | in responding to incident                        |  |  |  |
|  | CBU and Corporate Dashb<br>Performance Framework.  | poards in place and ar   | e part of updated                                |  |  |  |
| d  | Programme of quality revieue partments. Implemented apport.  |  |  |  |  |  |
| Refresh of CQAC to provide a more performance focussed approach  | Changes to ESR to underp   | oin workforce informat   | ion -  |  |  |  |
|  | Robust risk & governance single Oversight Frameworl  |  | to Board, linked to NHS                          |  |  |  |
|  | External review on IPCC resulted in action plan to address issues identified and track improvements.   |  |  |  |  |  |
| monitoring (CQAC)  | Quarterly 'themes' report fr<br>neeting & CQSG as multidis<br>earning.   |  |  |  |  |  |
| Assurance Evidence   | Gaps   | in Controls/Assura   | nce  |  |  |  |
| CQAC focus on performance.  Analysis of incident reports.  Monthly reporting of the Corporate Report to Board.  Improved reporting - in the top 20% of NRLS nationally  a  | Reduced investment opport<br>esult of financial situation.<br>full electronic access to spen<br>deditech issues identified a<br>udit data without extensive<br>lursing maternity leave con | ecialty performance re<br>s key challenge to obt<br>manual analysis by c | sults<br>aining accurate Sepsis<br>linical lead. |  |  |  |
| Actions Required to Reduce Risk to Target Rating   | Latest Progress on Actions   |  |  |  |  |  |
| Develop and build audit programme within Meditech to ensure continuous monitoring in place and deliver CQUIN   | Cey stakeholders working w   | ith IM&T to build audi   | programme  |  |  |  |
| Heads of Quality to take forward Quality Ward Accreditation Programme in R   | Revised framework agreed. On-going work in progress. Electronic sharing of information with the public - completed programme July.   |  |  |  |  |  |
| Successfully implement all Change Programme workstreams to improve efficiency and flow   | 16/17 year-end reports to CQAC. Actions to carry forwards into 17/18 change programme in association with PIDs and milestone trackers.   |  |  |  |  |  |
| Roll out PFCC model for all appropriate services   | PFCC model now forms par   | t of transformation too  | olkit  |  |  |  |
|  | Recruitment on-going. Furth<br>ndertaken (July 2017)   | er analysis of materni   | ty leave factors to be                           |  |  |  |
| Clinical lead for Sepsis in dialogue with Meditech team to develop solution to systems issues re data.   |  |  |  |  |  |  |
| Executive Lead's   | Assessment   |  |  |  |  |  |

MAY 2017: the Trust continues to maintain appropriate workforce levels ensuring care quality in a cost constrained environment. Achieving Monitor capped nursing agency targets

JUNE 2017: All nursing staff now trained in Sepsis triggers; medical staff training to take place in August & September. Re-introduction of matron role

across the Trust over next three months.

JULY 2017: Staffing requirements for winter assessed as part of refresh of successful winter plan from 2016/17; also early consideration of flexing beds and surgical capacity. Trust has agreed support for development of an additional four ANPs as part of overall workforce plan.

August 2017: Measures being taken to address unexpected gaps in senior nursing leadership due to sickness and other personal issues. Preparatory work underway for new cohort of newly qualified nurses commencing September.

SEPTEMBER 2017: HEI new recruits commenced September 2017 aligned to staff vacancies and winter plan.



| BAF Strategic Objective: Deliv  | very Of Outstanding Care   | Risk Title: M  | andatory & comp  | liance standards                         |  |  |
|---|--|--|--|--|--|--|
| Related CQC Themes: Safe, Caring,   | Responsive, Well Led, Effective  |  |  |  |  |  |
| Exec Lead: Erica Saunders   | Type: Internal, Known  | Current IxL:<br>5-1  | Target lxL:<br>3-1   | Trend: STATIC                            |  |  |
|   | Risk De  | scription  |  |  |  |  |
| Failure to deliver on all mandatory and   | compliance standards due to lack of  | engagement with internal thro  | oughput plans and tar  | gets                                     |  |  |
|   | Existing Con   | trol Measures  |  |  |  |  |
| New Operational Delivery Group (July<br>non-compliance relating to performance)   |  | Emergency Planning & Re  | silience meetings in p   | pace                                     |  |  |
| CBU Executive Review Meetings - no<br>meeting regularly each month  | w strengthened as of May 2016 and  | Regulatory status with: NH etc.  | ISI, CQC,NHSLA, ICC  | O, HSE, CPA, HTA,MHRA                    |  |  |
| Compliance tracked through the corp   | Risks to delivery addresse<br>then through to Board                              | d through RBD, CQA   | C, WOD & CQSG and  |  |  |  |
| Early Warning indicators now in place   | Weekly performance meetings in place to track progress                           |  |  |  |  |  |
| 6 weekly meetings with commissione  | rs (CQPG)  | Revised CBU leadership structure to implement clinically led leadership<br>team for CBU  |  |  |  |  |
| Weekly Performance meetings   |  |  |  |  |  |  |
| Assurance   | Evidence   | Gaps   | in Controls/Assura   | nce                                      |  |  |
| Regular reporting of delivery against or CQAC & Board. Monthly reporting to the Board via the 0 Monitor / NHSI governance risk rating Operational effectiveness measures (k measures) to RABD Compliance assessment against Monit CBU / Executive performance reviews Exceptions discussed / resolved at Ope Quarterly Report to NHSI | Corporate Report. ey risks with early warning or Provider Licence to go to Board | Critical Care bed capacity Some areas remain fragile e relating to learning disabilitie Assurance required to unde 'Horizon scanning' to anticip performance review meeting Work with CCG to manage of across PC Junior Doctor Rotas | es declaration<br>rpin CBU reporting or<br>ate risks & issues no | n CQC standards<br>w implemented through |  |  |
| Actions Required to Redu  | ce Risk to Target Rating   | Late   | st Progress on Action  | ons                                      |  |  |
| Ensure divisional governance embedde ward to board reporting  | ed and working effectively to reflect  | Awaiting the implementation  | of the Matron roles in   | n each CBU                               |  |  |
| Plans to ensure performance sustained embedded and maintained   | d across the year need to be   |  |  |  |  |  |
| Review bed capacity and staffing mode   | el for seasonal variation  | The Winter Plan was effective  | ve. Planning for next  | winter to commence early                 |  |  |

#### **Executive Lead's Assessment**

APR 2017: All access targets achieved at 31/3. Letter of congrats received from SoS for most improved ED 4 hour performance.

MAY 2017: Need to maintain grip on activity plan and ensure community waiting times are a focus in the short term especially CAMHS and SALT JUNE 2017 Compliant with all national targets in month. Registration of community services with CQC is resolved.

JULY 2017: A&E performance slipped to 93% for the month due to unseasonal levels of activity and gaps in medical cover; this has been recovered in August. All other national standards on track/on plan.

AUGUST 2017: Month end position not known at time of writing but no significant issues reported in-month.

SEPTEMBER 2017: ED performance back on track in August but dipping again in September; all other targets met.



| BAF<br>1.3  | , ,   |                                  | nips  | Risk Title: Management Contract arrangement with<br>Liverpool Community Health Trust |                    |               |  |
|---|---|----------------------------------|---|--|--------------------|---------------|--|
| Related CQ  | C Themes: Well Led, Respo   | nsive, Safe                      |   |  |                    |               |  |
| Exec Lead:  | Louise Shepherd   | Type: External, New              |   | Current IxL:<br>4-3  | Target lxL:<br>4-2 | Trend: STATIC |  |
|   | Risk Description  |                                  |   |  |                    |               |  |
| - Risk to ope<br>- Financial ri<br>- Risk to deli                     | sk to achieving the AH contro   | (quality & performance standards | 5)  |  |                    |               |  |
|   |   | Existing Con                     | trol Meas   | sures  |                    |               |  |
|   | Backfill arrangements for some key members of Exec Team in place & gaps actively being backfilled |                                  |   | MIAA due diligence process undertaken at LCH   |                    |               |  |
|   | Cross agency Transition Board place at LCH to oversee safe transfer of<br>remaining services      |                                  |   | Interim Provider Group in place to retain oversight of the Management<br>Contract    |                    |               |  |
|   | Assurance Ev  | idence                           | Gaps in Controls/Assurance  |  |                    |               |  |
| Interim governance arrangements in place including Exec Team meetings |   |                                  | Financial package not yet agreed with NHSI & Liverpool CCG<br>Some senior and support posts not yet filled<br>Potential for further quality risks to emerge<br>Staff engagement & motivation across the two sites |  |                    | ·             |  |
| Α   | ctions Required to Reduce   | Risk to Target Rating            |   | Latest Progress on Actions   |                    |               |  |
| Develop plan  |   | AH & LCH are managed safely      |   |  |                    |               |  |

#### **Executive Lead's Assessment**

MAY 2017: Plans continue to be developed to ensure services at both AH & LCH are managed safely and effectively JUNE 2017: Stock take report compiled for NHS I. Plans in place to ensure services at both AH & LCH are managed safely and effectively. Senior Roles and associated back fill confirmed and communicated to all AH staff.

JULY 2017: Sustained levels of performance across majority of areas; assurance committees continue to have oversight of all key KPIs and plans

including change programme

AUGUST 2017: A&E trajectory back on track following unseasonal levels of activity and concerted work by team. All corporate risks being validated through a structured process agreed by IGC at its meeting in July, led by Associate Director of Nursing and Governance. New Quality Ward round process to commence early September.

SEPTEMBER 2017: Performance against key metrics within both organisations receiving appropriate levels of scrutiny through Executive team and assurance processes; AH Quality Ward Rounds commenced and running effectively; risk revalidation exercise nearing completion; IGC receiving

additional assurance from revised reporting



| BAF Strategic Objective: St  | <b>č</b> ,   |  | Risk Title: New Hospital Environment |                  |  |
|--|--|--|--------------------------------------|------------------|--|
| Related CQC Themes: Safe, Effect   | ive, Well Led  |  |                                      |                  |  |
| Exec Lead: David Powell  | Type: Internal, Known  | Current IxL:<br>4-2  | Target IxL:<br>4-1                   | Trend: STATIC    |  |
|  | Risk De  | scription  |                                      |                  |  |
| Failure to deliver world class healtho   | are due to constraints of new environm   | ent  |                                      |                  |  |
|  | Existing Con   | trol Measures  |                                      |                  |  |
| Regular Fix-It Team reports to Execution   | cs, CQAC & IGC   | Interserve Reports & repre                                   | esentation at Health &               | Safety Committee |  |
| Monitoring & Fix-It Team in place re<br>of PFI Contractor ensuring services a  | esponsible for day to day management   | Fix-It Team governed by a                                    | Steering Group (mee                  | ts monthly)      |  |
| Joint Energy Committee to monitor  |  | Joint Water Committee to                                     | monitor performance                  | & compliance     |  |
| Survey of all departmental users to assess quality of service  |  | Review of Charter compliance or liaison committee            |                                      |                  |  |
| Assurance Evidence   |  | Gaps in Controls/Assurance                                   |                                      |                  |  |
| Tracker in place. Reporting compliance of PFI Service Confirmation that invoices and sums approve all invoices and expenditure Number of reported faults is falling. The items on the 'red list' i.e. main sr Further meeting arranged to review e Partnership Charter Liaison Committee - meeting minutes | are charged correct (Finance Lead to ).  nags have reduced significantly. energy performance | Delay in commissioning extr<br>Gap in reporting from Project |                                      |                  |  |
|  | luce Risk to Target Rating   | Latest Progress on Actions                                   |                                      |                  |  |
| Reviewing Health & Safety interface Team   | with Estates and Building Services   | Recommendation issued to                                     | Dir. of HR fro conside               | eration          |  |
| review of probation items  |  | Review postponed due to issues with energy                   |                                      |                  |  |
| conduct series of surveys (1 per qua   | rter) to assess progress.  | Second survey results received                               |                                      |                  |  |
| Implement recommendations in exte  | rnal H&S Review  |  |                                      |                  |  |
| Assess issues with energy and agree  | e action plan.   | Interim report received at Er                                | nergy Committee.                     |                  |  |
|  | Executive Lead   | d's Assessment   |                                      |                  |  |
| APR 2017: Review of progress at Lia  | aison Committee  |  |                                      |                  |  |

APR 2017: Review of progress at Liaison Committee
MAY 2017: Review and agree actions from H&S Report
JUNE 2017: Probation period ended. Main outstanding issue - energy
JULY 2017: Review of outstanding issues
AUGUST 2017: Agreement on Deed of variation to correct retrospective faults e.g. theatre floors
SEPTEMBER 2017: New ENR.



| BAF Strategic Objective: Stron  | Risk Title: Failur  | Risk Title: Failure to fully realise the Trust's Vision for   |                           |                        |  |  |
|---|---|---|---------------------------|------------------------|--|--|
| 2.2  Related CQC Themes: Responsive, W  | the Park  |   |                           |                        |  |  |
| Exec Lead: David Powell   | Type: Internal, Known   | Current lxL: Target lxL: Trend: STATION 4-3 4-2   |                           |                        |  |  |
|   | Risk De   | scription   |                           |                        |  |  |
| Failure to fully realise the Trust's vision future generations  | for the Park and campus, in partner   | ship with the local community   | and other key stakeho     | olders as a legacy for |  |  |
|   | Existing Con  | trol Measures   |                           |                        |  |  |
| Business Cases developed for various  | elements of the Park & Campus   | Alignment with the 'Alder F<br>Campus' visions  | ley in the Park' vision a | and the 'Alder Hey     |  |  |
| Heads of Terms agreed with LCC for j  | oint venture approved   | Redeveloped Steering Gro  | oup                       |                        |  |  |
| Monthly reports to Board & RABD   |   |   |                           |                        |  |  |
| Assurance E   | Evidence  | Gaps  | in Controls/Assuran       | ce                     |  |  |
| and the local community Approved Business Cases for various e approved Every Project has a dedicated Project N End user consultation events held Highlight reports to relevant assurance Representation at Springfield Park Shac Stakeholder events held Representation at Friends of Springfield | lanager assigned to it committees and through to Board dow Board                              | Risk quantification around the Joint business case approve  |                           |                        |  |  |
| Actions Required to Reduc   | e Risk to Target Rating   | Late  | st Progress on Action     | ns                     |  |  |
| Approval of Business Case at LCC / Dis  | scuss park Heads of Terms with  | dependent upon residential scheme (target date no Sept 2017)  |                           |                        |  |  |
| Income generation opportunities to be the applications) and reconcile requirement   |   | Draft Business Case prepared. Final requirement will depend upon contribution from residential scheme |                           |                        |  |  |
| Develop a Planning Process Communic   | ation Strategy  | Strategy to be presented at July board  |                           |                        |  |  |
| Confirm arrangements for the CIC to ru  | n the Park.   | Awaiting discussions with L0  | CC Mayor                  |                        |  |  |
|   | Executive Lea   | d's Assessment  |                           |                        |  |  |
| APR 2017: Shortlisted - first step as pre<br>MAY 2017: Compile draft Consultation<br>JUNE 2017: Consultation strategy pres<br>JULY 2017: Pre planning process cons<br>AUGUST 2017: Evaluation of options w<br>SEPTEMBER 2017: Public consultation   | Strategy. Consultation process held<br>ented at July board<br>dered with LCC<br>ith LCC Mayor |   |                           |                        |  |  |



| BAF Strategic Objective: Strong Foundations 2.3  |  | Risk Ti   | Risk Title: IT Strategic Development   |                          |  |  |
|--|--|---|--|--------------------------|--|--|
| Related CQC Themes: Safe, Carir  | ng, Effective, Responsive, Well Led  |   |  |                          |  |  |
| Exec Lead: John Grinnell   | Type: Internal, Known  | Current lxL:<br>3-4   | Target lxL:<br>3-3   | Trend: STATIC            |  |  |
|  | Risk De  | scription   |  |                          |  |  |
| Failure to deliver an IM&T Strategy  | which will place Alder Hey at the forefron   |   | nent in paediatric heal  | thcare                   |  |  |
|  | Existing Con   | trol Measures   |  |                          |  |  |
| Key projects and progress tracked<br>Informatics Steering Group and RAI  |  | Clinical Systems Informatengagement - ad hoc group  |  |                          |  |  |
| Forward Communications plan agr  | reed and tracked at steering group.  | Board approval "Asset Overwhelm of systems and commercial approval app |  | to ensure organisational |  |  |
| • Improvement scheduled training p workshops to address data quality is  | rovision including refresher training and ssues  | Formal change control pro   | ocesses now in place   |                          |  |  |
| Executive level CIO in place   | Executive level CIO in place   |   | Investment in IM&T Team (2016/17 budget)   |                          |  |  |
| Assurance Evidence   |  | Gaps in Controls/Assurance  |  |                          |  |  |
| Regular progress reports presented to RABD and Operational Board MIAA providing assurance role Board agreed change process Participate in Digital Alder Hey programme Internal Audit Reviews |  | IM&T Strategy out of date - update work in progress Internal Programme Assurance Reports Resources required to deliver Strategy proposed and aspirations of Trust review Oct 2016 - Strategy update deferred pending consultation with new restructure CBU leadership teams and outcome of Global Digital Excellential.   |  |                          |  |  |
| Actions Required to Re   | educe Risk to Target Rating  | Latest Progress on Actions  |  |                          |  |  |
| Link to innovation partnerships in pa  | aediatric healthcare   |   |  |                          |  |  |
| Conclude the review of IM&T Infras   | tructure   | currently being reviewed in   | relation to GDE bid a  | nd business case         |  |  |
| IM&T Strategy development & appro  | M&T Strategy development & approval  |   | Trust GDE bid submitted and approved by Board and NHSE Nov / Dec 2016. NHSE undertaking due diligence review pre sign off and approval of funding agreement. Full I&MT strategy to be updated Q4 2016/17 |                          |  |  |
|  | Continual improvement of MEDITECH and other clinical systems as prioritised by the Clinical Systems Informatics Steering Group |   | changes to software tracked by and reported to the Clinical Informatics Steering Group   |                          |  |  |
| Engage with iLinks programme to pr   | rogress interoperability   |   |  |                          |  |  |

### **Executive Lead's Assessment**

APR 2017: email confirmation from NHSE highlighting treasury approval - awaiting final confirmation
MAY 2017: escalated NHSE funding for GDE by FD as impacting on programme delivery
JUNE 2017: GDE funding confirmed and agreements signed / returned by DoF. Cash not received 27.06.17. Overall GDE programme milestones have slipped but on track to deliver objectives.

JULY 2017: £2.5m capital funding received 10th July.

AUGUST 2017: £0.8m revenue funding invoiced. Not yet paid as at 24th Aug. Overall GDE programme milestones have slipped but remain on track to deliver objectives

SEPTEMBER 2017: funding is now up to date, GDE project is green rated over all. The main risk that Board need to be aware of is the pace of realisation of benefits of the programme including specialty packages and VR.



|   |   |  |  | NHS Founda   | ition Irust   |  |
|---|---|--|--|--|---|--|
| BAF<br>2.4  | Strategic Objective: Strong   | Foundations  | Risk   | Title: Financial En  | vironment   |  |
| Related C   | CQC Themes: Safe, Effective,  | Responsive, Well Led   |  |  |   |  |
| Exec Lea  | d: John Grinnell  | Type: Internal, Known  | Current IxL:<br>5-4  | Target lxL:<br>3-4   | Trend: STATIC   |  |
|   |   | Risk De  | scription  |  |   |  |
| Failure to  | deliver Trust control total and F   | Risk rating Rating   |  |  |   |  |
|   |   | Existing Con   | trol Measures  |  |   |  |
| Organisa  | ation-wide financial plan.  |  | Monitor financial regime   | and financial risk rating  | S.  |  |
| Financial   | l systems, budgetary control an   | d financial reporting processes.   | Capital Planning Review  | Group  |   |  |
|   | performance review meetings v   | vith CBU Clinical/Management   | Financial Position (subje  | ct to regular monitoring   | ).  |  |
| Weekly meeting with CBUs to review forward look bookings for elective<br>and day case procedures to ensure activity booked meets contract and<br>recovery plans. Also review of status of outpatient slot utilisation |   | COO Task & Finish Group targeted at increasing activity in line with planned levels  |  |  |   |  |
| CIP subjection     management   |   | and sub-committee performance  |  |  |   |  |
| Assurance Evidence  |   |  | Gaps in Controls/Assurance   |  |   |  |
| RBDC. Specific R Monthly Po Internal an Daily activ delivery Pay cost of actions to   | eports (i.e. Monitor Plan Revierent Reports (i.e. Management Report External Audit reporting throughty tracker to support CBU performent 10 point plan introduced | orting with General Managers.  Jugh Audit Committee.  Jugh Audit Com | where slippage against ag<br>Ongoing cost of temporary<br>CBU recovery plans to hit<br>delivery of overall Trust fir<br>'Grip' on CIP<br>Based on month 7 run rate<br>recovery profile) and upda | reed recovery trajector<br>/ staff<br>yearend financial control<br>pencial plan.<br>performance (£0.3m a<br>te projections and risks<br>d risk of failure to delive<br>U control targets issue | ol targets to ensure adrift in month overall from a reported by Clinical er target control. In order to d to address risk profile |  |
|   | Actions Required to Reduce  | Risk to Target Rating  | Latest Progress on Actions   |  |   |  |
| Focus on a  | activity delivery   |  | Recovery plans under dev   | relopment and review   |   |  |
|   |   | elopments to meet local CCG<br>verpool, to achieve and exceed  | COO task & finish group e with planned levels  | established; targeted at   | increasing activity in line   |  |
|   | ddress CIP shortfall - scheme I ing against milestones agreed   | PIDs to be complete by end of May  | Trust in discussions with NHSI re. formal approval of required £8m intercash support   |  |   |  |
| implement   | t divisional recovery plan  |  |  |  |   |  |
|   |   |  |  |  |   |  |

### **Executive Lead's Assessment**

APR 2017: 16/17 control overachieved. 17/18 risks remain as CIP £4m, Activity run rate £3m, pay cost pressures (ward related) £3m MAY 2017: key risks highlighted: pay, activity & CIP. Individual Exec Leads in place. Tracking of internal improvements through Internal Recovery Team JUNE 2017: £0.3m behind control total at month 2. Residual Forecast financial risk of circa £5m identified by Divisions. Action Plan Produced and delivery tracked via Internal Recovery and RABD.

JULY 2017: Achieved Q1 control total of (£2.6m) deficit. Forecast financial risk of circa £6m identified by the Divisions.

AUGUST 2017: £0.1m behind year to date control total at month 4. Forecast financial risk now £6.3m. Delivery of the action plan continues to be tracked at the Internal Delivery Group and RABD.

SEPTEMBER 2017: year to date on track. Forecast risk remains at £6.3m, largely driven by variances in medicine, facilities, estates and surgery.

Recovery process implemented.



| BAF Strategic Objective: Sus   | Risk Title: Business Development and Growth.   |  |  |  |
|--|--|--|--|--|
| Related CQC Themes: Caring, Effect   | tive, Responsive, Safe, Well Led   |  |  |  |
| Exec Lead: Margaret Barnaby  | Type: External, Known  | Current IxL:<br>4-3  | Target lxL:<br>4-2                             | Trend: STATIC                                  |
|  | Risk De  | scription  |  |  |
| Risk to business development/growth as maximise growth opportunities   | due to NHS financial environment and   | d constraints on internal info   | rastructure to deliver b                       | ousiness as usual as well                      |
|  | Existing Con   | trol Measures  |  |  |
| CBU Performance Management France  | mework.  | Clear trajectories for chall   | enged specialities to o                        | leliver.                                       |
| Business Development Plan  |  | • 2016 Change Programme<br>Clinical Business and non N   | Projects (Strategic Panels Patient Services)   | artnerships & International                    |
| Five year plan agreed by Board and   | Governors in 2014  | Capacity Plan identifies be  | eds and theatres requ                          | ired to deliver BD Plan.                       |
| Service development strategy include<br>proposal approved by Council of Gove<br>off.   | Capacity Plan identifies be  | eds and theatres requ  | red to deliver BD plan                         |  |
| Jan 2016 :- Weekly meeting with CB<br>re elective and day case patient booki<br>meets contract requirements  |  |  |  |  |
| Assurance  | Evidence   | Gap  | s in Controls/Assura                           | nce  |
| Business growth and market analysis & Business Development Committee a Business Development Committee an RBDC. Business Development Plan reviewed Monitoring Report. Daily activity tracker and forecast mon CIPs in new Change Programme subjperformance management | and reported regularly to RBDC. d reported regularly to Board via monthly by RBDC via Contract itoring performance for all activity. | Ability to respond swiftly to<br>Workforce constraints in sp<br>Early warning indicators for<br>Potential delay to cardiac g<br>16/17 CIP target | ecialised services. leading indicators.        | £0.8m forecast against                         |
| Actions Required to Redu   | ice Risk to Target Rating  | Late   | est Progress on Action                         | ons  |
| Workshop held in June to identofy opt development gap  | ions for bridging business   | Alternative schemes being  | developed. Report to                           | RABD   |
| Identify models and services to provid offers  | e to non NHS patients / commercial   | Trust currently progressing services. Timeframe: June part of due diligence. Repo with surgical teams and Sto                                    | - end Aug 2016. Finar<br>rt to RABD and throug | ncial assessment will be to Board. Duscussions |
|  | Executive Lead   | d's Assessment   |  |  |
| ADD 2017: No shange in month   |  |  |  |  |

APR 2017: No change in-month.
MAY 2017: No change
JUNE 2017: 1) AH were awarded the Management Contract for Liverpool Community Health, (Liverpool Bundle) for May 2017. Future organisational structure being developed with NHSi, the 3 Acute Trusts, local authority, LCCG and local GP's. Opportunities for all to rationalise patient pathways.
2) Partnership with Al Jalia now entering Phase 2. Specific deliverables identified and agreed. Work due to commence in Q2. Non NHS patient stretch 2) Partnership with Al Jalia now entering Phase 2. Specific deliverables identified and agreed. work due to commence in Q2. target agreed and Q1 activity delivered.
3) MOUs signed with two hospitals in China and work in progress to identifying workstreams and benefits.
4) AH awarded contract for Design and Build Consultancy for Children's Hospital in Xian.
JULY 2017: Indication to bid to acquire LCH services NHS Trust.
AUGUST 2017: Bid to go to Trust Board on 5th September 2017.
SEPTEMBER 2017: Decision on bid expected early October 2017. Awaiting to hear from Dubai regarding phase 2 extension.



|   |  |   |  |  | Titis rounde   | ition must  |
|---|--|---|--|--|--|---|
| BAF<br>3.3  | Strategic Objective: Susta                                     | inability Through External Partnersh  | nips   | Risk Title: Developing the Paediatric Service Offer  |  |   |
| Related CQC Themes: Safe, Caring, Effective, Responsive, Well Led   |  |   |  |  |  |   |
| Exec Lead   | d: Margaret Barnaby  | Type: External, Known   |  | Current IxL:<br>4-3  | Target lxL:<br>4-2   | Trend: STATIC   |
|   |  | Risk De   | escription   | on   |  |   |
| Failure to ı  | maximise opportunities with re                                 | egard to service reconfiguration and  | potent   | al loss of accreditation   | n of key specialist ser  | vices   |
|   |  | Existing Cor  | ntrol Me   | asures   |  |   |
|   | eview of service specification oning review.                   | s as part of Specialist   | • Anal   | ysis of compliance and   | d actions agreed whe   | re not fully met.   |
|   | analysis against all draft nation plans developed.             | onal service specification undertake  | n • Accr   | editations confirmed th  | nrough national revie  | w processes.  |
| Complian  | nce with Neonatal Standards                                    |   | • Com  | pliance with All Age A   | CHD Standard   |   |
| Post impl   | ementation review of Trauma                                    | Business Case.  | • Curr   | ent derogations secure   | ed in relation to speci  | alist service specs.  |
|   | Through External Partnership<br>m (All Projects)               | s - Change Programme  | • Char   | Change Programme - 7 Day Working Project   |  |   |
| The 'Out general pa   |  | 6-month review of the shape of  |  |  |  |   |
|   | Assurance E  | Evidence  |  | Gaps   | in Controls/Assura   | nce   |
| Key developments monitored through CBU Boards. Risks highlighted to CRC. Monitored at Performance Management Group. Monthly to Board via RABD & Board Compliance with final national specifications   |  | Inability to recruit to highly specialist roles due to skill shortages nationally. Trust has sought derogation in a number of service areas where it does not meet certain standards and is progressing actions to ensure compliance by due date.  Potential elective underperformance due to cancelled sessions.  Awaiting final results re. CHD service at national level. Working with partners including CMFT to progress transfer of adult CHD services and to |  |  |  |   |
|   | Actions Required to Reduc                                      | e Risk to Target Rating   |  |  | st Progress on Action  | ons   |
| Monitoring  | of action plans.   |   | Now v  | vorking with NHS Engl  | and to secure a reso   | lution for the North  |
| Clear plan community  | for delivery of strategic service care, primary care, Vanguare | ces (cardiac, neonatal, rehab,<br>d, CAMHS)   |  |  |  |   |
| Pro-active  | recruitment in identified areas                                | S.  | Trust in discussion with Liverpool Women's re future service more neonates and in discussion with Liverpool Heart and Chest re fut for cardiac service |  |  |   |
| Develop a   | strong Community Service of                                    | fering for Children in Liverpool.   | Alder Hey has been awarded a Management Contract for 6 month deliver the LCH Community Services  |  |  | ntract for 6 months to  |
| Strengther  | ning the paediatric workforce                                  |   |  | Now part of Change Programme and 7 day service as Best in Acute Care led by Steve Ryan.                    |  |   |
| Actions Required to Reduce Risk to Target Rating  Monitoring of action plans.  Clear plan for delivery of strategic services (cardiac, neonatal, rehab, community care, primary care, Vanguard, CAMHS)  Pro-active recruitment in identified areas.  Develop a strong Community Service offering for Children in Liverpool.  Strengthening the paediatric workforce |  |   | Trust neona for call Alder delive  | n discussion with Live<br>tes and in discussion<br>diac service  Hey has been awarder<br>the LCH Community | and to secure a resolution and the resol | ture service models and Chest re future retract for 6 months to |

#### **Executive Lead's Assessment**

APR 2017: The ODN recommendation single service, single workforce, two site model has been accepted by NHS England and AH and LWH are now working on an implementation plan together with Alder Hey leading. There will be a need for some Capital funding to support the reconfiguration of the ICU and the number of cots required. This is a key work stream of the Trusts Change Programme for 2017/18.

Alder Hey has been awarded a Management Contract for 6 months to deliver the LCH Community Services.

MAY 2017:

JUNE 2017:

JULY 2017:

AUGUST 2017: Agreement that Liverpool Heart & Chest NHS Trust and Alder Hey provide Cardiac Services for Liverpool patients. This has not yet resulted in a change to the flow of cardiac patients to Liverpool. SEPTEMBER 2017: No change since last update.



| BAF Strategic Objective: The Best People Doing Their Best Work 4.1   |  | Risk Title: Wo  | Risk Title: Workforce Sustainability & Capability |     |  |  |
|--|--|---|---|-----|--|--|
| Related CQC Themes: Safe, Effecti  |  |   |   |     |  |  |
| Exec Lead: Melissa Swindell  | Type: Internal, Known                    | Current IxL: Target IxL: Trend: ST/<br>4-3 4-2  |   |     |  |  |
|  | Risk De                                  | escription  |   |     |  |  |
| Failure to always have the right peop  | le, with the right skills and knowledge, |   | time  |     |  |  |
|  | Existing Cor                             | ntrol Measures  |   |     |  |  |
| Compliance tracked through the cor   | porate report and CBU dashboards         | Performance Review Group  | ıb  |     |  |  |
| CBU Performance Meetings.  |  | Mandatory Training review   | ved in February 2017.                             |     |  |  |
| Mandatory training records available online and mapped to Core Skills<br>Framework   |  | Permanent nurse staffing pool   |   |     |  |  |
| Best People Doing our Best Work' Steering Group implemented  |  | Attendance management process to reduce short & long term absence   |   |     |  |  |
| Positive Attendance Policy   |  |   |   |     |  |  |
| Assurance Evidence   |  | Gaps in Controls/Assurance  |   |     |  |  |
| Regular reporting of delivery against compliance targets via corporate & CBU reports Monthly reporting to the Board via the Corporate Report Reporting at ward and SG level which supports Ward to Board |  | Inability to train staff due to clinical workforce and acuity preventing them leaving the clinical areas.  Not meeting compliance target in relation to mandatory training in specific areas  No proactive assessment of impact on clinical practice  Sickness Absence levels higher than target.  No formalised Education Strategy |   |     |  |  |
| Actions Required to Red  | uce Risk to Target Rating                | Late  | est Progress on Actio                             | ns  |  |  |
| Sickness Policy refreshed  |  | Training for managers on Sickness Absence Policy ongoing  |   |     |  |  |
| Recruitment & Retention Strategy to  | focus on specific groups                 | Currently being refreshed with action plan to support   |   | ort |  |  |
| Develop and support talent identified within the organisation and via local supply routes e.g. apprenticeships by leveraging networks via HEE and HENW to address future workforce supply challenges     |  | Apprenticeship Strategy ratified and under implementation. Corporate objective agreed to support a succession planning process fo business critical roles by end Dec 17   |   |     |  |  |

#### **Executive Lead's Assessment**

APRIL 2017: planning underway to support apprenticeship roll out. successful Recruitment Day for nursing, resulting in over 40 nurses being appointed. MAY 2017: Task & Finish Group with staff side reviewing approach and sickness absence June 2017: Temporary Staffing Project initiated JULY 2017: Plans in place to increase support for development of ANP's AUGUST 2017: Apprenticeship activity increased, with over 30 learners now registered for an apprenticeship. SEPTEMBER 2017: New nurse pool cohorts commenced their induction period. Recruitment team engaged with national RCN jobs fair.



| BAF 4.2 Strategic Objective: The Best People Doing Their Best Work  |                                     |  | Risk                | k Title: Staff Enga      | gement         |
|---|-------------------------------------|--|---------------------|--------------------------|----------------|
| Related CQC Themes: Safe, Effective,  | Responsive, Well Led                |  |                     |                          |                |
| Exec Lead: Melissa Swindell   | Type: Internal, Known               |  | Current IxL:<br>3-3 | Target lxL:<br>3-2       | Trend: STATIC  |
|   | Risk De                             | scription  |                     |                          |                |
| Failure to improve workforce engagement   | nt which impacts upon operational p | oerformance  | and achievemen      | t of strategic aims      |                |
|   | Existing Con                        | trol Measu   | res                 |                          |                |
| Internal Communications Strategy.   |                                     | Refine Tr  | ust Values.         |                          |                |
| Roll out of Leadership Development and Leadership Framework   |                                     |  | ans for Engageme    | ent, Values and Comm     | nunications.   |
| Medical Leadership development programme  |                                     | Staff Temperature Check Reports to Board (quarterly)       |                     |                          |                |
| Values based PDR process  |                                     | People Strategy Reports to Board (monthly)                 |                     |                          |                |
| Listening into Action methodology   |                                     | Staff surveys analysed and followed up (shows improvement) |                     |                          |                |
| Assurance E   | vidence                             | Gaps in Controls/Assurance                                 |                     |                          |                |
| Outcomes from Annual Staff Survey reported to the Board. PDR completion rates Quarterly Engagement Temperature Check reported to the Board. Quarterly Engagement Temperature Check local data now sent to CBUs or a quarterly basis to enable them to analyse data locally. Ongoing consultation and information sharing with staff side and LNC Progress reports from LiA to Board |                                     |  | Recognition sche    | mes embedded             |                |
| Actions Required to Reduce  | Risk to Target Rating               | Latest Progress on Actions                                 |                     |                          | ns             |
| Revised governance arrangements that underpin effective assurance mechanisms utilising the discipline and systems provided by Programme Management methodology  |                                     | Change pr  | ogramme monitor     | rs Listening into Action | n deliverables |
|   | Executive Lead                      | d's Assessi  | ment                |                          |                |

APR 2017: Progress continues with LiA and development of C&E Project. Quarterly Temperature Check launched. MAY 2017: Local staff survey conversations continue

JUNE 2017: Launch of the Big Conversations with staff from across the Trust. Executive Visibility Programme commenced

JULY 2017: Local staff survey conversations continue

AUGUST 2017: launch of the monthly 'Star Awards'. Preparation for the Staff Survey underway.

SEPTEMBER 2017: Medicine 100% compliance with local staff survey conversations, others on their way to full compliance. Staff Survey launched. 84%
PDR compliance as at 25/09/16.



| BAF 4.3 Strategic Objective: The Best People Doing Their Best Work   |  | Risk Title: Workforce Diversity & Inclusion               |                       |                           |
|--|--|---|-----------------------|---------------------------|
| Related CQC Themes: Well Led, Effecti  | ve   |   |                       |                           |
| Exec Lead: Melissa Swindell  | Type: Internal, Known  | Current lxL:<br>3-3                                       | Target lxL:<br>3-1    | Trend: STATIC             |
|  | Risk De  | scription   |                       |                           |
| Failure to proactively develop a future wo   | rkforce that reflects the diversity of   | the local population                                      |                       |                           |
|  | Existing Con   | trol Measures   |                       |                           |
| Equality, Diversity & Human Rights Group   | nb   | Workforce Committee re-e                                  | nforced and includes  | recruitment and education |
| Workforce Plan established   |  | Staff Survey results                                      |                       |                           |
| Workforce Planning Poilcy signed off at  | WOD June 2015  | Equality Analysis Policy                                  |                       |                           |
| Equality, Diversity & Human Rights Police  | су   |   |                       |                           |
| Assurance Evidence   |  | Gaps in Controls/Assurance                                |                       |                           |
| Monthly recruitment reports provided by F Quarterly reports to the Board via WOD of Workforce Plan Monthly Corporate Report (including work Taking forward actions for LiA - enabling culture Equality Impact Assessments undertaken Workforce Race Equality Standards EDS Publication | on the Workforce Strategy and  offorce KPIs) to the Board  achievement of a more inclusive | Recruitment Strategy to focu                              | is on specific groups |                           |
| Actions Required to Reduce   | Risk to Target Rating  | Late  | st Progress on Actio  | ons                       |
| Workforce Planning Policy  |  | Draft policy produced, howe workforce needs in light of c |                       |                           |
| Deliver on our new Recruitment and Rete optimum workforce is in place and that the local community   | ntion Strategy to ensure an e workforce reflects the diversity of                          | Currently being drafted with                              | action plan to suppor | t                         |
| Proactively utilise the EDS2 results to est workforce in order to target areas for impr  |  | Currently being refreshed with action plan to support     |                       |                           |

# **Executive Lead's Assessment**

APR 2017: scoping apprenticeship opportunities for local communities as part of our strategy development.

MAY 2017: Recruitment Policy reviewed. EDS2 scoring agreed and equality objectives approved

JUNE 2017: First BME Network meeting. HRD as Exec sponsor.

JULY 2017: BME Network meetings continue with some success, bespoke work undertaken in ICU

AUGUST 2017: Disability network in development. Apprenticeship recruitment planning underway.

SEPTEMBER 2017: Job Centre Plus initiative to support long term unemployed on work placements underway. 65 BTEC students from a range of local schools commenced industion. schools commenced induction.



| BAF 5.1 Strategic Objective: Game-Changing Research And Innovation   |  | n Risk Title: R   | Risk Title: Research, Education & Innovation |                |  |
|--|--|---|--|----------------|--|
| Related CQC Themes: Responsive   | e, Well Led                              |   |  |                |  |
| Exec Lead: David Powell  | Type: Internal, Known                    | Current lxL:<br>4-2   | Target lxL:<br>4-1                           | Trend: STATIC  |  |
|  | Risk De                                  | scription   |  |                |  |
| Failure to develop a cohesive appro  | each to research, innovation & education |   |  |                |  |
|  | Existing Con                             | trol Measures   |  |                |  |
| • Establishment of RIEC Steering B   | pard                                     | Steering Board reporting th   | rough to Trust Board                         |                |  |
| RABD review of contractual arrang  | gements                                  | Programme assurance via   | regular Programme E                          | Board scrutiny |  |
| Digital Exemplar budget completed  | d and reconciled                         | Innovation Co budget in plan  | ace  |                |  |
| Assuran  | ce Evidence                              | Gaps in Controls/Assurance  |  |                |  |
| Research Strategy Committee set u<br>Research, Education and Innovatio<br>Secured ERDF funding for Innovatio |  | Lack of integration with othe<br>Commercial research offer r<br>Education Strategy needs to | ot quantified                                |                |  |
| Actions Required to Re   | duce Risk to Target Rating               | Lates   | st Progress on Actio                         | ons            |  |
| Educational Partnerships to be cem   | ented                                    | Academy proposals agreed  | at execs                                     |                |  |
| Develop a robust Academy Busines   | s Model                                  | Agreed  |  |                |  |
| Establish pipeline structure for sens  | ors including finances                   | Proposal agreed in principle  |  |                |  |
| Appoint Academy Leadership Team  |  | Appointment made  |  |                |  |
| Launch Innovation Co. and secure f   | unding                                   | Funding plan agreed at Innovation Board   |  |                |  |
| Execute plan to increase research portfolio  |  | Outline plan develped   |  |                |  |
| Execute contract for RIE with back to and HEIs   | o back arrangements with the Charity     |   |  |                |  |
|  |  | d's Assessment  |  |                |  |

APR 2017: Issue around charitable commitment now MAY 2017: Institute Phase 2 building commenced JUNE 2017: Academy model agreed JULY 2017: Agreed funding plan for Innovation AUGUST 2017: Approved Head of Academy SEPTEMBER 2017: Head of Academy now in post.



# Resource and Business Development Committee Minutes of the meeting held on: Tuesday 1<sup>st</sup> August 2017, at 1330

Room 5, Level 1, Mezzanine

| Present:       | Ian Quinlan (Chair)   | Non-Executive Director   | IQ  |
|----------------|---|--|---|
| In Attendance: | Mags Barnaby<br>Sue Brown<br>Claire Liddy<br>Sharon Owens<br>Steve Ryan<br>Erica Saunders<br>Julie Tsao             | Interim Chief Operating Officer Project Manager and Decontamination Lead Deputy Director of Finance Head of HR Medical Director Director of Corporate Affairs Executive PA     | MB<br>SB<br>CLi<br>SP<br>SR<br>ES<br>JT       |
| Agenda item:   | Peter Young<br>Steve Begley<br>Alan Burgess<br>Joe Gibson<br>Mark Flannagan   | Chief Informatics Officer Head of Procurement Procurement Team Manager (observing) External Programme Director of Communication  | CF<br>SB<br>AB<br>JGi<br>MF                   |
| Apologies:     | Claire Dove Rob Griffiths John Grinnell Graham Dixon Christopher Gildea David Powell Lachlan Stark Melissa Swindell | Non-Executive Director Service Manager Theatres Director of Finance Head of Building Operational Lead PFI Development Director Head of Planning and Performance Director of HR | CD<br>RG<br>JGr<br>GD<br>CG<br>DP<br>LS<br>MS |

As Claire Dove had been unable to attend the meeting was not quorate. Items would still be approved subject to Claire's agreement.

# 17/18/50 Minutes of the previous meeting held on 28th June 2017

RABD received and approved the minutes of the previous meeting.

#### 17/18/51 Matters Arising and Action log

All items for discussion had been included on the agenda.

### 17/18/52 Global Digital Excellence Programme

Peter Young reported the first tranche of PDC funding £2.5m had been received. A discussion was held on Meditech upgrade taking place next Wednesday. Mags Barnaby noted the downtime may cause some areas to fall behind with activity however they would be able to get back on track by the end of the financial year.

#### Resolved:

RABD received and noted the content of the GDE report.

#### 17/18/53 Performance

Service Level Agreement Monitoring (SLAM) summary identifies continued mixed performance finish M3 at -£350k. Division continues to report significant challenges with medical staff sickness; maintenance of medical rota's and vacancies as major factors affecting their ability to deliver plan. A&E attendance was low for the month and significant underperformance noted within gastro, endocrinology and neurology. Division continues to develop plans to mitigate this where possible and improve their forecast.

#### Resolved:

RABD received and noted the content of the performance report.

Page 1 of 5

# 17/18/54 Finance report

For the month of June the Trust is reporting a trading deficit of £0.2m which ahead of plan by £0.3m. Income is ahead of plan by £0.9m but expenditure is higher than budgeted by £0.6m. The year to date position is a deficit of £2.6m which is ahead of plan by £0.1m. The Use of Resources risk rating is 3 which is in line with plan and cash in the bank of £3.7m.

Elective and day cases had both achieved the forecasted plan for the month. RABD congratulated Surgery on achieving this noting the vacancies they currently have and the extra sessions completed to achieve this.

A Workforce Sustainability Task and Finish group has been created which is chaired by the Director of HR and includes representation from the divisions, Finance, HR and nursing. This is meeting fortnightly and overseeing specific actions in relation to pay expenditure. One of the aims was to reduce temporary spend by a £1m at the end of the financial year, it was agreed an update would be received in October.

**Action: CL/MS** 

Due to changes with agency targets the Trust is currently in breach of NHSI in relation to the number of Medical Locums. The Workforce group are reviewing this to bring the Trust back in line.

The Trust Control Total is a surplus of £0.1m and it is imperative that all Divisions meet their financial objectives, so that the Trust achieves agreed Control Total, and secures the full £4.4m STF funding which is cash-backed. The Divisions have prepared a forecast which totals a £7.7m deficit and although this is a £1.6m improvement from last month none of the forecasts have been accepted. The expectation is that all divisions and departments will:

- Deliver activity plans
- Control Pay Expenditure
- Achieve full CIP target
- Break even against budget control totals

#### CIP

The month 3 CIP performance across the Trust showed an overachievement of £0.2m. For the year the Trust is forecasting savings of £6m against a target of £8m. The main gaps are in Medicine (£1.1m), Surgery (£0.2m) and Community (£0.4m) divisions.

### **Resolved RABD:**

Received and noted the content of the Finance report for month 1.

#### **Contracts**

#### **CCG Contract**

The acting as one agreement for North Merseyside is worth 25m, the agreement had been made to provide security on income. It was noted the agreement would provide opportunities in guarter 3.

Action: MB/CL

#### Welsh Contract

As reported at the last meeting the Welsh contract had not yet been signed. This is due to a dispute between the Welsh Commissioners and English hospitals as the new contract increases the value of Welsh activity. As Alder Hey's contract would reduce in value it was agreed a memorandum of understanding would be written to the Welsh Commissioners to confirm Alder Hey would continue to providing services to the Welsh Commissioners unless otherwise advised.

Action: MB/AMc

#### Resolved:

RABD noted the content of the contacts report.

#### **Capital report Quarter 1**

Following submission to NHS Improvement on the approved capital programme of £29.092m a paper summarising risks and issues in quarter 1 was presented.

# Potential Emerging Risks at Q1

- Following a CQC assessment one of the recommendations was to replace the current defibrillators to the same brand and replace the trolleys with a fleet expansion for the total of £419k for approval, to be funded in part by bringing forward 18/19 and in part as cost pressure. A discussion was held on the current defibrillators and whether they could be used for community. Claire Liddy agreed to discuss this with Barry Laithwaite.
- Audiology Booth Costs £50k, overage costs from PFI quote for approval.
- Capital Medical Equipment The Trust would need to allocate a further £0.4m to as contingency to ensure appropriate levels of service provision for noting.
- Health and Safety Building review estimates £60-£300k for noting.

During July and August an exercise will be completed by the Capital Programme Group to assess how much of this pressure can be handled via slippage and how much will result in an increased capital spend during 2017/18.

#### **Resolved RABD:**

Noted the contents of the report.

Approve the additional funding for Defibrillators and Audiology Booth.

Agreed further quarterly updates

#### **Reference Cost**

RABD received the reference cost report in relation to the combined reference costs/Education and Training prior to submission.

RABD requested an update at the September meeting on next steps for the service review.

**Action: Laurence Murphy** 

### Resolved:

RABD approved the recommendations:

- (a) the costing process ahead of the collection;
- (b) information, data and systems underpinning the return are reliable and accurate;
- (c) there are proper internal controls over the collection and reporting of the information included in the collection, and these controls are subject to review to confirm that they are working effectively in practice; and
- (d) costing teams are appropriately resourced to complete the return, including the self-assessment quality checklist and validations accurately within the timescales set out in the reference costs guidance.
- (e) they have, on behalf of the board, approved the final return prior to submission;
- (f) the return has been prepared in accordance with NHS Improvement's Approved Costing Guidance, which includes the combined costs collection guidance.

# **Corporate report**

#### **Resolved RABD:**

Received and noted the contents of the CR report for June.

#### 17/1855 CIP

The month 3 CIP performance across the Trust showed an overachievement of £0.2m. For the year the Trust is forecasting savings of £6m against a target of £8m. The main gaps are in Medicine (£1.1m), Surgery (£0.2m) and Community (£0.4m) divisions.

#### Resolved:

RABD received the content of the report.

#### 18/18/56 Procurement

Steve Begley gave a presentation on procurement's stocktake for 17/18 noting at month 4 the team are forecasting £722k against £1m target. This target is one of the highest in the North West. A slide on £37m expenditure scope was presented.

Steve Begley reported on the requirement for clinical engagement and the clinical procurement group that had been arranged. As Steve Ryan had previously supported reduction of procurement prices at a previous Trust it was agreed a meeting would be arranged for this to be discussed further outside of the meeting.

One of the aims when building the new hospital was to use natural sources or reused recycled energy. It was highlighted that whilst the Trust is trying to be environmentally friendly it is not a cost effective option, this was currently being reviewed.

RABD noted the reduction in waivers for items over £5k.

#### Resolved:

RABD received an update on Procurement and agreed to receive further quarterly updates. **Action: SB** 

# 17/18/57 Programme Assurance

As Joe Gibson had on leave at the time of the submission of papers his summary had not been included however he advised he agreed with the Executive Sponsor summary for all three of the workstreams.

Following the second meeting of the Programme Board (PB) an action list had been circulated for completion prior to the next (PB).

As Debbie Herring had now left the Trust John Grinnell is now Executive Sponsor for Growing Through External Partnerships.

Jeannette Richardson Programme Assurance support had left the Trust due to this Joe Gibson, John Grinnell and Claire Liddy are reviewing the process over the next 12 months to ensure the programmes are embedded.

### Resolved:

RABD noted the report and the work being undertaken to increase pace and benefit opportunities.

### 17/18/58 Weekly waiting times update

All core access standards have been achieved for June CAMHS waits have increased due to staffing shortages in key areas and impact of reduced funding to 3<sup>rd</sup> sector.

### Resolved:

RABD noted the report.

### 17/18/59 Marketing and Communication Activity report

The chair welcomed Mark Flannagan to his first RABD meeting. Overall media coverage for June had decreased from last month: this was in relation to two local incidents that had occurred in May.

Page 4 of 5

Mark advised since starting the Trust last month a review of internal communications has taken place and a review of external coms was to follow. Mark agreed to include further information on internal communications within the report once the review had been completed.

Action: MF Resolved:

RABD noted the report.

# 17/18/60 Quarter 1 Monitoring report

Resolved:

RABD received the Q1 Monitoring report for submission.

#### 17/18/62 Monthly Debt Write Off

Resolved:

RABD approved June's write offs for £366.43.

#### 17/18/63 PFI Contract Monitoring report

As Graeme Dixon and Chris Gildea had not been available to attend RABD asked for a response on the following queries:

- When is the deal expected to be settled.
- Have Theatres been updated with arrangements for changes to the floor?
- An energy update was requested for the August or September meeting.

# 17/18/64 Any Other Business August RABD

A discussion was held on whether an August meeting was required, it was agreed Julie Tsao would confirm if there was a substantive agenda for the meeting to go ahead.

**Date and Time of the next meeting:** Wednesday 27<sup>th</sup> September 2017 at 09:30, Room 5, Level 1 Mezzanine.

NB: Meeting moved to Thursday 28th September at 3:30pm Room 8, Level 1 Mezzanine.



# International Child Health at Alder Hey

# **Briefing Paper for Trust Board**

# **Purpose**

This paper seeks Board support for our vision for International Child Health (ICH) at Alder Hey and how this can be brought about. The paper summarises the current position in Alder Hey with respect to involvement in health activities abroad and proposes the development of a Department of International Child Health. If supported, we can work collaboratively on implementation and associated governance arrangements. This umbrella unit would be responsible for implementing a comprehensive strategy for ICH, coordinating all aspects of international work within a cohesive framework, and contribute to Alder Hey becoming recognised as one of the best children's hospitals in the World.

# **Executive Summary**

- Alder Hey has a long history of engagement with International Child Health, encompassing a wide range of activities by both individuals and departments.
- The Trust supported an initial vision statement (2011) and a proposed strategy (2012) regarding global child health and commissioned an independent review of ICH activities by Ernst Young in 2014.
- EY recognised benefits of pursuing ICH activities including reputational, recruitment and retention, research and educational and bringing in revenue.
- There has been progress with some business development opportunities particularly with Al Jalila Hospital, Dubai but it is proposed that there is great scope for significant expansion with the resultant benefits of a major income stream and enhanced standing of our organisation.. A clear business plan for commercial activities is required.
- Many activities overseas (including humanitarian, research and education) have taken place and are ongoing, driven by committed individuals. There is, however, only one formal partnership existing between Alder Hey and a developing country partner.
- A comprehensive ICH strategy would incorporate five key themes: international health partnerships (particularly with low-income countries); humanitarian 'mission' operations; education and training; research and commercial/business development.
- Alder Hey has many strengths in each of these areas with potential to fulfil its vision of being a world-leading children's hospital by developing all aspects of ICH.
- However, the existing ICH group has only met sporadically, suffered from inconsistent leadership and has not developed or delivered a cohesive strategy.
- Overall, engagement with international child health to date is patchy and, at present, there is no clearly defined Alder Hey "offer" with respect to any of the five areas of ICH.
- A department of ICH will provide the recognition and the key functions required to realise the vision of ICH being both truly valued and a key strategic aim.
- ICH is an area where Alder Hey can stand out from its competitors and move towards the status of an internationally-recognised children's hospital of excellence.



### **Background**

- In 2011, Barry Pizer was asked by Ian Lewis, on behalf of the Trust Board, to develop a
  vision statement for international child health (ICH). An ICH group was established and
  developed a strategy which was shared with the Board. This encompassed broad areas of
  work including commercial consultancy, treating overseas private patients, research and
  education, as well as international humanitarian and partnership work in resource-poor
  countries.
- An exercise was conducted (2013) to map out the areas of activity by Alder Hey staff around the World, that highlighted the scope and value of international collaboration and training (Appendix 1).
- EY (formerly Ernst Young), a London-based multinational professional services firm, were commissioned in 2014, to conduct a free-of-cost scoping exercise in ICH activity, which identified benefits as the 'four R's':
  - Reputation: One of Alder Hey's five key strategic aims, expressed in the Strategic Plan 2014-2019, was to "to grow existing operations and brand name beyond the domestic region by growing our international footprint." We provide excellent secondary and tertiary level services for our patients. However we do not hold the status as an internationally recognised children's hospital of excellence. Examples of such institutions include Great Ormond Street Hospital, the Hospital for Sick Kids, Toronto and Boston Children's Hospital. Enhanced participation in international activities will greatly enhance our ambition to be recognised as a world leading children's hospital.
  - Recruitment and Retention: 'We look to attract world-leading medical professionals and researchers and we recruit from a limited global pool of such individuals. We also want to retain our current world-leading professionals. Working internationally will improve our retention rate and improve satisfaction levels.
  - Research and Education: Our clinical academics and other staff have a very strong portfolio of research in ICH. Our research activities and our reputation as a leading centre for research will be enhanced by increasing engagement with research activities overseas. Increased international networks will support us to maintain our role as a leading education centre and enhance the development of the Alder Hey Academy.
  - Revenue: Our international work will lead to additional revenue for us, forecast at ~£8.7m over 5 years. This will be achieved through enhanced delivery of care provision to international patients both at our hospital and at the overseas partner institutions. It is envisaged that educational activities may also attract significant income-generation.
- EY outlined strategic steps but the original ICH strategy was not fully endorsed by the Board at that time, possibly due to competing priorities.
- With the Department of Health's support, Alder Hey started to explore more commercialbased initiatives which led to the appointment of Angie May as lead nurse and Esme Evans as accountant for international business.
- The ICH group continued to meet but suffered from inconsistency in leadership with a succession of different chairpersons (Sir David Henshaw, Therese Patten, Jon Stevens, Louise Dunn, Debbie Herring) and focus on the business aspect of ICH has taken precedence over other aspects.



# The Vision for International Child Health at Alder Hey

Our vision is that Alder Hey will be contributing to improving the health of the world's children, have an established, international paediatric brand with a reputation for excellence, be a proven partner with a track record of international delivery and have a balanced portfolio of income-generating and philanthropic activities in all areas of paediatric health delivery.

International Child Health will be fully integrated into strategic planning and Trust development, leading to Alder Hey establishing a reputation as a truly global organisation, rather than just a very good children's hospital.

The international child health portfolio will encompass the following five themes:

#### 1. Health Partnerships:

These are established, formal and equitable two-way health partnerships between institutions in high income and those in low income settings, with clear benefit to both partners. Examples at Alder Hey include our longstanding relationships in Malawi (currently informal), our 21 year association with Kanti Children's Hospital, Kathmandu (underpinned by a formal MOU) and several other links that are of somewhat shorter duration.

# 2. Humanitarian work:

There is an incredible amount of humanitarian work being undertaken by Alder Hey staff which has largely gone unrecognised. Examples include Ram Dhannapuneni's regular cardiac surgery health camps in India, Caron Moores' engagement with charities providing health camps in Nepal and Andrew Curran's links with India, among many others. Many of these activities involve wider teams of staff.

#### 3. Commercial activities:

Some progress has been made towards developing commercial activities overseas, including our relationship with Al Jalila. However, current plans fall short of what was initially anticipated when the Trust embarked on this area of work.

#### 4. Research:

World leading research is a corporate aim and, historically, much of Alder Hey's research has been carried out on a global basis: internationally-based clinical trials in oncology and other areas; world-leading research being conducted by high-profile individuals such as Enitan Carroll, Atif Rahman and Nigel Cunliffe.

# 5. Education:

This area offers tremendous potential to benefit Alder Hey with respect to global reputation, staff benefits and income generation. There are multiple opportunities for development, including formal visiting fellows programme, MSc and higher degree programmes.



# Why a Department of ICH?

- The five key themes of ICH have a degree of overlap between them. For example, international health partnerships may contain educational and/or research elements.
   Business development opportunities may well include a strong health partnership component and have education and training and research opportunities.
- There is potential for cross-subsidization principles between international private patient activity and other activities, including work in low income nations, as well as the core business.
- However, currently, there is no clear understanding of Alder Hey's "offer" in any of these
  areas. Where we have pursued opportunities, they have often been reactive in nature. We
  do need to fully understand what our offer is, why and how we are in the best position to
  deliver it and what are our comparative advantages over our competitors.
- Without this, we cannot maximise opportunity and are unable to describe and therefore realise expected commitments and benefits.
- The fragmented ICH group has not been able to devise and deliver the cohesive strategy described above. The establishment of a department recognises the importance of defined roles and responsibilities in key areas for the effective delivery of the above vision.
- This includes strong clinical leadership and experience in this field, which may mean recruiting external individual(s) with a proven track record.
- Additional core functions such as administration / financial / communications / legal / HR / IM&T support are required.
- The department's responsibilities will be devising and delivering Alder Hey's offer, taking into
  account a resourcing plan and due diligence. There must also be a formal review process for
  all international working with robust governance and commercial systems. Some of these
  "offers" may also be extended to UK opportunities, e.g. 'design and build' or research and
  education.
- A department of ICH provides a central point of information and contact, coordinating overseas work and links with other organisations.

# **Should the Board support this vision?**

Working internationally fully supports all aspects of our strategic plan: the Trust vision: "building a healthier future for children and young people"; the Trust aspiration: "to be World leading" and our goals for: delivery of outstanding care, the best people doing their best work, sustainability through external partnerships and game-changing research and innovation.

Historically, the Board has supported the principles of ICH and pursued some aspects of it.

#### Can we afford the investment now?

Significant investment in time and effort has already been made; there needs to be a focus on the return on investment from activities against previously defined strategic goals. It is not clear that there has been a routine approach to either tracking time and effort on international work or on the net returns.

Many staff throughout the Trust invest their own time and resources in overseas working, emphasising the value that is placed on this work by individuals throughout the organisation. This work has not been celebrated, meaning opportunities to promote our reputation, and potentially generate income, may have been missed.

#### Is there political support?

The UK government recognises the importance of addressing global health issues (see Appendix 2) and its commitment to do so is summarised in a DH paper entitled "The Framework for NHS Involvement in International Development" (March 2010). This document addresses issues including the UK policy context, the key principles for effective involvement in international development, the benefits of NHS involvement in international development, the architecture for NHS activity to support developing countries and good practice for organisations, individuals and employers.

# What are the benefits to Alder Hey?

There are well described benefits of global child work to NHS organisations which apply across all health provider roles. These include:

- Provision of better return on investment in training: staff return from visits abroad with a wide range of skills and a better ability to work in a challenging environment, and in teams, for minimal cost to the organisation.
- Enhanced leadership and professional skills for NHS clinicians and managers.
- Enhanced reputation of the organisation amongst the public, staff and the media
- Greater staff satisfaction and improved retention and productivity. Staff return refreshed.
- Greater understanding and sensitivities of the needs of individual patients.
- Greater organisation cohesion, innovation and corporate social responsibility which can embed key NHS values set out in the NHS constitution and can potentially lead to higher sustainable organisational performance and cultural competence.
- Education and research opportunities that can benefit patients in all communities.
- A greater understanding of social and ethnic diversity
- Greater understanding of global health issues and knowledge of diseases not routinely seen in the UK.
- Income generation

#### **Current strengths**

- 1. Existing strong UK partnerships
  - University of Liverpool: the University of Liverpool sees internationalisation as a key priority. Many Alder Hey staff members hold academic positions at the University of Liverpool, and many clinical academics from the University are based at Alder Hey.
  - Liverpool School of Tropical Medicine (LSTM): historic links include courses delivered at Alder Hey, clinical and research work. The journal 'Paediatrics and International Child Health' is based there. Tropical Health and Education Trust: this NGO co-manages the International Health Links Funding scheme (in which Alder Hey partnerships have been successful) and has built up considerable experience in developing, managing and evaluating links. International Health Links Centre, Liverpool: a one-stop shop resource centre set up in 2009 and based at LSTM.




- RCPCH (Royal College of Paediatrics and Child Health): has an International Board.
- The British Council
- Global Health NHS, North of England, Northwest Office
- 2. Long-standing successful international partnerships, in both low income countries (e.g. Nepal (formal link with MOU) and Malawi, as well as in the Middle East
- 3. Track record of successful grant applications for partnership work with potential to apply for larger grants.
- 4. Committed and enthusiastic staff: many people already engaged in overseas work through their own initiatives or with other organisations
- 5. Education: We have existing strong training and education programmes, recognised nationally and internationally, with particular strengths in infectious diseases, CAHMS, paediatric neurology and epilepsy, orthopaedics, pharmacy and medicines.
- **6.** Research: Alder Hey staff have led the way in many fields, e.g. vaccinations adopted by WHO, Infectious Diseases and Child and Maternal Mental Health.

#### **Conclusion:**

- Alder Hey has many strengths in international child health and a real opportunity to promote this aspect of working as a key part of its brand
- There is activity in all domains of ICH but this is not coordinated and there is little governance or accountability in some aspects.
- Establishment of a Department of International Child Health is an opportunity to coordinate and reduce inconsistency in these activities, develop strong and realistic offers within a clear framework, maximise income generation and mitigate risks.
- This paper seeks Board level support to adopt this vision as an organisational ambition.
- The next steps would be:
  - the identification of key personnel to take this forward
  - the formal establishment of a Department of ICH
  - a formal Alder Hey ICH strategy
  - a clear communications strategy for ICH
  - describing and mapping out work undertaken to date
  - identifying barriers and blockages to progress
  - designing realistic / aspirational future offers: high-level draft offers in each domain
  - outlining the risk and governance management framework that is needed for these offers

See the Timeline in Appendix 3.

Appendix 1: Map of overseas activities (2013)





Appendix 2: Department of Health documentation addressing overseas working

International Humanitarian and Health Work Toolkit to Support Good Practice (2003).

http://www.fph.org.uk/uploads/international\_humanitarian\_and\_healthwork\_toolkit.pdf

Working together for better health (2007)

http://www.who.int/pmnch/activities/advocacy/workingtogether.pdf

Global Health Partnerships: the UK contribution to health in developing countries, the Government Response (2008)

http://www.wales.nhs.uk/documents/DH 083510.pdf

Evaluation of links between north and south healthcare organisations (2008)

https://www.eldis.org/document/A72431

Health is Global: a UK Government strategy 2008-13 (2008)

 $\underline{\text{https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/215656/dh\_125671.p} \\ \underline{\text{df}}$ 

Eliminating World Poverty: Building our Common Future (2009)

https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/229029/7656.pdf

UK Government's Institutional Strategy for working with WHO (2009)

https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/67475/Building-stability-overseas-strategy.pdf

The Framework for NHS Involvement in International Development (2010)

 $\underline{\text{http://www.severndeanery.nhs.uk/assets/Internationalisation/TheFrameworkforNHSInvolvementinInternationalDevelopmenttcm79-26838.pdf}$ 



# Appendix 3: International Child Health at Alder Hey – 2 year Plan

|                        | Year 1   | Year 2   |
|------------------------|--|--|
| Overarching            | Appointment of ICH Group Chair and identification of membership  |  |
|                        | Appointment of ICH Administrator   |  |
|                        | Planning for Department of ICH   | Department of ICH in place   |
|                        | Development of ICH Strategy (describing 'offers' in each domain)   | Completion and Implementation of ICH Strategy Review with respect to 'offers'    |
|                        | Mapping Process of AH ICH Activities   |  |
|                        | Develop and Implement Risk assessment Tool   | Review and refine Risk assessment Tool   |
| Communicatio ns        | Appointment of part-time ICH Communications Officer  |  |
|                        | Develop communication framework  | Review and refine communications framework                                       |
|                        | Development of ICH Webpages  | Refinement of ICH Webpages   |
|                        | Develop Alder Hey International Brand Grand Round updates x 2  | Role out Alder Hey International Brand   |
|                        | Grand Round apactos X 2  | Grand Round progress reports x 2   |
|                        |  | Report activities in other media   |
| Health<br>Partnerships | MOU with Queen Elizabeth Central<br>Hospital, Blantyre, Malawi; scoping visit 1<br>(AH team to Malawi). Outline plan for | Scoping visit 2 (QECH team to AH). Finalise activity plan; start first activity. |
|                        | collaborative activities.  | Other MOUs / Engagement dependent on mapping process                             |
| Commercial             | Fully establish Overseas Business Unit (constitution/TOR)  | Review Overseas Business Unit  |
|                        | Discussions with Trust Board - Breath of Commercial Activities   | Expansion of Commercial Activities   |
|                        | Second Contract with Al Jalila Hospital  | Expansion of collaboration with Al Jalila (3 <sup>rd</sup> Contract)             |
|                        | Expansion of collaboration with Al Jalila [Neurosurgery/Neurosciences] Visiting Clinician programme Telemedicine         |  |
| Education              | Development of ICH Education Strategy  |  |
|                        | Host 3-4 RCPCH Visiting Fellows  | Host 3-4 RCPCH Visiting Fellows  |
|                        | 1 or 2 LSTM MSc Students (Nepal +/-other)  | 1 or 2 LSTM MSc Students (Nepal +/-<br>Malawi)                                   |

International Child Health Briefing Paper 3 Oct 2017 Authors: Sian Falder, Barry Pizer

rs: Sian Falder, Barry Pizer Page 9



|              | Engagement with Partners re Education (e.g. RCPCH)  |   |
|--------------|---|---|
|              | Development of Alder Hey International Fellowship Programme                                       | Start of Fellowship Programme                               |
|              | Business plan for joint AH/LSTM<br>Leadership in Global Child Health 6 week<br>course             | Deliver first course and review                             |
|              | Business plan for ETAT+ course<br>(Emergency Triage Assessment and<br>Treatment + continued care) | Deliver first course and review (Innovation Hub)            |
| Research     | Engagement with HEI Partners  | PhD Studentship   |
|              | Mapping and prioritisation of research themes   | Implementation plan   |
|              |   | Review activities   |
|              | Exploring opportunities through the Global Challenges Research Fund                               |   |
| Humanitarian | Review mapping process and<br>Implementation plan   | Collaboration with Commercial Partners re humanitarian work |
|              | Developing a theme to our humanitarian work   |   |



# **Trust Board of Directors**

# 05 October 2017

| Subject/Title   | Global Digital Excellence (GDE) Programme Update  |
|---|---|
| Paper prepared by   | Peter Young, Chief Information Officer<br>Cathy Fox, Associate Director of IM&T<br>Jenny Wood, GDE Programme Manager  |
| Action/Decision required  | The Trust Board is asked to note the updated progress towards participation in NHS England's GDE Programme and subsequent initiation of the Programme.                |
| Background papers   | N/A   |
| Link to:  | IM&CT Strategy  |
| <ul> <li>Trust's Strategic Direction</li> <li>Strategic Objectives</li> </ul> | Significant contribution to the strategic objectives for:-  - Clinical Excellence - Positive patient experience - Improving financial strength - World class facility |

# Summary of progress in last month

# **Funding**

The Trust received confirmation of the first tranche of PDC funding on Friday 16<sup>th</sup> June (approximately £2.5million), this was received and we were available to drawn down from on the 10<sup>th</sup> July.

The remaining revenue funding (approx. £800k) has been made available via the CCG.

# **Fast Follower**

The Alder Hey Fast Follower Trust, Clatterbridge, are currently undergoing 'due diligence' A site visit was conducted successfully on the 20<sup>th</sup> September 2017 and approval was given and Clatterbridge are now completing their funding agreement.

At the next Board a copy of the Funding Agreement and Letter of intent will be circulated for formal agreement and sign off

# **Programme Assurance**

NHS Digital has attended Alder Hey and completed their assurance testing for the second milestone.

The final assurance report is due and will be provided to the Board for overview.

# **Programme Delivery**

Work remains underway in preparations for the achievement of the phase 3 milestones:-

- Recruitment to all approved posts. It is anticipated the full team will be in place by the end of September.
- Revision of milestones has now been completed to take into account the delays to the funding at national level; this includes the movement of milestone three from March to February 2018 for financial reasons.
- The Statement of planned benefits has been completed and submitted for NHS Digital to review.
- Internal organisational engagement work ongoing with good progress.
- System development has been completed for two speciality packages, with development commencing on six "specialty packages"
- The additional eight specialities are mapping their requirements
- A "speciality package launch" is scheduled for seven specialities on the 9<sup>th</sup> October.
- The Voice Recognition project has now trained circa 250 users and is now live within Gen Paeds, Ortho, Ophthalmology, Amb and Neph.
- The average turnaround time has reduced from 16 days to 8.5 days.
- Scoping and development of the Paediatric Portal is underway with a launch being planned for key stakeholders
- Emergency Theatre List System (ELIS) is now live

- TCI Theatre Pathway re-design has commenced and is being led by Serive Manager, Sian Calderwood.
- IMO Clinical Terminology software implementation underway.

A copy of the GDE Programme Dashboard which summarises the status of all individual workstreams is included.

# **Next Steps**

- Continue working towards the delivery of milestone three (February 2018) respectively.
- Assurance testing results to be returned by NHS Digital for milestone two.

# **Recommendation**

The Trust Board is asked to:-

1. Note the progress with the GDE Programme and ongoing work to progress towards the third milestone due on 28<sup>th</sup> February 2017.

Peter Young

Chief Information Officer

22th August 2017

| GDE Programme Dashboard - Assurance |             |  |   |   |                               |                 |   |
|-------------------------------------|-------------|--|---|---|-------------------------------|-----------------|---|
| Version 0.1 10/04/17                |             |  |   |   | PROJECT<br>RAG                |                 |   |
| Project Ref                         | GDE?        | Project Title  | Project Description   | Delivery Date   | OVERALL PROJECT<br>RAG status | % Progress      | Comments for attention of the Project Team, Steering Group and sub-<br>Committee  |
| Workstream 1                        | - HIMSS lev | rel 7 EPR - System wide  | projects  |   |                               |                 |   |
| 1B(a)                               | GDE         | Voice recognition deployment                                   | Deploy voice recognition solution in MEDITECH                       | 30 September 2017 - Stage 1   |                               | Stage 1<br>100% | Live in Opthalmology. Video user guide created. FAQ pulled together.  |
| 1B(b)                               | GDE         | Voice recognition deployment                                   | Deploy voice recognition solution in Medisec                        | 30 September 2017 - Stage 1   |                               | Stage 1<br>100% | Live in Opthalmology. Video user guide created. FAQ pulled together.  |
| 1C(a)                               | IM&T        | Prescribing and<br>Medicines<br>Administration<br>Enhancements | Warfarin  | Thursday, March 1, 2018   |                               | 75%             | Review of resources in place. Awaiting response from clinical lead.   |
| 1C(b)                               | IM&T        | Prescribing and<br>Medicines<br>Administration<br>Enhancements | Antimicrobial   | Thursday, March 1, 2018   |                               | 35%             | Review of resources in place.   |
| 1C( c)                              | IM&T        | Prescribing and<br>Medicines<br>Administration<br>Enhancements | Bedside medication verification                                     | Thursday, March 1, 2018   |                               |                 |   |
| 1C(d)                               | GDE         | Prescribing and<br>Medicines<br>Administration<br>Enhancements | Continuous infusions  | Wednesday, February 28, 2018  |                               |                 | Pilot Date, no longer a Project   |
| 1C(e)                               | GDE         | Prescribing and<br>Medicines<br>Administration<br>Enhancements | Dose range checking   | 28 Febraury 2018  |                               |                 | Pilot Date  |
| 1E                                  | GDE         | MEDISEC enhancements   | Tertiary letter improvements  | Wednesday, February 28, 2018  |                               |                 | Scoping discussion required with associate COO's, Nik to facilitate   |
| 1E(b)                               | GDE         | MEDISEC enhancements   | Inclusion of letters into ImageNOW                                  | Saturday, September 30, 2017  |                               | 100%            | Completed   |
| 1F                                  | GDE         | POCT device integration  | Integration of POCT devices into the<br>MEDITECH system             | Wednesday, February 28, 2018  |                               |                 | 1H to be completed first  |
| 1G                                  | GDE         | GS1 Barcodes   | Enable technical solution for use of GS1 barcodes where appropriate | Wednesday, October 31, 2018   |                               |                 | Harvey Livingstone as clinical lead. This needs to be put to the GS1 Working Group.<br>Agree scope with organisation. Project Manager required. Next Wednesday. Survey-<br>Send wristbands to see if GS1 complaint. Request ID numbers from GS1 for locations.<br>Meeting required in relation to approach. |
| 1H                                  | GDE         | Vital Sign device<br>integration                               | Integration of Welch Alyn vital signs monitors into MEDITECH        | 30 December 2017 - Pilot<br>31 December 2017 - Roll out                     |                               | 45%             | ML/MD & NB around workflow change. Interface promoted to live Amanda Turton to review and sign off.   |
| 1J(a)                               | GDE         | Theatre improvements -<br>Emergency List.                      | Emergency list solution   | Saturday, September 30, 2017  | Completed                     | Stage 1<br>100% | Live  |
| 1J(b)                               | GDE         | Theatre improvements -<br>TCI to Theatre                       | TCI to Theatre improvements   | 30 September 2017 - Stage 1   |                               | Stage 1<br>100% | Update on Pre-Assessment business case required.  |
| 1K(a)                               | GDE         | Internal interfaces<br>Haemonetics                             | Haemonetics   | Procuremnt date: 30 September 2017<br>Implementation date: 28 February 2017 |                               | 10%             | Meeting to roll in with ~TAR and review implementation.   |
| 1K(b)                               | GDE         | Internal interfaces ECM  | ECM file import   | Saturday, September 30, 2017  |                               | 70%             | Badgemet pdf export Split this off on the dashboard.  |
| 1L                                  | GDE         | IMO implementation   | Implementation of Clinical interface terminology software           | Page 1 of 4<br>28 Febraury 2018   |                               | 25%             | Frank working to edit ERD form & Theatres. Changing look up. Roll-out with clinical sign off. Training required. Clinical Lead required with pathology and radiolofy lead.  |

| GDE Programme Dashboard - Assurance |              |  |   |  |                               |                 |  |
|-------------------------------------|--------------|--|---|--|-------------------------------|-----------------|--|
| Version 0.1 10/04/17                |              |  |   |  | PROJECT                       |                 |  |
|                                     |              |  |   |  | RAG                           |                 |  |
| Project Ref                         | GDE?         | Project Title                          | Project Description   | Delivery Date  | OVERALL PROJECT<br>RAG status | % Progress      | Comments for attention of the Project Team, Steering Group and sub-<br>Committee   |
| 1M                                  | GDE          | Day Forward Scanning                   | Automate the production and scanning of records   | Saturday, September 30, 2017                                 |                               | 100%            | Deployment within Cardiology.  |
| 1N                                  | GDE          | Historic data migration                | Complete migration of historical data from MEDITECH 5   | 30 September 2017 - Stage 1 procurement and proof of concept |                               | Stage 1<br>100% | Clinical Group required to review the data.  |
| 10a                                 | GDE          | PACS Other Ologies                     | EEG - Consolidation of all clinical images into the PACS system   | Thursday, May 31, 2018                                       |                               |                 |  |
| 10 b                                | GDE          | PACS Other Ologies                     | ECG - Consolidation of all clinical images into the PACS system   | Sunday, December 31, 2017                                    |                               |                 |  |
| 10(c)                               | GDE          | PACS Other Ologies                     | Gait Lab - Consolidation of all clinical images into the PACS system  | Sunday, December 31, 2017                                    |                               |                 | Gait lab procurement to be chased.   |
| 1P                                  | GDE          | Encoder implementation                 | Implement integrated encoding software for the Clinical Coding team   | Stage 1 - depoly coding solution 30<br>September 2017        |                               | 95%             | Training organised.  |
| 1R                                  | GDE          | Mobile Phlebotomy solution             | Adaptation of COWs to allow sample labels to be printed at the point of care  | Saturday, March 31, 2018                                     |                               |                 | Discussion with Hilda for Operation support. Upgrade of Meditech   |
| 18                                  | GDE          | Infrastructure                         | Provision of additional hardware (subject to approval) to suppport clinical processes including fast user switching | Saturday, September 30, 2017                                 |                               |                 |  |
| 1T                                  | IM&T         | Booking and Scheduling<br>Enhancements | Develop an enhanced solution to support<br>improvements to booking and scheduling<br>processes                      | Saturday, September 1, 2018                                  |                               | 10%             | Scope agreed.  |
| Workstream 2                        | - Speciality | / Packages                             |   |  |                               |                 |  |
| 2A                                  | GDE          | Emergency Department                   | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Friday, September 1, 2017                                    | Completed                     | 100%            | Completed and archived for Gateway 4 Post implemenation. Review meeting arranged for 15.11.17 with Birnall Metha and Colin Prayle. |
| 2B                                  | GDE          | Gynaecology                            | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Friday, September 1, 2017                                    | Completed                     | 100%            | Completed and archived for Gateway 4   |
| 2C                                  | GDE          | Rheumatology                           | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Saturday, September 30, 2017                                 |                               | 60%             | Meeting Monday to re-review feedback. 12days copying into go live. 4 weeks Monday.   |
| 2D                                  | GDE          | Gastroenterology                       | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Thursday, November 30, 2017                                  |                               | 10%             | Finish process mapping pathways. COP Friday will have all requirements.  |
| 2E                                  | GDE          | Neurosurgery                           | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Friday, November 3, 2017                                     |                               |                 | Development to commence. 2 weeks worth of dev.   |
| 2F                                  | GDE          | Respiratory                            | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Friday, November 3, 2017                                     |                               | 10%             | Process mapping of CF Clinic.  |
| 2G                                  | GDE          | CAMHS                                  | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Thursday, October 19, 2017                                   |                               | 40%             | Requirements received. 6 weeks to dev.   |
| 2H                                  | GDE          | Community Paeds                        | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways     | Page 2 of 4 Tuesday, October 24, 2017                        |                               | 5%              | Review of IHA, requirements for ASD pathway received. Review of deadline.  |

| GDE P               | rograi              | mme Dashb                                   | oard - Assurance  |  |                               |                 |  |
|---------------------|---------------------|---|---|--|-------------------------------|-----------------|--|
| rsion 0.1 10/04/17  |                     |   |   |  | PROJECT                       |                 |  |
|                     |                     |   |   |  | RAG                           |                 |  |
| Project Ref         | GDE?                | Project Title                               | Project Description   | Delivery Date  | OVERALL PROJECT<br>RAG status | % Progress      | Comments for attention of the Project Team, Steering Group and sub-<br>Committee   |
| 21                  | GDE                 | Dietetics                                   | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | Tuesday, October 31, 2017  |                               | 50%             | John developing. Friday to review.   |
| 2J                  | GDE                 | Junior Doctors                              | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | твс  |                               | 10%             | Generic docs - underway. Review of project plan required by ML/LF and JW           |
| 2K                  | GDE                 | LTV   | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | Friday, February 2, 2018   |                               | 1%              | Chased up  |
| 2L                  | GDE                 | Pre-Op                                      | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | Friday, February 2, 2018   |                               | 1%              | Requirements end of week   |
| 2M                  | GDE                 | Chronic Pain                                | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | Friday, February 2, 2018   |                               | 1%              | Requirements end of week.  |
| 2N                  | GDE                 | Immunology & Infectious<br>Diseases         | Delivery of electronic clinical documentation<br>workflow designed to reflect best practice<br>protocols and pathways | Friday, February 2, 2018   |                               | 1%              | Scope received. GS to be chased re requirements.                                   |
| 20                  | GDE                 | Transitional Care                           | Delivery of electronic clinical documentation workflow designed to reflect best practice protocols and pathways       | Friday, February 2, 2018   |                               | 1%              | Requirmeents being pulled together. Meeting to clinicall review and review by IM&T |
|                     |                     |   |   |  |                               |                 |  |
| Vorkstream 3:<br>3A | : Paediatric<br>GDE | Clinical Portal  Paediatric Clinical Portal | Provide secure access to multiple aspects of a pateint record in one place  | Stage 1 Scope and commence procurement 28<br>February 2017   |                               | 30%             | Test data populated by Friday.   |
| / 4                 | Detient De          |   |   |  |                               |                 |  |
| Vorkstream 4        | GDE                 | Patient Portal                              | To allow patients/families/carers secure access to patient records  | Wednesday, February 28, 2018   |                               |                 |  |
| Vorkstream 5:       | · Interepose        | hility & APIs                               |   |  |                               |                 |  |
| 5A                  | GDE                 | MESH  | Implementation of MESH standard for message exchange  | 31 Ocotober 2017   |                               | 85%             | Feedback from CCG.   |
| 5B                  | GDE                 | EMIS to MEDITECH interface                  | Electronic access to primary care records   | Tuesday, October 31, 2017  |                               | 10%             | Interface ordered but commercial debate.   |
| 5C                  | GDE                 | GP Ordering for<br>Diagnostics              | To provide the ability for GPs to order<br>Pathology investigations direct  | Saturday, March 31, 2018   |                               | 50%             | Testing on-going. Patient match issue to work through.                             |
| 5D                  | GDE                 | GP Ordering for<br>Diagnostics              | To provide the ability for GPs to order<br>Radiology investigations direct  | Saturday, March 31, 2018   |                               | 50%             | Testing on-going. Patient match issue to work through.                             |
| lorkotne em 0       | Impressio           | Detient Eventions                           |   |  |                               |                 |  |
| Vorkstream 6:       | : Improving<br>GDE  | Patient Experience PET App                  | Development of an App to improve patient experience   | 30 September 2017 - Stage 1, complete<br>engagement phase for PET App<br>28th February 2018 - Stage 2, build pilot for |                               | Stage 1<br>100% | Implementation underway for delivery Nov.  |
|                     |                     |   |   | PET-App-   |                               |                 |  |

| GDE Programme Dashboard - Assurance |         |                                |  |                           |                                |            |  |
|-------------------------------------|---------|--------------------------------|--|---------------------------|--------------------------------|------------|--|
| Version 0.1 10/04/17                |         |                                |  |                           |                                |            |  |
|                                     |         |                                |  |                           | PROJECT<br>RAG                 |            |  |
|                                     |         |                                |  |                           | ICAG                           |            |  |
| Project Ref                         | GDE?    | Project Title                  | Project Description  | Delivery Date             | OVER ALL PROJECT<br>RAG status | % Progress | Comments for attention of the Project Team, Steering Group and sub-<br>Committee   |
| 7A                                  | IM&T    | e-Referrals                    | e-Referral paper switch off programme  | Monday, October 1, 2018   |                                | 50%        | e-Referrals on track for delivery.   |
| 7B                                  | IM&T    | Emergency Care Data<br>Set     | Emergency Care data set to be added as part of IMO   | Sunday, October 1, 2017   |                                | 80%        | Live on Friday   |
|                                     |         |                                |  |                           |                                |            |  |
| Workstream 8                        | : Other |                                |  |                           |                                |            |  |
| 8A                                  | IM&T    | Chemocare HL7 Interface        | HL7 ADT Interface for Chemocare  | Thursday, March 1, 2018   |                                |            | Pending go live. Live next week.   |
| 8B                                  | IM&T    | R&E 2                          | The aim of the project is to complete Phase 2 of the RI & E building to a world class standard | Friday, June 1, 2018      |                                |            | Uni's to finalise requirements. Additional meetings scheduled. Costings. Occupancy June 18, staff / students Sept 18. Costing received.      |
| 8C                                  | IM&T    | Outpatient Coding              | Outpatient Coding  | Friday, September 1, 2017 |                                |            | Raised with reporting sub-group. Indication septe milestones delivery, october. To be chased. Build in test - 3 specialities to be reviewed. |
| 8D                                  | IM&T    | Sepsis Management              | Review of Sepsis Pathway   | Friday, September 1, 2017 |                                |            | MD to describe change to clinician process. End October all development to be completed. Urgent and cirticals.                               |
| 8D                                  | IM&T    | Data Centre back on site       | Move of the Data Centre back onto site   | Monday, January 1, 2018   |                                |            | Lack of confirmation of additional power.  |
| 8E                                  | IM&T    | A&E Capacity and<br>Demand App | Deployment of an A&E waiting time app across the STP footprint                                 | 01 January 2018?          |                                |            | STP initiative.  |

| r | Black - Failed/ Gap   |
|---|---|
| 0 | Red - Project team/workbook requiring significant assistance/management                     |
| j | Amber - Project team and workbook have issues and these are resolvable at the project level |
| 0 | Green - Project team in place with workbook overall in good order and proceeding to plan    |
|   |   |